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FOREWORD 
 
 
 
This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The 
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary. 
 
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein.  Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is 
also presented, but is described in less detail than the key studies.  The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced. 
 
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile 
begins with a public health statement that describes, in nontechnical language, a substance's relevant 
toxicological properties.  Following the public health statement is information concerning levels of 
significant human exposure and, where known, significant health effects.  The adequacy of information to 
determine a substance's health effects is described in a health effects summary.  Data needs that are of 
significance to protection of public health are identified by ATSDR. 
 
 Each profile includes the following: 
 
 (A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects; 
 
 (B) A determination of whether adequate information on the health effects of each substance 
is available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and 
 
 (C) Where appropriate, identification of toxicologic testing needed to identify the types or 
levels of exposure that may present significant risk of adverse health effects in humans. 
 
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and 
local levels; interested private sector organizations and groups; and members of the public.   
 
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been 
peer-reviewed.  Staffs of the Centers for Disease Control and Prevention and other Federal scientists have 
also reviewed the profile.  In addition, this profile has been peer-reviewed by a nongovernmental panel 
and was made available for public review.  Final responsibility for the contents and views expressed in 
this toxicological profile resides with ATSDR. 
Patrick N. Breysse, Ph.D., CIH
 
Director, National Center for Environmental Health and
 
Agency for Toxic Substances and Disease Registry
 
Centers for Disease Control and Prevention
 
  
 
 
 
 
*Legislative Background 
 
The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section 
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related 
authorities” of the statute.  This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the 
most significant potential threat to human health, as determined by ATSDR and the EPA. Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile 
for each substance on the list.  In addition, ATSDR has the authority to prepare toxicological profiles for 
substances not found at sites on the National Priorities List, in an effort to “…establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA 
Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise 
necessary to support the site-specific response actions conducted by ATSDR. 
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation
of available toxicologic and epidemiologic information on a substance.  Health care providers treating
patients potentially exposed to hazardous substances will find the following information helpful for fast
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets,
and assesses the significance of toxicity data to human health.
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical
setting.  Please refer to the Public Health Statement to identify general health effects observed
following exposure.
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues:
Chapter 1 How Can (Chemical X) Affect Children?
 
Chapter 1 How Can Families Reduce the Risk of Exposure to (Chemical X)?
 
Section 3.7 Children’s Susceptibility
 
Section 6.6 Exposures of Children
 
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)
Internet:  http://www.atsdr.cdc.gov
The following additional material is available online at www.atsdr.cdc.gov:
Case Studies in Environmental Medicine—Case Studies are self-instructional publications designed to 
increase primary care provider’s knowledge of a hazardous substance in the environment and to 
aid in the evaluation of potentially exposed patients.  
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Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials
incident.  Volumes I and II are planning guides to assist first responders and hospital emergency
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health. Contact: NIOSH, 395 E Street, S.W., Suite 9200, 
Patriots Plaza Building, Washington, DC 20201 • Phone: (202) 245-0625 or 1-800-CDC-INFO 
(800-232-4636).
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Clinical Resources
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266.
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1.	 Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying
end points.
2.	 Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each
profile, and makes recommendations for derivation of MRLs.
3.	 Data Needs Review. The Environmental Toxicology Branch reviews data needs sections to
assure consistency across profiles and adherence to instructions in the Guidance.
4.	 Green Border Review.  Green Border review assures the consistency with ATSDR policy.
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PEER REVIEW
 
A peer review panel was assembled for dinitrotoluenes.  The panel consisted of the following members:
1.	 William J. George, Ph.D., Department of Pharmacology SL83, Tulane University School of
Medicine, New Orleans, Louisiana;
2.	 James Klaunig, Ph.D., Professor and Director of Toxicology, Department of Pharmacology and 
Toxicology, Division of Toxicology, School of Medicine, Indiana University, Indianapolis, 
Indiana;
3.	 Volker Harth, MD, MPH, Professor of Occupational Medicine, University Medical Center
Hamburg-Eppendorf (UKE), Director Institute for Occupational and Maritime Medicine (ZfAM), 
Hamburg, Germany.
These experts collectively have knowledge of dinitrotoluene’s physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer
reviewers' comments and determined which comments will be included in the profile.  A listing of the
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their
exclusion, exists as part of the administrative record for this compound.  
The citation of the peer review panel should not be understood to imply its approval of the profile's final
content.  The responsibility for the content of this profile lies with the ATSDR.
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1DINITROTOLUENES
1. PUBLIC HEALTH STATEMENT FOR DINITROTOLUENES (DNTs)
This Public Health Statement summarizes the Division of Toxicology and Human Health Science’s
findings on DNTs, tells you about them, the effects of exposure, and describes what you can do to limit
that exposure.
WHAT ARE DNTs?
DNTs consist of a mixture of isomers (forms). These particular isomers have the same molecular weight
and molecular formula and the same nitro functional groups.  However, the functional groups are at
different positions on the chemical structure.  Two of the isomers of DNT, 2,4-DNT and 2,6-DNT, make
up 95% of DNTs.  The other 5% is mostly four other isomers (2,3-, 2,5-, 3,4-, and 3,5-DNT).  DNTs are
not natural substances and are commercially produced by reacting concentrated sulfuric and nitric acid 
with toluene.  
The U.S. Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation. These sites make up the National Priorities List (NPL) and are sites targeted for long-term federal
clean-up activities.  U.S. EPA has found DNTs in at least 98 of the 1,699 current or former NPL sites.
The total number of NPL sites evaluated for DNTs is not known.  But the possibility remains that as more
sites are evaluated, the sites at which DNTs are found may increase. This information is important
because these future sites may be sources of exposure, and exposure to DNTs may be harmful.
If you are exposed to DNTs many factors determine whether you’ll be harmed.  These include how much 
you are exposed to (dose), how long you are exposed (duration), and how you are exposed (route of
exposure).  You must also consider the other chemicals you are exposed to and your age, sex, diet, family
traits, lifestyle, and state of health.
Most DNTs are used in the production of toluene diisocyanate (TDI), which is used in the manufacture of
polyurethane foam. They are also used to make the explosive, TNT, and in the production of dyes and 
smokeless powders in the munitions industry.
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1. PUBLIC HEALTH STATEMENT FOR DINITROTOLUENES
WHERE ARE DNTs FOUND?
DNTs can be released into the air, water, and soil at places where they are produced or used.  They are not
commonly found outside of source areas such as DNT manufacturing facilities or contaminated waste 
sites.
HOW MIGHT I BE EXPOSED TO DNTs?
Workers in plants that use DNTs may be exposed by inhalation and skin contact. Other people are not
likely to be exposed to DNTs unless they live near facilities involved in production, use, storage, and/or
disposal of DNTs.  People living near such facilities may be exposed by skin contact with contaminated 
soil, by accidentally eating contaminated soil, by drinking contaminated water, or by skin contact with 
contaminated water. Most people are not likely to be exposed to DNTs by inhalation; however, one
might be exposed by breathing in DNT released to the air from DNT-contaminated bath or shower water.
HOW CAN DNTs ENTER AND LEAVE MY BODY?
If you breathe air containing DNTs, they will enter your body through your lungs. If present in drinking
water, DNTs will rapidly enter your body through the digestive tract. Some soil samples may contain a 
high level of DNTs.  People can be exposed by skin contact with DNT-contaminated soil or by 
swallowing DNT-contaminated soil or dust.  Such exposure would be more likely among young children 
playing in DNT-contaminated soil and/or placing it in their mouth. DNTs leave your body rapidly.  They 
DNTs are rarely detected in outside air, but are detected in workplace air where they are manufactured or
used. Military and industrial activities have led to reported release of DNTs into soil, groundwater, or
surface water.  DNT levels as high as 10 mg/L were reported in potable groundwater at the Joliet Army
Ammunition Plant located in Illinois.  It was unspecified as to what years these levels were reported;
levels were reported to be as high as 3.2 mg/L and 2.7 mg/L in 1989. Current levels of DNTs in the
groundwater may be significantly lower. DNTs are slowly broken down in water by microbial (bacterial
or other microscopic) organisms a can be broken down by sunlight in surface water. DNTs have been 
detected in soil at levels of ~100 mg/kg in areas like ammunition manufacturing sites and military firing
ranges. DNTs do not adsorb strongly to soil. Therefore, they can move from soil into groundwater, 
where they can contaminate drinking water. DNTs are not used extensively in consumer products and are
not often detected in food samples.
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break down into other chemicals that leave your body in the urine within 24 hours.  Small amounts of the
DNTs may also be present in the feces.
HOW CAN DNTs AFFECT MY HEALTH?
The health effects of DNTs depend on several factors, including how much DNTs you are exposed to and 
the length of that exposure.  Environmental monitoring data are limited, but they do suggest that any DNT
levels the public might encounter by contact through air, water, or soil are generally much lower than 
levels used in animal studies.
See Chapters 2 and 3 for more information on health effects of DNTs.
HOW CAN DNTs AFFECT CHILDREN?
This section discusses potential health effects of DNT exposure in humans from when they’re first
conceived to 18 years of age.
In one study of 457 munitions workers exposed to DNTs for periods ranging from 30 days to >5 years, 
there was some evidence for increased death from heart disease; however, the study was limited by the
small number of workers evaluated.  Animal studies have shown that breathing vapors or aerosols of
DNTs can cause damage to the lungs.  Animal studies have also shown that ingesting DNTs over short or
long periods causes anemia, and damage to the nervous system, male reproductive system, and liver.
Several studies in workers have looked for possible associations between DNT exposure and cancer.  No 
association was found between DNT exposure and liver cancer.  One study in mine workers reported an 
association between DNT exposure and kidney cancer. Three studies reported associations between DNT
exposure and bladder cancers in workers. However, there is no clear evidence that DNT causes cancer in
people. Laboratory animals ingesting DNTs during most of their lives developed cancer of the liver and
tumors in the kidneys. The U.S. EPA states that a mixture of 2,4- and 2,6-DNT is a probable human 
carcinogen, based on findings of cancer in animal studies. The International Agency for Research on
Cancer states that 2,4- and 2,6-DNT are possibly carcinogenic to humans, but that carcinogenicity for
3,5-DNT in humans cannot be determined due to a lack of information.
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No data describe the effects of exposure to DNTs on children or young animals.  Although we think that
children would likely show the same health effects as adults, we don’t know whether children are more
susceptible than adults to DNT effects.
We don’t know whether DNTs can harm an unborn child.  Results of animal studies show that newborns
of mothers exposed to DNTs during pregnancy can have anemia and nervous system damage at birth.  
These effects are similar to those seen in adult animals.
HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO DNTs?
If your doctor finds that you have been exposed to significant amounts of DNTs, ask whether your
children might also be exposed. Your doctor might need to ask your state health department to
investigate.
DNTs are not often detected in drinking water supplies. However, if you live close to areas where DNTs 
may contaminate soil or drinking water (for example near facilities where DNTs are produced or disposed 
of), limit your exposure to contaminated drinking water and soil.
ARE THERE MEDICAL TESTS TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO
DNTs?
DNTs and their breakdown products (metabolites) can be measured in urine.  However, the detection of
DNTs or metabolites cannot predict the kind of health effects that might develop from that exposure.
Because DNTs and their metabolites leave the body fairly rapidly, the tests need to be conducted within 
days after exposure.
For more information on the different substances formed by DNT breakdown and on tests to detect these
substances in the body, see Chapters 3 and 7.
WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT 
HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health.  Regulations
can be enforced by law.  Federal agencies that develop regulations for toxic substances include the
Environmental Protection Agency (EPA), the Occupational Safety and Health Administration (OSHA),
and the Food and Drug Administration (FDA).  Recommendations provide valuable guidelines to protect
public health but cannot be enforced by law.  Federal organizations that develop recommendations for
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toxic substances include the Agency for Toxic Substances and Disease Registry (ATSDR) and the 
National Institute for Occupational Safety and Health (NIOSH).
Regulations and recommendations can be expressed as “not-to-exceed” levels; that is, levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value usually based on levels that affect
animals; levels are then adjusted to help protect humans.  Sometimes these not-to-exceed levels differ
among federal organizations.  Different organizations use different exposure times (an 8-hour workday or
a 24-hour day), different animal studies, or emphasize some factors over others, depending on their
mission.
Recommendations and regulations are also updated periodically as more information becomes available.
For the most current information, check with the federal agency or organization that issued the regulation
or recommendation.
The U.S. EPA has determined that exposure to 2,4-DNT in drinking water at concentrations of 1 mg/L for 
1 or 10 days is not expected to cause any adverse effects in a child. OSHA set a legal limit of 1.5 mg/m3 
DNT in workplace air averaged over an 8-hour work day. NIOSH recommends a limit of 1.5 mg/m3 
DNT in workplace air averaged over a 10-hour work day.
WHERE CAN I GET MORE INFORMATION?
If you have any questions or concerns, please contact your community or state health or environmental
quality department, or contact ATSDR at the address and phone number below.  ATSDR can also provide
publically available information regarding medical specialists with expertise and experience recognizing,
evaluating, treating, and managing patients exposed to hazardous substances.
•	 Call the toll-free information and technical assistance number at

1-800-CDCINFO (1-800-232-4636) or
 
•	 Write to:
 
Agency for Toxic Substances and Disease Registry

Division of Toxicology and Human Health Sciences
 
1600 Clifton Road NE
 
Mailstop F-57
 
Atlanta, GA 30329-4027
 
Toxicological profiles and other information are available on ATSDR’s web site:
http://www.atsdr.cdc.gov.
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2.1  	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO DNT IN THE UNITED 
STATES 
Dinitrotoluene (DNTs) are generally produced as a mixture called technical-grade DNT (Tg-DNT), which
contains approximately 76.5% 2,4-DNT and 18.8% 2,6-DNT (with the remainder consisting of other
isomers and minor contaminants such as TNT and mononitrotoluenes).  It is primarily used as a chemical
intermediate for the production of toluene diisocyanate (TDI).  DNTs are also used in the production of
2,4,6-TNT, dyes, and polyurethane foams. 
When released to the environment, DNTs have the potential to leach into groundwater or contaminate
surface waters through soil runoff and erosion.  Volatilization from water bodies or soil surfaces occurs
slowly for DNTs and as a consequence, they are not frequently detected in ambient air.  DNTs generally 
biodegrade slowly under environmental conditions, but are rapidly degraded by photolysis in natural
water.  Measured bioconcentration factors in fish suggest that the potential for bioaccumulation is low in
fish and other aquatic organisms.
DNTs are very infrequently detected in drinking water.  There were no detections of 2,4-DNT in
3,251 samples taken from small public water systems and there was only 1 detection out of
30,513 samples obtained from large systems throughout the United States.  2,6-DNT was not detected in
any of the 33,765 samples (both large and small systems) for which it was tested. DNTs have been
detected in surface water and groundwater near source locations such as munitions sites.  Concentrations 
of 2,4- and 2,6-DNT obtained from a small brook and a river adjacent to a former ammunition plant were
0.5–13.0 and 0.1–7.6 μg/L, respectively.  DNT levels as high as 10,000 μg/L were reported in potable
groundwater at the Joliet Army Ammunition Plant located in Will County, Illinois.  2,3-, 2,5-, 3,4-, and 
3,5-DNT isomers were identified in both monitoring wells and a few private water supply wells near an 
Army ammunition site in Wisconsin. 2,4-DNT was measured in soil samples obtained from the Joliet
Army Ammunition at levels of <0.1 mg/kg (detection limit) to 117 mg/kg.  2,6-DNT was detected on this 
site at concentrations ranging from <0.1 to 8 mg/kg.
The major route of exposure to DNTs for populations residing near hazardous waste sites or munitions
facilities is via ingestion of contaminated water or dermal contact with contaminated soil.  Inhalation 
and/or dermal exposure to DNTs could also occur when washing or bathing with DNT-contaminated 
water or when cooking with DNT-contaminated water.  Occupational exposure by inhalation or dermal
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contact may occur at workplaces where DNT is manufactured or used.  Monitoring data suggest that
populations that do not live near source areas are not exposed to significant levels of DNTs.
2.2  SUMMARY OF HEALTH EFFECTS 
Data on health effects of DNTs are available from occupational exposure studies and studies in laboratory
animals.  Most occupational exposure studies evaluate health effects in workers exposed to 2,4-, 2,6-, or
Tg-DNT.  However, most of these studies were conducted before 1950 and provide very little information
on exposure concentrations.  Furthermore, interpretation of study results is limited due to the absence of
appropriate control groups, mixed exposures to other chemicals, and small number of workers studied.  
Nearly all studies in laboratory animals are oral exposure studies of 2,4-, 2,6-, or Tg-DNT, and include
data for acute, intermediate, and chronic exposure durations. Very little information is available 
regarding health effects of inhaled DNTs; however, systemic effects of DNTs are expected to be similar
for all routes of exposure.
Results of occupational exposure studies and studies in laboratory animals identify the hematological
(methemoglobinemia, anemia, and compensatory hematopoiesis) and nervous systems (clinical signs of
neurotoxicity, ataxia, tremors, leg weakness, and convulsions) as the most sensitive targets of
DNT-induced toxicity.  In addition to hematological and neurological effects, results of animal studies 
provide evidence that the liver, respiratory tract, and reproductive system also are targets for
DNT-induced toxicity.  However, effects to these other organ systems occur at levels that are higher than
those producing hematological effects or neurotoxicity under similar exposure conditions.
In occupational exposure studies, findings of anemia and cyanosis in workers exposed to 2,4- or Tg-DNT
are consistent with the DNT-induced hematological effects observed in laboratory animals; however,
available human data provide only limited evidence, as studies did not include adequate control groups or
report exposure concentrations.  Adverse hematological effects, especially methemoglobinemia and
anemia, have been reported in laboratory animals exposed to oral 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5-, or
Tg-DNT for acute, intermediate, and chronic durations.  Hematological effects of DNTs are initiated by
methemoglobin production, which occurs when the ferrous iron in complex with the heme groups of
hemoglobin is oxidized to ferric iron. Ferric iron does not bind oxygen and, therefore, reduces the
oxygen-carrying capacity of the blood.  Ferric iron also contributes to the denaturation of hemoglobin and 
subsequent removal of erythrocytes from the blood, resulting in anemia.  Heinz bodies (granules of
denatured hemoglobin) form and can be detected in erythrocytes.  Increased hematopoiesis is often
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observed as a compensatory response to decreased erythrocyte count.  Hematological parameters typically
affected by DNT exposure include increased blood methemoglobin levels, increased reticulocyte count,
decreased erythrocyte count, decreased hematocrit, and decreased blood hemoglobin levels, and the
presence of Heinz bodies; the severity of effects increases with dose.  In addition, extramedullary
erythropoiesis of the spleen, a compensatory response, may also occur. In acute-duration (14-day) oral
studies of rats, this effect was seen after exposure to each of the six isomers of DNT. Results of a single-
dose oral exposure study in rats indicate that the onset of hematological effects is rapid, with effects
observed 24 hours after administration of 99 mg/kg of 2,4- or 2,6-DNT.  For acute exposure durations, the
lowest daily oral dose associated with hematological effects is 4 mg/kg/day in dogs exposed to 2,6-DNT
for 14 consecutive days.  Similar hematological effects have been observed following intermediate-
duration exposure, with the development of methemoglobinemia, anemia, and compensatory 
erythropoiesis in dogs administered daily oral doses of 1.5 mg/kg of 2,4-DNT for 3–9 months.  
Extramedullary erythropoiesis of the spleen was observed in dogs administered ≥4 mg/kg/day of 2,6-DNT
for 4–13 weeks.  For chronic-duration exposure, hematological effects were observed following exposure
of dogs to 2,4-DNT at 1.5 mg/kg/day for 24 months.  Following cessation of exposure, hematological
effects showed complete reversal, although time to reversal increased with severity of effects.
In occupational exposure studies, neurological effects, including headache, dizziness, insomnia, 
unpleasant taste in the mouth, and pain, numbness, and tingling in the extremities, have also been reported 
in workers exposed to 2,4- or Tg-DNT; however, available human data provide only limited evidence, as 
studies did not include adequate control groups or report exposure concentrations. The nervous system is 
also identified as a sensitive target for DNT-induced toxicity, with symptoms of neurotoxicity reported in 
laboratory animals exposed to oral 2,4-, 2,6-, 3,4-, 3,5-, and Tg-DNT for acute, intermediate, and chronic
durations. However, results of these studies indicate that, in general, the nervous system is a less 
sensitive target than the hematological system.  Symptoms of neurotoxicity observed in laboratory
animals include weakness, stiffness, or rigid paralysis of the hind legs, abnormal gait, tremors, ataxia, and 
convulsions, with severity increasing with dose.  For acute- and intermediate-duration exposures, the
lowest doses producing symptoms of neurotoxicity were 25 mg/kg/day in dogs exposed to 2,4-DNT for 
12 days to 13 weeks and 20 mg/kg/day in dogs exposed to 2,6-DNT for 13 weeks. Demyelinization in the
cerebellum and brain stem was observed in rats exposed to dietary exposures of 93 mg/kg/day 2,4-DNT
for 13 weeks.  In chronic-duration exposure studies, the lowest dose producing neurotoxicity was
1.5 mg/kg/day 2,4-DNT in a 2-year study in dogs; however, this effect (loss of hindquarter control) was 
only observed intermittently in one of six dogs.  More severe signs of neurotoxicity and central nervous
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system lesions (vacuolization, hypertrophy, endothelial mitosis, focal gliosis in the cerebellum, and 
perivascular hemorrhage in the cerebellum and brain stem) occurred at 10 mg/kg/day.
Occupational exposure studies do not provide conclusive evidence of DNT-induced hepatotoxicity due to 
lack of appropriate controls.  Hepatic effects have been observed in animals exposed to 2,3-, 2,4-, 2,6-,
3,4-, or Tg-DNT in laboratory animals.  However, as discussed below, 2,4-, 2,6-, and Tg-DNT have been
shown to induce hepatocellular carcinoma following chronic-duration oral exposure.  Thus, hepatic
effects observed at less-than-chronic exposure durations may represent early stages of progressive 
development to hepatic cancer.  The potential for DNTs to induce liver cancer complicates interpretation
of study results showing possible effects in the liver, as hepatotoxicity may be a precursor to or a result
from the development of hepatic neoplasms.  Hepatic effects, including liver discoloration, inflammation,
increased liver weights, hepatocellular hyperplasia and hypertrophy, degeneration of hepatocytes,
hepatocellular necrosis, karyocytomegaly, proliferation of bile duct epithelium, and elevated blood levels
of hepatic enzymes, have been reported in oral exposure studies of 2,3-, 2,4-, 2,6-, 3,4-, or Tg-DNT in
laboratory animals.  Hepatic effects occurred after exposure to 2,3-DNT doses ≥275 mg/kg/day, to 
2,4-DNT doses ≥10 mg/kg/day, to 2,6-DNT doses ≥7 mg/kg/day, and to 3,4-DNT doses ≥113 mg/kg/day,
with severity related to dose and exposure duration.  At higher oral doses (≥50 mg/kg/day), onset of
hepatic toxicity appears to be rapid; congested sinusoids with sloughed hepatocytes, infiltration of
segmented neutrophils, pyknotic nuclei, microvesiculated cytoplasm, and apoptosis of hepatocytes were 
observed 48 hours after administration of 2,6-DNT.  Following chronic dietary exposure to 2,4-DNT for
1 year, hepatocellular alterations were observed in male rats at a dose of 0.6 mg/kg/day; however, 
neoplastic nodules of the liver were also observed in these animals at doses ≥0.6 mg/kg/day.  Biliary
hyperplasia was observed in dogs exposed to 2,4-DNT for 24 months, with no-observed-adverse-effect
level (NOAEL) and lowest-observed-adverse-effect level (LOAEL) values of 1.5 and 10 mg/kg/day,
respectively.
Adverse reproductive effects, including effects on male and female reproductive systems and decreased
neonatal viability, have been observed in laboratory animals following acute, intermediate, and chronic
oral exposure to 2,4-, 2,6-, 3,5-, or Tg-DNT.  Severity of reproductive effects is dose- and exposure
duration-related, and the male reproductive system is more sensitive than the female reproductive system
or neonatal viability. In males, adverse effects include decreased testes and epididymides weights,
decreased sperm production, testicular atrophy, degeneration of seminiferous tubules, multinucleated 
giant cell formation, and changes in Sertoli cell morphology.  The lowest dose producing effects to the
male reproductive system (testicular atrophy and decreased spermatogenesis) was 14 mg/kg/day in mice
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fed diets containing 2,4-DNT for up to 2 years.  Effects on the female reproductive system (ovarian
atrophy and nonfunctional follicles) were observed in mice fed 898 mg/kg/day 2,4-DNT.  Decreased
neonatal viability was observed in rats fed ≥34.5 mg/kg/day 2,4-DNT for up to 6 months in a three-
generation reproductive study.  Occupational exposure studies do not provide evidence of DNT-induced 
adverse reproductive effects due to both concomitant exposure of workers to other chemicals and 
reporting insufficiencies.  Dietary exposure of rats to 2,4-DNT for up 6 months in a three-generation 
reproductive study produced delayed eye opening at doses fed ≥35 mg/kg/day, but no other
developmental effects.  In neonates exposed to Tg-DNT during gestation, systemic effects similar to those 
observed in adult animals, including delayed eye opening and signs of mild neurological effects (cliff
avoidance behavior) and effects on hematological parameters, were observed at maternal doses 
≥100 mg/kg/day; recovery from these effects was observed by postpartum day 60.  Although no studies
were located regarding developmental effects in humans after oral exposure to DNTs, developmental
toxicity from DNTs could potentially occur because exposure to any substance that depletes the amount
of oxygen available to developing fetal tissues may cause toxicity to the developing organism.
Respiratory distress, pulmonary congestion, and increased relative lung weights were observed in rats 
following a single 6-hour inhalation exposure of rats to near-lethal or lethal concentrations of 2,6-DNT
(vapor or aerosol).  No effects on the respiratory system have been observed following acute,
intermediate, or chronic oral exposure of laboratory animals to DNTs.  Occupational studies do not
include reports of respiratory effects in workers.  
The carcinogenic activity of DNTs has been extensively studied in typical chronic bioassays and in some 
less-than-lifetime studies. Results show the development of renal cancer in mice fed 2,4-DNT at
95 mg/kg/day and hepatocellular carcinoma in male and female rats fed 2,4-DNT at doses of 34.5 and 
45.3 mg/kg/day, respectively.  Hepatocellular carcinomas were observed in rats administered 2,6-DNT at
doses ≥7 mg/kg/day.  2,4-DNT was a hepatic tumor promoter, but not a tumor initiator, using in vivo
hepatic initiation-promotion protocols.  Both tumor-initiating and -promoting activities of 2,6- and 
Tg-DNT in rat liver were reported.  A retrospective cohort mortality study at two army ammunition plants
that used Tg-DNT and/or 2,4-DNT showed no significant increases in mortality from malignant
neoplasms as a whole or from particular cancers (liver, lung, gallbladder, kidney, and connective tissues),
although interpretation of study results is limited by a small cohort size.  Three studies of German copper
miners exposed to high levels of Tg-DNT from explosives found increases in the incidence of urothelial
cancers.  An association between renal cancer and duration of Tg-DNT exposure has also been reported in
this cohort.  The National Toxicology Program (NTP) has not evaluated DNTs.  EPA has classified
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2,4-DNT/2,6-DNT mixture as a probable human carcinogen based on sufficient evidence of
carcinogenicity in animals.  The International Agency for Research on Cancer (IARC) has classified
2,4- and 2,6-DNT as possibly carcinogenic to humans, and 3,5-DNT as not classifiable as to its 
carcinogenicity to humans.
Heath effects of 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, and 3,5-DNT ingestion in laboratory animals and the dose 
ranges at which these effects occur are shown in Figures 2-1 through 2-6, respectively. Estimates of oral
doses posing minimal risk to humans (MRLs) are also presented in these figures.
2.3  MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for 2,3-, 2,4-, 2,5-, 
2,6-, 3,4-, and 3,5-DNT.  An MRL is defined as an estimate of daily human exposure to a substance that
is likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration 
of exposure. MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of
effect or the most sensitive health effect(s) for a specific duration within a given route of exposure.  
MRLs are based on noncancerous health effects only and do not consider carcinogenic effects. MRLs can
be derived for acute, intermediate, and chronic duration exposures for inhalation and oral routes.  
Appropriate methodology does not exist to develop MRLs for dermal exposure. 
Inhalation MRLs
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of
significant human exposure improve, these MRLs will be revised as appropriate.
Most of the data on health effects associated with inhalation exposure of humans to DNTs are from
studies of workers exposed to 2,4-, 2,6-, or Tg-DNT. However, most of these studies were conducted
before 1950 and provide very little information on exposure concentrations.  Furthermore, interpretation 
of study results is limited due to the absence of appropriate control groups, mixed exposures to other
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Figure 2-1.  Health Effects for Ingesting 2,3-Dinitrotoluene
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Figure 2-2.  Health Effects for Ingesting 2,4-Dinitrotoluene
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Figure 2-3.  Health Effects for Ingesting 2,5-Dinitrotoluene
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Figure 2-4.  Health Effects for Ingesting 2,6-Dinitrotoluene
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Figure 2-5.  Health Effects for Ingesting 3,4-Dinitrotoluene
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Figure 2-6.  Health Effects for Ingesting 3,5-Dinitrotoluene
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chemicals, and small number of workers studied.  Therefore, while available occupational studies provide
supportive information for observations in animals regarding identification of target organs, they do not
report dose-response data that can be used to derive MRLs for DNTs.  Regarding available animal data,
one study was located that examined the acute inhalation toxicity of 2,6-DNT in rats (CMA 1991).  This
study identified mortality and clinical signs of respiratory toxicity (exaggerated respiratory movements) in
rats exposed to 2,6-DNT as an aerosol at concentrations ≥196 mg/m3; rats that died showed increased 
relative lung weights and evidence of lung congestion.  No effects were observed in rats exposed nose-
only to 2,6-DNT as a vapor at 26 mg/m3 for 6 hours and observed 14 days after dosing.  No studies were 
located regarding inhalation exposure to 2,3-, 2,5-, 3,4-, or 3,5-DNT in experimental animals.  Thus, data 
were insufficient for the derivation of acute-, intermediate-, and chronic-duration inhalation MRLs for
2,3-, 2,4-, 2,5-, 2,6-, 3,4-, and 3,5-DNT.
Oral MRLs
Acute-Duration Oral MRL for 2,3-DNT
Acute-, intermediate-, and chronic-duration oral MRLs were derived for 2,4-DNT and acute- and 
intermediate-duration oral MRLs were derived for 2,6-DNT; acute-duration oral MRLs were derived for
2,3-, 2,5-, 3,4-, and 3,5-DNT.  For all isomers, studies in humans did not provide sufficient data regarding
exposure levels and their correlation with observed effects; thus, animal studies were used for the
derivation of these oral MRLs. Data were insufficient for the derivation of intermediate- and chronic-
duration oral MRLs for 2,3-, 2,5-, 3,4-, and 3,5-DNT and for the derivation of a chronic oral MRL for
2,6-DNT. Table 2-1 summarizes the oral MRLs for the DNT isomers.
•	 An MRL of 0.09 mg/kg/day has been derived for acute-duration oral exposure (≤14 days) to 

2,3-DNT.
 
No human acute-duration oral toxicity studies on 2,3-DNT were identified. For 2,3-DNT, the only 
available oral exposure studies are a 14-day gavage study in rats, in which a number of toxicological end
points were assessed (Lent et al. 2012a; USAPHC 2011a), and a single-dose gavage study, which reported
data on lethality only (Vernot et al. 1977).  Vernot et al. (1977) reported LD50 values of 1,120 and 
1,070 mg/kg in rats and mice, respectively.  The 14-day study in rats (Lent et al. 2012a; USAPHC 2011a) 
identified effects on survival and the kidney and hematopoietic system.  Groups of six male Sprague-
Dawley rats were given 2,3-DNT via gavage doses of 0, 17, 34, 69, 138, 275, or 550 mg/kg/day for
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Table 2-1.  Summary of Oral MRLs (mg/kg/day) for Dinitrotoluenes
Isomer Acute Intermediate Chronic
2,3-DNT 0.09 NA NA
2,4-DNT 0.05 0.007 0.001
2,5-DNT 0.007 NA NA
2,6-DNT 0.09 0.004 NA
3,4-DNT 0.03 NA NA
3,5-DNT 0.03 NA NA
DNT = dinitrotoluene; NA = not applicable; data are not adequate to derive MRL
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14 days; evaluations included morbidity, clinical observations, hematology, serum chemistry, gross
necropsy, organ weights, and histopathology.  At the highest dose (550 mg/kg/day), all rats died.  Rats 
exposed to 275 mg/kg/day 2,3-DNT exhibited renal tubular dilatation (2/6) and lymphocytic infiltration
(4/6), as well as trace extramedullary hematopoiesis (3/6 rats), lymphoid hyperplasia (1/6), and lymphoid 
depletion (1/6) in the spleen.  Histopathology examinations of the kidney and spleen were not performed 
on lower dose groups.  Although none of these incidences was statistically significantly increased in
pairwise comparisons with controls, the lack of statistical significance likely reflects the very small group
sizes rather than a lack of treatment-related effect, and the increases are considered to be biologically
significant. Results of this study identify an acute-duration LOAEL value for renal and splenic effects of
275 mg/kg/day in rats.  A NOAEL cannot be determined in the absence of histopathology examinations in 
lower dose groups.
Effects on the kidney and spleen were identified as the most sensitive effects of acute-duration oral
exposure to 2,3-DNT, based on the LOAEL value of 275 mg/kg/day in rats administered 2,3-DNT via
gavage for 14 days (Lent et al. 2012a; USAPHC 2011a).  The LOAEL value of 275 mg/kg/day was used 
as the point of departure (POD).  Available data were not suitable for benchmark dose (BMD) modeling,
as spleen and kidney histopathology examinations were limited to the 275 mg/kg/day group and the
control groups.  The POD of 275 mg/kg/day was divided by an uncertainty factor of 3,000 (10 for use of a
LOAEL, 10 for extrapolation from animals to humans, 10 for human variability, and 3 for database
limitations), resulting in an acute-duration oral MRL for 2,3-DNT of 0.09 mg/kg/day.
Acute-Duration Oral MRL for 2,4-DNT
•	 An MRL of 0.05 mg/kg/day has been derived for acute-duration oral exposure (≤14 days) to 

2,4-DNT.
 
No human acute-duration oral toxicity studies on 2,4-DNT were identified. Acute-duration studies in
animals identified the nervous system, hematological system, liver, and reproductive system as targets for
DNT-induced toxicity, with neurotoxicity as the most sensitive effect.
Dogs (4/sex/group) exposed to 2,4-DNT at 0, 1, 5, or 25 mg/kg/day in capsules for 13 weeks were 
observed for behavioral changes and clinical signs of toxicity during the first 14 days of treatment.  Signs
of neurotoxicity were evident at 25 mg/kg/day.  Onset of neurotoxicity (loss of hind leg control) was
observed in a female dog on day 12; three additional male dogs showed similar effects on day 14.  Signs
of neurotoxicity were reported in all dogs exposed to 25 mg/kg/day after treatment for 12–22 days.  No 
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clinical signs were observed in dogs treated with 1 or 5 mg/kg/day.  Results of this study identify acute-
duration no-observed-adverse-effect level (NOAEL) and lowest-observed-adverse-effect level (LOAEL)
values for neurotoxicity in dogs of 5 and 25 mg/kg/day, respectively.  Although comprehensive end
points were not evaluated at 14 days, data obtained following the 13-week portion of this study identify
the same NOAEL and LOAEL values of 5 and 25 mg/kg/day, respectively, for neurotoxicity,
hematological effects, and reproductive effects.  Thus, it is unlikely that hematological or reproductive
effects would occur at lower doses than neurotoxicity in the acute-duration portion of the study. 
Acute-duration studies in rodents identified the hematological system, liver, and reproductive system as 
targets of acute-duration exposure to 2,4-DNT.  The most sensitive hematological effect (slight cyanosis)
was observed in male Sprague-Dawley rats exposed to 2,4-DNT at 60 mg/kg/day (lowest tested dose) for
5 days (Lane et al. 1985).  The lowest LOAEL for hepatotoxicity (increased incidences of single cell
necrosis and glycogen deposition) was reported in male Sprague-Dawley rats treated at 36 mg/kg/day for
14 days; the NOAEL was 18 mg/kg/day (Lent et al. 2012a; USAPHC 2011b). The lowest LOAEL for
reproductive effects (decreased thickness of spermatogenic cell layers) was 78 mg/kg/day for male 
Sprague-Dawley rats administered 2,4-DNT for 14 days (McGown et al. 1983).  Lane et al. (1985)
identified a NOAEL of 60 mg/kg/day, with a LOAEL of 180 mg/kg/day, for decreased fertility in male
rats treated with 2,4-DNT for 5 days.  
Neurotoxicity (loss of hind limb control) was identified as the most sensitive effect of acute-duration oral
exposure to 2,4-DNT, based on the NOAEL value of 5 mg/kg/day in dogs administered 2,4-DNT via
capsules for 12–14 days (U.S. Army 1978b).  Based on the available data, neurotoxicity was selected as
the critical effect for the basis of the acute-duration oral MRL.  The NOAEL value for 5 mg/kg/day was
used as POD.  Neurotoxicity data were not suitable for BMD modeling, since effects were observed only
at the highest dose tested. The POD of 5 mg/kg/day was divided by an uncertainty factor of 100 (10 for
extrapolation from animals to humans and 10 for human variability), resulting in an acute-duration oral
MRL for 2,4-DNT of 0.05 mg/kg/day. 
Intermediate-Duration Oral MRL for 2,4-DNT
•	 An MRL of 0.007 mg/kg/day has been derived for intermediate-duration oral exposure (15–
 
364 days) to 2,4-DNT.
 
Information on effects of intermediate-duration oral exposure of laboratory animals is available from
studies treating animals with 2,4-DNT for intermediate durations (15–364 days) and from chronic­
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duration studies evaluating end points at intermediate-duration time points.  Results of studies in dogs, 
rats, and mice showed the development of hematological, neurological, and reproductive effects
following intermediate-duration exposure to 2,4-DNT, with the hematological effects as the most
sensitive end point.  Adverse hematological effects were observed in studies in dogs, rats, and mice, with 
the lowest LOAEL values of 1.5 and 10 mg/kg/day in females and males, respectively, observed 
following intermediate-duration oral exposure of dogs to 2,4-DNT (Ellis et al. 1985; U.S. Army 1979).  
As part of this 2-year study in dogs, hematological end points were evaluated in dogs administered 
2,4-DNT at 3, 6, and 9 months as part of a 2-year study in dogs administered 0, 0.2, 1.5, or 10 mg/kg/day.  
Hematological effects consistent with development of methemoglobinemia were observed at doses of
1.5 and 10 mg/kg/day at all intermediate-duration time points (3, 6, and 9 months).  Although effects at
all time points were qualitatively similar, hematological changes observed after 9 months of exposure
were more consistent and pronounced than those observed at the 3- and 6-month time periods.  Male and 
female dogs exposed for 9 months at doses of 1.5 and 10 mg/kg/day showed detectable amounts of
methemoglobin in the serum, with changes reaching statistical significance in males and females at
10 mg/kg/day. In female dogs administered 10 mg/kg/day, statistically significant decreases in
erythrocyte count, hematocrit, and hemoglobin, a statistically significant increase in reticulocyte count, 
and the presence of Heinz bodies in serum were observed.  Similar hematological effects were observed
in female dogs administered 0.2 and 1.5 mg/kg/day, although effects did not reach statistical significance, 
most likely because the power of the study to detect statistically significant changes was compromised by
the small number of dogs per treatment group.  However, based on a clinically significant increase in 
methemoglobin levels of 225% in female dogs administered 1.5 mg/kg/day, the NOAEL and LOAEL
values for hematological effects in this study are 0.2 and 1.5 mg/kg/day, respectively.  Similar effects 
were observed in male dogs, although changes did not reach statistical significance in the 10 mg/kg/day
group, possibly due to the small number of male dogs evaluated.  Comprehensive end points were not
evaluated at intermediate-duration time points in this study.  However, the chronic-duration portion of this
study, in which comprehensive end points were examined, identified hematological effects as the most
sensitive effect of chronic-duration exposure.  Thus, it is unlikely that effects to other target organs would 
occur at lower doses than the hematological effects for intermediate exposure durations (see overview of
chronic-duration oral data).
Intermediate-duration studies in animals administered higher daily doses show the development of similar
hematological effects, along with neurotoxicity and toxicity to the reproductive system.  Beagle dogs
administered 2,4-DNT for up to 13 weeks developed hematological effects (methemoglobinemia, anemia,
and compensatory hematopoiesis), neurological effects (incoordination, abnormal gait, and paralysis), and 
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reproductive effects (testicular degeneration and decreased spermatogenesis) at 25 mg/kg/day, with a
NOAEL for these effects of 5 mg/kg/day (Lee et al. 1985; U.S. Army 1979).  Hematological effects 
similar to those observed in dogs were reported in rats treated with 2,4-DNT at 93–371 mg/kg/day 
(Kozuka et al. 1979; U.S. Army 1978b) and in mice treated with 2,4-DNT at 413 and 468 mg/kg/day (for
males and females, respectively) for up to 13 weeks (Hong et al. 1985; U.S. Army 1978b).  The lowest
LOAEL for neurological effects (clinical signs of neurotoxicity and demyelination of the cerebellum and 
brain stem) in rodents was 93 mg/kg/day for male CD rats administered 2,4-DNT for 4 or 13 weeks; the
NOAEL for neurological effects in males was 34 mg/kg/day (Lee et al. 1985; U.S. Army 1978b).  In 
rodents, respective NOAEL and LOAEL values for reproductive effects (testicular atrophy and decrease 
or absent spermatogenesis) were 9–34 and 35–371 mg/kg/day in rats and 137–295 and 413– 
1,032 mg/kg/day in mice treated for 13 weeks (Bloch et al. 1988; Hong et al. 1985; Kozuka et al. 1979;
Lee et al. 1985; U.S. Army 1978b, 1979).
Based on the available data, changes to hematological parameters in dogs exposed to oral 2,4-DNT for
9 months (Ellis et al. 1985; U.S. Army 1979) were evaluated as possible PODs for the intermediate-
duration oral MRL for 2,4-DNT.  To determine the POD, all available continuous-variable models in the 
EPA BMD Software (BMDS, version 2.1) were fit to the data for selected hematological values
(methemoglobin, reticulocyte count, hemoglobin, erythrocyte count, and hematocrit) (see Appendix A for
detailed description of BMD modeling).  The BMD and the 95% lower confidence limit (BMDL) were
estimated for doses associated with a change of 1 standard deviation from the controls.  Neither the 
constant nor the non-constant variance model provided an adequate fit to the data for erythrocyte count or 
methemoglobin; therefore, these data were not considered suitable for BMD modeling.  Models provided 
an adequate fit to data for hematocrit, hemoglobin, and reticulocyte count.  Among all of the models
providing adequate fit to the data for these parameters, the lowest BMDL1SD values were 0.67 mg/kg/day
for hematocrit (exponential model 4), 3.66 mg/kg/day for hemoglobin (the exponential model 2), and 
5.64 mg/kg/day for reticulocyte count (polynomial 3-degree model); of these, the lowest BMDL1SD of
0.67 mg 2,4-DNT/kg/day for decreased hematocrit was selected as the POD. This value was divided by
an uncertainty factor of 100 (10 for animals to human extrapolation and 10 for human variability),
resulting in an intermediate-duration oral MRL of 0.007 mg/kg/day.
Chronic-Duration Oral MRL for 2,4-DNT
•	 An MRL of 0.001 mg/kg/day has been derived for chronic-duration oral exposure (≥1 year) to 
2,4-DNT.
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Information on effects of chronic-duration oral exposure is available from studies in dogs, rats, and mice.
Results of these studies indicate that hematological, neurological, hepatic, and reproductive effects are
associated with chronic-duration exposure to 2,4-DNT, with hematological effects and neurotoxicity as 
the most sensitive effects. Adverse hematological effects were observed in studies in dogs, rats, and
mice, with the lowest NOAEL and LOAEL values of 0.2 and 1.5 mg/kg/day, respectively, observed 
following chronic oral exposure of dogs to 2,4-DNT (Ellis et al. 1985; U.S. Army 1979).  Beagle dogs 
treated with 2,4-DNT at 1.5 and 10 mg/kg/day after 12 months developed hematological effects consistent
with methemoglobinemia, anemia, and compensatory hematopoiesis.  Female dogs administered 2,4-DNT
at 1.5 mg/kg/day for 12 months showed statistically significant reductions in erythrocyte count, 
hematocrit, and hemoglobin concentration.  At 10 mg/kg/day, more pronounced changes in these
hematological parameters were observed, including statistically significant reductions in erythrocyte 
count, hematocrit, and hemoglobin and a statistically significant increase in reticulocyte count.  Similar
hematological effects (decreased erythrocytes and decreased hematocrit) were observed in dogs treated
with 0.2 mg/kg/day, but changes did not reach statistical significance.  Although not statistically
significant, effects on hematological parameters in male dogs were also similar to those seen in female 
dogs.  In rodents, the lowest LOAEL for hematological effects was 3.9 mg/kg/day for decreased 
erythrocyte count (with no changes in methemoglobin or Heinz bodies) in male CD rats after treatment
with 2,4-DNT for 12 months; the NOAEL for this effect was 0.6 mg/kg/day (Lee et al. 1985; U.S. Army
1978b, 1979).
Neurotoxicity was also observed in dogs, rats, and mice orally exposed to 2,4-DNT for chronic durations.  
In chronic-duration exposure studies, the lowest dose producing neurotoxicity was 1.5 mg/kg/day
2,4-DNT in a 2-year study in dogs; however, this effect (loss of hindquarter control) was only observed 
intermittently in one of six dogs.  More severe signs of neurotoxicity and central nervous system lesions
(vacuolization, hypertrophy, endothelial mitosis, focal gliosis in the cerebellum, and perivascular
hemorrhage in the cerebellum and brain stem) occurred at 10 mg/kg/day (Ellis et al. 1985; U.S. Army
1979).  In rodents, the lowest LOAEL values for neurotoxicity were 35 and 45 mg/kg/day for male and 
female CD rats, respectively, treated with 2,4-DNT for 1–2 years (Lee et al. 1985; U.S. Army 1978b, 
1979).  In mice, neurotoxicity was reported at 898 mg/kg/day (but not at 95 mg/kg/day) (Hong et al. 
1985; U.S. Army 1979).
Hepatic effects have also been observed in laboratory animals following chronic-duration oral exposure to 
DNT.  However, these effects are often observed in conjunction with the development of hepatocellular
carcinoma and may represent precancerous changes.  For example, dietary exposure of male rats to
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0.6 mg/kg/day 2,4-DNT induced “hepatocellular” alterations; however, this exposure level also induced
neoplastic nodules (Lee et al. 1985).  Thus, interpretation of data on hepatic toxicity is complicated due to 
the potential of 2,4-DNT to induce hepatocellular carcinoma.  Biliary hyperplasia was observed in dogs
exposed to 2,4-DNT for 24 months, with NOAEL and LOAEL values of 1.5 and 10 mg/kg/day, 
respectively (U.S. Army 1979). The lowest LOAEL value for hepatic effects in mice was 14 mg/kg/day
for hepatocellular dysplasia following exposure to 2,4-DNT for 24 months (Hong et al. 1985; U.S. Army
1979).  Hepatocellular degeneration, vacuolization, and altered hepatocellular foci were also observed in
male F344 rats treated at 27 mg/kg/day for 52 weeks (Leonard et al. 1987).
Chronic-duration studies in laboratory animals have also demonstrated both male and female reproductive 
effects. The lowest LOAEL reported for reproductive effects is 14 mg/kg/day for atrophy of the testes
and decreased spermatogenesis in male CD-1 mice exposed to dietary 2,4-DNT for 12 months (Hong et
al. 1985).  Female mice fed 898 mg/kg/day 2,4-DNT had ovarian atrophy with non-functioning follicles, 
with no effects observed at 95 mg/kg/day (Hong et al. 1985).  Male CD rats that received 34 mg/kg/day 
2,4-DNT in the diet for 12 month showed an increased incidence of seminiferous tubule atrophy
compared to controls (100% affected at the high-dose versus 0% of controls) (Lee et al. 1985; U.S. Army
1978b, 1979).  No adverse reproductive effects were found in dogs fed 10 mg/kg/day 2,4-DNT for
24 months (Ellis et al. 1985; U.S. Army 1979).
Hematological effects and neurotoxicity were identified as the most sensitive effects of chronic-duration 
exposure to 2,4-DNT, with NOAEL and LOAEL values of 0.2 and 1.5 mg/kg/day, respectively, in dogs
exposed to 2,4-DNT for 12 months (Ellis et al. 1985; U.S. Army 1979). For derivation of the chronic-
duration oral MRL, hematological effects were selected as the critical effect rather than neurotoxicity,
which was observed only intermittently in one of six dogs exposed to 1.5 mg/kg/day.  Hematological data
are expressed as group means; therefore, these data are considered more robust than observations of
intermittent neurotoxicity in a single animal.  To determine the POD, all available continuous-variable 
models in the EPA BMDS (version 2.1) were fit to the hematological data for erythrocyte count, 
hematocrit, and hemoglobin in female dogs.  Hematological data from male dogs were not considered for
additional BMD analyses due to the low number of dogs evaluated in the 10 mg/kg/day group (data were
available for only two dogs).  The BMD and the 95% lower confidence limit (BMDL) were estimated for
doses associated with a change of 1 standard deviation from the controls.  A detailed description of BMD
modeling is provided in Appendix A.  Neither the constant nor the non-constant variance model provided 
an adequate fit to the data for hemoglobin; therefore, these data were not considered suitable for BMD
modeling.  Models provided an adequate fit to data for erythrocyte count and hematocrit.  Among all of
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the models providing adequate fit to the data for these parameters, the lowest BMDL1SD values were 
0.12 mg/kg/day for decreased hematocrit (exponential model 4) and 0.13 mg/kg/day for decreased
hemoglobin (exponential model 4); of these, the lowest BMDL1SD of 0.12 mg/kg/day for decreased 
erythrocyte count was selected as the POD.  This value was divided by an uncertainty factor of
100 (10 for animals to human extrapolation and 10 for human variability), resulting in a chronic-duration
oral MRL of 0.001 mg/kg/day.
Acute-Duration Oral MRL for 2,5-DNT
•	 An MRL of 0.007 mg/kg/day has been derived for acute-duration oral exposure (≤14 days) to 

2,5-DNT.
 
No human acute-duration oral toxicity studies on 2,5-DNT were identified.  For 2,5-DNT, the only 
available oral exposure studies are a 14-day repeated dose gavage study in rats, in which a number of
toxicological end points were assessed (Lent et al. 2012a; USAPHC 2011c), and a single-dose gavage
study, which reported data on lethality only (Vernot et al. 1977).  Vernot et al. (1977) reported oral LD50 
values of 710 and 1,230 mg/kg in rats and mice, respectively.  The 14-day study in rats (Lent et al. 2012a;
USAPHC 2011c) identified effects on survival, the hematopoietic system, and the heart; the
hematopoietic system was the most sensitive.  Groups of six male Sprague-Dawley rats were given
2,5-DNT via gavage doses of 0, 10, 19, 39, 77, 154, or 308 mg/kg/day for 14 days; evaluations included 
morbidity, clinical observations, hematology, serum chemistry, gross necropsy, organ weights, and 
histopathology.  At the highest dose (308 mg/kg/day), one rat died.  Of six rats exposed to 39 mg/kg/day
2,5-DNT, three exhibited mild-to-moderate extramedullary hematopoiesis, and all rats in higher dose 
groups exhibited this lesion; histopathology examinations were not performed in animals of lower dose
groups. Marked increases (≥90%) in absolute and relative spleen weight were observed at doses
≥77 mg/kg/day.  In addition, nonsignificant, but dose-related, increases (≥20%) in absolute and relative 
spleen weight were seen at doses ≥19 mg/kg-day. Results of this study identify an acute-duration 
LOAEL value for hematopoietic system effects (extramedullary hematopoiesis and increased absolute 
and relative spleen weight) of 39 mg/kg/day in rats.  A NOAEL cannot be defined in the absence of
spleen histopathology at lower doses, particularly in light of the spleen weight increases at lower doses.
The hematopoietic effects were identified as the most sensitive effects of acute-duration oral exposure to 
2,5-DNT, based on the LOAEL value of 39 mg/kg/day in rats administered 2,5-DNT via gavage for
14 days (Lent et al. 2012a; USAPHC 2011c).  Data on splenic lesions and absolute and relative spleen 
weights were subjected to BMD modeling to identify a POD for derivation of the acute oral MRL.  
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BMDLs for the best-fitting models were the BMDL10 of 2.05 for incidence of mild-to-moderate 
extramedullary hematopoiesis, the BMDL1SD of 7.78 mg/kg/day for absolute spleen weight, and the
BMDL1SD of 8.26 mg/kg/day for spleen weight relative to body weight.  Neither the homogenous nor
non-constant variance models within the EPA BMDS provided adequate fit to the data on spleen weight
relative to brain weight. The lowest BMDL value (BMDL10 of 2.05 mg/kg/day for extramedullary
hematopoiesis) was selected as the POD for derivation of the acute-duration oral MRL.  The POD of
2.1 mg/kg/day was divided by an uncertainty factor of 300 (10 for extrapolation from animals to humans,
10 for human variability, and 3 for database limitations), resulting in an acute-duration oral MRL for 
2,5-DNT of 0.007 mg/kg/day.
Acute-Duration Oral MRL for 2,6-DNT
•	 An MRL of 0.09 mg/kg/day has been derived for acute-duration oral exposure (≤14 days) to 

2,6-DNT.
 
Information on effects of acute-duration oral exposure of laboratory animals to 2,6-DNT are available
from a single-dose lethality studies in rats (Deng et al. 2011; Lee et al. 1975; U.S. Army 1978a; Vernot et 
al. 1977), a 14-day gavage study in Sprague-Dawley  rats (Lent et al. 2012a; USAPHC 2011d), and from
an intermediate-duration study in dogs that evaluated clinical signs of toxicity, hematology, and clinical
chemistry after 14 days of exposure (U.S. Army 1976).  Results of these studies show that acute exposure
to 2,6-DNT induces hematological effects, neurotoxicity, and hepatotoxicity, with hematological effects
(methemoglobin-induced anemia and compensatory hematopoiesis) as the most sensitive effect. Results 
of acute lethality studies provide very little information on 2,6-DNT-induced toxicity at nonlethal levels. 
When groups of six male rats were given 14 gavage doses of 2,6-DNT (0, 4, 7, 14, 35, 68, or
134 mg/kg/day), reductions in body weight of at least 10% were seen in rats exposed to doses
≥35 mg/kg/day, and statistically significant, dose-related reductions in hemoglobin and hematocrit were
seen at 134 mg/kg/day.  Significant alterations in the leukocyte differential occurred primarily at the
highest dose, including increased neutrophils, increased monocytes, and increased percentages of
neutrophils and lymphocytes.  Gross necropsy showed small testes in all rats receiving 134 mg/kg/day; 
this was accompanied by marked decreases in absolute and relative testes weight at this dose.  At the
highest dose, absolute and relative (to brain weight) epididymides weights were decreased by ~30%, and
absolute and relative (to brain weight) spleen weights were increased by ~50%. Animals treated with
2,6-DNT exhibited microscopic lesions in the testes (at doses ≥68 mg/kg/day), liver (doses 
≥35 mg/kg/day), kidney (at 134 mg/kg/day), and spleen (≥35 mg/kg/day).  A LOAEL of 35 mg/kg/day
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was identified for this study based on liver (hepatocellular hyperplasia, oval cell hyperplasia, and 
hepatocellular hypertrophy) and spleen (lymphoid hyperplasia) lesions.  The NOAEL was 14 mg/kg/day.
Administration of 2,6-DNT to dogs at 20 and 100 mg/kg/day (but not 4 mg/kg/day) for 2 weeks produced 
hematological effects consistent with the development of methemoglobin-induced anemia and 
compensatory hematopoiesis (U.S. Army 1976).  Dogs treated with 20 mg/kg/day showed a statistically
significant decrease in erythrocyte count and a significant increase in mean cell hemoglobin.  At
100 mg/kg/day, more pronounced changes in these hematological parameters were observed; dogs 
showed statistically significant reductions in erythrocyte count, hematocrit, and hemoglobin and a
statistically significant increase in reticulocyte count. In the 4 mg/kg/day group, similar hematological 
effects (decreased erythrocyte count, hemoglobin, and hematocrit, and increased reticulocytes) were 
observed, but these changes did not achieve statistical significance.  No effects on clinical chemistry
parameters were observed at any dose.  Results of this study identify a NOAEL and a LOAEL of 4 and 
20 mg/kg/day, respectively, for hematological effects in dogs treated with 2,6-DNT for 2 weeks. The
LOAEL from this study (20 mg/kg/day; U.S. Army 1976) was lower than the LOAEL from the rat study
(35 mg/kg/day; Lent et al. 2012a, USAPHC 2011d).  Although comprehensive end points were not
evaluated after 2 weeks in the dog study, the identification of hematological effects as the most sensitive 
effect after acute-duration exposure is consistent with the most sensitive effect identified after
intermediate-duration exposure to 2,6-DNT.
In addition to hematological effects, clinical signs of neurotoxicity were observed in dogs administered 
2,6-DNT at 100 mg/kg/day (U.S. Army 1976).  The study authors noted that at least three dogs (gender
not specified) developed neurotoxicity (listlessness, incoordination, lack of balance, and weakness, 
particularly of the hind limbs) and other clinical signs of toxicity (pale gums, dark urine) within the first 
2 weeks of the exposure (incidence data were not reported).  At this dose, one male dog died during the
second week of exposure.  No clinical signs of toxicity were observed at doses up to 20 mg/kg/day during
the first 14 days of exposure, although similar (but milder) symptoms were reported at this dose following
4 weeks of treatment.
Hepatotoxicity, including increased alanine aminotransferase (ALT) activity and histopathological 
changes to the liver (congested sinusoids with sloughed hepatocytes and segmented neutrophils, 
disorganized midzonal regions characterized by infiltration of erythrocytes and hepatocytes with pyknotic
nuclei and microvesiculated cytoplasm, and apoptotic hepatocytes) were reported in rats administered 
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doses of 2,6-DNT (Deng et al. 2011).  Results of this study identify acute-duration NOAEL and LOAEL
values for hepatotoxicity for 2,6-DNT of 25 and 50 mg/kg/day, respectively.
Based on the available data, toxicity to the hematological system (anemia and compensatory
hematopoiesis) was identified as the most sensitive effect of acute-duration oral exposure to 2,6-DNT.  In
dogs exposed for 14 days, a statistically significant decrease in erythrocyte count and a statistically
significant increase in mean cell hemoglobin were observed after treatment with 2,6-DNT at
20 mg/kg/day for 2 weeks (U.S. Army 1976).  Changes to other hematological parameters only reached 
statistical significance at 100 mg/kg/day.  Therefore, the most sensitive hematological parameters were 
erythrocyte count and mean cell hemoglobin.  To determine the POD for derivation of the acute-duration 
oral MRL for 2,6-DNT, all available continuous-variable models in the EPA BMDS (version 2.1) were fit
to the data for erythrocyte count and mean cell hemoglobin.  The BMD and the 95% lower confidence
limit (BMDL) were estimated for doses associated with a change of 1 standard deviation from the 
controls.  A detailed description of BMD modeling is provided in Appendix A.  Neither the constant nor
the non-constant variance model provided an adequate fit to the data for mean cell hemoglobin; therefore, 
these data were not considered suitable for BMD modeling.  With the nonconstant variance model
applied, the linear, polynomial, and power models provided an adequate fit to the data for erythrocyte
count. The polynomial and power models converged to the linear model.  The BMDL1SD value of
9.31 mg/kg/day derived from this model was selected as the POD. This value was divided by an
uncertainty factor of 100 (10 for animals to human extrapolation and 10 for human variability), resulting 
in an acute-duration oral MRL of 0.09 mg/kg/day. 
Intermediate-Duration Oral MRL for 2,6-DNT
•	 An MRL of 0.004 mg/kg/day has been derived for intermediate-duration oral exposure (15–
 
364 days) to 2,6-DNT.
 
Information on effects of intermediate-duration oral exposure of laboratory animals is available from a 
13-week study in beagle dogs, CD rats, and CD-1 mice (U.S. Army 1976).  Results of this study show
that 2,6-DNT produces hematological, neurological, reproductive, and hepatic toxicity, with 
histopathological changes of the spleen (extramedullary erythropoiesis) that are likely secondary to
methemoglobinemia and anemia.
Intermediate-duration oral exposure of beagle dogs to 2,6-DNT at 4 mg/kg/day (lowest tested dose)
produced extramedullary erythropoiesis (formation of erythrocytes outside of the bone marrow) in the
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spleen secondary to methemoglobinemia and anemia (U.S. Army 1976).  The incidence and severity of
this lesion was dose-related.  Changes in hematological parameters associated with anemia and
compensatory hematopoiesis, including decreased hematocrit and hemoglobin and increased numbers of
reticulocytes, were observed at 20 and 100 mg/kg/day.  However, mortality also occurred in dogs exposed
to these doses.  Results of this study identify a LOAEL of 4 mg/kg/day for extramedullary hematopoiesis
secondary to hematological effects in dogs treated with 2,6-DNT for 13 weeks (U.S. Army 1976).  In 
rodents exposed for 13 weeks, the lowest LOAELs for hematological effects (extramedullary
erythropoiesis) were 7 mg/kg/day for rats and 51 mg/kg/day for mice (U.S. Army 1976).
Hepatic, neurological, and reproductive effects were also observed following a 13-week exposure of dogs, 
rats, and mice to 2,6-DNT (U.S. Army 1976); however, these effects occurred at doses higher than those
producing extramedullary erythropoiesis (4 mg/kg/day) in dogs.  Note that in dogs, lethality also occurred 
at doses of 20 and 100 mg/kg/day.  The lowest NOAEL and LOAEL values for hepatic effects (bile duct
hyperplasia and degeneration and inflammatory changes to the liver) were 4 and 20 mg/kg/day, 
respectively, in dogs treated with 2,6-DNT for 13 weeks (U.S. Army 1976).  Bile duct hyperplasia was
observed at higher doses in rats (35 mg/kg/day) and mice (51 mg/kg/day) fed 2,6-DNT for 13 weeks (U.S. 
Army 1976).  Neurotoxic effects (listlessness, incoordination, and lack of balance) were observed in dogs
treated with 20 and 100 mg/kg/day.  No signs of neurotoxicity were observed in rats at doses up to
145 and 155 mg/kg/day (for males and females, respectively) or in mice at doses up to 289 and 
299 mg/kg/day (for males or females, respectively) for 13 weeks (U.S. Army 1976).  For reproductive
effects following 13-week exposure to 2,6-DNT, the lowest NOAEL and LOAEL values of 4 and
20 mg/kg/day, respectively, were reported in dogs for testicular degeneration (U.S. Army 1976).  NOAEL
and LOAEL values for reproductive effects were 11 and 51 mg//kg/day, respectively, in male mice for
decreased spermatogenesis and 7 and 35 mg/kg/day, respectively, in male mice for testicular atrophy
(U.S. Army 1976).
The LOAEL value of 4 mg/kg/day for an increased incidence of extramedullary erythropoiesis in the
spleens of dogs was identified as the POD for derivation of the intermediate-duration oral MRL for
2,6-DNT (U.S. Army 1976).  Histopathology data were not suitable for BMD modeling, since the number
of animals evaluated at each dose and time was small (n=2 animals). Therefore, the LOAEL value for
4 mg/kg/day was used as the POD.  This value was divided by an uncertainty factor of 1,000 (10 for use of
a LOAEL, 10 for extrapolation from animals to humans, and 10 for human variability), resulting in an 
intermediate-duration oral MRL for 2,6-DNT of 0.004 mg/kg/day.
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Chronic-Duration Oral MRL for 2,6-DNT
The only chronic exposure study identified for 2,6-DNT is a 1-year study in F344 rats (Leonard et al. 
1987).  In this study, oral exposure to 7 and 14 mg/kg/day 2,6-DNT produced hepatocellular carcinoma, 
cellular alterations to hepatocytes (vacuolization accompanied by acidophilic and basophilic foci), and
increased liver weights and serum hepatic enzyme activity.  Hepatocellular carcinoma was observed in
85 and 100% of rats treated with 7 and 14 mg/kg/day, respectively.  No other effects of 2,6-DNT were
reported in this study.  Data from this study are not appropriate for derivation of a chronic-duration oral
MRL for 2,6-DNT, as no noncancer effects were reported.
Acute-Duration Oral MRL for 3,4-DNT
•	 An MRL of 0.03 mg/kg/day has been derived for acute-duration oral exposure (≤14 days) to 

3,4-DNT.
 
No human acute-duration oral toxicity studies on 3,4-DNT were identified.  For 3,4-DNT, the only 
available oral exposure study is a 14-day gavage study in rats in which a number of toxicological end
points were assessed (Lent et al. 2012a; USAPHC 2011e). Lent et al. (2012a; USAPHC 2011e) identified
effects on body weight, the hematopoietic system, the kidneys, and the neurological system; the 
hematopoietic system was affected at lower doses than the other target systems.  Groups of six male 
Sprague-Dawley rats were given 3,4-DNT via gavage doses of 0, 7, 14, 28, 57, 113, or 227 mg/kg/day for
14 days; evaluations included morbidity, clinical observations, hematology, serum chemistry, gross
necropsy, organ weights, and histopathology.  All rats survived.  Clinical signs in the highest dose 
animals included cyanosis, lethargy, facial twitching, and hypoactivity or staring behavior.  A 10%
reduction in body weight was seen at the highest dose (227 mg/kg/day); at this dose, trace-to-mild renal
lesions (proximal tubular degeneration, tubular basophilia, and lymphocytic infiltration) were seen, as
were mild fibrosis, inflammation, and necrosis in the heart of one rat. Splenic lesions, including trace-to­
mild extramedullary hematopoiesis and lymphoid hyperplasia, were observed at doses ≥57 mg/kg/day.  
Spleens were not examined in lower dose groups.  Results of this study identify an acute-duration 
LOAEL value for hematopoietic system effects of 57 mg/kg/day in rats.  A NOAEL for hematopoietic
system effects cannot be determined in the absence of histopathology examinations in lower dose groups.
Hematopoietic system toxicity was identified as the most sensitive effect of acute-duration oral exposure
to 3,4-DNT, based on the LOAEL value of 57 mg/kg/day in rats administered 3,4-DNT via gavage for
14 days (Lent et al. 2012a; USAPHC 2011e).  Incidences of trace-to-mild extramedullary hematopoiesis 
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and lymphoid hyperplasia were subjected to BMD modeling.  The best-fitting model for both end points
yielded the same BMDL10 of 8.05 mg/kg/day; this value was selected as the POD.  The POD of
8.05 mg/kg/day was divided by an uncertainty factor of 300 (10 for extrapolation from animals to
humans, 10 for human variability, and 3 for database limitations), resulting in an acute-duration oral MRL
for 3,4-DNT of 0.03 mg/kg/day.
Acute-Duration Oral MRL for 3,5-DNT
•	 An MRL of 0.03 mg/kg/day has been derived for acute-duration oral exposure (≤14 days) to 

3,5-DNT.
 
No human acute-duration oral toxicity studies on 3,5-DNT were identified.  For 3,5-DNT, the only 
available oral exposure study is a 14-day gavage study in rats, in which a number of toxicological end
points were assessed (Lent et al. 2012a; USAPHC 2011f). Lent et al. (2012a; USAPHC 2011f) identified
effects on survival, the reproductive tissues, and neurological system; effects on the reproductive tissues
were the most sensitive.  Groups of six male Sprague-Dawley rats were given 3,5-DNT via gavage doses 
of 0, 5, 10, 19, 39, 77, and 155 mg/kg/day for 14 days; evaluations included morbidity, clinical
observations, hematology, serum chemistry, gross necropsy, organ weights, and histopathology.  At doses
≥77 mg/kg/day, all rats died; in addition, one rat exposed to 39 mg/kg/day died.  Animals exposed to 
39 mg/kg/day exhibited neurological signs progressing from facial twitching to paralysis of the lower
forelimbs.  Rats exposed to ≥19 mg/kg/day 3,5-DNT exhibited testicular lesions including mild-to-severe 
tubular degeneration and trace-to-severe multinucleated giant cell formation.  Results of this study
identify acute-duration NOAEL and LOAEL values for testicular lesions of 10 and 19 mg/kg/day, 
respectively, in rats. 
Testicular toxicity was identified as the most sensitive effect of acute-duration oral exposure to 3,5-DNT,
based on the LOAEL value of 19 mg/kg/day in rats administered 3,5-DNT via gavage for 14 days (Lent et
al. 2012a; USAPHC 2011f).  The NOAEL value of 10 mg/kg/day was used as the POD.  Available data 
were not suitable for BMD modeling, as the incidences of testicular lesions increased from 0/6 in the
control group to 6/6 at the LOAEL.  The POD of 10 mg/kg/day was divided by an uncertainty factor of
300 (10 for extrapolation from animals to humans, 10 for human variability, and 3 for database
limitations), resulting in an acute-duration oral MRL for 3,5-DNT of 0.03 mg/kg/day. 
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3.1  INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of 2,3-, 2,4-, 2,5-, 
2,6-, 3,4-, and 3,5-DNT.  It contains descriptions and evaluations of toxicological studies and 
epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and 
toxicokinetic data to public health.
3.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure 
periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.  
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not
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the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
The primary focus of this document is information on 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, and 3,5-DNT.  However,
some information on technical-grade DNT (Tg-DNT) is also provided.  Tg-DNT contains approximately
76% 2,4-DNT, 19% 2,6-DNT, and <5% 3,4-, 2,3-, and 2,5-DNT.  For each route of exposure (inhalation, 
oral, and dermal), human data will be discussed first. Available data for individual isomers (2,3-, 2,4-, 
2,5-, 2,6-, 3,4-, and 3,5-DNT, in that order) will be presented followed by data for Tg-DNT.  Studies
conducted in experimental animals will be discussed thereafter, with data on the individual isomers
preceding data for Tg-DNT.
3.2.1 Inhalation Exposure 
Most of the data on health effects associated with exposure of humans to DNTs are from studies of
workers exposed to 2,4-, 2,6-, or Tg-DNT.  Exposure monitoring of workers in the past has generally
been inadequate; consequently, few dose-response data based on human exposure to DNT isomers are
available.  No data were identified regarding inhalation exposure of humans to 2,3-, 2,5-, 3,4-, or
3,5-DNT.  Regarding available animal data, one study was located that examined the acute inhalation
toxicity of 2,6-DNT in experimental animals.  No studies were located regarding inhalation exposure to 
2,3-, 2,5-, 3,4-, or 3,5-DNT in experimental animals.
Human exposure to chemicals in an occupational setting can occur via multiple routes:  inhalation,
dermal, and inadvertent ingestion (Hamill et al. 1982).  Although the low vapor pressure of DNTs makes 
inhalation of vapors unlikely, it can occur when contaminated particulate material is in the air.  In 
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addition, some dermal exposure is probable, and some ingestion may also occur as the result of eating or
smoking without prior handwashing.
3.2.1.1  Death 
In a retrospective cohort mortality study of 457 munitions workers who were exposed to either 2,4-DNT
or Tg-DNT at two geographically different U.S. manufacturing plants, significant increases in death rates
due to ischemic heart disease and residual diseases of the circulatory system were found (standardized
mortality ratios [SMRs] of 126 and 143; 95% confidence intervals [CIs] of 65–234 and 112–179, 
respectively) (Levine et al. 1986a).  Residual diseases of the circulatory system include congestive heart
failure, cardiac arrest, and arteriosclerosis.  The workers had been exposed to unreported concentrations
of either 2,4-DNT (98% pure) or Tg-DNT for periods ranging from 30 days to >5 years (Levine et al.
1986a).  Cigarette smoking was not taken into account in this study, but the study authors suggested that
it may not have been a risk factor because mortality from lung cancer was less than expected.  Among
workers at both plants, there appeared to be a latency period of >15 years for a significant increase in
mortality due to ischemic heart disease. There also appeared to be a relationship between heart disease 
and the intensity of exposure to DNTs.  No statistical increase was found in death due to cancer, either
from malignant neoplasms as a whole or from individual cancers, although the statistical power of the 
study was insufficient to detect anything but gross changes in the death rate due to cancer.
The Levine et al. (1986a) retrospective cohort mortality study was limited by small cohort size, and thus, 
the study had diminished power to detect an effect.  As a result, the finding of elevated mortality from
heart disease among workers in two plants from different parts of the United States linked only by
exposure to DNTs is unusual. Workers in the United States generally have lower rates of heart disease 
than the general population because of the "healthy worker effect." At both plants, mortality from
ischemic heart disease during the first 15 years following cohort entry was less than expected, and 
mortality increased only in later years.  Suggestive, but not significant, is evidence of a relationship
between heart disease and duration and intensity of exposure, also reported by Levine et al. (1986a).  No 
studies were identified with respect to mortality after inhalation exposure of humans to 2,3-, 2,5-, 2,6-, or
3,5-DNT.
In an acute-duration study, no mortality was observed in male or female F344 rats (5/sex/group) exposed 
nose-only to 2,6-DNT as a vapor at 26 mg/m3 for 6 hours and observed 14 days after dosing (CMA 1991).  
In the same study, groups of male and female rats exposed to 2,6-DNT at 0, 196, 473, or 694 mg/m3 as an
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aerosol exhibited mortality at ≥196 mg/m3. Two of five males (and no females) died at 196 mg/m3; all 
males and three of five females died at 694 mg/m3. Rats that died showed evidence of lung congestion 
and had increased relative lung weights compared to controls.  An LC50 of 0.43 mg/L was identified in
rats, with LC50 values for males and females of 0.24 and 0.66 mg/L, respectively.  
No studies were located regarding death in animals after inhalation exposure to 2,3-, 2,4-, 2,5-, 3,4-, or
3,5-DNT.
3.2.1.2  Systemic Effects
No studies were located regarding dermal, ocular, endocrine, or body weight effects in humans or animals 
after inhalation exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.  No studies were located regarding
respiratory effects in humans after inhalation exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT or in
animals after inhalation exposure to 2,3-, 2,4-, 2,5-, 3,4-, or 3,5-DNT.
Respiratory Effects. No studies were identified with respect to respiratory effects after inhalation
exposure of humans to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
In an acute-duration study, groups of male and female rats were exposed to 2,6-DNT at 0, 196, 473, or
694 mg/m3 as an aerosol for 6 hours and observed 14 days after dosing (CMA 1991).  Rats exposed to 
2,6-DNT as an aerosol at ≥196 mg/m3 exhibited signs of respiratory distress (exaggerated respiratory
movements) for several days following exposure; recovery from this effect occurred by day 5 of the
observation period.  Rats that died showed evidence of lung congestion and had increased relative lung
weights compared to controls.
No studies were identified with respect to respiratory effects after inhalation exposure of animals to 2,3-, 
2,4-, 2,5-, 3,4-, or 3,5-DNT.
Cardiovascular Effects. No studies were identified with respect to cardiovascular effects after
inhalation exposure of humans to 2,3-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Levine et al. (1986a) reported a significant increase in deaths from diseases of the circulatory system in 
workers involved in the manufacture and processing of 2,4-DNT and/or Tg-DNT. The preponderance of
circulatory disease deaths was due to ischemic heart disease.  The SMR was significantly elevated for
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ischemic heart disease when compared to the U.S. male population and to persons living in the area.
When workers were divided by exposure duration, the significant increase in cardiovascular deaths was 
only observed in workers exposed for at least 5 months. Although the study did not control for cigarette
smoking, a known risk factor for heart disease, the investigators noted that the study did not find 
significant increases in lung cancer or disease deaths.
No studies were located regarding cardiovascular effects in animals after inhalation exposure to 2,3-, 2,4-, 
2,5-, 2,6-, 3,4-, or 3,5-DNT.
Gastrointestinal Effects. Vomiting and nausea were mentioned as health complaints in a survey of
male workers involved in the production of smokeless gunpowders during World War II (McGee et al.
1947).  The exposure concentrations of 2,4-DNT were not specified. The investigators noted that prior to
improving industrial hygiene practices, a much higher incidence of gastrointestinal symptoms was found.  
Since exposure to other compounds cannot be ruled out, attribution of these symptoms to DNT cannot be
verified.
No studies were identified with respect to gastrointestinal effects after inhalation exposure of humans to 
2,3-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.  No studies were located regarding gastrointestinal effects in animals 
after inhalation exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Hematological Effects. Several hematological effects, including anemia and cyanosis, were found in
male workers employed by a munitions factory during World War II (McGee et al. 1947).  In some cases,
there were increases in leukocyte count, which may be related to prolonged exposure to DNT.  The study
authors presumed that the exposure concentrations to 2,4-DNT were relatively high because of the 
relatively primitive industrial hygiene practices at that time.  Although 36 of 154 workers were anemic in
the earlier study and 73 of 714 workers were anemic in the follow-up study, no control groups were used 
as a basis for comparison. Because of possible exposure to other compounds, lack of work histories, lack
of exposure monitoring, lack of a control population, and small cohort size, the results obtained are
equivocal and may be best used as qualitative descriptions of symptoms.  Marked cyanosis and other
incapacitating symptoms were reported after exposure to unspecified concentrations of Tg-DNT in a
study of French workers in a DNT production plant during World War I (Perkins 1919).  It is assumed 
that workers were exposed to high concentrations of Tg-DNT via both inhalation and dermal pathways, 
since the processes described involved direct handling of large amounts of Tg-DNT without protective
equipment.
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No studies were identified with respect to hematological effects after inhalation exposure of humans to 
2,3-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
In an acute-duration study, male and female F344 rats (5/sex/group) were exposed to 2,6-DNT as a vapor
at 0 or 26 mg/m3 or as an aerosol at 0, 196, 473, or 694 mg/m3 for 6 hours and observed 14 days after
dosing (CMA 1991).  Blood was analyzed for serum methemoglobin concentration 24 hours prior to 
dosing and 1, 24, and 48 hours and 7 days after dosing.  Although the study authors noted slight increases
in serum methemoglobin in 2,6-DNT-exposed animals in the first 24 hours after exposure, these changes 
were not clearly dose-related and were not statistically significantly different from control animals.  No
other hematological end points were evaluated.
No studies were located regarding hematological effects in animals after inhalation exposure to 2,3-, 2,4-, 
2,5-, 3,4-, or 3,5-DNT.
Musculoskeletal Effects. Joint pain, especially in the knees, and other incapacitating symptoms
were found in unspecified numbers of French workers in a plant that produced DNTs during World War I 
(Perkins 1919).  No exposure concentrations were reported, but it is assumed that they were high because 
of the direct handling of large amounts of Tg-DNT without protective equipment, which also suggests
that the workers were exposed dermally.  However, because exposure to other compounds cannot be ruled 
out and no control data are available, caution must be used when interpreting these results.
No studies were located regarding musculoskeletal effects humans after inhalation exposure to 2,3-, 2,5-, 
2,6-, 3,4-, or 3,5-DNT or in animals after inhalation exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Hepatic Effects. A study of 714 workers at a munitions plant found that 29 experienced liver
tenderness (McGee et al. 1947).  Other factors, such as alcohol consumption, may account for these
results which should be viewed with caution because of the lack of control data, lack of information on 
exposure concentrations, and possible multiple chemical exposure. Medical surveys of 52 male workers 
exposed to Tg-DNT in a chemical plant that manufactured toluenediamine (TDA) revealed no differences 
in hepatic blood chemistry profiles (NIOSH 1982).  Air samples contained concentrations ranging from
0.026 to 0.890 mg/m3 Tg-DNT (mean 0.207 mg/m3).
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No studies were located regarding hepatic effects in humans after inhalation exposure to 2,3-, 2,5-, 2,6-, 
3,4-, or 3,5-DNT, or in animals after inhalation exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Renal Effects. No effects were observed on either of the renal parameters (blood urea nitrogen 
[BUN], creatinine) monitored in blood chemistry in a medical survey of 52 male workers exposed to
Tg-DNT in a chemical plant that manufactured TDA (NIOSH 1982).  Exposure concentrations in air
samples taken for this study ranged from 0.026 to 0.890 mg/m3 Tg-DNT (mean 0.207 mg/m3).  The study
was limited by a small exposure population and lack of historical individual exposure monitoring.
Evidence of tubular and/or glomerular damage (alterations in urinary protein excretion patterns) was
found among a cohort of approximately 160 workers at a copper mine exposed to Tg-DNT explosives 
(Brüning et al. 2001).  Dividing the workers into exposure categories resulted in a significant dose-related
trend for the incidence of tubular and/or glomerular damage among the workers without renal cell cancer
or urothelial cancer.  Approximately 80% of the 25 workers in the very high exposure category had 
evidence of renal damage. Dose-related increases in the excretion of α1-microglobulins and glutathione­
S-transferase-α were also observed suggesting proximal tubule damage.  The lack of effect on 
glutathione-S-transferase-π levels suggested a lack of damage to the distal tubules.
No studies were located regarding renal effects in humans or animals after inhalation exposure to 2,3-, 
2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
3.2.1.3  Immunological and Lymphoreticular Effects 
No studies were located regarding immunological or lymphoreticular effects in humans or animals after
inhalation exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
3.2.1.4  Neurological Effects 
Dizziness and headache were reported by Perkins (1919) in a study of French workers exposed to 
Tg-DNT at a production plant during World War I.  Although no exposure concentrations were reported, 
it is assumed that the workers were exposed to high concentrations of Tg-DNT via both inhalation and 
dermal pathways, since the manufacturing processes required workers to handle large amounts of
Tg-DNT without protective equipment.  Exposure to chemicals other than DNT in this environment could 
not be ruled out.  Health effects of munitions workers exposed to unspecified levels of what was
presumed to be 2,4-DNT were studied by McGee et al. (1947).  Neurological signs reported by these 
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workers included headache, dizziness, and pain, numbness, and tingling in the extremities.  The 2,4-DNT
exposure concentrations were not specified, but were considered by these authors to be relatively high as
a result of the lack of safety practices.
No studies were located regarding neurological effects in humans after inhalation exposure to 2,3-, 2,5-, 
2,6-, or 3,5-DNT or in animals after inhalation exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
3.2.1.5  Reproductive Effects
Studies of men occupationally exposed to Tg-DNT at DNT and TDA plants showed no significant
differences in sperm counts or morphology, follicle stimulating hormone (FSH) levels, or incidence of
miscarriage in their wives compared to controls (Hamill et al. 1982; NIOSH 1982).  In the NIOSH (1982)
study, Tg-DNT concentrations ranged from 0.026 to 0.890 mg/m3 (mean 0.207 mg/m3).  Interpretation of
these studies is somewhat confounded by the lack of distinction between DNT and TDA exposure and the 
lack of information regarding exposure concentration in the Hamill et al. (1982) study.  The limitations of
these studies are similar (small exposure populations and the lack of individual exposure monitoring) and 
limit the ability of the studies to detect adverse effects.
No significant effects on the fertility of workers occupationally exposed to Tg-DNT have been found in 
several studies (Hamill et al. 1982; Levine et al. 1985a; NIOSH 1982).  However, Levine et al. (1985a)
estimate that only a 50–70% reduction in fertility could have been detected in the worker population that
they studied.
One study by the CDC (1981) noted that sperm counts were decreased by >50% in workers in a Kentucky
chemical plant exposed to DNTs and TDA compared to workers not exposed to these chemicals.  The 
study was limited because of multiple chemical exposures and the small numbers of workers examined.
Thirty workers participated in the study:  9 currently exposed, 12 previously exposed, and 9 with no 
history of exposure to DNTs/TDA.
No studies were located regarding reproductive effects in humans or animals after inhalation exposure to 
2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
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3.2.1.6  Developmental Effects 
No studies were located regarding developmental effects in humans or animals after inhalation exposure
to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
3.2.1.7  Cancer
The mortality of a cohort of 4,989 men who worked at least 5 months in a munitions facility was analyzed 
to determine whether DNT exposure was associated with an increased risk of cancer of the liver and
biliary tract (Stayner et al. 1993). Workers were considered exposed if they had worked at least 1 day on 
a job with probable exposure to DNT.  In this study, a significant increase in hepatobiliary cancer
mortality (standard rate ratio [SRR]=3.88, 95% CI 1.04–14.41) was observed among DNT-exposed 
workers compared to non-exposed control workers.  However, no significant changes were noted when
compared to the U.S. population, the SRR for hepatobiliary cancer being 2.67 (95% CI 0.98–5.83;
p=0.052).  No quantitative data were available on the DNT exposure of these men.  This study is limited 
by the small numbers of hepatobiliary cancer cases, small numbers of workers with long term exposure to 
DNT, and possible exposure of the workers to other chemicals.  However, no significant increases in 
mortality from malignant neoplasms as a group or from particular cancers (liver, lung, gallbladder,
kidney, and connective tissues) were observed in workers occupationally exposed to 2,4-DNT and/or
Tg-DNT (Levine et al. 1986b).  Exposures were not quantified and the cohort was small.  The study
authors estimated that an 8-fold increase in liver and gallbladder cancer in exposed workers would be
necessary in order to be detected at the p=0.05 level; thus, the statistical analysis was not strong enough to
detect small increases in cancer.
Among 500 workers in an underground copper mine where Tg-DNT-containing explosives were 
extensively used, increases, as compared to the German national cancer registry, in the incidence of renal
cell cancer and urothelial cancer incidence were observed (Brüning et al. 1999).  However, when the
workers were divided by exposure categories, no apparent relationship between renal cell cancer
incidence and exposure category was found.  In contrast, four of the six workers with urothelial cancer
cases were in the high exposure group (one was in the lowest group and the other was in the highest
exposure group).  The genotype distribution of several polymorphic xenobiotic enzymes, including
N-acetyltransferase 2 and glutathione-S-transferases M1 (GSTM1) and T1 (GSTT1), was examined in the
14 workers with renal cell cancer and 6 workers with urothelial cancer.  The genotype distribution among
the renal cell cancer cases did not differ from the normal German population.  Similarly, the distribution 
of GSTM1 and GSTT1 genotypes for the urothelial cancer cases was similar to the German population.  
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However, all of the urothelial cancer cases were found to be “slow acetylators” compared to a 58%
distribution in the German population.
Harth et al. (2005) reported three cases of urothelial carcinoma of the urinary bladder among 60 workers
exposed to Tg-DNT at a German explosive manufacturing facility.  The investigators noted that this
cancer rate was 15.9 times higher than the expected incidence in the federal state.
Seidler et al. (2014a) examined the cancer incidence through 2005 in a cohort of 16,441 male copper
miners who worked between 1953 and 1990 in one of two German mines that used Tg-DNT explosives.  
The mean duration of employment was 6.8 years.  Compared with the cancer incidence in the general
population of the region in Germany where the mines were located (Saxony-Anhalt), the cancer
incidences in the miners were not significantly increased for any cancer other than lung cancer
(standardized incidence ratio [SIR] = 1.29, 95% CI 1.13–1.46).  Moderate, but not statistically significant,
increases in the incidences of kidney and bladder cancer (SIRs of 1.25 and 1.41 for kidney and bladder
cancer, respectively, among workers with >20 years of employment with exposure to Tg-DNT) were seen
when the data were stratified by duration of employment with Tg-DNT exposure.  A follow-up case-
cohort study of this group, with follow-up through 2006, compared the Tg-DNT exposure history (by job 
exposure matrix) of 109 renal cancer cases with that of 999 randomly chosen cohort members (Seidler et
al. 2014b). The Cox proportional hazard ratio (HR) was elevated, but not significantly, for high 
inhalation exposure to Tg-DNT (HR 1.36, 95% CI 0.84–2.21).  When combined across medium and high 
exposure categories for both dermal and inhalation exposure, the HR for renal cancer was significantly
increased (HR 2.12, 95% CI 1.03–4.37).  
No studies were located regarding cancer in humans following inhalation exposure to 2,3-, 2,5-, 3,4-, or
3,5-DNT or in animals following inhalation exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
3.2.2 Oral Exposure
No studies were located regarding health effects in humans following oral exposure to 2,3-, 2,4-, 2,5-, 
2,6-, 3,4-, or 3,5-DNT.  However, it is assumed that oral ingestion could be a secondary route for
occupationally exposed humans.
In one series of studies performed at the U.S. Army Public Health Command (Lent et al. 2012a;
USAPHC 2011a, 2011b, 2011c, 2011d, 2011e, 2011f), groups of male Sprague-Dawley rats were
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administered one of the DNT isomers (2,3-DNT, 2,4-DNT, 2,5-DNT, 2,6-DNT, 3,4-DNT, or 3,5-DNT)
by gavage in corn oil vehicle for 14 days at doses ranging from 1/128th or 1/64th of the reported LD50 
value to 1/4 or 1/2 LD50. The observed isomer-specific differences in hematological, hepatic, renal,
neurological, and reproductive effects are discussed at the end of each corresponding subsection of
Section 3.2.2.
3.2.2.1  Death 
No studies were located regarding death in humans after oral exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or
3,5-DNT.
2,4-DNT is lethal to experimental animals after oral administration.  Animals generally developed
cyanosis and ataxia after dosing.  In general, rats are more sensitive than mice to the lethal effects of
2,4-DNT.  The LD50 values that have been determined for rats after gavage dosing with 2,4-DNT range
from 270 to 650 mg/kg (U.S. Army 1975, 1978a; Vernot et al. 1977); in mice, LD50 values were reported
to be between 1,340 and 1,954 mg/kg after 2,4-DNT administration (U.S. Army 1975, 1978a; Vernot et
al. 1977).  In female Sprague-Dawley rats (5/group) administered a single dose of 2,4-DNT (in 5% v/v 
DMSO in corn oil) via gavage at 398 mg/kg and observed for 24 or 48 hours after dosing, two of five
animals and one of five animals died within 24 and 48 hours, respectively (Deng et al. 2011).  No deaths 
occurred in rats administered 2,4-DNT at 5, 50, 99, or 198 mg/kg.  In a dominant lethal study by Lane et
al. (1985), 8 of 15 male Sprague-Dawley rats died after receiving five daily doses of 240 mg/kg 2,4-DNT.
No deaths were reported when male and female Sprague-Dawley rats were fed 78 or 82 mg/kg/day 
2,4-DNT, respectively, in the diet for 14 days (McGown et al. 1983). When male Sprague-Dawley rats 
were given gavage doses of 284 mg/kg/day for 14 days, all six exposed rats died (Lent et al. 2012a;
USAPHC 2011b).
Death has been reported after intermediate- and chronic-duration exposure to 2,4-DNT in numerous
studies.  One of eight male and eight of eight female CD rats died after 3–13 weeks of ingesting 2,4-DNT
in the diet (Lee et al. 1985; U.S. Army 1978b).  Concentrations in the feed causing these deaths were 
equivalent to doses of 93 and 145 mg/kg/day in males and females, respectively.  Death has also been
reported in rodents fed concentrations equivalent to doses of 371–413 mg/kg 2,4-DNT in the diet for up 
to 6 months (Hong et al. 1985; Kozuka et al. 1979; U.S. Army 1978b).  No treatment-related deaths were 
reported in rats fed up to 16.5 mg/kg/day 2,4-DNT or mice fed up to 28.5 mg/kg/day 2,4-DNT for
4 weeks, or in rats fed up to 22 mg/kg/day 2,4-DNT or mice fed up to 76 mg/kg/day 2,4-DNT for
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78 weeks (NCI 1978).  In a 3-generation reproductive study, there appeared to be an increased incidence
of death among F0 dams during parturition after receiving 45.3 mg/kg/day 2,4-DNT in the diet for
6 months (U.S. Army 1979).  These deaths were associated with prolonged parturition, hemorrhage, and 
placental retention.  However, because these effects were also seen to a lesser extent in control animals, it
may be that the effects of 2,4-DNT simply enhanced effects caused by the advancing age of the dams 
(U.S. Army 1979).
In a 13-week study, some dogs fed 25 mg/kg/day became moribund after ≥22 days and had to be
terminated, whereas no treatment-related deaths were reported in dogs fed 5 mg/kg/day (Ellis et al. 1985;
U.S. Army 1978b).  In addition to severe weight loss, severe neurological effects and histopathological
changes were found in these animals, including vacuolization and focal gliosis in the cerebellum and 
perivascular hemorrhages in the cerebellum and brain stem, as well as peripheral neuropathy, testicular
degeneration, and biliary hyperplasia.  In a 24-month study of dogs, the administration of 10 mg/kg/day 
2,4-DNT by capsule caused death within 6 months, but no deaths were reported at 1.5 mg/kg/day; clinical 
signs prior to death were similar to those reported in the 13-week study (Ellis et al. 1985; U.S. Army
1979).  Decreased longevity was reported in 1–2-year studies of CD rats at average daily intakes as low as 
3.9 mg/kg/day (males) and 5.1 mg/kg/day (females), and of CD-1 mice at 898 mg/kg/day (Hong et al. 
1985; Lee et al. 1985; U.S. Army 1978b, 1979).
The experimental data are more limited for 2,6-DNT than for 2,4-DNT.  After administration of 2,6-DNT,
LD50 values have been reported to range from 180 to 795 mg/kg in rats and from 621 to 807 mg/kg in
mice (U.S. Army 1975, 1978a; Vernot et al. 1977).  Complete lethality was reported in female Sprague-
Dawley rats (5/group) administered a single dose of 2,6-DNT via gavage (in 5% v/v DMSO in corn oil) at
398 mg/kg (Deng et al. 2011).  No deaths occurred in animals administered 5–199 mg/kg and observed 
for 2 days after dosing.  Mortality was reported in a dose-range finding study of male rats given oral doses
of 200 mg/kg/day 2,6-DNT in corn oil for 3 days; no rats died at 100 mg/kg/day (Rothfuss et al. 2010).  
The maximum tolerated dose (MTD) of 2,6-DNT corresponding to 100% survival of A/J mice after
6 doses over a 2-week period was 250 mg/kg (Schut et al. 1983). No male Sprague-Dawley rats died
when groups of six rats were given 14 consecutive daily gavage doses up to 134 mg/kg/day 2,6-DNT
(Lent et al. 2012a; USAPHC 2011d).
All six male rats exposed to oral doses of 33 mg/kg/day 2,6-DNT in corn oil for 29 consecutive days 
survived the treatment (Rothfuss et al. 2010). Intermediate-duration studies have shown an increase in 
mortality of mice and dogs after 2,6-DNT administration.  After feeding 51 mg/kg/day 2,6-DNT to male
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Swiss albino mice in the diet for up to 13 weeks, 8 of 16 of these animals died; 6 of 16 females fed
55 mg/kg/day 2,6-DNT also died (U.S. Army 1976).  No treatment-related deaths were reported when rats 
were fed up to 155 mg/kg/day 2,6-DNT for the same duration (U.S. Army 1976).  Two of eight dogs
treated with 20 mg/kg 2,6-DNT by capsule died in a 13-week study (U.S. Army 1976).  Thus, dogs seem
to be the most sensitive of the three species to intermediate-duration oral 2,6-DNT exposure.
Vernot et al. (1977) reported LD50 values for 2,3- DNT of 1,120 mg/kg/day in male Sprague-Dawley rats 
and 1,070 mg/kg/day in male CF-1 mice.  No cause of death or additional information was reported.
Exposure to 550 mg/kg/day 2,3-DNT via gavage for 14 days resulted in the deaths of 6/6 male Sprague-
Dawley rats; no deaths occurred at doses of ≤275 mg/kg/day (Lent et al. 2012a; USAPHC 2011a). 
For 2,5-DNT, LD50 values of 710 and 1,230 mg/kg/day, respectively, were reported in male Sprague-
Dawley rats and male CF-1 mice (Vernot et al. 1977); no additional information was provided. One rat in 
a group of six male Sprague-Dawley rats died after 14 consecutive daily gavage doses of 308 mg/kg/day
2,5-DNT (Lent et al. 2012a; USAPHC 2011c).
Lent et al. (2012a; USAPHC 2011e, 2011f) provide the only acute-duration lethality data for 3,4- and 
3,5-DNT. When groups of six male Sprague-Dawley rats received gavage doses of 3,4-DNT up to 
227 mg/kg/day for 14 days, there were no deaths.  In contrast, 3,5-DNT was lethal to 1/6 rats at a dose of
39 mg/kg/day and to all rats at doses of 77 and 155 mg/kg/day.
Administration of up to 150 mg/kg/day Tg-DNT for 14 days was lethal to 6 of 13 pregnant F344 rats
when administered by gavage during gestation (Jones-Price et al. 1982), yet this same concentration of
Tg-DNT fed in the diet for 30 days did not kill any of the same strain of rats in another study (Hazleton 
Laboratories 1977).  Decreased survival was found in CDF rats fed 35 mg/kg/day Tg-DNT for 52 weeks 
or 14 mg/kg/day Tg-DNT for 104 weeks (Hazleton Laboratories 1982).
All LOAEL values from each reliable study for death in each species and duration category for 2,3-, 
2,4-DNT, 2,5-, 2,6-, 3,4-, and 3,5-DNT are recorded in Tables 3-1, 3-2, 3-3, 3-4, 3-5, and 3-6, 
respectively, and plotted in Figures 3-1, 3-2, 3-3, 3-4, 3-5, and 3-6, respectively.  
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Table 3-1 Levels of Significant Exposure to 2,3-Dinitrotoluene - Oral 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
ACUTE EXPOSURE 
Death 
1 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
550 M (6/6 died) 
Reference 
Chemical Form 
Lent et al. 2012a 
2,3-DNT 
Comments 
2 Rat 
(Sprague-
Dawley) 
once 
(G) 
1120 M (LD50) Vernot et al. 1977 
2,3-DNT 
3 Mouse 
(CF-1) 
Systemic 
4 Rat 
(Sprague-
Dawley) 
once 
(G) 
1 x/d 
14 d 
(G) 
Cardio 275 M 
1070 M (LD50) Vernot et al. 1977 
2,3-DNT 
Lent et al. 2012a 
2,3-DNT 
Hemato 
b 
275 M (extramedullary 
hematopoiesis and 
lymphoid hyperplasia of 
spleen, lymphoid 
depletion) 
Hepatic 275 M 
Renal 275 M (trace tubular dilatation 
and lymphocytic 
infiltration) 
Bd Wt 275 M 
Neurological 
5 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
275 M Lent et al. 2012a 
2,3-DNT 
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Table 3-1 Levels of Significant Exposure to 2,3-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
Reproductive 
6 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
275 M Lent et al. 2012a 
2,3-DNT 
No effects on testes or 
epididymides weight or 
histopathology. 
a The number corresponds to entries in Figure 3-1. 
b Used to derive an acute-duration oral minimal risk level (MRL) of 0.09 mg/kg/day; the MRL was derived by dividing the LOAEL of 275 mg/kg/day by an uncertainty factor of 3000 
(10 for use of a LOAEL, 10 for animal-to-human extrapolation, 10 for human variability, and 3 for database limitations). 
Bd Wt = body weight; Cardio = cardiovascular; d = day(s); (G) = gavage; Hemato = hematological; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = 
male; NOAEL = no-observed-adverse-effect level; x = time(s) 
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Figure 3-1  Levels of Significant Exposure to 2,3-Dinitrotoluene - Oral
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
ACUTE EXPOSURE 
Death 
1 Rat 
(Sprague-
Dawley) 
5 d 
1 x/d 
(GO) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
240 M (8/15 died) 
Reference 
Chemical Form 
Lane et al. 1985 
2,4-DNT 
Comments 
2 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
284 M (6/6 died) Lent et al. 2012a 
2,4-DNT 
3 Rat 
(CD) 
once 
(GO) 
568 M (LD50) 
650 F (LD50) 
U.S. Army 1975; U.S. Army 
1978a 
2,4-DNT 
4 Rat 
(Sprague-
Dawley) 
once 
(G) 
270 M (LD50) Vernot et al. 1977 
2,4-DNT 
5 Mouse 
(Swiss albino) 
once 
(GO) 
1954 M (LD50) 
1340 F (LD50) 
U.S. Army 1975 
2,4-DNT 
6 Mouse 
(CF-1) 
once 
(G) 
1630 M (LD50) Vernot et al. 1977 
2,4-DNT 
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral	 (continued) 
a 
Key to Species 
Figure (Strain) 
Systemic 
7 Rat 
(Sprague-
Dawley) 
8	 Rat 
(Sprague-
Dawley) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
once 
(GO) 
Hepatic 50 F 99 F  Significantly decreased 
levels of serum albumin 
(13% lower than controls) 
Deng et al. 2011 
2,4-DNT 
The NOAEL for renal 
effects is based on the 
absence of effects on 
levels of creatinine or 
urea in the serum. 
Renal 
Bd Wt 
398 F 
198 F 398 F Decreased body weight 
gain (1 to 4 g compared 
to 17 g for controls) 
5 d 
1 x/d 
(GO) 
Hemato 60 M (slight cyanosis) Lane et al. 1985 
2,4-DNT 
Bd Wt 180 M 240 M (weight loss) 
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
9 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
Cardio 142 M Lent et al. 2012a 
2,4-DNT 
Hemato 36 M 71 M (mild to moderate 
extramedullary 
hematopoiesis of the 
spleen) 
Hepatic 18 M 36 M (trace-to-mild single cell 
necrosis and glycogen 
deposition) 
Renal 142 M 
Bd Wt 71 M 142 M (terminal Bd Wt 12% 
lower than control) 
53
189
260.9
272.7
260.9
272.7
260.9
272.7
78.3
81.8
78.3
81.8
260.9
272.7
260.9
272.7
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
10 Rat 
(Sprague-
Dawley) 
14 d 
ad lib Resp 
Cardio 
Gastro 
Hepatic 
Renal 
Dermal 
Ocular 
LOAEL 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
260.9 M McGown et al. 1983 
2,4-DNT
272.7 F 
260.9 M 
272.7 F 
260.9 M 
272.7 F 
78.3 M (increased alanine 
aminotransferase and 
cholesterol) 
81.8 F (increased cholesterol) 
78.3 M (hyaline droplet 
formation) 
81.8 F (hyaline droplet 
formation) 
260.9 M 
272.7 F 
260.9 M 
272.7 F 
54
237
134
134
134
192
260.9
272.7
215
142
191
5
25
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral	 (continued) 
System 
Hemato 
Musc/skel 
Bd Wt 
NOAEL 
(mg/kg/day) 
134 F 
260.9 M 
272.7 F 
142 M 
b 
5 
LOAEL 
a 
Key to Species 
Figure (Strain) 
11 Mouse 
(C57BL/6N) 
Immuno/ Lymphoret 
12 Rat 
(Sprague-
Dawley) 
Neurological 
13 Rat 
(Sprague-
Dawley) 
14	 Dog 
(Beagle) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
Less Serious	 Serious 
(mg/kg/day)	 (mg/kg/day) 
134 F	 (swim-to-exhaustion time 
decreased by 82% 
relative to controls) 
134 F	 (2.7-fold greater body 
weight loss than control) 
25	 (incoordination, stiffness, 
abnormal gait) 
Reference 
Chemical Form 
Wilbanks et al. 2014 
2,4-DNT 
McGown et al. 1983 
2,4-DNT 
Lent et al. 2012a 
2,4-DNT 
Ellis et al. 1985; U.S. Army 
1978b 
2,4-DNT 
Comments 
No change in 
hematocrit, reticulocyte 
percent, or relative 
spleen weight. 
14 days 
daily 
(G) 
14 d 
ad lib 
1 x/d 
14 d 
(G) 
12 d 
1 x/d 
(C) 
55
460 180
213
71
142
190
78.3
66
250
21
371
6
93
145
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
Reproductive 
15 Rat 
(Sprague-
Dawley) 
5 d 
1 x/d 
(GO) 
60 M 180 M (decreased fertility) Lane et al. 1985 
2,4-DNT 
16 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
71 M 142 M (decreased absolute and 
relative testes weight and 
decreased absolute 
epididymis weight; 
tubular degeneration, 
multinucleated giant cell 
formation, and interstitial 
atrophy of the testes) 
Lent et al. 2012a 
2,4-DNT 
17 Rat 
(Sprague-
Dawley) 
14 d 
ad lib 78.3 M (decreased thickness of spermatogenic sperm 
layers) 
McGown et al. 1983 
2,4-DNT 
18 Mouse 
DBA/2J 
2 d 
1 x/d 
(G) 
INTERMEDIATE EXPOSURE 
Death 
19 Rat 
(Wistar) 
6 mo 
ad lib 
(F) 
250 M (decreased fertility) 
371 M (71% died) 
Soares and Lock 1980 
2,4-DNT 
Kozuka et al. 1979 
2,4-DNT 
20 Rat 
(CD) 
4 or 13 wk 
ad lib 
(F) 
93 M (1/8 died) 
145 F (8/8 died) 
Lee et al. 1985 
2,4-DNT 
56
140
45.3
135
413
151
25
160
10
24
76.7
156.4
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral	 (continued) 
a 
Key to Species 
Figure (Strain) 
21	 Rat 
(CD) 
22	 Mouse 
(CD-1) 
23	 Dog 
(Beagle) 
24	 Dog 
(Beagle) 
Systemic 
25 Rat 
(Sprague-
Dawley) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
3 or 6 mo 
ad lib 
(F) 
45.3 F (increased incidence of 
death during parturition) 
U.S. Army 1979 
2,4-DNT 
4 or 13 wk 
ad lib 
(F) 
413 (2/16M, 2/16F died) Hong et al. 1985; U.S. Army 
1978b 
2,4-DNT 
4 or 13 wk 
1 x/d 
(C) 
25 (5/8 died) Ellis et al. 1985; U.S. Army 
1978b 
2,4-DNT 
6 mo 
1 x/d 
(C) 
10 M (4/6 died) U.S. Army 1979, Ellis et al. 
1985 
2,4-DNT 
3 wk 
ad lib 
(F) 
Bd Wt 76.7 M 156.4 M (10% decrease body 
weight) 
Bloch et al. 1988 
2,4-DNT 
57
20
371
371
371
371
50
27
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
26 Rat 
(Wistar) 
6 mo 
ad lib 
(F) 
Hemato 371 M (increased 
methemoglobin) 
Kozuka et al. 1979 
2,4-DNT 
Hepatic 371 M (increased relative liver 
weight; increased SGOT, 
LDH, alkaline 
phosphatase, acid 
phosphatase, 
triglycerides, glucose; 
formation of puruloid 
matter) 
Renal 371 M 
Bd Wt 371 M (41% decrease body 
weight) 
27 Rat 
(Fischer- 344) 
6 or 26 wk 
ad lib 
(F) 
Bd Wt 27 M (11% decrease body 
weight) 
Leonard et al. 1987 
2,4-DNT 
58
534
38
93
108
266
145
266
145
266
145
34
38
141
34.5
45.3
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
28 Rat 
(CD) 
4 or 13 wk 
ad lib 
(F) 
Hemato 34 M 
38 F 
93 M (reticulocytosis; 
hemosiderosis) 
108 F (reticulocytosis; 
hemosiderosis) 
266 M (anemia) 
145 F (anemia) 
U.S. Army 1978b, Lee et al. 
1985 
2,4-DNT 
Hepatic 266 M 
145 F 
Renal 266 M 
145 F 
Bd Wt 34 M (75% decrease body 
weight gain with 
decreased food 
consumption) 
38 F (94% decrease body 
weight gain with 
decreased food 
consumption) 
29 Rat 
(CD) 
3 or 6 mo 
ad lib Bd Wt 34.5 M (23-25% decrease in body weight) 
U.S. Army 1979 
2,4-DNT 
45.3 F (10-23% decrease in 
body weight) 
59
138
137
147
413
468
47
147
137
468
413
468
413
468
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
30 Mouse 
(CD-1) 
4 or 13 wk 
ad lib 
(F) 
Hemato 137 M 
147 F 
413 M 
468 F (mild anemia, 
reticulocytosis) 
Hong et al. 1985; U.S. Army 
1978b 
2,4-DNT 
Hepatic 47 M 
147 F 
137 M 
468 F (mild hepatocellular 
dysplasia) 
Renal 413 M 
468 F 
Bd Wt 413 M 
468 F (body weight loss with 
decreased food 
consumption) 
60
149
5 25
25
25
200
1.5
1.5
0.2
10
10
1.5
163
371
150
25
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
31 Dog 
(Beagle) 
4 or 13 wk 
1 x/d 
(C) 
Hemato 5 25 (anemia, Heinz bodies) Ellis et al. 1985; U.S. Army 
1978b 
2,4-DNT 
Hepatic 25 
Renal 25 
32 Dog 
(Beagle) 
9 mo 
1 x/d 
(C) 
Hemato 1.5 M 
1.5 F 
c 
0.2 F 
10 M (increased Heinz bodies 
and methemoglobin) 
10 F (decreased erythrocyte 
count, hemoglobin, and 
hematocrit; increased 
reticulocytes and Heinz 
bodies) 
U.S. Army 1979, Ellis et al. 
1985 
2,4-DNT 
1.5 F (increased 
methemoglobin) 
Immuno/ Lymphoret 
33 Rat 
(Wistar) 
6 mo 
ad lib 
(F) 
371 M (increased relative 
spleen weight) 
Kozuka et al. 1979 
2,4-DNT 
34 Dog 
(Beagle) 
4 or 13 wk 
1 x/d 
(C) 
25 Ellis et al. 1985; U.S. Army 
1978b 
2,4-DNT 
61
22
347
15
34
108
93
145
136
413
468
147
5
25
25
76.7 153.4
23
371
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral	 (continued) 
Exposure/ LOAEL 
Duration/
a 
Key to Species 
Figure (Strain) 
Neurological 
35 Rat 
(Wistar) 
36	 Rat 
(CD) 
37	 Mouse 
(CD-1) 
38	 Dog 
(Beagle) 
Reproductive 
39 Rat 
(Sprague-
Dawley) 
40	 Rat 
(Wistar) 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
Serious 
(mg/kg/day) 
6 mo 
ad lib 
(F) 
347 M (humpback 
incoordination) 
4 or 13 wk 
ad lib 
(F) 
34 M 
108 F 
93 M 
145 F (demyelination of 
cerebellum and brain 
stem; widespread and 
stiff-legged gait) 
4 or 13 wk 
ad lib 
(F) 
413 M 
468 F 
4 or 13 wk 
1 x/d 
(C) 
5 25 (incoordination, abnormal 
gait, paralysis) 
3 wk 
ad lib 
(F) 
76.7 M (multinucleated 
spermatids, mild 
irregularity of basal 
lamina, vacuolation and 
lipid accumulation in 
Sertoli cells) 
153.4 M (extensive degeneration 
of spermatids and 
spermatocytes; 
ultrastructural changes in 
Sertoli cells; 63% 
decrease sperm count) 
6 mo 
ad lib 
(F) 
371 M (testicular atrophy) 
Reference 
Chemical Form Comments 
Kozuka et al. 1979 
2,4-DNT 
U.S. Army 1978b, Lee et al. 
1985 
2,4-DNT 
Hong et al. 1985; U.S. Army 
1978b 
2,4-DNT 
Ellis et al. 1985; U.S. Army 
1978b 
2,4-DNT 
Bloch et al. 1988 
2,4-DNT 
Kozuka et al. 1979 
2,4-DNT 
62
186
9.3 93
7
34
93
139
34.5
45.3
142
34.5
45
137
137
468
413
152
295 1032
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral	 (continued) 
Exposure/ LOAEL 
Duration/
a 
Key to Species 
Figure (Strain) 
41	 Rat 
(CD) 
42	 Rat 
(CD) 
43	 Rat 
(CD) 
44	 Rat 
(CD) 
45	 Mouse 
(CD-1) 
46	 Mouse 
(albino-
Swiss) 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
Serious 
(mg/kg/day) 
13 wk 
ad lib 
(F) 
9.3 M 93 M (decreased fertility) 
4 or 13 wk 
ad lib 
(F) 
34 M 93 M (severe decrease in 
spermatogenesis) 
3 or 6 mo 
ad lib 
(F) 
34.5 M 
45.3 F (decreased fertility; 
difficult parturition) 
3 or 6 mo 
ad lib 
(F) 
34.5 M 45 M (decreased fertility; 
severe 
atrophy/degeneration of 
seminiferous tubules) 
4 or 13 wk 
ad lib 
(F) 
137 M 
468 F 
413 M (mild degeneration of 
seminiferous tubules) 
4 wk 
(C) 
295 M 1032 M (decreased fertility index) 
Reference 
Chemical Form Comments 
U.S. Army 1978b, Lee et al. 
1985 
2,4-DNT 
U.S. Army 1978b, Lee et al. 
1985 
2,4-DNT 
U.S. Army 1979 
2,4-DNT 
U.S. Army 1979 
2,4-DNT 
Hong et al. 1985; U.S. Army 
1978b 
2,4-DNT 
U.S. Army 1978b 
2,4-DNT 
63
148
5
25
25
185
5.1 45.3
9
3.9
5.1
130
898
47
27
27
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral	 (continued) 
Exposure/ LOAEL 
Duration/
a FrequencyKey to Species	 NOAEL Less Serious(Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) 
47 Dog	 4 or 13 wk 5 M1 x/d(Beagle) 
(C) 25 F 
Developmental 
48 Rat 3 or 6 mo 5.1 Fad lib(CD) 
(F) 
CHRONIC EXPOSURE 
Death 
49 Rat 1-2 yr 
ad lib(CD) 
(F) 
50 Mouse	 24 mo 
ad lib(CD-1) 
(F) 
Systemic 
51 Rat 52 wk Hepaticad lib(Fischer- 344) 
(F) 
Bd Wt 
Serious 
(mg/kg/day) 
25 M (testicular degeneration, 
decreased 
spermatogenesis) 
45.3 F (difficult parturition) 
3.9 M 
5.1 F (decreased survival) 
898 (decreased survival) 
27 M (hepatocellular 
degeneration and 
vacuolation; basophilic 
and acidophilic foci of 
cellular alteration) 
27 M (25% body weight
 
decrease)
 
Reference 
Chemical Form Comments 
Ellis et al. 1985; U.S. Army 
1978b 
2,4-DNT 
U.S. Army 1979 
2,4-DNT 
U.S. Army 1978b; U.S. Army 
1979; Lee et al. 1985 
2,4-DNT 
U.S. Army 1979; Hong et al. 
1985 
2,4-DNT 
Leonard et al. 1987 
2,4-DNT 
64
80
8
8.8
20
22
10
0.6
5.1
3.9 34.5
45.3
34.5
45.3
3.9
5.1
34.5
45.3
81
14.4
72
15.2
76
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral (continued) 
Exposure/ LOAEL 
Duration/
a FrequencyKey to Species NOAEL Less Serious Serious(Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) 
52 Rat 78 wk Bd Wt 8 M 20 Mad lib(Fischer- 344) 
(F) 8.8 F 22 F (25% decrease body 
weight) 
53 Rat 1-2 yr Hemato 0.6 M 3.9 M (decreased RBC count) 34.5 M (anemia)ad lib(CD) 
(F) 5.1 F 45.3 F (anemia) 
Renal 34.5 M 
45.3 F 
Bd Wt 3.9 M 34.5 M (30% decrease body 
weight with decreased
5.1 F food consumption) 
45.3 F (27% decrease body 
weight with decreased 
food consumption) 
54 Mouse 78 wk Bd Wt 14.4 M 72 M (18% decrease in body 76 F (24% decrease in bodyad lib(C57BL/6N) weight gain) weight gain)
(F) 
15.2 F (11% decrease in body 
weight gain) 
Reference 
Chemical Form Comments 
NCI 1978 
2,4-DNT 
U.S. Army 1978b, 1979; Lee et 
al. 1985 
2,4-DNT 
NCI 1978 
2,4-DNT 
65
132
95
898
95 14
898
14
14
95
95 898
144
0.2
1.5
1.5 10
10
207
0.2
11
34.5
45.3
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral	 (continued) 
a 
Key to Species 
Figure (Strain) 
55	 Mouse 
(CD-1) 
56	 Dog 
(Beagle) 
57	 Dog 
(Beagle) 
Neurological 
58 Rat 
(CD) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
24 mo 
ad lib 
(F) 
24 mo 
1 x/d 
(C) 
12 mo 
1 x/d 
(C) 
1-2 yr 
ad lib 
(F) 
LOAEL 
NOAEL Less Serious	 Serious 
System (mg/kg/day) (mg/kg/day)	 (mg/kg/day) 
Hemato 95 898	 (anemia; reticulocytosis; 
Heinz bodies) 
Hepatic 95 F	 14 M (hepatocellular dysplasia) 
898 F (hepatocellular dysplasia) 
Renal 14 M (cystic dysplasia; toxic 
nephropathy) 
Bd Wt 14 M 95 M (16% decrease in body 898 F (20% decrease in body 
weight) weight)
95 F 
Hemato 0.2 1.5	 (methemoglobinemia, 
anemia) 
Hepatic 1.5 ( 10	 Biliary hyperplasia 
Renal 10 
d 
Hemato 0.2 F	 (increased reticulocytes) 
34.5 M (wide-spread and 
stiff-legged gait) 
45.3 F (wide-spread and 
stiff-legged gait) 
Reference 
Chemical Form Comments 
U.S. Army 1979; Hong et al. 
1985 
2,4-DNT 
U.S. Army 1979, Ellis et al. 
1985 
2,4-DNT 
U.S. Army 1979, Ellis et al. 
1985 
2,4-DNT 
US Army 1978b, 1979; Lee et 
al. 1985 
2,4-DNT 
66
131
95
898
146
0.2
1.5
202
3.9
34.5
12
34
134
95
14
898
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral	 (continued) 
Exposure/ LOAEL 
Duration/
a 
Key to Species 
Figure (Strain) 
59	 Mouse 
(CD-1) 
60	 Dog 
(Beagle) 
Reproductive 
61 Rat 
(CD) 
62	 Rat 
(CD) 
63	 Mouse 
(CD-1) 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
Serious 
(mg/kg/day) 
24 mo 
ad lib 95 898 (stiff-legged gait, hyperactivity) 
24 mo 
1 x/d 
(C) 
0.2 1.5 (loss of hindquarter 
control, convulsions) 
1-2 yr 
ad lib 
(F) 
3.9 M 34.5 M Atophy of seminiferous 
tubules, 
aspermatogenesis 
1-2 yr 
ad lib 
(F) 
34 M 
24 mo 
ad lib 95 F 14 M (decreased spermatogenesis and 
degenerative change; 
testicular atrophy) 
898 F (ovarian atrophy; 
nonfunctioning follicles) 
Reference 
Chemical Form Comments 
U.S. Army 1979; Hong et al. 
1985 
2,4-DNT 
U.S. Army 1979, Ellis et al. 
1985 
2,4-DNT 
U.S. Army 1978b, 1979; Lee et 
al. 1985 
2,4-DNT 
U.S. Army 1978b; U.S. Army 
1979; Lee et al. 1985 
2,4-DNT 
U.S. Army 1979; Hong et al. 
1985 
2,4-DNT 
67
145
10
78
7.5
22
13
34.5
45.3
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral	 (continued) 
Exposure/ LOAEL 
Duration/
a FrequencyKey to Species	 NOAEL Less Serious Serious(Route)Figure (Strain)	 System (mg/kg/day) (mg/kg/day) (mg/kg/day) 
64 Dog 24 mo 10 M1 x/d(Beagle) 
(C) 
Cancer 
65 Rat 78 wk 7.5 M (CEL: skin andad lib(Fischer- 344) subcutaneous fibroma)
(F) 
22 F	 (CEL: mammary 
fibroadenoma) 
66 Rat 1-2 yr 34.5 M (CEL: hepatocellularad lib(CD) carcinoma; mammary
(F) and skin tumors) 
45.3 F (CEL: hepatocellular 
carcinoma, mammary 
and skin tumors) 
Reference 
Chemical Form Comments 
U.S. Army 1979, Ellis et al. 
1985 
2,4-DNT 
NCI 1978 
2,4-DNT 
U.S. Army 1978b, 1979; Lee et 
al. 1985 
2,4-DNT 
68
133
95
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Table 3-2 Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
67 Mouse 
(CD-1) 
24 mo 
ad lib U.S. Army 1979; Hong et al. 1985 
2,4-DNT 
95 M (CEL: renal solid 
carcinoma, cystic 
papillary carcinoma and 
adenoma, cystic 
adenoma) 
a The number corresponds to entries in Figure 3-2. 
b Used to derive an acute-duration oral minimal risk level (MRL) of 0.05 mg/kg/day; the MRL was derived by dividing the NOAEL of 5 mg/kg/day by an uncertainty factor of 100 (10 for 
animal-to-human extrapolation and 10 for human variability). 
c Used to derive an intermediate-duration oral minimal risk level (MRL) of 0.007 mg/kg/day; the MRL was derived by dividing the BMDL1SD of 0.67 mg/kg/day by an uncertainty 
factor of 100 (10 for animal-to-human extrapolation and 10 for human variability). 
d Used to derive a chronic-duration oral minimal risk level (MRL) of 0.001 mg/kg/day; the MRL was derived by dividing the BMDL1SD of 0.12 mg/kg/day by an uncertainty factor of 
100 (10 for animal-to-human extrapolation and 10 for human variability). 
ad lib = ad libitum; Bd Wt = body weight; (C) = capsule; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); (F) = feed; F = Female; (G) = gavage; Gastro = 
gastrointestinal; (GO) = gavage in oil; Hemato = hematological; LD50 = lethal dose, 50% kill; LDH = ; LOAEL = lowest-observed-adverse-effect level; M = male; mo = month(s); 
NOAEL = no-observed-adverse-effect level; RBC = red blood cell; Resp = respiratory; SGOT = ; x = time(s); wk = week(s); yr = year(s) 
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Figure 3-2  Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral
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Figure 3-2  Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral (Continued)
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Figure 3-2  Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral (Continued) 
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Figure 3-2  Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral (Continued)
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Figure 3-2  Levels of Significant Exposure to 2,4-Dinitrotoluene - Oral (Continued)
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Table 3-3 Levels of Significant Exposure to 2,5-Dinitrotoluene - Oral 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
ACUTE EXPOSURE 
Death 
1 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
308 M (1/6 died) 
Reference 
Chemical Form 
Lent et al. 2012a 
2,5-DNT 
Comments 
2 Rat 
(Sprague-
Dawley) 
once 
(G) 
710 M (LD50) Vernot et al. 1977 
2,5-DNT 
3 Mouse 
(CF-1) 
Systemic 
4 Rat 
(Sprague-
Dawley) 
once 
(G) 
1 x/d 
14 d 
(G) 
Cardio 154 M 308 M (increased absolute and 
relative heart weight; 
mild-to-moderate fibrosis 
and trace-to-moderate 
inflammation) 
1230 M (LD50) Vernot et al. 1977 
2,5-DNT 
Lent et al. 2012a 
2,5-DNT 
Hemato 
b 
39 M (dark spleen; mild to 
moderate extramedullary 
hematopoiesis) 
Hepatic 308 M 
Renal 308 M 
Bd Wt 308 M 
Neurological 
5 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
308 M Lent et al. 2012a 
2,5-DNT 
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Table 3-3 Levels of Significant Exposure to 2,5-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
Reproductive 
6 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
308 M Lent et al. 2012a 
2,5-DNT 
No effect on testes of 
epididymides weight or 
histopathology. 
a The number corresponds to entries in Figure 3-3. 
b Used to derive an acute-duration oral minimal risk level (MRL) for 2,5-DNT of 0.007 mg/kg/day; the MRL was derived by dividing the BMDL10 of 2.05 mg/kg/day by an uncertainty 
factor of 300 (10 for animal-to-human extrapolation, 10 for human variability, and 3 for database limitations). 
Bd Wt = body weight; Cardio = cardiovascular; d = day(s); (G) = gavage; Hemato = hematological; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = 
male; NOAEL = no-observed-adverse-effect level; x = time(s) 
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Figure 3-3  Levels of Significant Exposure to 2,5-Dinitrotoluene - Oral
Acute (≤14 days) 
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Table 3-4 Levels of Significant Exposure to 2,6-Dinitrotoluene - Oral 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
ACUTE EXPOSURE 
Death 
1 Rat 
(CD) 
once 
(GO) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
535 M (LD50) 
795 F (LD50) 
Reference 
Chemical Form 
U.S. Army 1975; U.S. Army 
1978a 
2,6-DNT 
Comments 
2 Rat 
(Sprague-
Dawley) 
once 
(G) 
180 M (LD50) Vernot et al. 1977 
2,6-DNT 
3 Mouse 
(CD) 
once 
(GO) 
621 M (LD50) 
807 F (LD50) 
U.S. Army 1975 
2,6-DNT 
4 Mouse 
(CF-1) 
Systemic 
5 Rat 
(Sprague-
Dawley) 
once 
(G) 
once 
(GO) 
Renal 199 F 
1000 M (LD50) Vernot et al. 1977 
2,6-DNT 
Deng et al. 2011 
2,6-DNT 
The NOAEL for renal 
effects is based on the 
absence of effects on 
levels of creatinine or 
urea in the serum. 
Bd Wt 25 F 50 F Decreased body weight 
gain (1 to 4 g compared 
to 17 g for controls) 
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Table 3-4 Levels of Significant Exposure to 2,6-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
6 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
Cardio 134 M Lent et al. 2012a 
2,6-DNT 
Hemato 68 M (extramedullary 
hematopoiesis and 
lymphoid depletion of the 
spleen) 
Hepatic 14 M 35 M (hepatocellular 
hyperplasia, oval cell 
hyperplasia, and 
hepatocellular 
hypertrophy) 
Renal 134 M (proximal tubule 
degeneration and renal 
tubular basophilia) 
Bd Wt 14 M 35 M (terminal body weight 
10% lower than controls) 
7 Rat 
(Sprague-
Dawley) 
1 x/d 
3 d 
(G) 
Hepatic 100 M (diffuse hepatocellular 
hypertrophy) 
Rothfuss et al. 2010 
2,6-DNT 
Bd Wt 100 M 
8 Dog 
(Beagle) 
2 wk 
ad lib 
(C) 
Hemato 
b 
4 20 (decreased erythrocytes 
and increased mean cell 
hemoglobin) 
US Army 1976 
2,6-DNT 
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234
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Table 3-4 Levels of Significant Exposure to 2,6-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) System 
Exposure/ 
Duration/ 
Frequency 
(Route) 
NOAEL 
(mg/kg/day) 
LOAEL 
Less Serious 
(mg/kg/day) 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
Neurological 
9 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
Reproductive 
10 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
134 M 
35 M 68 M (tubular degeneration, 
multinucleated giant cell 
formation, and interstitial 
atrophy of the testes) 
Lent et al. 2012a 
2,6-DNT 
Lent et al. 2012a 
2,6-DNT 
INTERMEDIATE EXPOSURE 
Death 
11 Rat 
(Sprague-
Dawley) 
1 x/d 
29 d 
(G) 
33 M Rothfuss et al. 2010 
2,6-DNT 
12 Mouse 
(Swiss-
albino) 
4 or 13 wk 
ad lib 
(F) 
51 M (8/16 died) 
55 F (6/16 died) 
US Army 1976 
2,6-DNT 
13 Dog 
(Beagle) 
4 or 13 wk 
ad lib 
(C) 
Systemic 
14 Bd WtRat 
(Fischer- 344) 
6 or 26 wk 
ad lib 
(F) 
7 M 
20 F (2/8 died) 
14 M (20% decrease body 
weight) 
US Army 1976 
2,6-DNT 
Leonard et al. 1987 
2,6-DNT 
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Table 3-4 Levels of Significant Exposure to 2,6-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
15 Rat 
(Sprague-
Dawley) 
1 x/d 
29 d 
(G) 
Hepatic 33 M (hepatocellular 
hypertrophy, single cell 
necrosis, bile duct 
hyperplasia, focal 
hepatocellular 
vacuolation) 
Rothfuss et al. 2010 
2,6-DNT 
Bd Wt 33 M (decreased body weight) 
81
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7
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7
35
37
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155
7 35
37
145
155
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Table 3-4 Levels of Significant Exposure to 2,6-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
16 Rat 
(CD) 
4 or 13 wk 
ad lib 
(F) 
Hemato 7 F 37 F (splenic hemosiderosis; 
extramedullary 
hematopoiesis) 
U.S. Army 1976 
2,6-DNT 
7 F Increased incidence of 
extramedullary 
hematopoiesis of the 
spleen at 4 weeks 
Hepatic 35 M (bile duct 
hyperplasia;hemosiderosi 
37 F (bile duct hyperplasia; 
hemosiderosis) 
Renal 145 M 
155 F 
Bd Wt 7 35 M 145 M 
37 F (decreased body weight 
gain) 
155 F (body weight loss) 
82
183
11
11
51
55
11 51
55
289
299
11 51
55
178
4
4
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4
20
4
20
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Table 3-4 Levels of Significant Exposure to 2,6-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
17 Mouse 
(Swiss-
albino) 
4 or 13 wk 
ad lib 
(F) 
Hemato 11 M 
11 F 
51 M (extramedullary 
hematopoiesis) 
US Army 1976 
2,6-DNT 
55 F (extramedullary 
hematopoiesis) 
Hepatic 
Renal 
11 
289 M 
51 M (bile duct hyperplasia) 
55 F (bile duct hyperplasia) 
299 F 
Bd Wt 11 51 M (weight loss) 
55 F (weight loss) 
18 Dog 
(Beagle) 
4 or 13 wk 
ad lib 
(C) 
Hemato 
c 
4 (mild extramedullary 
erythropoiesis) 
US Army 1976 
2,6-DNT 
Hepatic 4 20 (bile duct hyperplasia; 
degenerative and 
inflammatory liver 
changes) 
Renal 4 20 (dilated tubules, 
degenerative foci) 
Bd Wt 4 20 (body weight loss with 
decreased food 
consumption) 
83
169
145
155
176
20 100
168
145
155
180
289
299
175
4
20
170
7
155
35
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Table 3-4 Levels of Significant Exposure to 2,6-Dinitrotoluene - Oral (continued) 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form Comments 
Immuno/ Lymphoret 
19 Rat 
(CD) 
4 or 13 wk 
ad lib 
(F) 
145 M 
155 F 
U.S. Army 1976 
2,6-DNT 
20 Dog 
(Beagle) 
Neurological 
21 Rat 
(CD) 
4 or 13 wk 
ad lib 
(C) 
4 or 13 wk 
ad lib 
(F) 
20 
145 M 
155 F 
100 (thymic involution) US Army 1976 
2,6-DNT 
U.S. Army 1976 
2,6-DNT 
22 Mouse 
(Swiss-
albino) 
4 or 13 wk 
ad lib 
(F) 
289 M 
299 F 
US Army 1976 
2,6-DNT 
23 Dog 
(Beagle) 
Reproductive 
24 Rat 
(CD) 
4 or 13 wk 
ad lib 
(C) 
4 or 13 wk 
ad lib 
(F) 
4 
7 M 
155 F 
20 (incoordination, lack of 
balance) 
35 M (decreased 
spermatogenesis; 
degeneration of testes) 
US Army 1976 
2,6-DNT 
U.S. Army 1976 
2,6-DNT 
84
182
11
299
51
177
4
100
20
48
7
7
45
7
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Table 3-4 Levels of Significant Exposure to 2,6-Dinitrotoluene - Oral (continued) 
Exposure/ LOAEL 
Duration/
a FrequencyKey to Species NOAEL Less Serious Serious(Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) 
25 Mouse 4 or 13 wk 11 M 51 M (decreasedad lib(Swiss- spermatogenesis)
albino) (F) 299 F 
26 Dog 4 or 13 wk 4 M 20 M (testicular degeneration)ad lib(Beagle) 
(C) 100 F 
CHRONIC EXPOSURE 
Systemic 
27 Rat 52 wk Hepatic 7 M (hepatocellularad lib(Fischer- 344) degeneration,
(F) vacuolation; acidophilic 
and basophilic foci of 
cellular alteration) 
Bd Wt 7 M (18% decrease body 
weight) 
Cancer 
28 Rat 52 wk 7 M (CEL:ad lib(Fischer- 344) cholangiocarcinoma,
(F) hepatocellular 
carcinoma) 
Reference 
Chemical Form Comments 
US Army 1976 
2,6-DNT 
US Army 1976 
2,6-DNT 
Leonard et al. 1987 
2,6-DNT 
Leonard et al. 1987 
2,6-DNT 
a The number corresponds to entries in Figure 3-4. 
b Used to derive an acute-duration oral minimal risk level (MRL) of 0.09 mg/kg/day; the MRL was derived by dividing the BMDL1SD of 9.31 mg/kg/day by an uncertainty factor of 100 
(10 for animal-to-human extrapolation and 10 for human variability). 
c Used to derive an intermediate-duration oral minimal risk level (MRL) of 0.004 mg/kg/day; the MRL was derived by dividing the LOAEL of 4 mg/kg/day by an uncertainty factor of 
1000 (10 for use of a LOAEL, 10 for animal-to-human extrapolation and 10 for human variability). 
ad lib = ad libitum; Bd Wt = body weight; (C) = capsule; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); (F) = feed; F = Female; (G) = gavage; (GO) = gavage in oil; 
Hemato = hematological; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = no-observed-adverse-effect level; x = time(s); wk = 
week(s) 
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Figure 3-4  Levels of Significant Exposure to 2,6-Dinitrotoluene - Oral
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Figure 3-4  Levels of Significant Exposure to 2,6-Dinitrotoluene - Oral (Continued)
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Figure 3-4  Levels of Significant Exposure to 2,6-Dinitrotoluene - Oral (Continued)
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Table 3-5 Levels of Significant Exposure to 3,4-Dinitrotoluene - Oral 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
ACUTE EXPOSURE 
Systemic 
1 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
System 
Cardio 
NOAEL 
(mg/kg/day) 
113 M 
Less Serious 
(mg/kg/day) 
227 M (myocardial fibrosis, 
inflammation, and 
necrosis) 
LOAEL 
Serious 
(mg/kg/day) 
Reference 
Chemical Form 
Lent et al. 2012a 
3,4-DNT 
Comments 
Hemato 
b 
57 M (extramedullary 
hematopoiesis and 
lymphoid hyperplasia) 
Hepatic 227 M 
Renal 227 M (proximal tubule 
degeneration, renal 
tubule basophilia, and 
lymphocytic infiltration) 
Bd Wt 113 M 227 M (terminal body weight 
10% less than controls) 
Neurological 
2 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
113 M 227 M (facial twitching, 
hypoactivity, staring) 
Lent et al. 2012a 
3,4-DNT 
Reproductive 
3 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
227 M Lent et al. 2012a 
3,4-DNT 
No effects on testes or 
epididymides weight or 
histopathology. 
a The number corresponds to entries in Figure 3-5. 
b Used to derive an acute-duration oral minimal risk level (MRL) of 0.03 mg/kg/day; the MRL was derived by dividing the BMDL10 of 8.05 mg/kg/day by an uncertainty factor of 300 
(10 for animal-to-human extrapolation, 10 for human variability, and 3 for database limitations). 
Bd Wt = body weight; Cardio = cardiovascular; d = day(s); (G) = gavage; Hemato = hematological; LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = 
no-observed-adverse-effect level; x = time(s) 89
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Figure 3-5 Levels of Significant Exposure to 3,4-Dinitrotoluene - Oral 
Acute (≤14 days) 
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Table 3-6 Levels of Significant Exposure to 3,5-Dinitrotoluene - Oral 
a 
Key to 
Figure 
Species 
(Strain) 
Exposure/ 
Duration/ 
Frequency 
(Route) 
ACUTE EXPOSURE 
Death 
1 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
System 
NOAEL 
(mg/kg/day) 
Less Serious 
(mg/kg/day) 
LOAEL 
Serious 
(mg/kg/day) 
39 M (1/6 died) 
Reference 
Chemical Form 
Lent et al. 2012a 
3,5-DNT 
Comments 
Systemic 
2 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
Cardio 39 M Lent et al. 2012a 
3,5-DNT 
Hemato 39 M 
Hepatic 39 M 
Renal 39 M 
Bd Wt 39 M 
Neurological 
3 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
19 M 39 M (facial twitching and 
paralysis; inflammatory 
infiltrates in the brain) 
Lent et al. 2012a 
3,5-DNT 
Reproductive 
4 Rat 
(Sprague-
Dawley) 
1 x/d 
14 d 
(G) 
b 
10 M 19 M (small testes; significantly 
reduced testes weight; 
tubular degeneration and 
multinucleated giant cell 
formation in the testes) 
Lent et al. 2012a 
3,5-DNT 
a The number corresponds to entries in Figure 3-6. 
b Used to derive an acute-duration oral minimal risk level (MRL) 3,5-DNT of 0.03 mg/kg/day; the MRL was derived by dividing the NOAEL of 10 mg/kg/day by an uncertainty factor of 
300 (10 for animal-to-human extrapolation, 10 for human variability, and 3 for database limitations). 
Bd Wt = body weight; Cardio = cardiovascular; d = day(s); (G) = gavage; Hemato = hematological; LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = 
no-observed-adverse-effect level; x = time(s) 
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Figure 3-6 Levels of Significant Exposure to 3,5-Dinitrotoluene - Oral 
Acute (≤14 days) 
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3.2.2.2  Systemic Effects
The systemic effects observed after oral exposure of humans and animals to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or
3,5-DNT are discussed below.  No studies were located regarding musculoskeletal effects in humans or
animals after oral exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
All LOAEL values from each reliable study for systemic effects in each species and duration category for
2,3-, 2,4-, 2,5-, 2,6-, 3,4-, and 3,5-DNT are recorded in Tables 3-1, 3-2, 3-3, 3-4, 3-5, and 3-6, 
respectively, and plotted in Figures 3-1, 3-2, 3-3, 3-4, 3-5, and 3-6, respectively.
Respiratory Effects. No studies were located regarding respiratory effects in humans after oral
exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
No histopathological effects on the lungs were found when Sprague-Dawley rats were fed 261 mg/kg/day 
(males) or 273 mg/kg/day (females) 2,4-DNT for 14 days (McGown et al. 1983).
No respiratory system effects were observed when CDF rats were fed 14 mg/kg/day Tg-DNT for 2 years 
(Hazleton Laboratories 1982).  Histopathological examination of the lungs and respiratory tract tissues of
rats exposed to 14 mg/kg/day Tg-DNT for 2 years or 35 mg/kg/day for 1 year did not reveal any
abnormalities (Hazleton Laboratories 1982).
No studies were located regarding respiratory effects in animals after oral exposures to 2,3-, 2,5-, 2,6-, 
3,4-, or 3,5-DNT.
Cardiovascular Effects. No studies were located regarding cardiovascular effects in humans after
oral exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Neither changes in heart weight nor microscopic lesions in the heart were observed in male Sprague-
Dawley rats receiving gavage doses up to 275 mg/kg/day 2,3-DNT for 14 days (Lent et al. 2012a;
USAPHC 2011a).
No histopathological effects on the cardiovascular system were found after Sprague-Dawley rats received
261 mg/kg/day (males) or 273 mg/kg/day (females) 2,4-DNT in the diet for 14 days (McGown et al.
1983). Neither changes in heart weight nor microscopic lesions in the heart were observed in male 
   
 
    
 
 
       
  
 
   
   
   
 
  
  
     
      
     
 
     
   
     
  
     
 
      
 
 
   
     
 
 
      
  
 
  
  
 
      
 
 
 
 
 
 
94DINITROTOLUENES
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Sprague-Dawley rats receiving gavage doses up to 142 mg/kg/day 2,4-DNT for 14 days (Lent et al.
2012a; USAPHC 2011b).
Increased absolute and relative heart weight, along with mild-to-moderate fibrosis in 4/5 animals and 
trace-to-moderate inflammation in 2/5 animals, were noted in male rats receiving 308 mg/kg/day
2,5-DNT via gavage for 14 days (Lent et al. 2012a; USAPHC 2011c).
One of six male Sprague-Dawley rats exposed to 227 mg/kg/day 3,4-DNT (the highest dose tested)
exhibited cardiac lesions consisting of mild myocardial fibrosis, inflammation, and necrosis; heart weight
was not affected at this dose or at the lower doses tested (Lent et al. 2012a; USAPHC 2011e). Exposure
to 14 days of gavage doses up to 39 mg/kg/day 3,5-DNT did not result in changes in heart weight or
microscopic lesions in the hearts of male Sprague-Dawley rats (Lent et al. 2012a; USAPHC 2011f).
At the 26-week interim sacrifice in a 104-week study in which CDF rats were fed 0, 3.5, 14, or
35 mg/kg/day Tg-DNT in the diet, an increased incidence and severity of myocarditis was noted in males 
at 35 mg/kg/day (Hazleton Laboratories 1982).  It was believed that this spontaneous inflammatory
condition was exacerbated by ingestion of Tg-DNT in the high-dose animals.  Although this condition 
was also observed at the 55-week sacrifice, it was not observed at 52 or 104 weeks.
Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans after
oral exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
There were no histopathological effects on the gastrointestinal tract of Sprague-Dawley rats fed
261 mg/kg/day (males) or 273 mg/kg/day (females) 2,4-DNT in the diet for 14 days (McGown et al.
1983).
Treatment of rats with up to 35 mg/kg/day Tg-DNT for up to 1 year or 14 mg/kg/day for up to 2 years did
not cause any histopathological changes in the gastrointestinal tract (Hazleton Laboratories 1982).
No studies were located regarding gastrointestinal effects in animals after oral exposures to 2,3-, 2,5-, 
2,6-, 3,4-, or 3,5-DNT.
Hematological Effects. No studies were located regarding hematological effects in humans after
oral exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
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Hematological effects were noted in virtually all animal studies of oral exposure to DNTs in which 
circulating blood was examined.  The most common findings were methemoglobinemia, anemia, 
reticulocytosis, and an increase in Heinz bodies. The hematological effects are caused by oxidation of the 
iron in hemoglobin, producing methemoglobin.  Heinz bodies are granules in erythrocytes that are
believed to result from denatured hemoglobin.  Reticulocytosis, a finding in many animals in these 
studies, is caused by the increased production of immature erythrocytes (red blood cells) and is seen as a
compensatory mechanism in anemia resulting from exposure to 2,4- and 2,6-DNT.  This hematotoxic
syndrome is a common effect of exposure to aromatic amines and most organic and inorganic nitrates,
and it has been implicated for many oxidizing agents (Smith 1996; U.S. Army 1979).
When male Sprague-Dawley rats were treated for 14 days with gavage doses of 275 mg/kg/day 2,3-DNT,
hematological effects included extramedullary hematopoiesis and lymphoid hyperplasia of the spleen and 
lymphoid depletion (Lent et al. 2012a; USAPHC 2011a).
Female Sprague-Dawley rats (5/group) administered 2,4-DNT via gavage (in 5% v/v DMSO in corn oil)
and observed for 24 or 48 hours after dosing showed evidence of erythrocytosis, as indicated by
significant increases in hemoglobin, hematocrit, and/or erythrocyte and granulocyte counts, at doses 
≥99 mg/kg (Deng et al. 2011).  Relative to controls, erythrocyte and granulocyte counts were increased by
11 and 552% at 99 mg/kg after 24 hours; elevations in hemoglobin (27–31%) and hematocrit (29–33%)
were only statistically significant in rats treated at 198 or 398 mg/kg and evaluated at 48 hours.  No 
significant changes in hematological end points were observed in rats treated with 2,4-DNT at 5 or
50 mg/kg and evaluated 24 or 48 hours after dosing.  Development of erythrocytosis 48 hours following a
single exposure to 2,4-DNT may be a secondary effect of dehydration, rather than a direct effect on the
hematological system; however, no information on drinking water consumption was reported in this
study.  Slight cyanosis was observed in rats administered 60 mg/kg 2,4-DNT by gavage for 5 days (Lane 
et al. 1985).  No changes in hematological parameters were found in Sprague-Dawley rats fed
261 mg/kg/day (males) or 273 mg/kg/day (females) 2,4-DNT in the diet for 14 days (McGown et al.
1983).  In male rats receiving 2,4-DNT by gavage for 14 days, red blood cell count was significantly
decreased at 142 mg/kg/day, while extramedullary hematopoiesis and lymphoid hyperplasia of spleen 
were seen at doses ≥71 mg/kg/day (Lent et al. 2012a; USAPHC 2011b).  Hematocrit, percent
reticulocytes, and relative spleen weight were not different from controls in C57Bl/6N mice exposed to
134 mg/kg/day 2,4-DNT via gavage for 14 days (Wilbanks et al. 2014).  Kozuka et al. (1979) found 
methemoglobin concentrations increased to 7 times those of controls in the blood of rats fed a time­
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weighted average (TWA) dose of 371 mg/kg/day 2,4-DNT in the diet for 6 months.  Anemia was
observed in a 13-week feeding study in which male and female CD rats were fed 266 and 145 mg/kg/day,
respectively, in the diet; milder effects, such as reticulocytosis and hemosiderosis or abnormal pigment in 
the spleen, were found at 93 and 108 mg/kg/day in males and females, respectively (Lee et al. 1985; U.S. 
Army 1978b).  No hematological effects were observed in males and females administered 34 and 
38 mg/kg/day, respectively.  Mild anemia (as indicated by decreases in erythrocyte count, hematocrit, or
hemoglobin concentration) and concurrent reticulocytosis were also observed in male and female CD-1 
mice administered 413 and 468 mg/kg/day 2,4-DNT, respectively, in the diet for 13 weeks (Hong et al.
1985; U.S. Army 1978b). Anemia, accompanied by the presence of Heinz bodies, was observed in beagle 
dogs given 25 mg/kg/day 2,4-DNT in capsules (Ellis et al. 1985; U.S. Army 1978b).
As part of a 2-year study in Beagle dogs (6/sex/group) exposed to 2,4-DNT at doses of 0.2, 1.5, or
10 mg/kg/day, effects on hematological parameters were evaluated after 3, 6, and 9 months of treatment
(U.S. Army 1979).  At these intermediate-duration timepoints, hematological effects consistent with
development of methemoglobinemia, anemia, and compensatory hematopoiesis (including decreased 
hemoglobin, hematocrit, and erythrocyte counts, and increased serum methemoglobin and reticulocyte 
counts) were observed in beagle dogs administered oral 2,4-DNT at 1.5 or 10 mg/kg/day.  In female dogs
administered 10 mg/kg/day, statistically significant decreases in erythrocyte count, hematocrit, and 
hemoglobin, a statistically significant increase in reticulocyte count, and the presence of Heinz bodies in 
serum were observed.  Similar hematological effects were observed in female dogs administered 0.2 and
1.5 mg/kg/day, although effects did not reach statistical significance, most likely because the power of the 
study to detect statistically significant changes was compromised by the small number of dogs per
treatment group. However, a clinically significant increase in methemoglobin levels of 225% was 
observed in female dogs administered 1.5 mg/kg/day; no significant hematological effects were observed 
at 0.2 mg/kg/day.  Although effects at all time points were qualitatively similar, hematological changes
observed after 9 months of exposure were more consistent and pronounced than those observed at the
3- and 6-month time periods.  
Chronic studies of animals administered 2,4-DNT provide data that strengthen the weight-of-evidence 
supporting hematological effects.  In a 24-month study, hematological effects consistent with
development of methemoglobinemia, anemia, and compensatory hematopoiesis (including decreased 
hemoglobin, hematocrit, and erythrocyte counts, and increased serum methemoglobin and reticulocyte
counts) were observed in beagle dogs (6/sex/group) administered oral 2,4-DNT at 1.5 or 10 mg/kg/day for
12 months of continuous dosing (U.S. Army 1979). No significant hematological effects were observed
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in dogs administered 2,4-DNT at 0.2 mg/kg/day.  After treatment for 18 or 24 months, only slight or no 
anemia, near normal reticulocyte levels, no Heinz bodies, and minimal amounts of methemoglobin were
detected, likely reflective of an adaptive response (Ellis et al. 1985; U.S. Army 1978b).  
In a 2-year study (with a 1-year interim sacrifice) in which CD rats were fed 0.6, 3.9, or 34.5 mg/kg/day 
(males) or 0.7, 5.1, or 45.3 mg/kg/day (females) 2,4-DNT, significant decreases in red blood cell count
were found in mid-dose males compared to controls, and anemia (as indicated by further reductions in red 
blood cell count, decreased hematocrit, decreased hemoglobin, and a compensatory increase in 
reticulocytes) was found in high-dose animals after 1 year (Lee et al. 1985; U.S. Army 1978b, 1979).  No 
changes in methemoglobin or Heinz bodies were found.  CD-1 mice that were administered 14, 95, or
898 mg/kg/day 2,4-DNT in the diet for 24 months were found to be anemic (as shown by significant
reductions in erythrocytes and hemoglobin) at the high concentration, with compensatory increases in 
reticulocytes (Hong et al. 1985; U.S. Army 1979).
Dark spleen and mild-to-moderate extramedullary hematopoiesis were observed in male Sprague-Dawley
rats treated for 14 days with gavage doses ≥39 mg/kg/day 2,5-DNT (Lent et al. 2012a; USAPHC 2011c).  
Dose-related hematology changes were noted, including decreased red blood cells at ≥77 mg/kg/day; 
increased mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) at
≥154 mg/kg/day; and increased red blood cell distribution width (at 77 and 154 mg/kg/day, but not at
308 mg/kg/day).  Total white blood cell count was increased at 308 mg/kg/day, resulting from a
nonsignificant increase in lymphocytes; in addition, the percent of eosinophils was decreased at this dose
(Lent et al. 2012a; USAPHC 2011c).
Female Sprague-Dawley rats (5/group) administered 199 mg/kg 2,6-DNT as a single dose via gavage (in
5% v/v DMSO in corn oil) showed evidence of erythrocytosis, as indicated by statistically significant 
increases in serum hemoglobin (45%), hematocrit (41%), and erythrocyte (61%) and granulocyte
(11-fold) counts 48 hours after dosing (Deng et al. 2011).  Increased numbers of reticulocytes (44%
higher than controls), which were associated with mature erythrocytes containing Heinz bodies, were also
observed in rats administered 199 mg/kg and evaluated at 24 hours.  No significant changes in 
hematological end points were observed in rats administered 2,6-DNT at 5–99 mg/kg and evaluated 24 or
48 hours after dosing.  Development of erythrocytosis 48 hours following a single exposure to 2,6-DNT
may be a secondary effect of dehydration, rather than a direct effect on the hematological system;
however, no information on drinking water consumption was reported in this study.  Lent et al. (2012a; 
USAPHC 2011d) reported hematology changes consisting of significantly reduced hemoglobin and 
   
 
    
 
 
    
   
 
  
 
   
   
  
  
   
   
 
 
    
   
   
   
 
 
  
 
 
 
  
  
   
   
  
  
 
     
  
 
 
 
 
 
98DINITROTOLUENES
3. HEALTH EFFECTS
hematocrit, as well as increased neutrophils, increased monocytes, and increased percentages of
neutrophils and lymphocytes, in male rats exposed by gavage to 134 mg/kg/day of 2,6-DNT.  
Nonsignificant decreases in hemoglobin and hematocrit were seen at all doses in this study (4– 
134 mg/kg/day).  As part of a 13-week study in Beagle dogs (4/sex/group) exposed to 2,6-DNT at doses 
of 4, 20, or 100 mg/kg/day, effects on hematological parameters were evaluated after 2 weeks of
treatment (U.S. Army 1976).  Dogs treated at 20 mg/kg/day showed a statistically significant decrease in
erythrocyte count (16%) and a significant increase in mean cell hemoglobin (5%) after dosing for
2 weeks.  At 100 mg/kg/day, more pronounced changes consistent with development of
methemoglobinemia, anemia, and compensatory hematopoiesis were observed; dogs showed statistically
significant reductions in erythrocyte count, hematocrit, and hemoglobin and an increase in reticulocyte
count after 2 weeks of continuous dosing (U.S. Army 1976).
Subchronic administration (13 weeks) of 2,6-DNT in dogs and rats provide data that strengthen the
weight-of-evidence supporting hematological effects. Significant hematological effects were observed in
beagle dogs (4/sex/group) after administration of 2,6-DNT at 20 and 100 mg/kg/day, but not 4 mg/kg/day
(U.S. Army 1976).  Dogs treated at 20 mg/kg/day showed a statistically significant decrease in
erythrocyte count (12%) after dosing for 4 weeks.  At 100 mg/kg/day, more pronounced changes
consistent with development of methemoglobinemia, anemia, and compensatory hematopoiesis were
observed; dogs showed statistically significant reductions in erythrocyte count, hematocrit, and 
hemoglobin and an increase in reticulocyte count after 4 weeks of continuous dosing.  Histopathological
evaluation of the spleen showed an increased incidence of extramedullary erythropoiesis in dogs treated 
with 2,6-DNT at 4, 20, or 100 mg/kg/day for 4 or 13 weeks; this effect is an adaptive response to 
2,6-DNT-induced methemoglobinemia and anemia.  
Subchronic (13-week) administration of 2,6-DNT in CD rats induced changes in hematological
parameters (measured at 4, 8, and 13 weeks) indicative of anemia and compensatory hematopoiesis 
(including significant decreases in erythrocytes, hematocrit, and hemoglobin and increased reticulocytes)
at the highest tested dose (145 and 155 mg/kg/day for male and female rats, respectively) only; these 
effects were most pronounced after treatment for 4 weeks (U.S. Army 1976).  No significant
hematological changes were observed at 7 and 35 mg/kg/day (males) or 7 and 37 mg/kg/day (females).  
However, histopathological effects (extramedullary hematopoiesis and/or splenic hemosiderosis),
indicative of an adaptive response to anemia and compensatory erythropoiesis, were observed in male and
female rats administered 2,6-DNT at doses ≥7 mg/kg/day.  Although histopathological effects 
(extramedullary hematopoiesis) were observed in CD-1 mice administered 2,6-DNT at ≥51 mg/kg/day
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(but not 11 mg/kg/day) for 4 or 13 weeks, no statistically significant changes in hematological parameters 
were seen at levels up to 289 mg/kg/day (males) or 299 mg/kg/day (females). The study authors indicated
that some blood samples clotted, making hematological analyses impossible to perform.  The small
number of animals evaluated likely contributed to the identification of histopathological findings of the
spleen in the apparent absence of 2,6-DNT-induced hematological effects.  The 2,6-DNT isomer was not
tested for hematological end points in studies of chronic duration.
Fourteen-day gavage exposure of male Sprague-Dawley rats to 3,4-DNT resulted in reduced hemoglobin
and hematocrit at all doses, with statistically significant reductions at doses of 14, 28, and 113 mg/kg/day; 
however, the authors indicated that both parameters remained within reference ranges at all doses (Lent et
al. 2012a; USAPHC 2011e).  Splenic lesions, of trace-to-mild severity, were observed at doses 
≥57 mg/kg/day, including extramedullary hematopoiesis and lymphoid hyperplasia.
In the corresponding 14-day rat study of 3,5-DNT, Lent et al. (2012a; USAPHC 2011f) observed no 
changes in hematology parameters and no splenic lesions at doses up to 39 mg/kg/day.
Hematological changes consistent with those observed in anemia were found in pregnant F344 rats 
administered 100 mg/kg Tg-DNT by gavage during gestation days 7–20 (Jones-Price et al. 1982).  
Administration of Tg-DNT to rats in the diet for 4 weeks (Hazleton Laboratories 1977) or 26 weeks 
(Hazleton Laboratories 1982) resulted in dose- and duration-related adverse effects on hematological
parameters.  In the 4-week study at 37.5 mg/kg/day, significant increases in reticulocytes and percentage 
of Heinz bodies were noted in both sexes and significant increases in methemoglobin levels were found in 
females; anemia was observed at 100 mg/kg/day in both sexes (Hazleton Laboratories 1977).  Spleens of
rats fed 150 mg/kg Tg-DNT for 30 days in the diet were altered in appearance; these alterations included
discoloration, enlargement, and surface irregularity (Hazleton Laboratories 1977). An increased
incidence of extramedullary hematopoiesis was noted in the splenic red pulp of male, but not female, rats 
fed 35 mg/kg/day Tg-DNT in the diet for 52 weeks (Hazleton Laboratories 1982). In rats sacrificed after
26 weeks in a 24-month study, no effects on hematological parameters were observed at 14 mg/kg/day 
Tg-DNT.  However, at 35 mg/kg/day, there were increases in reticulocytes and methemoglobin and
decreases in red blood cells along with hemosiderosis and extramedullary hematopoiesis in males, and 
increases in MCV in females (Hazleton Laboratories 1982).  After 1 year, slight-to-moderate myeloid and 
erythroid hyperplasia was noted in the bone marrow of most male rats treated with 35 mg/kg/day Tg-DNT
(Hazleton Laboratories 1982).  In a 24-month study in which Tg-DNT was administered to rats in the
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diet, anemia was observed at 14 mg/kg/day in males but not in females; the NOAEL for this effect in
males was 3.5 mg/kg/day Tg-DNT (Hazleton Laboratories 1982).
The consistent observation of adverse hematological effects following exposure of laboratory animals to
DNTs indicates that the blood is a primary target of DNT toxicity. As noted previously and shown in 
Table 3-7, the various DNT isomers elicited isomer-specific differences in selected hematological
parameters following 14 days of gavage treatment of male Sprague-Dawley rats (Lent et al. 2012a;
USAPHC 2011a, 2011b, 2011c, 2011d, 2011e, 2011f). The 2,4- and 2,5-DNT isomers were the only
ones causing decreases in red blood cell counts, with 2,5-DNT being more potent than 2,4-DNT.
Increased spleen weight was observed at similar concentrations of 2,4-, 2,5-, and 2,6-DNT. Splenic
lesions were observed after acute exposure to all DNT isomers except 3,5-DNT; the available data 
suggest that the 2,5-DNT isomer is more potent than the other isomers. 
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans after
oral exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5-, or Tg-DNT or in animals after oral exposure to 2,3-, 2,5-, 
2,6-, 3,4-, 3,5-, or Tg-DNT. Swim-to-exhaustion time was decreased by 82% (relative to controls) in
C57Bl/6N mice exposed to 134 mg/kg/day 2,4-DNT via gavage for 14 days (Wilbanks et al. 2014).
Hepatic Effects. No studies were located regarding hepatic effects in humans after oral exposure to
2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
The hepatotoxic effects of DNTs have been consistently observed in animals. The liver appears to be a 
target organ of DNT toxicity, particularly when administered to rats, but hepatotoxic effects have also
been observed in mice and dogs.  Hepatic effects of DNTs include liver discoloration and inflammation, 
alteration of hepatocytes, proliferation of bile duct epithelium, and hyperplastic foci.  However, as 
discussed in Section 3.2.2.7 (Cancer), 2,4-, 2,6-, and Tg-DNT have been shown to induce hepatocellular
carcinoma following chronic-duration oral exposure. Thus, hepatic effects observed at less-than-chronic
exposure durations or at lower doses may represent early stages of progressive development to hepatic 
cancer.
In male Sprague-Dawley rats receiving gavage doses of 2,3-DNT for 14 days, mean relative (but not
absolute) liver weight was increased at 275 mg/kg/day, but this increase was likely attributable to lower
body weight at this dose (Lent et al. 2012a; USAPHC 2011a).  Dose-related clinical chemistry changes 
were not observed, and no histopathology lesions were seen in the liver.
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Table 3-7. NOAELs and LOAELs for Hematological Effects Following 14-Day 

Gavage Dosing of Male Sprague-Dawley Rats with Individual DNT Isomers

Decreased red blood Increased spleen Increased incidence 
Effect cell count weight splenic lesions
Effect level (mg/kg/day) NOAEL LOAEL NOAEL LOAEL NOAEL LOAEL
Isomer
2,3-DNT 275 – 275 – 138 275
2,4-DNT 71 142 36 71 36 71
2,5-DNT 39 77 39 77 19 39
2,6-DNT 134 – 35 68 35 68
3,4-DNT 227 – 227 – 28 57
3,5-DNT 39 – 39 – 39 –
DNT = dinitrotoluene; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level
Sources: Lent et al. 2012a; USAPHC 2011a, 2011b, 2011c, 2011d, 2011e, 2011f
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In female Sprague-Dawley rats (5/group) administered 2,4-DNT via gavage (in 5% v/v DMSO in corn
oil) and observed for 48 hours, significantly decreased levels of serum albumin (13–51% lower than 
controls) were observed at doses ≥99 mg/kg (Deng et al. 2011).  Although relative liver weight was also
significantly increased at 99 mg/kg, this effect was not observed at 198 or 398 mg/kg.  Hepatic sinusoid
congestion was observed in rats administered 398 mg/kg 2,4-DNT in the absence of other
histopathological effects. Significantly increased (14% higher than controls) relative liver weight was
observed in wild type C57Bl/6N mice exposed to 134 mg/kg/day 2,4-DNT via gavage for 14 days; serum
triglycerides and glucose levels were not affected (Wilbanks et al. 2014).  Increased blood cholesterol was 
found in male and female Sprague-Dawley rats fed 78 or 82 mg/kg/day 2,4-DNT, respectively, in the diet
for 14 days, and increased alanine aminotransferase levels were found in males (McGown et al. 1983).
Blood glucose levels trended upward in all male and female groups in this study, but were increased 
significantly only in females fed 273 mg/kg/day. Trace-to-mild single cell necrosis occurred in the livers 
of male Sprague-Dawley rats receiving gavage doses of 18, 36, 71, and 142 mg/kg/day 2,4-DNT; vehicle 
controls and rats exposed to 9 mg/kg/day did not exhibit this effect (Lent et al. 2012a; USAPHC 2011b).  
In addition, the authors observed trace apoptosis in the livers of 1/6 rats in each of the 36 and 
71 mg/kg/day groups, and increases in glycogen deposition at ≥36 mg/kg/day. No clinical chemistry
changes were seen at any dose.
Oral administration of 2,4-DNT for 13 weeks to rats (266 or 145 mg/kg/day in males and females,
respectively) and dogs (25 mg/kg/day) did not result in liver toxicity (Ellis et al. 1985; U.S. Army 1978b).  
After 26 weeks of treatment, rats fed 27 mg/kg/day in the diet had significant increases in epoxide
hydrolase (EH) activity, which is sometimes considered to be a phenotypic marker of neoplastic nodules;
however, hepatocellular lesions did not develop in these animals when treatment was carried through
52 weeks (Leonard et al. 1987). Mild hepatocellular dysplasia was observed in mice fed 137 mg/kg/day 
(males) or 468 mg/kg/day (females) of 2,4-DNT for 13 weeks (Hong et al. 1985; U.S. Army 1978b).
Hepatic effects have also been observed in laboratory animals following chronic-duration oral exposure to 
DNTs.  However, these effects are often observed in conjunction with the development of hepatocellular
carcinoma and may represent precancerous changes.  For example, dietary exposure of male rats to
0.6 mg/kg/day 2,4-DNT induced “hepatocellular” alterations; however, neoplastic nodules were noted at
this dose level and higher as well (Lee et al. 1985).  Hepatocellular degeneration and vacuolation 
accompanied by acidophilic foci and occasional basophilic foci of cellular alteration were found in F344 
rats fed 27 mg/kg/day 2,4-DNT for 52 weeks (Leonard et al. 1987). The incidences of focal areas of 
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alteration were less in the 2,4-DNT-treated rats than they were in rats similarly treated with 2,6-DNT or
Tg-DNT.  Wistar rats fed a TWA dose of 371 mg/kg/day 2,4-DNT in the diet for 6 months had increased 
relative liver weights, formation of puruloid matter, and increased levels of serum glutamic-oxaloacetic 
transaminase (SGOT), lactate dehydrogenase (LDH), alkaline and acid phosphatase, triglycerides, and
blood glucose levels compared to controls (Kozuka et al. 1979).  In this study, the levels of serum
albumin and the albumin/globulin ratios were decreased.  Hepatocellular dysplasia was found in male and 
female CD-1 mice fed 14 or 898 mg/kg/day 2,4-DNT, respectively, for 24 months (Hong et al. 1985; U.S. 
Army 1979).  Administration of 10 mg/kg/day 2,4-DNT for 24 months resulted in biliary hyperplasia in 
dogs; this effect was not seen in dogs administered 1.5 mg/kg/day (Ellis et al. 1985; U.S. Army 1979).
When 2,5-DNT was administered to male Sprague-Dawley rats via gavage for 2 weeks at doses up to
308 mg/kg/day, there were no treatment-related adverse effects on serum liver enzyme activity, liver
weight, or liver histology (Lent et al. 2012a; USAPHC 2011c).
Increased ALT activity and histopathological changes to the liver were observed in individual female 
Sprague-Dawley rats administered 50 and 99 mg/kg 2,6-DNT (in 5% DMSO in corn oil) by gavage and 
observed for 48 hours (Deng et al. 2011).  Serum ALT activity was significantly increased 7-fold 
compared to controls in rats administered 50 and 99 mg/kg 2,6-DNT, but no increase in serum ALT level
was observed at lower dose levels (5–25 mg/kg).  Histopathological changes to the liver observed in rats
administered 2,6-DNT at 50 or 99 mg/kg included congested sinusoids with sloughed hepatocytes and 
segmented neutrophils, disorganized midzonal regions characterized by infiltration of erythrocytes and 
hepatocytes with pyknotic nuclei and microvesiculated cytoplasm, and apoptotic hepatocytes (severity of
effects not specified).  ALT levels were similar to controls and hepatocytes were mostly undamaged in
rats administered 2,6-DNT at 199 mg/kg, although evidence of sinusoid congestion, occasional
erythrocyte infiltration (with no signs of necrosis), and enlarged nuclei in several hepatocytes were noted.  
Three consecutive daily oral doses of 100 mg/kg/day 2,6-DNT resulted in mild diffuse hepatocellular
hypertrophy in male Sprague-Dawley rats (Rothfuss et al. 2010). After 2 weeks of gavage doses of 68 or
134 mg/kg/day 2,6-DNT, male rats exhibited significant increases in serum ALT and aspartate 
aminotransferase (AST), as well as a nonsignificant but dose-related increase in alkaline phosphatase 
(ALP) (Lent et al. 2012a; USAPHC 2011d).  Liver lesions consisting of hepatocellular and oval cell
hyperplasia and hepatocellular hypertrophy occurred at doses ≥35 mg/kg/day.  Additional lesions
(increases in mitotic activity, single cell necrosis, and karyocytomegaly) occurred at higher doses of 68 
and 134 mg/kg/day (Lent et al. 2012a; USAPHC 2011d).  
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Intermediate duration exposure to 2,6-DNT also results in liver toxicity.  After oral exposure to
33 mg/kg/day 2,6-DNT for 29 consecutive days, male rat livers exhibited hepatocellular hypertrophy, 
single cell necrosis, bile duct hyperplasia, and focal hepatocellular vacuolation, in the absence of changes 
in serum liver enzyme levels (Rothfuss et al. 2010). Six weeks of dietary consumption of 7 mg/kg/day 
2,6-DNT caused a 380% increase in EH levels in rats but did not increase the level of DT-diaphorase
(DTD) (Leonard et al. 1987).  In the same study, both of these enzymes were elevated after 6 weeks of
treatment with 14 mg/kg/day of 2,6-DNT.  Dosing of rats, mice, and dogs with 2,6-DNT for 13 weeks 
resulted in liver toxicity (U.S. Army 1976).  Bile duct hyperplasia was observed in rats fed 35 mg/kg/day 
and mice fed 51 mg/kg/day 2,6-DNT for 13 weeks (U.S. Army 1976).  Liver degeneration and bile duct
hyperplasia were observed in dogs dosed with 20 mg/kg/day 2,6-DNT but were not seen in dogs dosed 
with 4 mg/kg/day (U.S. Army 1976). After 52 weeks of treatment with 7 mg/kg/day 2,6-DNT,
hepatocellular degeneration and vacuolation accompanied by acidophilic and basophilic foci of cellular
alteration were found in F344 rats (Leonard et al. 1987).
Gavage doses up to 227 mg/kg/day 3,4-DNT did not alter clinical chemistry or liver histology in male
Sprague-Dawley rats (Lent et al. 2012a; USAPHC 2011e). Significant increases in relative, but not
absolute liver weight were noted at 113 and 227 mg/kg/day, but were likely attributable to reduced body
weights at these doses.
In the 14-day gavage study of rats by Lent et al. (2012a; USAPHC 2011f), no exposure-related changes in
serum liver enzymes, liver weight, or histopathology were seen at doses up to 39 mg/kg/day of 3,5-DNT.
Irregular liver surfaces were found in male F344 rats fed 37.5 mg/kg/day Tg-DNT for 30 days (Hazleton 
Laboratories 1977).  Hepatocytic necrosis, nonsupportive pericholangitis, and periportal megalocytosis
were found in CDF rats fed 14 mg/kg/day for 26 weeks, and when treatment of these animals was 
extended to 2 years, slight-to-severe biliary cirrhosis was found in males (Hazleton Laboratories 1982).  It
has been suggested that this latter lesion may be a precursor to cholangiocarcinoma (Hazleton 
Laboratories 1982).  Hepatocytic degeneration and acidophilic and basophilic foci of cellular alteration 
were observed in F344 rats fed 35 mg/kg/day Tg-DNT in the diet for 52 weeks (Leonard et al. 1987).
When administration of Tg-DNT was continued for 24 months, liver discoloration resulted at
3.5 mg/kg/day and liver nodules and malignancies at 14 mg/kg/day (Hazleton Laboratories 1982).
As shown in Table 3-8, 2,4- and 2,6-DNT were the only isomers that elicited hepatic effects in Sprague-
Dawley rats following 14 days of gavage treatment (Lent et al. 2012a; USAPHC 2011a, 2011b, 2011c, 
   
 
    
 
 
 
 
   
 
  
 
  
       
    
       
       
       
       
       
       
 
   
 
     
 
 
 
 
 
105DINITROTOLUENES
3. HEALTH EFFECTS
Table 3-8. NOAELs and LOAELs for Hepatic Effects Following 14-Day Gavage 

Dosing of Male Sprague-Dawley Rats with Individual DNT Isomers

Increased serum liver Increased incidence 
Effect Increased liver weight enzyme activity hepatic lesions
Effect level (mg/kg/day) NOAEL LOAEL NOAEL LOAEL NOAEL LOAEL
Isomer
2,3-DNT 275 – 275 – 275 –
2,4-DNT 71 142 142 – 18 36
2,5-DNT 308 – 308 – 308 –
2,6-DNT 134 – 35 68 14 35
3,4-DNT 227 – 227 – 227 –
3,5-DNT 39 – 39 – 39 –
DNT = dinitrotoluene; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level
Sources: Lent et al. 2012a; USAPHC 2011a, 2011b, 2011c, 2011d, 2011e, 2011f
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2011d, 2011e, 2011f).  The 2,4-DNT isomer caused increased liver weight (LOAEL=142 mg/kg/day) and 
increased incidences of single cell necrosis and glycogen deposition (LOAEL=36 mg/kg/day).  The
2,6-DNT isomer caused increased serum liver enzyme activity (LOAEL=68 mg/kg/day) and increased
incidences of hepatocellular hypertrophy and hyperplasia and oval cell hyperplasia 
(LOAEL=35 mg/kg/day).
Renal Effects. No studies were located regarding renal effects in humans after oral exposure to 2,3-, 
2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Exposure to 2,3-DNT by daily gavage for 14 days did not result in serum chemistry changes indicative of
renal toxicity, or changes in kidney weight in male rats; however, increased incidences of renal tubular
dilatation (2/6 rats) and renal lymphocytic infiltration (4/6) were observed (Lent et al. 2012a; USAPHC
2011a).
Sprague-Dawley rats (5/group) administered 2,4-DNT (in 5% DMSO in corn oil) via gavage at doses up 
to 398 mg/kg and evaluated at 24 or 48 hours showed no effects on levels of serum creatinine or urea
(Deng et al. 2011).  Hyaline droplet accumulation in the epithelium of the proximal convoluted tubule
was found in both sexes of Sprague-Dawley rats after they were administered 78, 104, 165, or
261 mg/kg/day 2,4-DNT (males) or 82, 109, 173, or 273 mg/kg/day 2,4-DNT (females) in the diet
(McGown et al. 1983).  Although this effect was observed at all concentrations, there was no dose
response evident. The kidney was not a target organ of 2,4-DNT in male rats exposed via gavage for
14 days at doses up to 142 mg/kg/day; serum chemistry and kidney weight were not affected by exposure, 
nor were there histopathology findings in the kidney (Lent et al. 2012a; USAPHC 2011b).  Oral
administration of 2,4-DNT to mice (413 mg/kg/day), rats (145 mg/kg/day), and dogs (25 mg/kg/day) for
13 weeks did not result in significant adverse effects in the kidney (Hong et al. 1985; U.S. Army 1978b).  
Treatment of the same species for 24 months resulted in renal dysplasia in male mice at a dose of
14 mg/kg/day of 2,4-DNT, but no renal effects were observed in rats or dogs dosed with 34.5 mg/kg/day 
or 10 mg/kg/day, respectively (U.S. Army 1979).  Adverse effects in the kidneys of mice included cystic 
dysplasia in the tubular epithelium, atypical epithelium lining the cysts, and a variety of tumors (Hong et
al. 1985). These effects were more pronounced in male mice than in female mice.
Exposure to 2,5-DNT for 14 days at gavage doses up to 308 mg/kg/day did not result in kidney effects in 
male rats, as assessed by serum chemistry, kidney weight, and histopathology (Lent et al. 2012a; 
USAPHC 2011c).
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Renal tubular degeneration and proximal tubule degeneration were observed in male rats exposed by
gavage to 2,6-DNT at 134 mg/kg/day (the highest dose tested) for 14 days (Lent et al. 2012a; USAPHC
2011d).
Female Sprague-Dawley rats (5/group) administered 2,6-DNT (in 5% DMSO in corn oil) via gavage at
doses up to 199 mg/kg showed no effects on levels of serum creatinine or urea at 24 or 48 hours (Deng et
al. 2011).  Dosing of dogs with 20 mg/kg/day 2,6-DNT for 13 weeks resulted in dilated tubules, foci of
inflammation, and degeneration of the kidney (U.S. Army 1976).  No treatment-related effects on the
kidney were found when rats were fed 2,6-DNT for 13 weeks (U.S. Army 1976).  The severe renal effects 
observed after 2,4-DNT administration in mice were not observed when mice were fed 289 mg/kg/day 
2,6-DNT for 13 weeks (U.S. Army 1976).  However, the renal toxicity of 2,4-DNT in mice was observed
only after chronic administration.  Chronic studies of 2,6-DNT have not been performed in mice.
After 26 or 52 weeks of dietary consumption of 35 mg/kg/day Tg-DNT, BUN levels were significantly
increased in CDF rats (Hazleton Laboratories 1982).  Exacerbation of chronic interstitial nephritis that
was also observed in controls was observed at 14 mg/kg/day Tg-DNT in a chronic study in rats (Hazleton
Laboratories 1982).
Renal effects were observed in male rats exposed to 3,4-DNT by gavage for 14 consecutive days (Lent et
al. 2012a; USAPHC 2011e). These effects consisted of proximal tubule degeneration, renal tubule
basophilia, and lymphocytic infiltration at the highest dose tested (227 mg/kg/day); however, renal
histopathology was not examined at lower doses.
In the corresponding study of 3,5-DNT (Lent et al. 2012a; USAPHC 2011f), no effects on kidney weight, 
kidney histopathology, or serum parameters indicative of renal toxicity were seen in male rats exposed by
gavage to doses up to 39 mg/kg/day for 14 days.
The kidney does not appear to be a sensitive target of DNT toxicity for all species tested. Severe renal 
effects were observed only in CD-1 mice fed 14 mg/kg/day 2,4-DNT for 24 months, and less severe renal
effects were observed in dogs administered 20 mg/kg/day 2,6-DNT for 13 weeks.
In the 14-day gavage studies that compared the effects of the various DNT isomers on the kidneys of male 
Sprague-Dawley rats (Lent et al. 2012a; USAPHC 2011a, 2011b, 2011c, 2011d, 2011e, 2011f), only the
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2,3-, 2,6-, and 3,4-DNT elicited adverse effects.  Increased kidney weight accompanied by increased
incidences of histopathologic lesions (trace tubular dilatation and lymphocytic infiltration) were observed 
for 2,3-DNT (LOAEL=275 mg/kg/day).  Increased kidney weight (LOAEL=68 mg/kg/day) and increased 
incidences of proximal tubule degeneration and renal tubular basophilia were observed for 2,6-DNT
(LOAEL=134 mg/kg/day).  Increased incidences of proximal tubule degeneration, renal tubule
basophilia, and lymphocytic infiltration were noted for 3,4-DNT (LOAEL=227 mg/kg/day).
Endocrine Effects. No studies were located regarding endocrine effects in humans after oral
exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Administration of 2,4-DNT in the diet for 14 days, at 78 mg/kg/day for males or 82 mg/kg/day for
females did not cause any histopathological changes in adrenal, pituitary, or thyroid glands of Sprague-
Dawley rats (McGown et al. 1983).
No histopathological effects on adrenal, pituitary, or thyroid glands were found in rats treated with
14 mg/kg/day Tg-DNT for up to 2 years or 35 mg/kg/day for 1 year (Hazleton Laboratories 1982). 
Increases in the incidence and severity of parathyroid hyperplasia (males) and increases in the incidence 
and severity of fatty metamorphosis and vascular ectasia (males and females) were found in rats fed
14 mg/kg/day Tg-DNT in the diet in a chronic study (Hazleton Laboratories 1982).
No studies were located regarding endocrine effects in animals after oral exposure to 2,3-, 2,5-, 2,6-, 3,4-, 
or 3,5-DNT.
Dermal Effects. No studies were located regarding dermal effects in humans after oral exposure to
2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Concentrations of up to 261 mg/kg/day 2,4-DNT for males or 273 mg/kg/day 2,4-DNT for females
administered in the diet for 14 days to Sprague-Dawley rats caused no histopathological changes in their
skin (McGown et al. 1983).
No effects were found on the skin of rats treated for up to 2 years with 14 mg/kg/day Tg-DNT or up to 
1 year with 35 mg/kg/day Tg-DNT (Hazleton Laboratories 1982).
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No studies were located regarding dermal effects in animals after oral exposure to 2,3-, 2,5-, 2,6-, 3,4-, or
3,5-DNT.
Ocular Effects. No studies were located regarding ocular effects in humans after oral exposure to
2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
The eyes of male and female Sprague-Dawley rats administered up to 261 or 273 mg/kg/day 2,4-DNT,
respectively, in the diet for 14 days did not exhibit any alterations upon histopathological examination 
(McGown et al. 1983).
No effects were found on the eyes of rats treated for up to 2 years with 14 mg/kg/day Tg-DNT in feed or
up to 1 year with 35 mg/kg/day Tg-DNT in feed (Hazleton Laboratories 1982).
No studies were located regarding ocular effects in animals after oral exposure to 2,3-, 2,5-, 2,6-, 3,4-, or
3,5-DNT.
Body Weight Effects. No studies were located regarding body weight effects in humans after oral
exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Adverse effects on body weight and body weight gain in rats, mice, and dogs were observed after oral
administration of 2,4-DNT, 2,6-DNT, and Tg-DNT, and in rats exposed to 3,4-DNT.  In most of these
studies, a concurrent decrease in food consumption was also observed.  Because exposure resulted from
intake of the test article in feed in most of these studies, it is possible that some of the body weight
changes resulted from unpalatability.
Body weight was not altered in male rats receiving doses up to 275 mg/kg/day 2,3-DNT by gavage for
14 days (Lent et al. 2012a; USAPHC 2011a).
Adverse effects on body weight, including body weight loss, have been reported after almost all acute-, 
intermediate-, and chronic-duration oral administration of 2,4-DNT (Bloch et al. 1988; Deng et al. 2011;
Ellis et al. 1985; Hazleton Laboratories 1982; Hong et al. 1985; Kozuka et al. 1979; Lane et al. 1985; Lee
et al. 1985; Lent et al. 2012a; USAPHC 2011b; Leonard et al. 1987; McGown et al. 1983; NCI 1978; U.S. 
Army 1978b, 1979).  Female Sprague-Dawley rats (5/group) administered 2,4-DNT (in 5% DMSO in
corn oil) via gavage at 398 mg/kg showed decreased body weight gain (1–4 g compared to 17 g for
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controls) 48 hours after dosing (Deng et al. 2011).  In another acute study, rats dosed by gavage with 
240 mg/kg 2,4-DNT for 5 days lost weight (Lane et al. 1985). Lent et al. (2012a; USAPHC 2011b) 
reported a 12% decrease in body weight (relative to controls) in male rats given 2,4-DNT by gavage for
14 days at a dose of 142 mg/kg/day. Wilbanks et al. (2014) observed greater body weight loss 
(0.96 versus 0.35 g), compared with untreated controls, in wild type C57Bl/6N mice exposed to 
134 mg/kg/day 2,4-DNT via gavage for 14 days. In general, there were losses of 10–40% in body weight
in acute-, intermediate-, and chronic-duration studies in rats.  After 6 months, decreases in body weight
gain were noted in rats fed 27 mg/kg/day 2,4-DNT (Leonard et al. 1987), and a 25% decrease in body
weight was seen in rats fed 34.5 mg/kg/day (Lee et al. 1985; U.S. Army 1978b, 1979).  This reduction in 
body weight gain tended to become more pronounced when 2,4-DNT was continued for periods of 1– 
2 years (Leonard et al. 1987).  Body weight was decreased 25% in rats that received 20 mg/kg/day 
2,4-DNT in the diet for 78 weeks; the NOAEL in this study was 8 mg/kg/day (NCI 1978).  Mice showed
similar decreases in body weight after intermediate- (13 weeks) and chronic-duration (78–104 weeks)
exposure, but the doses of the test article needed to evoke this effect were considerably higher than in rats 
(Hong et al. 1985; NCI 1978; U.S. Army 1978b).  An 18–24% decrease in body weight was seen in rats 
receiving 72–76 mg/kg/day 2,4-DNT in the diet for 78 weeks (NCI 1978).
In a 14-day study of 2,5-DNT, body weight was not altered in male rats receiving doses up to
308 mg/kg/day (Lent et al. 2012a; USAPHC 2011c).
Female Sprague-Dawley rats (5/group) administered 2,6-DNT (in 5% DMSO in corn oil) via gavage at
50 or 99 mg/kg gained less weight than control animals over the 48-hour observation period (1–4 g 
compared to 17 g for controls); rats from the same study administered 2,6-DNT at 199 mg/kg lost weight
over the course of 48 hours (Deng et al. 2011). Body weight reductions of at least 10% were observed in 
male rats receiving gavage doses ≥35 mg/kg/day for 14 days, although the reductions were statistically
significant only at the highest dose of 134 mg/kg/day (Lent et al. 2012a; USAPHC 2011d).  Reduced 
body weight was reported in male Sprague-Dawley rats exposed to 29 consecutive daily oral doses of
33 mg/kg/day 2,6-DNT (Rothfuss et al. 2010).  Administration of 2,6-DNT also caused decreased body
weight gain or body weight loss in rats, mice, and dogs at doses ranging from 14 to 145 mg/kg/day in
intermediate-duration studies (U.S. Army 1976).  Treatment with 7 mg/kg/day 2,6-DNT for 52 weeks
decreased body weight in rats by 18% (Leonard et al. 1987).
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A 10% reduction in terminal body weight was seen in male rats exposed to 227 mg/kg/day 3,4-DNT by
gavage for 14 days; however, the difference from control weight was not statistically significant (Lent et 
al. 2012a; USAPHC 2011e).
Body weight was not altered in male rats receiving gavage doses up to 39 mg/kg/day 3,5-DNT for
14 days (Lent et al. 2012a; USAPHC 2011f).
A 29% decrease in absolute maternal weight gain was observed in dams fed 14 mg/kg/day Tg-DNT for 
14 days during gestation (Jones-Price et al. 1982).  Decreased body weight or decreased body weight gain
was reported in rats at levels as low as 14 mg/kg/day Tg-DNT in intermediate- or chronic-duration studies
(Hazleton Laboratories 1982).  Other intermediate- and chronic-duration studies also confirmed these
body weight effects (Hazleton Laboratories 1977; Leonard et al. 1987; NCI 1978).
Metabolic Effects. No studies were located regarding metabolic effects in humans after oral exposure 
to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Female Sprague-Dawley rats (5/group) administered 2,4-DNT (at 198 or 398 mg/kg) or 2,6-DNT (at
199 mg/kg) via gavage (in 5% DMSO in corn oil) showed small but statistically significant reductions in
sodium levels in the serum (4–11% lower than controls) 24 and/or 48 hours after dosing (Deng et al. 
2011).  Rats treated with 2,4-DNT at 398 mg/kg also had elevated levels of blood glucose (increased
2.6-fold) 48 hours after dosing.
No studies were located regarding metabolic effects in animals after oral exposure to 2,3-, 2,5-, 3,4-, or
3,5-DNT.
3.2.2.3  Immunological and Lymphoreticular Effects 
No studies were located regarding immunological and lymphoreticular effects in humans after oral
exposure to 2,3-, 2,4-, 2,5-, 2,6-, or 3,5-DNT.
Testing for immunological effects of DNTs is limited. Acute (14-day) exposure of male rats to 2,3-DNT
resulted in lymphoid hyperplasia of the spleen and lymphoid depletion at gavage doses of 275 mg/kg/day
(Lent et al. 2012a; USAPHC 2011a).  In the corresponding study of 2,4-DNT, lymphoid hyperplasia was
seen at doses ≥35 mg/kg/day, and lymphoid depletion was seen at 134 mg/kg/day (Lent et al. 2012a; 
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USAPHC 2011b). No changes in serum concentrations of IgE were observed in rats and dogs
administered 2,4-DNT at levels up to 206 and 25 mg/kg/day, respectively, for 13 weeks (Ellis et al. 1985;
Lee et al. 1985; U.S. Army 1978b).  In these studies, the rats received the test article in feed, while the 
dogs received it in capsules.  No histopathological changes were found in the spleen or thymus of
Sprague-Dawley male rats fed 78 mg/kg/day 2,4-DNT or female rats fed 82 mg/kg/day 2,4-DNT in the
diet for 14 days (McGown et al. 1983).
Administration of 2,6-DNT to dogs (up to 100 mg/kg) and rats (up to 145 mg/kg/day) for 13 weeks 
resulted in no observable changes in IgE serum concentrations (U.S. Army 1976).  IgE is the antibody
associated with allergic or hypersensitive reactions, and so it may be expected that the human sensitizing
potential of 2,4- and 2,6-DNT would be low.  Involution of the thymus was noted when dogs were
administered 100 mg/kg 2,6-DNT, but was not noted when they were administered 20 mg/kg 2,6-DNT by
capsule for 13 weeks (U.S. Army 1976).
Exposure to 3,4-DNT by gavage for 14 days induced lymphoid hyperplasia of the spleen in male rats
exposed to doses ≥57 mg/kg/day (Lent et al. 2012a; USAPHC 2011e).
All LOAEL values from each reliable study for immunological/lymphoreticular effects in each species 
and duration category for 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, and 3,5-DNT are recorded in Tables 3-1, 3-2, 3-3, 
3-4, 3-5, and 3-6, respectively, and plotted in Figures 3-1, 3-2, 3-3, 3-4, 3-5, and 3-6, respectively.  
No studies were located regarding immunological and lymphoreticular effects in animals after oral
exposure to 2,5- or 3,5-DNT, although Lent et al. (2012a; USAPHC 2011c, 2011f) did not observe
splenic lymphoid lesions in rats exposed to these two compounds for 14 days.
3.2.2.4  Neurological Effects 
No studies were located regarding neurological effects in humans after oral exposure to 2,3-, 2,4-, 2,5-, 
2,6-, 3,4-, or 3,5-DNT.
Neurotoxicity appears to be a characteristic syndrome of subchronic and chronic DNT poisoning of
animals.  Neurotoxic symptoms, of decreased severity compared to dogs, were observed in mice and rats 
at doses higher than neurotoxic doses in dogs; however, the test article was administered in feed to
rodents and in capsules to dogs.
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Acute (14-day) oral exposure of male Sprague-Dawley rats to 2,3-DNT at doses up to 275 mg/kg/day or
2,4-DNT at doses up to 142 mg/kg/day did not lead to any clinical signs of neurotoxicity, nor was brain 
weight affected (Lent et al. 2012a; USAPHC 2011a).
In a subchronic study, beagle dogs (4/sex/group) administered 2,4-DNT at 1 or 5 mg/kg/day showed no 
signs of behavioral changes or clinical signs of neurotoxicity.  Neurotoxicity was observed at
25 mg/kg/day, with signs of neurotoxicity (loss of hind leg control) first observed in a female dog on day
12 of treatment.  Three additional male dogs showed similar signs (signs not specified) on day 14 of
treatment.  All dogs administered 25 mg/kg/day showed signs of neurotoxicity after treatment for 12– 
22 days. The onset and severity of toxic signs reportedly varied among dogs within the same treatment
group; some dogs were moribund at the same time that others began experiencing symptoms.  In 
individual dogs, symptom severity varied over time, with no duration-related pattern of severity.  The 
specific neurotoxic effects in dogs affected within the first 14 days of treatment were not specified. The 
NOAEL for the neurotoxicity observed after 12 days was 5 mg/kg/day.  No histopathological changes
were found in the brain or spinal cord of male and female Sprague-Dawley rats fed 2,4-DNT for 14 days 
in the diet at doses of 78 and 82 mg/kg/day, respectively (McGown et al. 1983).  
Neurotoxicity has been reported in laboratory animals after intermediate- or chronic-duration exposure to 
2,4-DNT with symptoms ranging from tremors, convulsions, and ataxia to paralysis. These effects were
observed in 13-week studies of rats and dogs.  Administration of 93 mg/kg/day 2,4-DNT in the diet for
13 weeks caused demyelinization in the cerebellum and brain stem of 1 male rat, while at 266 mg/kg/day,
some rats exhibited a widespread or stiff-legged gait that did not progress to the rigid paralysis observed
in dogs (Lee et al. 1985; U.S. Army 1978b).  After 3 months of being fed 2,4-DNT at 0.5% in the diet (an 
estimated dose of 350 mg/kg/day based on body weight and feed consumption data provided by the study
authors), Wistar rats exhibited humpback and jerky incoordination (Kozuka et al. 1979).  Dogs that were
administered 25 mg/kg/day 2,4-DNT in capsules for 13 weeks began to show neurotoxic effects within
2 months; these effects included incoordination, abnormal gait, rigid paralysis of the hind legs, eventually
progressing to paralysis up to the neck (Ellis et al. 1985; U.S. Army 1978b).  No neurological signs were
observed in mice fed 413 mg/kg/day in males or 468 mg/kg/day in females 2,4-DNT in the diet for
13 weeks (Hong et al. 1985; U.S. Army 1978b).
An abnormal gait was also observed in chronic studies of laboratory animals fed 2,4-DNT.  The
characteristic widespread and stiff-legged gait was observed after feeding 34.5 or 45.3 mg/kg/day 
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2,4-DNT to male and female rats, respectively, for up to 2 years (Lee et al. 1985; U.S. Army 1978b, 
1979).  This stiff-legged gait and hyperactive behavior were also noted in mice fed 898 mg/kg/day in the
diet for 24 months but were not observed in mice at 95 mg/kg/day (Ellis et al. 1985; U.S. Army 1979).  In 
dogs dosed at 1.5 mg/kg/day 2,4-DNT in a 2-year study, one of six dogs showed intermittent loss of
hindquarter control (Ellis et al. 1985; U.S. Army 1979).  Central nervous system lesions were identified in
high-dose (10 mg/kg/day) dogs in this study and included vacuolization, hypertrophy, endothelial mitosis,
and focal gliosis in the cerebellum, as well as some perivascular hemorrhage in the cerebellum and brain 
stem (Ellis et al. 1985; U.S. Army 1979).
Male rats exposed for 14 days by gavage to 2,5-DNT at doses up to 308 mg/kg/day or 2,6-DNT at doses 
up to 134 mg/kg/day did not display clinical signs of neurotoxicity or alterations in brain weight (Lent et 
al. 2012a; USAPHC 2011c).  
Dogs dosed with 20 or 100 mg/kg/day of 2,6-DNT for 13 weeks exhibited dose-related neurotoxic
symptoms that included muscular incoordination, weakness, tremors, and paralysis (U.S. Army 1976).  
Rats and mice dosed at 145 and 289 mg/kg/day of 2,6-DNT, respectively, for 13 weeks did not display 
neurotoxic symptoms (U.S. Army 1976).
Clinical signs of neurotoxicity consisting of facial twitching, hypoactivity, and staring were noted in male 
rats exposed by gavage to 227 mg/kg/day 3,4-DNT for 14 days (Lent et al. 2012a; USAPHC 2011e).  
Male rats exposed to ≥39 mg/kg/day 3,5-DNT by gavage for 14 days were reported to exhibit
neurological signs progressing from facial twitching to paralysis of the forelimbs (Lent et al. 2012a;
USAPHC 2011f).  However, all rats exposed to higher doses died or were sacrificed moribund, as did one
rat exposed to 39 mg/kg/day. It is not clear whether these signs were seen only in the animals that were 
moribund or if some neurological signs were seen in animals that survived treatment.  Animals in the
39 mg/kg/day group also showed a 30% increase (compared with controls) in brain weight relative to 
body weight, as well as mild or moderate inflammatory infiltrates in the brain (Lent et al. 2012a; 
USAPHC 2011f).
Administration of 150 mg/kg/day Tg-DNT to F344 dams during gestation days 7–20 caused hind limb
weakness in 7 of 13 animals (Jones-Price et al. 1982). No clinical signs of neurotoxicity or
histopathological changes were found in rats fed up to 35 mg/kg/day Tg-DNT in the diet for 26 or
52 weeks (Hazleton Laboratories 1982).
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In the 14-day gavage studies that compared the effects of the various DNT isomers on neurological end
points in male Sprague-Dawley rats (Lent et al. 2012a; USAPHC 2011a, 2011b, 2011c, 2011d, 2011e, 
2011f), adverse effects were elicited only by 3,4-DNT (facial twitching, hypoactivity, staring; 
LOAEL=227 mg/kg/day) and 3,5-DNT (facial twitching and paralysis, inflammatory infiltrates in the
brain; LOAEL=39 mg/kg/day).  
All LOAEL values from each reliable study for neurological effects in each species and duration category
for 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, and 3,5-DNT are recorded in Tables 3-1, 3-2, 3-3, 3-4, 3-5, and 3-6, 
respectively, and plotted in Figures 3-1, 3-2, 3-3, 3-4, 3-5, and 3-6, respectively.  
3.2.2.5  Reproductive Effects 
No studies were located regarding reproductive effects in humans after oral exposure to 2,3-, 2,4-, 2,5-, 
2,6-, 3,4-, or 3,5-DNT.
Studies in laboratory animals have shown that oral exposure to 2,4-DNT can result in adverse effects on
reproduction, as shown by decreased fertility and the development of lesions of the male and female 
reproductive tracts. The male reproductive system seems to be particularly sensitive; observed effects 
include decreased sperm production, testicular atrophy, changes in Sertoli cell morphology, and 
degenerated seminiferous tubules (Bloch et al. 1988; Kozuka et al. 1979; Lane et al. 1985; McGown et al. 
1983; U.S. Army 1976, 1978b, 1979).  In the female reproductive system, ovarian atrophy and 
dysfunction were observed (U.S. Army 1979).
Fourteen-day exposure to 2,3-DNT at doses up to 275 mg/kg/day did not result in alterations in testes or
epididymides weights in male Sprague-Dawley rats exposed by gavage (Lent et al. 2012a; USAPHC
2011a).
The effects on the male reproductive system have been reported in studies of brief durations.  Decreased
fertility was noted in male rats dosed with 180 mg/kg 2,4-DNT for 5 days; no dominant lethal effect was 
observed at this dose (Lane et al. 1985).  Decreased absolute and relative testes weight, seminiferous
tubular degeneration, multinucleated giant cell formation, and interstitial atrophy of the testes were noted
in male rats after 14 days of gavage doses of 142 mg/kg/day 2,4-DNT (Lent et al. 2012a; USAPHC
2011b).  Sprague-Dawley rats administered 104, 165, or 261 mg/kg/day 2,4-DNT in the diet for 14 days
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exhibited oligospermia with degenerative changes, such as syncytial cell formation and focal spermatic
granuloma, in a dose-related manner (McGown et al. 1983).  A dose of 78 mg/kg/day 2,4-DNT caused a 
decrease in the thickness of spermatogenic cell layers. No histopathological changes were found in the 
reproductive organs of females in this study (McGown et al. 1983).  Although no changes were found in 
sperm morphology of male mice that were administered 250 mg/kg/day 2,4-DNT for 2 days, significant
decreases in fertile matings of these animals were observed during weeks 2, 3, and 6 post-treatment 
(Soares and Lock 1980).  However, sperm morphology was examined at 8 weeks post-treatment, so it is
possible that a toxic effect was selective for specific types of sperm cells.
In intermediate studies of 2,4-DNT, serious effects on the male reproductive system have been observed
in numerous animal studies.  In a series of three dominant lethal studies using male rats for 13 weeks,
45 mg/kg/day 2,4-DNT in the diet caused severe atrophy and degeneration of the seminiferous tubules, 
resulting in decreased fertility, although no dominant lethal effect was observed (U.S. Army 1979).  
Another study using CD rats found that spermatogenesis was impaired after 4 weeks of feeding
93 mg/kg/day 2,4-DNT in the diet and had completely ceased after 13 weeks (Lee et al. 1985; U.S. Army
1978b). This effect was not reversible after a 4-week post-treatment period.  Higher concentrations of
2,4-DNT were needed to cause these effects in mice. Testicular atrophy and aspermatogenesis occurred
in CD-1 mice fed 413 mg/kg/day 2,4-DNT for 13 weeks (Hong et al. 1985; U.S. Army 1978b) and rats
fed a TWA dose of 371 mg/kg/day 2,4-DNT for 6 months in feed (Kozuka et al. 1979).  Decreased 
fertility was observed after male mice were treated with 1,032 mg/kg/day, but not 295 mg/kg/day,
2,4-DNT in the feed for 4 weeks in a dominant lethal study (U.S. Army 1978b). The decreased fertility
was not observed in mice fed 295 mg/kg/day (U.S. Army 1978b).  The testicular atrophy was considered
to be due to a direct toxic effect on spermatogenic cells.  Mild-to-severe testicular degeneration with
decreased spermatogenesis has also been observed in dogs administered 25 mg/kg 2,4-DNT in capsules
for 13 weeks (Ellis et al. 1985; U.S. Army 1978b).  No testicular effects were found at 5 mg/kg in the
study.
Histopathological examination of the testes after treatment with 2,4-DNT revealed changes, which
suggest specific causes for the male infertility observed in animal studies.  Dose-related changes in sperm
cell morphology were found in Sprague-Dawley rats fed 76.7 or 153.4 mg/kg/day 2,4-DNT in the diet for
3 weeks (Bloch et al. 1988).  At the low dose, vacuolation and lipid accumulation were noted in Sertoli
cells; multinucleated spermatid and irregularities of the basal lamina were also found. These changes 
were limited and variable with most samples, demonstrating patchy damage.  More extensive
degenerative changes in both spermatocytes and spermatids were found at the high dose as well as 
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ultrastructural changes in Sertoli cells; epididymal sperm counts were decreased 63%. The high-dose
animals also had increased levels of serum luteinizing hormone (LH) and FSH but not testosterone (Bloch 
et al. 1988).
Chronic-duration studies in laboratory animals have also demonstrated both male and female reproductive 
effects.  Male CD-1 mice fed 14 mg/kg/day 2,4-DNT for 12 months showed atrophy of the testes and
decreased spermatogenesis (Hong et al. 1985).  Female mice fed 898 mg/kg/day 2,4-DNT in this study
had ovarian atrophy with non-functioning follicles, with a NOAEL of 95 mg/kg/day (Hong et al. 1985).  
Male CD rats that received 34 mg/kg/day 2,4-DNT in the diet for 12 months showed an increased 
incidence of seminiferous tubule atrophy compared to controls (100% affected at the high dose versus 0%
of controls), with a NOAEL of 3.9 mg/kg/day (Lee et al. 1985; U.S. Army 1978b, 1979).  No adverse
reproductive effects were found in dogs fed 10 mg/kg/day 2,4-DNT for 24 months (Ellis et al. 1985; U.S. 
Army 1979).
A three-generation reproductive toxicity study was performed in rats fed 2,4-DNT for up to 6 months
before mating of original prenatal animals (U.S. Army 1979).  Effects on neonatal viability were observed 
at the highest concentration of 2,4-DNT used, 40 mg/kg/day.  Reductions in neonatal viability became
more severe with successive litters within each generation, such that no second litters were produced by
the second generation of high-dose animals, which were fed 34.5 mg/kg/day (male) or 45.3 mg/kg/day 
(female) 2,4-DNT.  Decreased fetal viability was attributed to maternal neglect and maternal death during
parturition.  Decreases in the number of fetal implants were attributed to the adverse impact of 2,4-DNT
on sperm production.
No effects on testes or epididymides weights were observed in male rats receiving 308 mg/kg/day
2,5-DNT by gavage for 14 days (Lent et al. 2012a; USAPHC 2011c).
In contrast, seminiferous tubular degeneration, multinucleated giant cell formation, and interstitial atrophy
of the testes were reported in rats after gavage doses ≥68 mg/kg/day 2,6-DNT for 14 days (Lent et al. 
2012a; USAPHC 2011d).  At the highest dose (134 mg/kg/day 2,6-DNT), these effects were accompanied
by marked decreases (49–57% compared with controls) in absolute and relative testes weight (Lent et al.
2012a; USAPHC 2011d).
In studies of rats, mice, and dogs dosed with 2,6-DNT for 13 weeks (U.S. Army 1976), decreased
spermatogenesis was observed in male mice administered 51 mg/kg/day, but normal spermatogenesis was 
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observed in animals dosed with 11 mg/kg/day.  Testicular atrophy was reported in rats administered
35 mg/kg/day 2,6-DNT, and no effects were observed in rats dosed with 7 mg/kg/day (U.S. Army 1976).  
Dogs dosed with 20 and 100 mg/kg/day had testicular degeneration, but no effects were observed in dogs
dosed with 4 mg/kg/day (U.S. Army 1976).
3,4-DNT doses up to 227 mg/kg/day administered by gavage for 14 days to male Sprague-Dawley rats 
did not result in any changes in testicular or epididymides weights (Lent et al. 2012a; USAPHC 2011e).  
Exposure to 3,5-DNT, in contrast, resulted in significant reductions in absolute and relative testes weights 
(≥40% lower than controls), as well as seminiferous tubular degeneration and multinucleated giant cell
formation in the testes of male rats after exposure to doses of 19 and 39 mg/kg/day for 14 days (Lent et al. 
2012a; USAPHC 2011f).  
Based upon the testicular effects observed after administration of 2,4-, 2,6-, and 3,5-DNT it is not 
surprising that these effects are found after treatment with Tg-DNT.  Testicular degeneration was found in 
male rats fed 35 mg/kg/day Tg-DNT for 26 weeks, but since the finding was unilateral, the relationship to
treatment may be considered equivocal (Hazleton Laboratories 1982).  When treatment with this
concentration was carried through 52 weeks, however, bilateral mild-to-severe testicular degeneration and
hypospermatogenesis were observed (Hazleton Laboratories 1982). No changes were found in the
fertility or sperm morphology of male mice that received 250 mg/kg Tg-DNT by gavage for 2 days in a 
dominant lethal study (Soares and Lock 1980).
In the 14-day gavage studies that compared the effects of the various DNT isomers on reproductive end
points in male Sprague-Dawley rats (Lent et al. 2012a; USAPHC 2011a, 2011b, 2011c, 2011d, 2011e, 
2011f), adverse effects were elicited only by 2,4-DNT (decreased weights of testis and epididymis, 
tubular degeneration, multinucleated giant cell formation, and interstitial atrophy of the testes;
LOAEL=142 mg/kg/day), 2,6-DNT (decreased testis weight at a LOAEL of 134 mg/kg/day; tubular
degeneration, multinucleated giant cell formation, and interstitial atrophy of the testes at a LOAEL of
68 mg/kg/day), and 3,5-DNT (small testes, significantly reduced testes weight, tubular degeneration and
multinucleated giant cell formation in the testes; LOAEL=19 mg/kg/day).
The highest NOAEL values and all reliable LOAEL values for reproductive effects in each species and
duration category for 2,3-, 2,4-, 2,5-, 2,6, 3,4-, and 3,5-DNT are recorded in Tables 3-1, 3-2, 3-3, 3-4, 
3-5, and 3-6, respectively, and plotted in Figures 3-1, 3-2, 3-3, 3-4, 3-5, and 3-6, respectively.
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3.2.2.6  Developmental Effects 
No studies were located regarding developmental effects in humans after oral exposure to 2,3-, 2,4-, 2,5-, 
2,6-, 3,4-, or 3,5-DNT.  However, developmental toxicity from DNTs could potentially occur because 
exposure to any substance that depletes the amount of oxygen available to developing fetal tissues may
have adverse consequences. U.S. Army (1979) conducted a 3-generation reproductive study in which 
2,4-DNT was administered to male and female rats at doses up to 34.5 and 45.3 mg/kg/day, respectively.
Normal birth weights, liveborn index, and weight at weaning were observed.  Decreases in pup viability
at 45.3 mg/kg/day in this study resulted from maternal neglect and a high incidence of maternal death 
during parturition; these decreases did not appear to result from pup defects since no anomalies were
detected in offspring from any generation.  These effects were not observed in animals fed 5.1 mg/kg/day 
2,4-DNT (U.S. Army 1979).
Tg-DNT was administered by gavage to pregnant rats for 14 days during gestation, and pups were
evaluated for developmental toxicity either at gestation day 20 or postpartum day 60 (Jones-Price et al.
1982).  Adverse effects on hematologic parameters and altered organ weights were observed in both dams
and fetuses when dams were administered 100 or 150 mg/kg/day.  However, the fetal toxicity was not
dose related.  A decrease in relative liver weight was observed, however, in the postpartum pups at the 
low dose of 14 mg/kg/day; this dose is considered to be a LOAEL.  Dose-related effects on postnatal
development were not observed in pups when dams were administered 35 or 75 mg/kg/day.  Transient
and statistically significant signs of neurotoxicity, which were not dose-related, included delayed eye
opening and cliff avoidance when dams were treated with 35 or 75 mg/kg/day.  No evidence of toxicity 
was found in pups at postpartum day 60 of the postnatal study.
No studies were located regarding developmental effects in animals after oral exposure to 2,3-, 2,5-, 2,6-, 
3,4-, or 3,5-DNT.
The highest NOAEL values and all reliable LOAEL values for developmental effects in each species and
duration category for 2,4-DNT are recorded in Table 3-1 and plotted in Figure 3-1.
3.2.2.7  Cancer
No studies were located regarding cancer in humans after oral exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or
3,5-DNT.
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The carcinogenic activity of DNTs has been extensively studied in typical chronic bioassays and in some 
less-than-lifetime studies.  2,4-DNT produced renal tumors in male mice and was hepatocarcinogenic in
rats.  2,6-DNT and Tg-DNT are potent hepatocarcinogens in rats (Lee et al. 1985; U.S. Army 1978b, 
1979).
2,4-DNT (98% 2,4-DNT, 2% 2,6-DNT) produced renal tumors (76%) in male CD-1 mice fed
95 mg/kg/day for 2 years (U.S. Army 1979).  A statistically significant increase in renal tumors in female 
mice was not observed.  A National Cancer Institute (NCI) bioassay (NCI 1978) of 2,4-DNT (95%
2,4-DNT, the other components not specified) did not detect a carcinogenic effect in mice dosed with
72 mg/kg/day for 78 weeks.  The NCI bioassay used the C57BL/6N strain of mouse, lower doses, and a
shorter treatment schedule than did U.S. Army (1979).
Hepatocellular carcinoma were significantly increased in male CD rats fed 34.5 mg/kg/day 2,4-DNT and 
in females fed 45.3 mg/kg/day 2,4-DNT for 2 years (U.S. Army 1979).  The tumor response in females
was higher than in the males.  Two other studies of rats in which malignancies were not observed used the 
F344 strain, lower doses, and shorter exposure durations than did U.S. Army (1979):  10 mg/kg/day for
78 weeks (NCI 1978) and 27 mg/kg/day for 52 weeks (Leonard et al. 1987).  NCI (1978) reported 
significant increases in subcutaneous tissue fibroma in male rats at 7.5–8 mg/kg/day and mammary gland 
fibroadenomas in female rats at 22 mg/kg/day. U.S. Army (1979) found significant increases in 
subcutaneous tissue fibromas in male rats at 34.5 mg/kg/day and mammary gland fibroadenomas in 
female rats at 45.3 mg/kg/day; these were benign tumors.
2,4-DNT was not found to be carcinogenic in the Strain A/J mouse pulmonary tumor bioassay when 
250 mg/kg was administered by gavage twice a week for 12 weeks (Stoner et al. 1984).  2,4-DNT was a
hepatic tumor promoter, but not a tumor initiator, using in vivo hepatic initiation-promotion protocols
(Leonard et al. 1986).
2,6-DNT administered for 1 year at 7 and 14 mg/kg/day produced hepatocellular carcinomas in 85% and 
100%, respectively, of male F344 rats (Leonard et al. 1987).  Pulmonary metastases of hepatocytic origin 
were also observed.  Both tumor-initiating and tumor-promoting activities of 2,6-DNT in rat liver were
reported (Leonard et al. 1983, 1986; Mirsalis and Butterworth 1982).  2,6-DNT was not found to be a 
lung carcinogen in the Strain A/J mouse pulmonary tumor bioassay when 250 mg/kg was administered by
gavage twice a week for 12 weeks (Schut et al. 1983; Stoner et al. 1984).
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The effect of diet-induced changes in gut microflora on the hepatocarcinogenicity of 2,6-DNT was
studied in male F344 rats (Goldsworthy et al. 1986). Groups of the rats were placed on one of three diets
containing 2,6-DNT at doses of 0, 0.6–0.7, or 3–3.5 mg/kg/day.  Ten animals from each group were
sacrificed at 3, 6, and 12 months, and their livers were evaluated histopathologically.  The diets used were 
NIH-07, an open formula cereal-based diet high in pectin content; AIN-76A, a purified pectin-free diet; or 
AP, which is AIN-76A supplemented with 5% pectin.  The number and size of γ-glutamyl transpeptidase­
staining foci in the liver increased in a dose- and time-related manner in animals given 2,6-DNT in the
NIH-07 diet.  Hepatocellular carcinomas and neoplastic nodules were observed only in rats fed NIH-07 
containing 2,6-DNT. No tumor was observed in rats receiving the control diets or 2,6-DNT in the
AIN-76 diet with or without pectin.  This finding suggested that pectin did not influence the tumor
outcome of the experiment.  Unidentified contaminants in cereal-based diets may influence liver foci and 
tumor production in the rat liver during carcinogen treatment.
Tg-DNT provided positive hepatocarcinogenic results in two bioassays of less-than-lifetime duration.  In 
a 52-week study of male rats dosed with 35 mg/kg/day of Tg-DNT, Leonard et al. (1987) observed a 47%
increase in hepatocellular carcinoma; cholangiocarcinomas were also found in 10% of rats treated with
35 mg/kg/day Tg-DNT in the Leonard et al. (1987) study.  Hazleton Laboratories (1982) reported that
dietary administration of 35 mg/kg/day Tg-DNT to rats for 55 weeks resulted in an increased incidence 
(100% in males and 55% in females) of hepatocellular carcinoma; this lesion was found in some animals
treated at this level for 26 weeks.  The administration of 3.5 mg/kg/day Tg-DNT for 104 weeks caused
hepatocellular carcinoma in 9 of 70 males compared to 1 of 61 controls.  Mammary fibroadenoma and 
subcutaneous fibroma were also found in both sexes at 3.5 mg/kg/day after 104 weeks (Hazleton
Laboratories 1982).  Administration of 14 mg/kg/day Tg-DNT for 104 weeks caused cholangio­
carcinomas and parathyroid adenomas in males and hepatocellular carcinomas and hepatocholangio­
carcinomas in females (Hazleton Laboratories 1982).
Tg-DNT contains about 76% 2,4-DNT and 19% 2,6-DNT, as well as small amounts of other isomers.
Rats that received 35 mg/kg/day in the Leonard et al. (1987) and Hazleton Laboratories (1982) studies
were provided approximately 28 and 7 mg/kg/day of 2,4- and 2,6-DNT, respectively.  This dose of
2,6-DNT in Tg-DNT bioassays is equivalent to the low dose of 2,6-DNT administered to rats by Leonard 
et al. (1987) that produced hepatocellular carcinomas.
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In hepatic tumor initiation-promotion protocols, Tg-DNT was reported to have tumor-promoting and 
tumor-initiating activity (Leonard et al. 1983, 1986; Mirsalis and Butterworth 1982).  The results of the
initiation-promotion protocols for 2,4-, 2,6-, and Tg-DNT indicate that 2,6-DNT is a complete 
hepatocarcinogen and is primarily responsible for the carcinogenic activity of Tg-DNT.
No studies were located regarding cancer in animals after oral exposure to 2,3-, 2,5-, 3,4-, or 3,5-DNT.
3.2.3 Dermal Exposure 
There are no data regarding adverse health effects associated with dermal exposure of humans or animals 
to 2,3-, 2,5-, 3,4-, or 3,5-DNT.  There are data on occupational exposure of humans to 2,4-DNT and
Tg-DNT (see Section 3.2.1) in which dermal exposure probably occurred, but the primary route of
exposure in these studies is believed to be inhalation.  The relative contribution of dermal exposure to
total occupational exposure cannot be determined from these studies.  Levine et al. (1985b) reported that
small amounts of 2,4-DNT were detected on the hands, face, and forehead when a wipe-sample survey
was conducted on workers in a DNT manufacturing plant.  The highest quantity found on a worker’s skin 
was 180 μg (obtained from wipe sampling of hands and face; total surface area wiped was not reported)
and may account for the quantity of excreted urinary metabolites that exceeded the amount of inhaled 
DNT in the operators and loaders.  Animal data associated with dermal exposure of animals to DNTs are 
limited to studies of dermal irritation, eye irritation, and dermal sensitization of 2,4-, 2,6-, or Tg-DNT in
rabbits.
3.2.3.1  Death 
No studies were located regarding mortality in humans associated with dermal exposure to 2,3-, 2,5-, 2,6-,
3,4-, or 3,5-DNT.
One study was located that examined death among humans exposed to DNTs.  A retrospective mortality
study of munitions workers exposed to either 2,4-DNT or Tg-DNT revealed an increased death rate due to
ischemic heart disease and residual diseases of the circulatory system in the exposed cohort (Levine et al.
1986a, 1986b).  Exposure concentrations to 2,4-DNT or Tg-DNT were not reported.  The residual
diseases included cardiac arrest and arteriosclerosis.  Exposure levels were not reported, and the study is 
further limited by the small cohort size and concurrent inhalation exposure of the workers.
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No studies were located regarding death in animals after dermal exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or
3,5-DNT.
3.2.3.2  Systemic Effects
No studies were located regarding respiratory, renal, body weight, or endocrine effects in humans or
animals after dermal exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans 
associated with dermal exposure to 2,3-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Gastrointestinal complaints of munitions workers exposed to either 2,4-DNT or Tg-DNT included nausea
and vomiting (McGee et al. 1947).  These workers also presumably inhaled DNT in the occupational
setting.  Exposure concentrations to 2,4-DNT or Tg-DNT were not reported.
No studies were located regarding gastrointestinal effects in animals after dermal exposure to 2,3-, 2,4-, 
2,5-, 2,6-, 3,4-, or 3,5-DNT.
Cardiovascular Effects. No studies were identified with respect to cardiovascular effects after
dermal exposure of humans to 2,3-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Levine et al. (1986a) reported a significant increase in heart disease mortality in workers involved in the 
manufacture and processing of 2,4-DNT and/or Tg-DNT.
No studies were located regarding cardiovascular effects in animals after dermal exposure to 2,3-, 2,4-, 
2,5-, 2,6-, 3,4-, or 3,5-DNT.
Hematological Effects. No studies were located regarding hematological effects in humans 
associated with dermal exposure to 2,3-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Hematological effects, such as anemia and cyanosis (which can be indicative of anemia), have been found
in men employed at munitions factories (McGee et al. 1947; Perkins 1919).  These workers were exposed 
to either 2,4-DNT or Tg-DNT.  Because these studies lacked worker histories, exposure data, and 
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reported on small cohorts, the results are equivocal and are best used to qualitatively describe symptoms.
In addition, the workers probably received their primary exposure via the inhalation pathway.
No studies were located regarding hematological effects in animals after dermal exposure to 2,3-, 2,4-, 
2,5-, 2,6-, 3,4-, or 3,5-DNT.
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans 
associated with dermal exposure to 2,3-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
Muscle weakness and joint pain have been reported by munitions workers after occupational exposure to
unspecified concentrations of 2,4-DNT or Tg-DNT (McGee et al. 1947; Perkins 1919).
In the Perkins (1919) study, joint pain and other incapacitating symptoms were noted following exposure
to what were presumed to be very high concentrations of Tg-DNT since the processes described required
direct handling without protective equipment.  In both of these studies, however, no exposure data were 
available; exposure to other compounds may have occurred, and concomitant exposure via inhalation was
also likely.
No studies were located regarding musculoskeletal effects in animals after dermal exposure to 2,3-, 2,4-, 
2,5-, 2,6-, 3,4-, or 3,5-DNT.
Hepatic Effects. No studies were located regarding hepatic effects in humans associated with dermal
exposure to 2,3-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
In a study of male munitions workers exposed to unspecified concentrations of 2,4-DNT, 29 of
714 workers displayed tenderness of the liver (McGee et al. 1947).  No other clinical evaluation was 
performed that might provide further insight into the significance of this finding.  These workers were
also exposed to DNTs via inhalation.
No studies were located regarding hepatic effects in animals after dermal exposure to 2,3-, 2,4-, 2,5-, 2,6-, 
3,4-, or 3,5-DNT.
Dermal Effects. No studies were located regarding dermal effects in humans associated with dermal
exposure to 2,3-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
   
 
    
 
 
 
        
    
  
 
  
 
 
  
 
 
       
  
 
  
   
 
 
  
 
 
  
 
 
  
 
   
    
 
 
  
 
 
 
 
 
 
125DINITROTOLUENES
3. HEALTH EFFECTS
A study of dermal effects of topical exposure to 2,4-DNT in workers employed by a munitions factory
during World War II reported that 32 of 714 workers complained of dermatitis (McGee et al. 1947).  
Exposure levels were not quantified in this study.
Both 2,4- and 2,6-DNT were shown to be mild primary dermal irritants in rabbits (U.S. Army 1975, 
1978a).
No studies were located regarding dermal effects in animals after dermal exposure to 2,3-, 2,5-, 3,4-, or
3,5-DNT.
Ocular Effects. No studies were located regarding ocular effects in humans after dermal exposure to
2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
No ocular irritation was found in rabbits in a primary eye irritation test using unspecified concentrations
of 2,4- or 2,6-DNT (U.S. Army 1975, 1978a).  However, mild eye irritations were reported in rabbits 
treated with 2,4-DNT (Ford 1981).
No studies were located regarding ocular effects in animals after dermal exposure to 2,3-, 2,5-, 3,4-, or
3,5-DNT.
3.2.3.3  Immunological and Lymphoreticular Effects 
No studies were located regarding immunological and lymphoreticular effects in humans after dermal
exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
In dermal sensitization tests, 2 of 10 guinea pigs exhibited mild sensitization to 2,6-DNT, but no
sensitization was evident when 2,4-DNT was tested (U.S. Army 1975, 1978a).
No studies were located regarding immunological and lymphoreticular effects in animals after dermal
exposure to 2,3-, 2,5-, 3,4-, or 3,5-DNT.
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3.2.3.4  Neurological Effects
No studies were located regarding neurological effects in humans after dermal exposure to 2,3-, 2,5-, 2,6-, 
3,4-, or 3,5-DNT.
Various neurological symptoms, including headache, vertigo, and pain or numbness in the extremities, 
have been reported in surveys of munitions workers exposed to unspecified concentrations of 2,4-DNT
(McGee et al. 1947).  Although it is assumed that some dermal exposure to 2,4-DNT occurred in these
workers, inhalation was the probable primary route of exposure.
No studies were located regarding neurological effects in animals after dermal exposure to 2,3-, 2,4-, 2,5-, 
2,6-, 3,4-, or 3,5-DNT.
3.2.3.5  Reproductive Effects
No significant effects on fertility were observed in workers occupationally exposed to Tg-DNT (Levine et
al. 1985a).  However, Levine et al. estimated that only a 50–70% reduction in fertility could have been 
detected in the worker population that they studied.
No studies were located regarding reproductive effects in animals after dermal exposure to 2,3-, 2,4-, 2,5-, 
2,6-, 3,4-, or 3,5-DNT.
3.2.3.6  Developmental Effects 
No studies were located regarding developmental effects in humans or animals after dermal exposure to
2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
3.2.3.7  Cancer
In a case-cohort study of German copper miners with exposure to Tg-DNT (see Section 3.2.1 for
additional detail), Seidler et al. (2014b) observed elevated Cox proportional HRs for renal cancer among
workers with medium or high dermal exposure to Tg-DNT (HR 2.73, 95% CI 1.0–7.42 for medium
exposure and HR 1.81, 95% CI 0.75–4.33 for high exposure).  When combined across medium and high 
exposure categories for both dermal and inhalation exposure, the HR for renal cancer was significantly
increased (HR 2.12, 95% CI 1.03–4.37).  
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No studies were located regarding cancer in humans or animals after dermal exposure to 2,3-, 2,4-, 2,5-, 
2,6-, 3,4-, or 3,5-DNT.
3.3  GENOTOXICITY
Data are available for 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5-, and Tg-DNT from in vitro tests in prokaryotic
organisms (gene mutation in Salmonella typhimurium) and in mammalian cell systems (gene mutation,
chromosomal aberrations, DNA damage, and morphological transformation).  Results of in vitro
genotoxicity assays are presented in Table 3-9.  In vivo data for 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5-, and 
Tg-DNT, including evaluations of unscheduled DNA synthesis (UDS), DNA damage and DNA binding, 
gene mutations, and/or chromosomal aberrations, are presented in Table 3-10.  Some isomers of DNT
(2,4-DNT and especially 2,6-DNT) have tested positive in vitro and/or in vivo in other genotoxicity
assays, with evidence of chromosomal aberrations, DNA damage and adduct formation, and
morphological transformation.  2,3-, 2,5-, and 3,5-DNT generally tested negative in genotoxicity assays.  
Taken together, results of in vitro studies do not provide strong evidence that DNT directly induces gene 
mutations; however, there is some evidence that 2,4-DNT induces mutations in vivo.
In vitro studies assessing genotoxicity of DNT have yielded mixed results in S. typhimurium, presumably
due to differences in the need for metabolic activation and the sensitivity of the tester strains.  2,3-, 2,4-, 
2,5-, 2,6-, 3,4-, and 3,5-DNT have been shown to induce gene mutations in S. typhimurium in the
presence or absence of metabolic activation in some assays, but produced negative or equivocal results in
several others (Couch et al. 1981; Dellarco and Prival 1989; Einistö et al. 1991; Kawai et al. 1987; Mori
et al. 1982; Neuwoehner et al. 2007; Padda et al. 2003; Sayama et al. 1989; Simmon et al. 1977;
Spanggord et al. 1982b; Suzuki et al. 2011; Tokiwa et al. 1981; U.S. Army 1978a).  Sayama et al. (1998)
showed that 2,4-DNT was mutagenic in S. typhimurium strains possessing high levels of nitroreductase
and O-acteyltransferase and 2,6-DNT was mutagenic in strains possessing high levels of
O-acetyltransferase.  2,4-DNT was nonmutagenic in Escherichia coli (Dunkel et al. 1985).  Mixed results
were found for 2,4-DNT in tests of DNA damage in bacteria; positive results were found in the umu test
using S. typhimurium and negative results were found in the SOS chromotest using E. coli (Öztürk and
Durusoy 1999). In general, 2,3-, 2,4-, 2,5-, 2,6-, and 3,5-DNT did not induce gene mutations in 
mammalian cells (Abernathy and Couch 1982; Styles and Cross 1983); however, positive results were
obtained for 2,4- and/or 2,6-DNT in assays that evaluated chromosomal aberrations in Chinese hamster
lung fibroblasts or human peripheral lymphocytes (Huang et al. 1996; Suzuki et al. 2011), morphological
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Table 3-9.  Genotoxicity of Dinitrotoluene Isomers In Vitro
Results
With Without
Species (test system) Isomer End point activation activation Reference
Prokaryotic organisms:
Salmonella typhimurium, 2,3-DNT Gene mutation + + Couch et al. 1981
TA98 
S. typhimurium, TM677 2,3-DNT Gene mutation – – Couch et al. 1981
S. typhimurium, TA98, 2,3-DNT Gene mutation – – Dellarco and Prival
TA100 1989
S. typhimurium, TA98; 2,3-DNT Gene mutation + NT Dellarco and Prival
with flavin (modified assay) 1989
mononucleotide (FMN)
S. typhimurium, TA100; 2,3-DNT Gene mutation – NT Dellarco and Prival
with FMN (modified assay) 1989
S. typhimurium, TA98 2,3-DNT Gene mutation – + Spanggord et al.
1982b
S. typhimurium, TA100 2,3-DNT Gene mutation + + Spanggord et al.
1982b
S. typhimurium, TA1538 2,3-DNT Gene mutation – + Spanggord et al.
1982b
S. typhimurium, TA1535, 2,3-DNT Gene mutation – – Spanggord et al.
TA1537, TA100 NR3 1982b
S. typhimurium, TA100 2,3-DNT Gene mutation ± – Kawai et al. 1987
S. typhimurium, TA98 2,3-DNT Gene mutation – ± Kawai et al. 1987
S. typhimurium, TA98, 2,4-DNT Gene mutation + + Couch et al. 1981
TM677
S. typhimurium 2,4-DNT Gene mutation NT – Chiu et al. 1978
S. typhimurium, TA98, 2,4-DNT Gene mutation – + Tokiwa et al. 1981
TA100
S. typhimurium, TA98, 2,4-DNT Gene mutation – – Dellarco and Prival
TA100 1989
S. typhimurium, TA98; 2,4-DNT Gene mutation + NT Dellarco and Prival
with FMN (modified assay) 1989
S. typhimurium, TA100; 2,4-DNT Gene mutation – NT Dellarco and Prival
with FMN (modified assay) 1989
S. typhimurium 2,4-DNT Gene mutation NT + Mori et al. 1982
S. typhimurium, TA100 2,4-DNT Gene mutation – + Spanggord et al.
1982b
S. typhimurium, TA100 2,4-DNT Gene mutation + – Spanggord et al.
NR3 1982b
S. typhimurium, TA1535, 2,4-DNT Gene mutation – – Spanggord et al.
TA1537, TA1538, TA98 1982b
S. typhimurium, TA100 2,4-DNT Gene mutation + – U.S. Army 1978a
S. typhimurium, TA1535 2,4-DNT Gene mutation – + U.S. Army 1978a
S. typhimurium, TA98, 2,4-DNT Gene mutation – – U.S. Army 1978a
1537
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Table 3-9.  Genotoxicity of Dinitrotoluene Isomers In Vitro
Results
With Without
Species (test system) Isomer End point activation activation Reference
S. typhimurium, TA1538 2,4-DNT Gene mutation + + U.S. Army 1978a
S. typhimurium 2,4-DNT Gene mutation + NT Pearson et al. 1978
S. typhimurium, TA98, 2,4-DNT Gene mutation NT + Einistö et al. 1991
 
TA98 NR, TA98/,8-DNP6, 

YG1021, YG1024
 
S. typhimurium, TA100 2,4-DNT Gene mutation ± ± Kawai et al. 1987
 
S. typhimurium, TA98 2,4-DNT Gene mutation – – Kawai et al. 1987
 
S. typhimurium, TA100 2,4-DNT Gene mutation NT – Padda et al. 2003
 
S. typhimurium, TA98, 2,4-DNT Gene mutation NT – Sayama et al. 1998
 
S. typhimurium, TA100 2,4-DNT Gene mutation NT + Sayama et al. 1998
 
YG1021, YG1024,
 
YG1041, YG1026,
 
YG1029, YG1042
 
Escherichia coli 2,4-DNT Gene mutation – – Dunkel et al. 1985
 
S. typhimurium, NM2009, 2,4-DNT DNA damage (umu NT + Öztürk and 

NM3009 test) Durusoy 1999
 
E. coli, PQ37 2,4-DNT DNA damage (SOS – – Öztürk and 
chromotest) Durusoy 1999
S. typhimurium, TA98, 2,5-DNT Gene mutation + + Couch et al. 1981
TM677
S. typhimurium, TA98 2,5-DNT Gene mutation ± No data Dellarco and Prival
1989
S. typhimurium, TA100 2,5-DNT Gene mutation – – Dellarco and Prival
1989
S. typhimurium, TA98; 2,5-DNT Gene mutation + NT Dellarco and Prival
with FMN (modified assay) 1989
S. typhimurium, TA100; 2,5-DNT Gene mutation – NT Dellarco and Prival
with FMN (modified assay) 1989
S. typhimurium, TA1535, 2,5-DNT Gene mutation + + Spanggord et al.
TA1538, TA98, TA100 1982b
S. typhimurium, TA1537, 2,5-DNT Gene mutation – – Spanggord et al.
TA100 NR3 1982b
S. typhimurium, TA98, 2,6-DNT Gene mutation + + Couch et al. 1981
TM677 
S. typhimurium, TA100, 2,6-DNT Gene mutation – – U.S. Army 1978a
TA1535, TA1537, TA98 
S. typhimurium, TA1538 2,6-DNT Gene mutation – + U.S. Army 1978a
S. typhimurium 2,6-DNT Gene mutation NT + Simmon et al. 1977
S. typhimurium, TA98, 2,6-DNT Gene mutation – – Sayama et al. 1989
TA100
S. typhimurium, TA98, 2,6-DNT Gene mutation – + Tokiwa et al. 1981
TA100
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Table 3-9.  Genotoxicity of Dinitrotoluene Isomers In Vitro
Results
With Without
Species (test system) Isomer End point activation activation Reference
S. typhimurium, TA100 2,6-DNT Gene mutation + + Spanggord et al.
1982b
S. typhimurium, TA1535, 2,6-DNT Gene mutation – – Spanggord et al.
TA1537, TA1538, TA98, 1982b
TA100 NR3
S. typhimurium, TA98, 2,6-DNT Gene mutation – – Dellarco and Prival
TA100 1989
S. typhimurium, TA98; 2,6-DNT Gene mutation + NT Dellarco and Prival
with FMN (modified assay) 1989
S. typhimurium, TA100; 2,6-DNT Gene mutation – NT Dellarco and Prival
with FMN (modified assay) 1989
S. typhimurium, TA98, 2,6-DNT Gene mutation + + Suzuki et al. 2011
TA100, TA1537
S. typhimurium, TA98, 2,6-DNT Gene mutation NT + Einistö et al. 1991
TA98/1,8-DNP,
YG1021,YG1024
S. typhimurium, TA98 NR 2,6-DNT Gene mutation + – Einistö et al. 1991
S. typhimurium 2,6-DNT Gene mutation + NT Pearson et al. 1979
S. typhimurium, TA98, 2,6-DNT Gene mutation ± ± Kawai et al. 1987
TA100
S. typhimurium, TA100 2,6-DNT Gene mutation NT – Padda et al. 2003
S. typhimurium, TA98, 2,6-DNT Gene mutation NT – Sayama et al. 1998
TA100 YG1021, 
S. typhimurium, YG1024, 2,6-DNT Gene mutation NT + Sayama et al. 1998
YG1041, YG1026,
YG1029, YG1042
S. typhimurium, TA100 3,4-DNT Gene mutation + + Kawai et al. 1987
S. typhimurium, TA98 3,4-DNT Gene mutation – – Kawai et al. 1987
S. typhimurium, TA100 3,4-DNT Gene mutation + + Spanggord et al.
1982b
S. typhimurium, TA1535, 3,4-DNT Gene mutation – – Spanggord et al.
TA1537, TA1538, TA98, 1982b
TA100 NR3
S. typhimurium, TA98 3,4-DNT Gene mutation – – Tokiwa et al. 1981
S. typhimurium, TA100 3,4-DNT Gene mutation – + Tokiwa et al. 1981
S. typhimurium, TA98, 3,5-DNT Gene mutation + + Couch et al. 1981
TM677
S. typhimurium, TA1537, 3,5-DNT Gene mutation + + Spanggord et al.
TA1538, TA98, TA100 1982b
S. typhimurium, TA1535, 3,5-DNT Gene mutation – – Spanggord et al.
TA100 NR3 1982b
   
 
    
 
 
 
 
 
 
 
131DINITROTOLUENES
3. HEALTH EFFECTS
Table 3-9.  Genotoxicity of Dinitrotoluene Isomers In Vitro 
 
Results 
With Without 
Species (test system) Isomer End point activation activation Reference 
S. typhimurium, TA98, Tg-DNT Gene mutation + + Couch et al. 1981 
TM677 
S. typhimurium	  Tg-DNT Gene mutation NT + Chadwick et al. 
1990 
Mammalian cells: 
CHO cells  2,4-DNT Sister chromatid + – Loveday et al. 
exchange 1989 
CHO cells 2,4-DNT Chromosomal – – Loveday et al. 
aberrations 1989 
CHO/HGPRT 2,3-DNT Gene mutation – – Abernethy and 
Couch 1982 
CHO/HGPRT 2,4-DNT Gene mutation – – Abernethy and 
Couch 1982 
CHO/HGPRT 2,4-DNT Gene mutation – – Abernethy and 
Couch 1982 
CHO/HGPRT 2,5-DNT Gene mutation – – Abernethy and 
Couch 1982 
CHO-HGPRT 2,6-DNT Gene mutation – – Abernethy and 
Couch 1982 
CHO/HGPRT 3,5-DNT Gene mutation – – Abernethy and 
Couch 1982 
CHO-HGPRT Tg-DNT Gene mutation – – Abernethy and 
Couch 1982 
P388 mouse lymphoma 2,4-DNT Gene mutation – +	  Styles and Cross 
TK 	 1983 
P388 mouse lymphoma 2,6-DNT Gene mutation – – 	 Styles and Cross 
TK 1983 
P388 mouse lymphoma Tg-DNT Gene mutation – – Styles and Cross 
TK 1983 
Chinese hamster lung 2,6-DNT Chromosomal + + Suzuki et al. 2011 
fibroblasts aberrations 
SHE cells 2,4-DNT Morphological NT – Holen et al. 1990 
transformation 
SHE cells 2,4-DNT Morphological NT + Engelhardt et al. 
transformation 2004 
SHE cells 2,6-DNT Morphological NT + Engelhardt et al. 
transformation 2004 
SHE cells 2,6-DNT Morphological NT – Holen et al. 1990 
transformation 
Kumming rat Sertoli cells 2,4-DNT DNA damage NT + Yang et al. 2005 
(comet assay) 
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Table 3-9.  Genotoxicity of Dinitrotoluene Isomers In Vitro 
 
Results 
With Without 
Species (test system) Isomer End point activation activation Reference 
Kumming rat Sertoli cells 2,6-DNT DNA damage NT + Yang et al. 2005 
(comet assay) 
Human peripheral 2,4-DNT Chromosomal NT + Huang et al. 1996 
lymphocytes aberrations 
 
+ = positive; – = negative; ± = weakly positive or equivocal; CHO = Chinese hamster ovary; DNA = deoxyribonucleic 
acid; DNT = dinitrotoluene; FMN = flavin mononucleotide; NT = not tested; SHE = Syrian hamster embryo; 
Tg = technical grade 
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Table 3-10. Genotoxicity of Dinitrotoluene Isomers In Vivo
Species (test system) Isomer End point Results Reference
DNT and TNT workers Tg-DNT Chromatid-type chromosomal + Sabbioni et al.
aberrations 2006
Rat hepatocyte 2,4-DNT UDS + Mirsalis et al. 1989
Rat hepatocyte 2,4-DNT UDS + Mirsalis and 
Butterworth 1982
Rat hepatocyte (male; AP or 2,4-DNTa UDS + Ashby et al. 1985
F344)
Rat hepatocyte 2,4-DNT S-phase synthesis + Mirsalis et al. 1989
 
Rat hepatocyte (male; 2,3-DNT DNA damage; comet assay – Lent et al. 2012b
 
Sprague-Dawley)
 
Rat hepatocyte (male; 2,4-DNT DNA damage; comet assay – Lent et al. 2012b
 
Sprague-Dawley)
 
Rat hepatocyte (male; 2,5-DNT DNA damage; comet assay – Lent et al. 2012b
 
Sprague-Dawley)
 
Rat hepatocyte (male; 2,6-DNT DNA damage; comet assay + Lent et al. 2012b
 
Sprague-Dawley)
 
Rat hepatocyte (male; 2,6-DNT DNA damage; comet assay + Suzuki et al. 2011
 
Crl:CD(SD)
 
Rat hepatocyte (male; 2,6-DNT DNA damage; comet assay + Rothfuss et al.
 
Sprague-Dawley) 2010
 
Rat hepatocyte (male; 3,5-DNT DNA damage; comet assay – Lent et al. 2012b
 
Sprague-Dawley)
 
Rat peripheral blood (male; 2,6-DNT DNA damage; comet assay + Rothfuss et al.
 
Sprague-Dawley) 2010
Rat hepatocyte 2,4-DNT DNA binding (adduct formation) + La and Froines
1993
Rat hepatocyte (male; F344) 2,4-DNT DNA binding (adduct formation) + Chadwick et al.
1993
Rat hepatocyte (female; 2,4-DNT DNA binding (adduct formation) + Jones et al. 2005a
Wistar)
Rat hepatocyte (female; 2,6-DNT DNA binding (adduct formation) + Jones et al. 2005a
Wistar)
Rat (male; F344) and mouse 2,6-DNT DNA binding (adduct formation) + George et al. 1996
(male; B6C3F1) hepatocytes
Rat peripheral blood (male; 2,3-DNT Chromosomal aberrations; – Lent et al. 2012b
Sprague-Dawley) micronucleus assay
Rat hepatocyte (male; F344) 2,4-DNT Chromosomal aberrations; + Suzuki et al. 2009
micronucleus assay
Rat hepatocyte (male; F344) 2,4-DNT Chromosomal aberrations; + Takasawa et al.
micronucleus assay 2010
Rat peripheral blood (male; 2,4-DNT Chromosomal aberrations; – Lent et al. 2012b
Sprague-Dawley) micronucleus assay
Rat peripheral blood (male; 2,5-DNT Chromosomal aberrations; – Lent et al. 2012b
Sprague-Dawley) micronucleus assay
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Table 3-10. Genotoxicity of Dinitrotoluene Isomers In Vivo
Species (test system) Isomer End point Results Reference
Rat peripheral blood (male; 2,6-DNT Chromosomal aberrations; – Lent et al. 2012b
Sprague-Dawley) micronucleus assay
Rat hepatocyte (male; F344) 2,6-DNT Chromosomal aberrations; ± Takasawa et al.
micronucleus assay 2010
Rat peripheral blood (male; 3,5-DNT Chromosomal aberrations; – Lent et al. 2012b
Sprague-Dawley) micronucleus assay
Rat bone marrow (male; 2,6-DNT Chromosomal aberrations; – Rothfuss et al.
Sprague-Dawley) micronucleus assay 2010
Mouse bone marrow (male; 2,4-DNTa Chromosomal aberrations; – Ashby et al. 1985
CBA x BALBc)F1) micronucleus assay
Mouse (female; C57BL/6J or 2,4-DNTa Gene mutation, spot test – Soares and Lock
T stock) 1980
aThe test substance is referred to in the publication as technical-grade 2,4-DNT.
+ = positive result; – = negative result; ± = equivocal result; DNA = deoxyribonucleic acid; DNT = dinitrotoluene;
Tg = technical grade; TNT = trinitrotoluene; UDS = unscheduled DNA synthesis
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transformation in Syrian hamster embryo cells (Engelhardt et al. 2004; Holen et al. 1990), or DNA
damage in rat Sertoli cells (Yang et al. 2005).
UDS and/or S-phase synthesis (SPS) were induced in vitro in the hepatocytes of F344 rats treated with 
2,4-DNT or Tg-DNT in vivo (Ashby et al. 1985; Mirsalis et al. 1989).  The mutagenicity of several of the
metabolites of 2,6-DNT have been tested in S. typhimurium. Although neither 2,6-DNT nor its
metabolites, 2-amino-6-nitrotoluene, 2,6-dinitrobenzylalcohol, 2-acetylamino-6-nitrobenzoic acid, and 
2-amino-6-nitrobenzoic acid, were mutagenic in this assay with or without S9 activation, other
metabolites of 2,6-DNT were found to possess mutagenic activity (Sayama et al. 1989). The putative 
metabolite 2,6-dinitrobenzaldehyde was a direct acting mutagen (i.e., it did not require activation)
(Sayama et al. 1989).  Urine from F344 rats administered 75 mg/kg 2,6-DNT by gavage tested positive
for mutagenicity using S. typhimurium TA98 without S9 activation (Chadwick et al. 1993).  
2,4-DNT induced lethal mutations but not reciprocal translocations in mutagenicity testing using
Drosophilia melanogaster (Woodruff et al. 1985).  Color coat mutations were also observed in the 
offspring of pregnant C57BL/6J or T stock mice administered 1,000 mg/kg technical-grade 2,4-DNT via
gavage or intraperitoneal injection on gestation day 10 (Soares and Lock 1980).
Micronuclei formation was observed in two assays in liver cells of 2,4-DNT-treated F344 rats (Suzuki et
al. 2009; Takasawa et al. 2010), but were not observed in the peripheral blood of 2,4-DNT-treated
Sprague-Dawley rats (Lent et al. 2012b).  Similarly, no micronuclei were observed in the peripheral blood 
of Sprague-Dawley rats administered 2,6-DNT via gavage for 2 or 14 days (Lent et al. 2012b; Takasawa 
et al. 2010) or in the bone marrow of Sprague-Dawley rats exposed for 3 or 29 days (Rothfuss et al. 
2010); however, micronuclei were induced in the hepatocytes of 2,6-DNT-treated rats.  Other isomers of
DNT (2,3-, 2,5-, or 3,5-DNT) tested negative in micronucleus assays in rats (Lent et al. 2012b). In
workers at a DNT and TNT manufacturing facility, significant increases in chromatid-type chromosomal
aberrations were observed, as compared to factory controls (Sabbioni et al. 2006). When workers were 
divided into three age categories, a significant association between 2,4-DNT hemoglobin adducts and
chromosomal frequency was observed in the youngest group, but not in the two older groups.
The formation of DNA adducts is generally thought to indicate carcinogenic risk (La and Froines 1993). 
Both 2,4- and 2,6-DNT have induced DNA adducts in rat liver.  Following treatment with 2,4-DNT at up
to 375 mg/kg via intraperitoneal injection, three DNA adducts were found in the liver of F344 rats (La
and Froines 1992).  Four adducts, identified as 4-amino-2-nitrotoluene (4A2NT), 24TDA, and 
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4-acetylamino-2-aminotoluene (4AA2AT) (with 4A2NT being the predominant form) were found in the
liver of Wistar rats administered 0.5 mmol/kg (approximately 91 mg/kg) 2,4-DNT as a single gavage dose 
(Jones et al. 2005a).  Following treatment with 2,6-DNT, four DNA adducts (not identified) were found
in the liver of rats treated with 75 mg/kg 2,6-DNT by gavage (Chadwick et al. 1993).  In Wistar rats 
treated with 2,6-DNT at 0.5 mmol/kg (about 91 mg/kg) via gavage as a single dose, three adducts, 
identified as 2-amino-6-nitrotoluene (2A6NT), 26TDA, and 2-acetylamino-6-aminotoluene (2AA6AT)
(with 2A6NT being the predominant form) were detected (Jones et al. 2005a).  Two types of DNA
adducts were detected in liver DNA of B6C3F1 mice administered 2,6-DNT at 50 mg/kg via gavage;
these adducts differed from the four types of adducts identified in F344 rats administered 2,6-DNT via
gavage (George et al. 1996).  The formation of 4 DNA adducts was also observed after intraperitoneal
administration of 219 mg/kg 2,6-DNT to F344 rats (La and Froines 1992, 1993).  One adduct accounts for
the majority of the radioactivity measured; about 85% of the total was in one adduct in the study using
2,4-DNT, while in the study with 2,6-DNT, about 60% of the total adducts measured were from a single
adduct with the other adducts constituting 10–15% of the total (La and Froines 1992, 1993).  No 
quantitative or qualitative differences in adduct formation were found when treatment occurred by gavage 
or intraperitoneal injection (La and Froines 1992).  The proximate DNA binding species has been 
postulated to be 2-hydroxylamino-6-nitrobenzyl alcohol (La and Froines 1993; Rickert et al. 1984).  The
DNA adducts formed after exposure to 2,4- or 2,6-DNT were persistent over time; the persistence of these
adducts was slightly >40% in the 2 weeks after exposure (La and Froines 1992). 
Comet assays, which evaluated the ability of DNT to induce DNA damage in the hepatocytes of treated
rats, were negative for 2,3-, 2,4-, 2,5-, and 3,5-DNT (administered via gavage at up to 275, 142, 308, or
39 mg/kg/day, respectively), but positive in Sprague-Dawley rats treated with 2,6-DNT via gavage at
doses from 33 to 134 mg/kg/day (Lent et al. 2012b; Suzuki et al. 2011; Rothfuss et al. 2010). DNA 
damage (as measured by comet assay) was not detected in peripheral blood of Sprague-Dawley rats 
exposed to 100 mg/kg/day for 3 days or to 33 mg/kg/day for 29 days (Rothfuss et al. 2010)
Studies of the effects of various DNT isomers (2,4-, 2,6-, or 3,5-DNT) on sperm morphology (Soares and 
Lock 1980), spermatocyte DNA repair (Working and Butterworth 1984), and dominant lethal mutations
(Soares and Lock 1980, U.S. Army 1979) were generally negative for these specific end points.  Mice 
administered 2,4-DNT at 250 mg/kg on two consecutive days via gavage or intraperitoneal injection did 
not show evidence of an increase in morphologically aberrant sperm (Soares and Lock 1980), and UDS
was not induced in the spermatocytes of rats treated with a single dose of 20 mg/kg 2,6-DNT via gavage
(Working and Butterworth 1984).  Dominant lethal effects were not induced in rats administered 2,4-DNT
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at up to 0.07% (34 mg/kg) in the diet for 13 weeks (U.S. Army 1979) or in mice administered 250 mg/kg
2,4-DNT or 3,5-DNT on two consecutive days via gavage or intraperitoneal injection (Soares and Lock
1980).  However, a significant increase in the number of dead implants/total implants was reported in
females mated to males treated with 2,4-DNT at 0.2% in the diet for 13 weeks (Hodgson et al. 1976). 
3.4  TOXICOKINETICS
3.4.1 Absorption 
3.4.1.1  Inhalation Exposure 
No studies were located regarding absorption of inhaled of 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT in 
humans or laboratory animals.  However, detection of DNT metabolites in the urine of workers at DNT
manufacturing plants provides evidence that DNT may be absorbed following presumed inhalation 
exposure (Levine et al. 1985b; Turner 1986; Woollen et al. 1985).
3.4.1.2  Oral Exposure
Rickert et al. (1983) suggested that the rapid disappearance of radioactivity from the first quarter of the 
small intestine of rats following the oral administration of uniformly [14C]-ring-labeled 2,4- or 2,6-DNT
indicates rapid and fairly complete absorption.
Excretion data and observed systemic effects indicate that DNTs are absorbed following oral
administration to experimental animals.  Several strains of rats, New Zealand rabbits, beagle dogs, and
Rhesus monkeys excreted 55–90% of the radioactivity from orally-administered radiolabeled DNTs in the
urine, primarily within the first 24 hours (Long and Rickert 1982; Rickert and Long 1981; U.S. Army
1978b).  In mice, most of the radioactivity from 3H-labeled 2,6-DNT was excreted in the urine (about
50% in 8 hours) (Schut et al. 1983), whereas most of the radioactivity from 14C-labeled 2,4-DNT
administered to mice was excreted in the feces, and only about 10% was excreted in the urine (U.S. Army
1978b).  Increased fecal excretion could be due to reduced absorption or to greater excretion via the bile.
Studies on absorption of 2,3-, 2,5-, 2,6-, 3,4-, or 3,5-DNT following oral exposure of humans or animals
were not identified.
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3.4.1.3  Dermal Exposure 
There were no in vivo data available specifically on the absorption of 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or
3,5-DNT via the dermal route of exposure.  Two studies of occupational exposure to Tg-DNT have
suggested that dermal absorption can be a significant route of entry for DNT in humans since the levels of
urinary metabolites of 2,4- and 2,6-DNT in loaders and operators at a DNT manufacturing plant exceeded
those that would have resulted from the inhaled concentrations (Levine et al. 1985b; Woollen et al. 1985).
An in vitro study examined the dermal absorption of 2,4- and 2,6-DNT in soil or acetone using excised 
pigskin (Reifenrath et al. (2002).  When in acetone, 36 and 24% of the 2,4- and 2,6-DNT, respectively,
was absorbed. The absorption of radiolabel from soil was less; 15 or 16%, respectively, was absorbed
from a low carbon soil and 5.4 and 3.8%, respectively, was absorbed from a high carbon soil. 
3.4.2 Distribution 
3.4.2.1  Inhalation Exposure 
No studies were located regarding distribution in humans or animals following inhalation exposure to
2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
3.4.2.2  Oral Exposure
The tissue distribution of 2,4-DNT and its metabolites was studied by Rickert and Long (1980).  2,4-DNT
was administered orally to male and female rats at doses of 10, 35, or 100 mg of 14C-labeled 2,4-DNT/kg.
When distribution is studied solely by detecting a radioisotope label, it is the labeled atom(s) that are
being followed, and this label may be part of either the parent DNT molecule or a metabolite.  Peak
concentrations of radioactivity in plasma, red blood cells, liver, and kidney were proportional to dose.  
Levels in liver and kidney were 5–10 times higher than those in plasma or red blood cells.  Levels of
radioactivity in other tissues were lower than those in plasma. The only clear differences between males 
and females were the higher retention of radioactivity in red blood cells of females and the concentration
of radioactivity in livers of females, which was only half that found in males.  In addition, concentrations
of 2,4-DNT in male kidneys peaked at 4–8 hours and were 3–10 times higher than the concentrations in 
female kidneys, which peaked 1 hour after the dose.
Rickert et al. (1983) observed that hepatic concentrations of radioactivity in male rats increased in
two stages, with the first peak occurring 1–2 hours and a second peak occurring 8–12 hours after an oral
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dose of 10 or 35 mg/kg of radiolabeled 2,4- or 2,6-DNT. The second peak was followed by a gradual
decline up to 16 days and was thought to be the result of enterohepatic cycling.
In mice administered 3H-labeled 2,6-DNT, the distribution of the label was similar in the blood, liver, 
kidneys, lungs, and small and large intestines at 8 hours after administration, with very low levels
detected in the brain, lungs, heart, and spleen (Schut et al. 1983).  
In a radioisotope labeling study in dogs and monkeys, total 2,4-DNT and its metabolites recovered in
blood and other tissues were approximately 3.6% (dogs) and 2.2% (monkeys) of the administered dose
(U.S. Army 1978b).  Relative to blood concentrations, the liver had the highest levels of 2,4-DNT or
metabolites.  Detectable levels of 2,4-DNT or metabolites were also found in the kidney and in skeletal
muscle (U.S. Army 1975, 1978b).
No studies were located regarding distribution in humans or animals following inhalation exposure to
2,3-, 2,5-, 3,4-, or 3,5-DNT.
3.4.2.3  Dermal Exposure 
No studies were located regarding distribution in humans or animals following dermal exposure to 2,3-, 
2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
3.4.3 Metabolism
The metabolism of DNTs in humans has been studied in workers exposed to Tg-DNT by the analysis of
urinary metabolites.  The routes of exposure in these studies were multiple.  Since the amounts of
metabolites excreted could not be accounted for by the inhalation exposure route alone, dermal contact
and ingestion routes of exposure may also be of importance (Levine et al. 1985b; Woollen et al. 1985).  
Woollen et al. (1985) found that the major metabolite excreted in the urine of workers exposed to 
Tg-DNT was 2,4-dinitrobenzoic acid (conjugates were hydrolyzed before analysis).  There were wide 
variations in the excretion of the metabolites in different workers.  Concentrations of 2,4-dinitrobenzoic
acid in end-of-shift urine samples from 20 male and 8 female workers, however, did not suggest a
difference in the excretion of this metabolite between males and females. The study authors stated that
lesser amounts of the following metabolites were also found in the urine:  2-amino-4-nitro-, 4-amino­
2-nitro-, and 2-amino-6-nitrobenzoic acids, and 4-(N-acetyl)amino-2-nitrobenzoic acid.  Trace levels of
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DNTs were also detected. Dinitrobenzyl alcohols were not detected.  Neither amounts nor relative 
percentages of metabolites were reported.
Studies of workers at a Tg-DNT manufacturing plant (Levine et al. 1985b; Turner et al. 1985) provide
more detailed information regarding the metabolism of Tg-DNT in occupationally exposed men and 
women.  The principal metabolites detected in the urine of 14 men were dinitrobenzoic acids (2,4- and 
2,6-) and 2-amino-4-nitrobenzoic acid.  In the urine of three women, these metabolites were detected
together with dinitrobenzyl alcohol glucuronides (2,4- and 2,6-).  Expressed as percent of total urinary
metabolites, the dinitrobenzoic acids, 2-amino-4-nitrobenzoic acid, and the dinitrobenzyl glucuronides
constituted 52.5, 37.2, and 9.5%, respectively, of the total urinary DNT metabolites in men and 28.8, 
37.6, and 33.3%, respectively, of the total urinary DNT metabolite in women.  2,4-DNT and 2,6-DNT
metabolites were present in roughly the same proportions as in the Tg-DNT.  Both men and women 
excreted relatively small amounts (<1% of urinary metabolites) of 2-(N-acetyl)amino-4-nitrobenzoic acid 
(Levine et al. 1985b).
In contrast to the findings in the Levine et al. (1985b) study, 2,4-dinitrobenzoic acid was not one of the
primary urinary metabolites in Chinese workers exposed to Tg-DNT and mononitrotoluenes (Jones et al.
2005b).  In these workers, 2,6-dinitrobenzoic acid, 4-amino-2-nitrobenzoic acid, 2-amino-4-nitrobenzoic
acid, and 2,6-dinitrobenzl alcohol comprised 27.3, 26.0, 21.6, and 18.3%, respectively, of the total DNT
metabolites.
Studies in rats have identified a complex pathway for the metabolism of 2,4-DNT (Figures 3-7 and 3-8) 
and 2,6-DNT (Figure 3-9).  Metabolism occurs in the liver and also in the intestine by microflora (Long 
and Rickert 1982; Rickert et al. 1981).  Both oxidized and reduced metabolites are excreted in the urine
after oral administration of the compounds.  The main urinary metabolites of 2,4- and 2,6-DNT are the
corresponding dinitrobenzyl alcohol glucuronide, dinitrobenzoic acid, and aminonitrobenzoic acid (Long
and Rickert 1982).  An additional urinary metabolite of 2,4-DNT is 4-(N-acetyl)amino-2-nitrobenzoic
acid (Rickert et al. 1981).  Although very little information on metabolism of 2,3-, 2,5-, or 3,5-DNT was
identified, it is anticipated that metabolism of these isomers would follow similar pathways as those 
identified for 2,4- and 2,6-DNT. Results of an in vitro metabolism study using rat liver homogenate show
that 2,3- and 2,5-DNT are reduced to monoaminonitrotoluenes and hydroxylaminonitrotoluenes (Kozuka
et al. 1978).
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Figure 3-7.  Proposed Metabolic Pathways for the Hepatic Metabolism of
2,4-Dinitrotoluene
Sources:  Bond and Rickert 1981; Bond et al. 1981; Smith et al. 1995
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Figure 3-8.  Proposed Pathways for the Anaerobic Metabolism of 
2,4-Dinitrotoluene in Rat Intestinal Microflora
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Figure 3-9.  Proposed Pathways for Metabolism of 2,6-Dinitrotoluene
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Oxidative metabolism by cytochrome P450 predominates in the liver of experimental animals, leading to 
the formation of dinitrobenzyl alcohol, which is either converted to glucuronide conjugate or further
oxidized to dinitrobenzoic acid.  Dinitrobenzyl alcohol glucuronide is partially excreted into the bile, 
followed by metabolism by gut microflora and enterohepatic cycling (Long and Rickert 1982; Medinsky
and Dent 1983; Mori et al. 1997; Rickert and Long 1981).  Thus, DNTs appear to be first metabolized by
the liver with the metabolites being excreted into the bile; the biliary metabolites are hydrolyzed and
further metabolized in the intestine; after reabsorption and circulation back to the liver, the metabolites
are activated and bound to macromolecules (Chadwick et al. 1993; Long and Rickert 1982).
2,4- and 2,6-dinitrobenzyl glucuronide have been detected directly in the bile following administration of
2,4- and 2,6-DNT to the male Wistar rat (Mori et al. 1997), accounting for about 35 and 51% of the dose
respectively.  Four other metabolites, 2-amino-4-nitrotoluene, 4-amino-2-nitrotoluene, 2,4-diamino­
toluene, and 4-acetylamino-2-nitrobenzoic acid accounted for 0.02–0.12% of the dose; in addition to 
2,4-dinitrobenzyl alcohol, 2,4-dinitrobenzaldehyde, and 2,4-dinitrobenzoic acid (0.09–0.14%) were
detected in the bile of rats given 2,4-DNT.  2,6-Dinitrobenzyl alcohol, 2-amino-6-nitrotoluene, and 
2,6-dinitrobenzaldehyde were detected in the bile of rats given 2,6-DNT.
Reductive metabolism of 2,3-, 2,4-, 2,5, and 2,6-DNT occurs by Escherichia coli isolated from human 
intestine (Mori et al. 1984).  For all isomers, E. coli reduced DNTs to monoaminonitrotoluenes and 
hydroxylaminonitrotoluenes.  Results are consistent with E. coli reduction of DNTs via hydroxylamino­
nitrotoluenes to monoaminonitrotoluenes.  Study authors suggest that reduced metabolites of DNT may
play a role in the development of DNT-induced methemoglobinemia and anemia observed in humans and
animals.
Studies of the metabolism of 2,4-DNT by intestinal microflora in rats and mice (Guest et al. 1982; Mori et 
al. 1985) and studies in germ-free rats (Rickert et al. 1981) have shown that intestinal microflora are 
responsible for reductive metabolism of DNTs.  Intestinal microorganisms hydrolyze and reduce 2,4- and 
2,6-dinitrobenzyl alcohol glucuronide to the corresponding aminonitrotoluenes, probably through nitroso 
derivatives and hydroxylamino derivatives (Mori et al. 1997).  The deconjugated metabolites are
reabsorbed and transported back to the liver by enterohepatic circulation (Medinsky and Dent 1983).  In 
the liver, the newly formed amine group is N-hydroxylated by cytochrome P450 and conjugated with 
sulfate (Kedderis et al. 1984). The sulfate conjugate is unstable and can be decomposed to form a 
carbonium or nitrenium ion that can be bound to hepatic macromolecules; this ostensibly leads to 
mutations and the formation of liver tumors.  Thus, sulfation may be involved in the initiation stage of
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hepatocarcinogenesis by 2,6-DNT.  Metabolism by intestinal microflora appears to be essential for the 
production of metabolites that bind covalently to liver macromolecules.
The intestinal biotransformation of 2,6-DNT was investigated in vitro using suspended microflora
preparation from the intestinal contents of male Wistar rats (Sayama et al. 1993). It was determined that
the metabolites formed with the incubation of 2,6-DNT were 2-nitroso-, 2-hydroxyl amino-, and 2-amino­
6-nitrotoluene and 2,6-diaminotoluene.  Since no metabolites were detected when 2,6-diaminotoluene was
incubated and the recovery of 2,6-diaminotoluene was about 95%, it appears that 2,6-diaminotoluene is 
the terminal intestinal metabolite of 2,6-DNT (Sayama et al. 1993).  When 2,4-DNT was examined in this
system, two nitroazoxy compounds (2,2'-dimethyl-5-5'-dinitroazoxybenzene and 4,4'-dimethyl­
3,3'-dinitro azoxybenzene) were detected in addition to other known metabolites, such as nitrosonitro­
toluenes, hydroxyl aminonitrotoluenes, aminonitrotoluenes, and diaminotoluene (Sayama et al. 1993).  
The nitroazoxy compounds were believed to be non-enzymatic products (Sayama et al. 1993).
The metabolites formed by the anaerobic incubation of potassium 2,4-dinitrobenzyl glucuronide or
potassium 2,6-dinitrobenzyl glucuronide with rat intestinal microflora have been examined (Mori et al.
1997).  Metabolites transformed from 2,4-dinitrobenzyl glucuronide were 2,4-dinitrobenzyl alcohol, 
4-amino-2-nitrobenzyl alcohol, and 2-amino-4-nitrobenzyl alcohol, which peaked at 30, 75, and 
120 minutes of the incubation. 2,6-Dinitrobenzyl alcohol and 2-amino-6-nitrobenzyl alcohol were 
detected from potassium 2,6-dinitrobenzyl glucuronide incubation.  Thus, intestinal metabolism includes
the deconjugation of the glucuronide and the reduction of the nitro compound.
In rats, sex differences in the metabolism of 2,4-DNT have been observed.  A larger percentage of the 
administered dose is excreted in the bile of male rats than is excreted in the bile of females.  In females, a 
greater percentage of the dose is excreted in urine as the dinitrobenzyl alcohol glucuronide (Medinsky and
Dent 1983; Rickert and Long 1981).  The quantitative differences in urinary versus biliary excretion of
the glucuronide conjugates by females may account for the sex differences in the susceptibility of the rat
to the hepatocarcinogenic effects of 2,4-DNT (U.S. Army 1979).  Greater urinary excretion may decrease 
the amount of the glucuronide available to the intestinal microflora for metabolism to a carcinogenic 
metabolite. 
Metabolism studies in rats, rabbits, dogs, and monkeys with 2,4-DNT revealed the major urinary
metabolites as glucuronide conjugates of 2,4-dinitrobenzyl alcohol (20–33% of the dose) and 
2,4-aminonitro-benzyl alcohols (8–19% of the dose). Lesser amounts of aminonitrotoluene, 2,4-diamino­
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toluene, 2,4-aminobenzyl alcohol, and 2,4-dinitrobenzoic acid were also identified in all four species.
Mice were also evaluated in this same group of studies.  In mice, approximately 3% of the administered 
dose was excreted in the urine as the glucuronide conjugate of the 2,4-dinitrobenzyl alcohol and 
approximately 3% as the glucuronide conjugates of 2,4-aminonitrobenzyl alcohol (U.S. Army 1978b).
Another study using rats dosed with either 2,4- or 2,6-DNT also demonstrated that the primary urinary
conjugate was the respective dinitrobenzyl alcohol glucuronide (11–17% of administered dose) (Mori et
al. 1996).  Other metabolites in rats administered 2,4-DNT included 2-amino-4-nitrobenzoic acid 
(0.71%), 4-amino-2-nitrobenzoic acid (0.52%), 4-acetylamino-2-nitrobenzoic acid (3.9%), 4-amino­
2-nitrotoluene (0.04%), 2,4-dinitrobenzyl alcohol (0.25%), 2,4-dinitrobenzoic acid (6.9%), and 
4-acetylamino-2-aminobenzoic acid (3.4%).  After administration of 2,6-DNT, other metabolites in urine
included 2,6-dinitrobenzoic acid (0.17%), 2-amino-6-nitrotoluene (0.44%), and 2,6-dinitrobenzyl alcohol
(0.53%) (Mori et al. 1996).
The urinary metabolites of DNTs, and probably the glucuronides resulting from occupational exposure of
humans, are qualitatively the same as those resulting from oral administration to rats, but the proportions
of nitro-reduced metabolites were lower relative to oxidized metabolites in the urine from humans (Turner
et al. 1985).  These differences may be due more to the particular routes of exposure (inhalation and
dermal for humans; oral for rats) than differences in species.  As seen in experimental animals, female 
subjects excreted a higher proportion of urinary metabolites as dinitrobenzyl alcohol glucuronides than
did males.
Metabolism of DNTs has not been studied in children.  However, fetuses and neonates have been shown 
to be limited in their ability to biotransform xenobiotics.  Although the cytochrome P450 isoforms
responsible for DNT metabolism have not been identified, cytochromes CYP2E1, CYP2B1/2, and 
CYP2C11/6 are known to contribute to the side-chain oxidation of toluene by the rat liver, and multiple
cytochrome P450 isoforms may contribute to the side-chain oxidation of DNTs (Chapman et al. 1993).  In 
humans, CYP2E1 protein is absent from fetal and neonatal livers, but steadily increases during the first
year of life (Vieira et al. 1996).  Other isoforms’ expression in fetuses and neonates is also qualitatively
and quantitatively different from the expression observed in adults (Komori et al. 1990; Leeder and 
Kearns 1997).  In rats, while sulfotransferase (the enzyme that catalyzes sulfation) activity is almost at 
adult levels at birth, UDP-glucuronosyltransferase (the enzyme that produces glucuronide conjugates)
activity towards different xenobiotics varies with maturation (Young and Lietman 1978).  Similarly, in 
humans, sulfation capabilities develop faster than glucuronidation capabilities (Leeder and Kearns 1997).  
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While the activity of some isoforms of sulfotransferase may exceed those seen in adults during infancy
and early childhood, the activity of UDP-glucuronosyltransferase depends on the specific isoforms of the 
enzyme, and adult levels are generally attained by 6–18 months (Leeder and Kearns 1997).  Since DNTs
undergo bioactivation in the liver and by the intestinal microflora, the toxicity of DNTs may be different
in children.  Newborns have a transient deficiency in methemoglobin reductase (Gruener 1976) and have
a high concentration of fetal hemoglobin in their erythrocytes.  Consequently, they are highly sensitive to 
methemoglobin-generating chemicals and to methemoglobinemia generated by DNTs.
3.4.4 Elimination and Excretion 
3.4.4.1  Inhalation Exposure 
In occupational settings, in addition to inhalation, some oral and dermal exposure can occur. The
elimination of DNTs in the urine of workers exposed to Tg-DNT has been studied by several investigators
(Levine et al. 1985b; Turner et al. 1985; Woollen et al. 1985).
Woollen et al. (1985) observed that the highest rates of excretion of 2,4-dinitrobenzoic acid occurred near
the end of the work shift. The half-life for urinary excretion of 2,4-dinitrobenzoic acid was calculated to 
be 2–5 hours. This estimate appears to be the initial phase of a biphasic elimination profile since even
3 days after the last exposure, detectable levels of 2,4-dinitrobenzoic acid were present in urine.
Turner et al. (1985) determined the metabolic profiles in workers exposed to DNTs.  The half-life for 
excretion of DNT metabolites in urine ranged from 0.8 to 4.5 hours.  The half-lives for 2,4-dinitrobenzoic
acid and 2,4-dinitrobenzyl alcohol glucuronide tended to be shorter than those for the metabolites that
resulted from both oxidative and reductive metabolism.
No studies investigating elimination and excretion of 2,3-, 2,5-, 2,6-, 3,4-, or 3,5-DNT following
inhalation exposure of humans or animals were located.
3.4.4.2  Oral Exposure
No studies were located regarding excretion in humans following oral exposure to 2,3-, 2,4-, 2,5-, 2,6-, 
3,4-, or 3,5-DNT.
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Schut et al. (1983) reported that in mice, urine was the main route of elimination of 3H-labeled 2,6-DNT,
with about 50% excreted after 8 hours.  U.S. Army (1978b) observed that most of the radioactivity from
14C-labeled 2,4-DNT administered to mice was excreted in the feces and only about 10% in the urine.
Differences between these two studies could be due, in part, to the use of different species of mice.
Male and female rats excreted 55–90% of the radioactivity from 14C-2,4-DNT or 14C-2,6-DNT in the
urine, and 15–30% in the feces, within 72 hours after dosing (Long and Rickert 1982; Rickert and Long
1981).  With 2,4-DNT, the females excreted a greater percentage of the dose in the urine as 
2,4-dinitrobenzylalcohol glucuronide than did the males (except at the highest dose), but with 2,6-DNT,
no sex-related difference in urinary excretion was seen.
In experiments with bile duct-cannulated rats, male rats excreted 25% of the radioactivity from
14C-2,4-DNT into the bile over a 36-hour period, whereas female rats excreted 18% (Medinsky and Dent
1983).  Biliary excretion of radioactivity was linearly related to dose in males; females were evaluated
only at one dose.  Biliary excretion of radioactivity was virtually complete within 24 hours for males and 
12 hours for females. Mean half-times of biliary excretion ranged from 3.3 to 5.3 hours.  Urinary
excretion was also significant, with greater amounts of radioactivity excreted in the urine of rats from
which bile was not collected (60–90% of the dose) than in the urine of rats from which bile was collected 
(20–60% of the dose).  This finding indicates that biliary metabolites were absorbed from the intestines
(enterohepatic cycling).  Whether or not bile was collected, female rats excreted more radioactivity in
urine than did male rats.  Greater than 90% of the urinary excretion of labeled metabolites appeared in
urine collected during the first 24 hours.  At the end of 36 hours, only 0.02–0.05% of the radioactivity
was detectable in the livers; 20–60% of this was covalently bound.
No studies investigating elimination and excretion of 2,3-, 2,5-, 3,4-, or 3,5-DNT following oral exposure
of humans or animals were located.
3.4.4.3  Dermal Exposure 
There are no kinetic data in humans in which the route of exposure was specifically dermal.  Occupational
exposure studies available for Tg-DNT involved multiple routes of exposure (Levine et al. 1985b; Turner
et al. 1985; Woollen et al. 1985).  The major routes of exposure in these studies were considered to be
inhalation and dermal.  The results were discussed previously in Section 3.4.4.1.
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No studies were located regarding excretion in animals following dermal exposure to 2,3-, 2,4-, 2,5-, 2,6-, 
3,4-, or 3,5-DNT.
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of
PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these
solutions.  
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The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems. If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.
Figure 3-10 shows a conceptualized representation of a PBPK model.
If PBPK models for 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, and 3,5-DNT exist, the overall results and individual 
models are discussed in this section in terms of their use in risk assessment, tissue dosimetry, and dose,
route, and species extrapolations.
A PBPK model has not been developed for 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.
3.5  MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms
No information was located regarding the mechanism of absorption of 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or
3,5-DNT.  It is known that absorption occurs after inhalation exposure based on the metabolites found in 
the urine of workers at DNT manufacturing plants (Levine et al. 1985b; Turner 1986; Woollen et al. 
1985).  In studies of rats, rabbits, dogs, and monkeys, most orally administered 2,4- or 2,6-DNT has been 
shown to be absorbed (Long and Rickert 1982; Rickert and Long 1981; U.S. Army 1978b).  There
appears to be minimal accumulation of these compounds after a single exposure. After repeated oral
exposure in rats, 2,4-DNT and its metabolites were preferentially distributed to the liver, kidney, brain, 
lung, and skeletal muscle. The primary metabolite of 2,4-DNT excreted by humans exposed via
inhalation and dermal routes of exposure in occupational studies or animals exposed via the oral route is
2,4-dinitrobenzyl alcohol and/or its glucuronide (EPA 1992).  In addition to this, humans also excrete 
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Figure 3-10.  Conceptual Representation of a Physiologically Based 

Pharmacokinetic (PBPK) Model for a 

Hypothetical Chemical Substance
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Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source:  Krishnan and Andersen 1994
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2-amino-4-nitrobenzyl alcohol in the urine.  2,4-Dinitrobenzoic acid is another major metabolite (EPA
1992).  Both 2-nitroso-4-nitrotoluene and 2-amino-4-nitrotoluene, metabolites of 2,4-DNT in humans, 
have been shown to be mutagenic in vitro (EPA 1992).  It has been suggested that these intermediates 
may bind covalently to hepatic macromolecules, such as DNA and RNA (EPA 1992).
3.5.2 Mechanisms of Toxicity
Effects of Metabolism on Toxicity. The primary mechanism of toxicity for DNTs involves bioactivation
to form reactive intermediates (Kedderis et al. 1984; Sayama et al. 1989).  Detailed information on the
biotransformation of DNTs is presented in Section 3.4.3.  Briefly, metabolism of DNTs begins in the
liver, where it is oxidized by cytochrome P450 and conjugated with glucuronic acid to form the major
metabolite, dinitrobenzyl alcohol glucuronide, and is excreted in bile or urine (Long and Rickert 1982;
Medinsky and Dent 1983). The glucuronide excreted in bile undergoes biotransformation by intestinal
microflora, where the conjugate is hydrolyzed and subsequently reduced by nitroreductase to the
corresponding aminonitrobenzyl alcohol (Chadwick et al. 1993; Guest et al. 1982; Mori et al. 1985), 
probably through nitroso derivatives and hydroxylamino derivatives.  The deconjugated metabolites are
reabsorbed and transported back to the liver by enterohepatic circulation (Medinsky and Dent 1983).  In 
the liver, the newly formed amine group is N-hydroxylated by cytochrome P450 and conjugated with 
sulfate (Kedderis et al. 1984). The sulfate conjugate is unstable and can be decomposed to form a 
carbonium or nitrenium ion that can be bound to hepatic macromolecules; this ostensibly leads to 
mutations and the formation of liver tumors.  Thus, sulfation may be involved in the initiation stage of
hepatocarcinogenesis by 2,6-DNT.
Target Organ Toxicity. The mechanism of toxicity of the hematological effects of DNTs is described by
U.S. Army (1979).  The effect of DNTs on the blood is also produced by aromatic amines and most
organic and inorganic nitrates.  These compounds or their metabolites oxidize the ferrous ion in 
hemoglobin and produce methemoglobin.  Hydroxylamine is probably the oxidizing species, because it is 
an intermediate in the reduction of nitro to amines.  Within limits, the body can correct methemoglobin­
emia, but the corrective measures can be overwhelmed, producing numerous secondary effects including
anoxia.  The presence of methemoglobin leads to the formation of aggregates of hemoglobin degradation 
products called Heinz bodies.  The presence of Heinz bodies is a sensitive indicator of blood toxicity as it
indicates that some hemoglobin has been destroyed.  High levels of methemoglobin are removed by
catabolism, leading to the development of anemia.  The body compensates for the destruction of red blood
cells by increasing erythrocyte production, resulting in large numbers of immature erythrocytes, called
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reticulocytes, in the blood. If the toxic dose is not too severe, these compensatory mechanisms suffice.
Thus, "compensated anemia," normal erythrocyte levels with reticulocytosis, may exist in exposed
individuals.  When the production of red blood cells can no longer keep pace with the hemolysis, frank
anemia may be present (U.S. Army 1979).
As discussed in Section 3.2.2.7 (Oral Exposure; Cancer), 2,4-, 2,6-, or Tg-DNT have been shown to 
induce hepatocellular carcinoma following chronic-duration oral exposure.  Thus, hepatic effects 
observed at less than chronic exposure durations or at lower doses may represent early stages of
progressive development to hepatic cancer or threshold level effects for development of cancer; however,
the mechanism of toxicity for hepatic effects has not been elucidated.  A study examining changes in gene
expression in the livers of female rats administered 2,4-DNT at 5–398 mg/kg/day or 2,6-DNT at 5– 
199 mg/kg/day via gavage as a single dose showed that treatment with these compounds perturbed
pathways involved in DNA damage response, cell death signaling, detoxification and lipid metabolism, 
the oxidative stress response, and the immune response 24 and 48 hours after dosing (Deng et al. 2011).
There are limited data on the mechanisms of hepatotoxicity for the six isomers.  Spanggord et al. (1990)
exposed rat hepatocytes to each of the six isomers of DNT in vitro and observed greater toxicity to 
hepatocytes (based on dose-response relationships for protein synthesis and LDH release) from 2,3-, 2,5-, 
and 3,4-DNT than from 2,4-, 2,6-, or 3,5-DNT.
The mechanisms of toxicity for reproductive effects (testicular atrophy, degeneration of the seminal
vesicles, and decreased sperm production) observed in animal studies (Bloch et al. 1988; U.S. Army
1976, 1978b, 1979) have not been elucidated.  However, data from in vitro studies indicate that testicular
degeneration may be associated with structural changes in Sertoli cells (Reader and Foster 1990).  Bloch
et al. (1988) reported that diminished sperm counts in rats acutely exposed to 2,4-DNT were accompanied
by fine structural alterations of Sertoli cells.  Increased serum levels of FSH, also indicative of Sertoli cell
malfunction, were also reported (Bloch et al. 1988).  Reader and Foster (1990) reported that Sertoli cell
cultures prepared from the testes of Wistar rats and treated with up to 100 μM 2,3-, 2,4- or 2,6-DNT
remained intact; however, cells treated with 2,3-, 2,4-, or 2,6-DNT showed some evidence of damage 
(absence of germ cells and some Sertoli cells containing cytoplasmic vacuoles). Treatment of the Sertoli 
cell cultures with 100 µM 3,4-DNT, in contrast, resulted in subconfluent monolayers with a significant
decrease in total cellular protein, as well as stellate appearance and prominent cytoplasmic vacuolation.
Germ cell detachment from Sertoli germ cell cocultures was significantly increased (p<0.05) compared to
controls at 10 μM 2,4- or 2,6-DNT and at 0.01 µM 2,3- or 3,4-DNT (Reader and Foster 1990).  Further
evidence of disruption of Sertoli cell function was observed as increased production of lactate and 
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pyruvate (including marked increases in pyruvate production with exposure to 3,4-DNT), although 
increases in pyruvate production were minimal with 2,6-DNT (Reader and Foster 1990).  Another study
showed that adult immortalized rat Sertoli cells exposed to 2,4-DNT at 25–200 µmol/L showed increased 
numbers of autophagosomes and autophagic lysosomes, which may signal the removal of cellular
components damaged by exposure or impending apoptosis (Sorenson and Brabec 2003).  Thus, it appears
that structural changes in the Sertoli cells may be precipitating events responsible for reproductive effects 
observed in animals exposed to DNTs.
The effects of 2,4-DNT on body weights of animals may be mediated through PPARα signaling.  
Wilbanks et al. (2014) observed decreased body weight and lower swim-to-exhaustion times in wild type
C57Bl/6N mice exposed to 134 mg/kg/day 2,4-DNT via gavage for 14 days, while these effects were 
much less severe in exposed PPARα-null mice. Additional support for the role of PPARα signaling was
shown by the decreases in expression of genes downstream of this signaling pathway (especially those 
involved in fatty acid transport) in wild type mice.  Wilbanks et al. (2014) proposed that impairment of
the PPARα signaling pathway was a key event in the mechanism of 2,4-DNT-induced effects on energy
metabolism and weight loss.
Carcinogenesis. The mechanisms of DNT-induced carcinogenicity have not been described.  However, 
genotoxicity assays in vitro and in vivo indicate that DNT isomers have the potential to induce gene 
mutations and other forms of DNA damage (DNA adduct formation, chromosomal aberrations, and 
UDS).  The mechanism underlying the development of renal tumors in CD-1 male mice exposed to oral
2,4-DNT at 95 mg/kg/day for 2 years (U.S. Army 1979) has not been determined.  However, workers
exposed occupationally to explosives containing 30% Tg-DNT with renal cancer typically showed
pathological patterns of urinary excretion, indicated by the molecular weight of excreted proteins
(i.e., increased excretion of tubular proteins of low molecular weight and glomerular leakage with
excretion of high molecular weight proteins), and/or specific biomarkers of damage to the proximal
tubule of the nephron (α1-microglobulin and glutathione-S-transferase α). These data are consistent with
the hypothesis that renal tumors are initiated by DNT isomers and that promotion occurs via damage to 
the proximal tubule of the nephron (Brüning et al. 2001).
In hepatic tumor initiation-promotion experiments, Tg-DNT and 2,6-DNT were found to have tumor-
promoting and tumor-initiating activity; 2,4-DNT showed only tumor-promoting activity (Leonard et al.
1983, 1986; Mirsalis and Butterworth 1982; Popp and Leonard 1982).  2,6-DNT was indicated to be a 
complete hepatocarcinogen and is primarily responsible for the carcinogenic activity of Tg-DNT. Hepatic 
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DNA adducts have been detected by 32P-postlabeling technique in 2,6-DNT-treated B6C3F1 mice and
F344 rats (George et al. 1996).  In male Wistar rats administered 2,4- or 2,6-dinitrobenzyl glucuronide, 
the major compounds excreted in the bile after treatment with 2,4- or 2,6-DNT, secondary metabolism led 
to the production of genotoxic agents in the urine and bile (Mori et al. 2000).  2,4-Dinitrobenzaldehyde
(mutagenic in the Ames assay using S. typhimurium strains TA98 and TA100) and 2,4-diaminotoluene
(carcinogenic) were detected in the urine and bile of 2,4-dintrobenzyl glucuronide-treated rats; 2-amino­
6-nitrobenzyl alcohol (genotoxic) was detected in 2,6-dintrobenzyl glucuronide-treated rats.  The 
formation of these metabolites may contribute to the hepatocarcinogenesis induced by 2,4- and 2,6-DNT.
2,6-Dinitrobenzaldehyde, another metabolite of 2,6-DNT, was found to be a direct-acting mutagen in the
S. typhimurium strain TA98 and TA100 systems, not requiring metabolic activation by the S9 mix.  
4-Amino-2-nitrobenzyl alcohol, 2-amino 4 nitrobenzyl alcohol, and 2-amino-6-nitrobenzyl alcohol are
also mutagenic metabolites of 2,4- and 2,6-DNT, with their mutagenicity requiring metabolic activation
(Mori et al. 1982; Sayama et al. 1989). Kedderis et al. (1984) proposed a bioactivation mechanism
relating to the genotoxicity of 2,6-DNT in male F344 rats.  They showed that the active metabolite of
2,6-DNT in the male F344 rat is the hydroxylamino sulfate of aminonitrobenzyl alcohol formed by the
intestinal metabolism of benzyl glucuronide of 2,6-dinitrobenzyl alcohol excreted in bile. The sulfate
conjugate is unstable, and the formation of electrophilic carbonium or nitrenium ions from these
conjugates leads to subsequent binding to DNA.
3.5.3 Animal-to-Human Extrapolations 
Correlation of toxic effects between humans and animals for 2,4- and 2,6-DNT with regard to hemato­
logic and neurological effects has been noted (Ellis et al. 1985; Hong et al. 1985; Lane et al. 1985; Lee et
al. 1985; McGee et al. 1947; U.S. Army 1978b, 1979).  Other effects for 2,4- and 2,6-DNT, such as 
reproductive, hepatic, renal, and cancer have been noted in animals (Ellis et al. 1985; Hong et al. 1985;
Lee et al. 1985; Leonard et al. 1983, 1986; McGown et al. 1983; Stoner et al. 1984; U.S. Army 1976, 
1978b, 1979), but insufficient data are available to state definitively whether they are effects in humans.
Two mutagenic metabolites of 2,4-DNT have been found in humans, mice, and rats (EPA 1992).  
Although rats appear to be more sensitive to the effects of 2,4-, 2,5-, 2,6-, and 3,4-DNT than mice (Hong
et al. 1985; Lane et al. 1985; U.S. Army 1975, 1978a, 1978b; Vernot et al. 1977), dogs appear to be the
most sensitive of the three species (Ellis et al. 1985; U.S. Army 1976, 1978b, 1979).  However, limited 
intermediate-duration data using 2,6-DNT have shown mice to be more sensitive than rats (U.S. Army
1976).  It should be noted that dogs were fed DNTs by capsule in experimental studies, whereas the 
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rodents received the test chemical in feed (Ellis et al. 1985; Hong et al. 1985; Lee et al. 1985; U.S. Army
1975, 1976, 1978b, 1979).
Extrapolating animal toxicity data to predict human risk from exposure to 2,4- and 2,6-DNT appears to be 
reasonable because of qualitative similarities in metabolism and known toxic effects. Based on what is
known about these two isomers, extrapolation from animal toxicity data to predict human risk from
exposure to the remaining isomers (2,3-, 2,5-, 3,4-, and 3,5-DNT) is also assumed to be reasonable.
3.6  TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial,
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought
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to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
No studies were located regarding endocrine disruption in humans and/or animals after exposure to 2,3-, 
2,4-, 2,5-, 2,6-, 3,4-, and 3,5-DNT.
No in vitro studies were located regarding endocrine disruption of 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, and 
3,5-DNT.
3.7  CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed.
Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage. There are 
critical periods of structural and functional development during both prenatal and postnatal life, and a
particular structure or function will be most sensitive to disruption during its critical period(s). Damage 
may not be evident until a later stage of development. There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek
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1966; Widdowson and Dickerson 1964). The fetus/infant has an immature (developing) blood-brain 
barrier that past literature has often described as being leaky and poorly intact (Costa et al. 2004).
However, current evidence suggests that the blood-brain barrier is anatomically and physically intact at 
this stage of development, and the restrictive intracellular junctions that exist at the blood-CNS interface 
are fully formed, intact, and functionally effective (Saunders et al. 2008, 2012).
However, during development of the blood-brain barrier, there are differences between fetuses/infants and
adults which are toxicologically important. These differences mainly involve variations in physiological
transport systems that form during development (Ek et al. 2012).  These transport mechanisms (influx and 
efflux) play an important role in the movement of amino acids and other vital substances across the
blood-brain barrier in the developing brain; these transport mechanisms are far more active in the 
developing brain than in the adult.  Because many drugs or potential toxins may be transported into the
brain using these same transport mechanisms—the developing brain may be rendered more vulnerable
than the adult.  Thus, concern regarding possible involvement of the blood-brain barrier with enhanced 
susceptibility of the developing brain to toxins is valid.  It is important to note however, that this potential
selective vulnerability of the developing brain is associated with essential normal physiological
mechanisms; and not because of an absence or deficiency of anatomical/physical barrier mechanisms.
The presence of these unique transport systems in the developing brain of the fetus/infant is intriguing; as 
it raises a very important toxicological question as to whether these mechanisms provide protection for 
the developing brain or do they render it more vulnerable to toxic injury.  Each case of chemical exposure
should be assessed on a case-by-case basis.  Research continues into the function and structure of the 
blood-brain barrier in early life (Kearns et al. 2003; Saunders et al. 2012; Scheuplein et al. 2002).
Many xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of
growth and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also
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have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
No specific health effects resulting from DNT exposure have been observed in children.  Generally, 
health effects observed in adults should also be of potential concern in children.
No direct information is available regarding the effects of DNTs on the developmental process in humans, 
and there are few developmental studies on animals. When Tg-DNT was administered by gavage to
pregnant rats for 14 days during gestation, and pups were evaluated for developmental toxicity either at
gestation day 20 or postpartum day 60 (Jones-Price et al. 1982), adverse effects on hematologic
parameters and altered organ weights were observed in both dams and fetuses when dams were 
administered 100 or 150 mg/kg/day.  However, the fetal toxicity was not dose-related. A decrease in
relative liver weight was observed in the postpartum pups at the low dose of 14 mg/kg/day.  Dose-related
effects on postnatal development were not observed in pups when dams were administered 35 or 
75 mg/kg/day.
No consistent changes were observed in the number of preimplantation losses, implantation sites, or
living or non-living fetuses in male Sprague-Dawley rats gavaged with 2,4 DNT at 0, 60, 180, or
240 mg/kg/day for 5 days (Lane et al. 1985).  Exposure of male animals to DNTs does not cause 
dominant lethal mutation or increases in the proportion of nonviable conception (U.S. Army 1979).
DNTs have been found to be genotoxic using in vivo test systems (Ashby et al. 1985; Huang et al. 1995;
Mirsalis et al. 1989).  Although 2,6-DNT itself showed no mutagenicity towards S. typhimurium strains 
TA98 and TA100 with or without activation by S9 mix, 2,6-dinitrobenzaldehyde, a metabolite of
2,6-DNT, was found to be a direct-acting mutagen, not requiring metabolic activation (Sayama et al.
1989).  The reason that DNTs are not shown to bind to DNA and cause mutations in most of the short-
term in vitro assays for genotoxicity is that the formation of DNA-reactive DNT metabolites involved
several different biotransforming enzymes in the intestinal microflora and in the liver.  However, DNTs
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did not cause dominant lethal mutation or increases in the proportion of nonviable conceptions following
exposure of male animals (U.S. Army 1979), so it is not clear if the genotoxic form of DNT might
potentially reach the germ cells following oral, inhalation, or dermal exposure. 
It is unlikely that DNTs and its metabolites will accumulate in maternal tissues because of its low octanol­
water partition coefficient. No studies are available that demonstrate DNTs or their metabolites cross the 
placenta or get into breast milk.  Thus, it is unlikely that the developing fetus or nursing infant would be
exposed to DNTs as a consequence of maternal exposure prior to gestation.  However, developmental
toxicity from DNTs could potentially occur because of its ability to deplete the amount of oxygen 
available to the developing fetus.  Pregnant women and their fetuses may be susceptible to the oxygen
depletion implied by the hematotoxicity of DNTs based on a study of rats (Jones-Price et al. 1982).  
Newborns have a transient deficiency in methemoglobin reductase which reduces methemoglobin back to 
hemoglobin (Gruener 1976).  They also have a high concentration of fetal hemoglobin in their
erythrocytes (Smith 1996).  Thus, newborns are unusually sensitive to methemoglobin-generating
chemicals such as DNT. The metabolism of DNTs has not been studied in children or appropriate animal
models.  However, while some of the enzymes involved in DNT metabolism reach or exceed adult levels 
during infancy and early childhood, other enzymes such as UDP-glucuronosyltransferase may attain adult
levels by 6–18 months of age (Leeder and Kearns 1997).  Thus, the toxicity of DNTs may be different in 
children.
3.8  BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment
of an organism (NAS/NRC 1989).  The preferred biomarkers of exposure are generally the substance
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta.  However, several
factors can confound the use and interpretation of biomarkers of exposure.  The body burden of a
substance may be the result of exposures from more than one source. The substance being measured may
be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from
exposure to several different aromatic compounds).  Depending on the properties of the substance (e.g.,
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biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and 
all of its metabolites may have left the body by the time samples can be taken.  It may be difficult to
identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids
(e.g., essential mineral nutrients such as copper, zinc, and selenium).  Biomarkers of exposure to 2,3-, 
2,4-, 2,5-, 2,6-, 3,4-, and 3,5-DNT are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung
capacity.  Note that these markers are not often substance specific. They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused
by DNTs are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
There are no biomarkers of exposure or effects that have been validated in children or in adults exposed
as children.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to DNTs
Workers exposed to DNTs in a manufacturing plant excreted 2,4-DNT, 2,6-DNT, and their metabolites in
the urine (Levine et al. 1985b).  The concentrations of DNT in air ranged from 0.1 to 5.9 mg/m3. 
Concentrations of DNTs and metabolites ranged from 1.68 to 16.74 mg/day (or 1.74–17.31 mg/L, based 
on an average daily urine volume of 967 mL), with widespread daily variations.  Estimates of inhaled 
DNTs ranged from 0.5 to 4.9 mg/day, less than the total excreted suggesting that dermal exposure, and 
possibly oral exposure, contributed to the body burden of DNTs. Jones et al. (2005b) did not find a
significant correlation between the levels of air concentrations of 2,4- and 2,6-DNT and the sum of urine
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metabolites among workers at a DNT and mononitrotoluene manufacturing facility.  The 8-hour TWA air
concentrations were 0.043 and 0.014 mg/m3 for 2,4- and 2,6-DNT, respectively.
Woollen et al. (1985) determined that the urinary concentration of a Tg-DNT metabolite, 2,4-dinitro­
benzoic acid, was <1 mg/L at the beginning of the work week and ranged from 3.4 to 41 mg/L at the end 
of the shift. Atmospheric DNT levels of undetectable to 0.03 mg/m3 were monitored with personal air
samples.  Static samples near dusty process areas monitored were 0.02–2.68 mg/m3. The study authors
estimate that inhalation exposures ranged from 1 to 14 mg/day.  As in Levine et al. (1985b), inhalation 
exposure does not account for the entire amount of DNT metabolites excreted in urine.  Dermal and 
ingestion exposures are, therefore, likely to have occurred.
Significant correlations between urinary levels of hemoglobin adducts and urinary metabolites were found
for 2,4- and 2,6-DNT in workers exposed to Tg-DNT (Sabbioni et al. 2006).  The hemoglobin adducts
resulting in exposure to 2,4-DNT were 4-amino-2-nitrotoluene and 2,4-toluenediamine; the hemoglobin 
adducts from 2,6-DNT exposure were 2-amino-6-nitrotoluene and 2,6-toluenediamine.  The best
correlations between urinary metabolites and hemoglobin adducts were 2,4-dinitrobenzyl alcohol and 
2,6-dinitrobenzyl alcohol with hemoglobin 2-4-nitrotoluene and hemoglobin-2-amino-6-nitrotoluene, 
respectively.
3.8.2 Biomarkers Used to Characterize Effects Caused by DNTs
After exposure to DNTs, methemoglobin levels in the blood may be elevated (Bentur and Keyes 2004).  
The methemoglobinemia present may be quite profound and its onset is often delayed by up to 4 hours
(Bentur and Keyes 2004).  Another hematological change that might be present in individuals who have
undergone repeated or prolonged exposure to DNTs is that which is consistent with Heinz bodies and 
hemolytic anemia.
DNA adducts have been found in the livers of rats treated orally with either 2,4- or 2,6-DNT (La and
Froines 1992, 1993).  The formation of DNA adducts is believed to be indicative of carcinogenic risk.
Decreased spermatogenesis has been reported in treated rats, mice, and dogs (Bloch et al. 1988; U.S. 
Army 1979).  However, decrease in sperm counts in workers exposed to DNTs has been reported in only
one study (CDC 1981).
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3.9  INTERACTIONS WITH OTHER CHEMICALS
Perkins (1919) reported that “alcoholic subjects have very little resistance to DNT.”
Exposure of male rats to 2,6-DNT for 5 days reduced the rate of metabolism of phenobarbital; exposure to
2,6-DNT for 4 weeks increased phenobarbital metabolism (Short and Lee 1980).  Exposure of rats to
2,4-DNT did not affect the rate of phenobarbital metabolism.
The effects of the herbicide, 2,4,5-trichlorophenoxyacetic acid (2,4,5-T), on 2,6-DNT genotoxicity were
examined in male weanling F344 rats (George et al. 1992). The rats were treated orally with 54.4 mg/kg 
2,4,5-T for 4 weeks, then with 75 mg/kg 2,6-DNT, 1, 2, or 4 weeks after the first dose of 2,4,5-T; urine
was then collected for 24 hours.  In animals treated for 1 week with 2,4,5-T, there was a decrease in
transformation of 2,6-DNT to mutagenic metabolites in the urine, but there were no changes in intestinal
enzyme activities (George et al. 1992).  Longer treatments with 2,4,5-T did not alter urine genotoxicity
compared to controls, and there was a transient increase in cecal azo reductase and nitroreductase after
2 weeks with a decrease in intestinal β-glucuronidase activity, but all levels were normal after 4 weeks.
Pretreatment of rats with alachlor for 3 weeks prior to a single oral administration of 75 mg/kg 2,6-DNT
resulted in the production of genotoxic metabolites, as evaluated in a S. typhimurium histidine reversion
bioassay in the absence of S9 activation (George et al. 1998).  Significant increases, compared to 
2,6-DNT-only exposed rats, were not observed in rats exposed to alachlor for 1 or 5 weeks.
Interaction of DNTs with other chemicals has not been observed in children.
3.10  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to DNTs than will most persons
exposed to the same level of DNTs in the environment.  Reasons may include genetic makeup, age, health 
and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These parameters
result in reduced detoxification or excretion of DNTs, or compromised function of organs affected by
DNTs.  Populations who are at greater risk due to their unusually high exposure to DNTs are discussed in
Section 6.7, Populations with Potentially High Exposures.
Several studies have examined the possible association between DNT toxicity and genetic 
polymorphisms.  Sabbioni et al. (2006) found that workers exposed to DNTs and TNT with the
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glutathione S-transferase T1 null genotype or N-acetyltransferase 1 fast acetylators genotype had 
significantly more chromatid-type chromosomal aberrations than controls of the same genotypes.  
Workers with the sulfotransferase 1A1 Arg/Arg or sulfotransferase 1A2 Asn/Asn genotypes or
N-acetyltransferase 1 fast acetylators had significantly more total aberrations than controls with the same 
genotypes. These results suggest differences in susceptibility to DNT toxicity. In contrast, Brüning et al. 
(1999) found that all of the workers at a copper mine using Tg-DNT explosives with urothelial cancer
were slow acetylators.
Humans sensitive to DNTs may include individuals with cardiovascular problems.  Hematological effects 
associated with exposure to 2,4-DNT may place persons with anemia, including sickle cell anemia or
other diseases of the blood, at an increased risk.
Persons with chronic neurological disorders may also have an increased sensitivity to DNT exposure.
Although there are insufficient data available to draw firm conclusions, it appears that pregnant women
and their fetuses may be susceptible to the oxygen depletion implied by the hematotoxicity of DNTs
based on a study on rats (Jones-Price et al. 1982).  Although it has been reported that alcoholics may have
a decreased resistance to the effects of Tg-DNT (Perkins 1919), the extent of this compromise has not
been determined.
The susceptibility of children to the health effects of DNTs may be different from that of adults, as
discussed in Section 3.7.
3.11  METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of
exposure to DNTs.  However, because some of the treatments discussed may be experimental and
unproven, this section should not be used as a guide for treatment of exposures to DNTs.  When specific 
exposures have occurred, poison control centers and medical toxicologists should be consulted for
medical advice.  The following texts provide specific information about treatment following exposures to 
DNTs:  
Bentur Y, Keyes DC.  2004.  Explosives.  In:  Dart RC, ed.  Medical Toxicology.  3rd ed.  Philadelphia, 
PA:  Lippincott Williams & Wilkins, 1258-1279.
Currance PL, Clements B, Bronstein AC.  2007. Dinitrophenol and related compounds.  In:  Emergency
care for hazardous materials exposure.  St. Louis, MO:  Mosby Jems, 335-338.
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There are no known pediatric-specific methods for reducing peak absorption following exposure,
reducing burden, or interfering with the mechanism of action for toxic effects.
3.11.1 Reducing Peak Absorption Following Exposure 
Limited information from humans indicates that DNTs is absorbed after inhalation exposure, while
animal data suggest that DNTs are rapidly and completely absorbed after oral exposure.  Efforts to reduce
absorption following acute exposure to DNTs should focus on removing the individual from the site of
exposure and decontaminating exposed areas of the body.  Contaminated clothing and jewelry should be
removed and skin should be washed with soap and water; eyes exposed to DNTs should be immediately
irrigated with water and normal saline (Bentur and Keyes 2004; Currance et al. 2007).  If ingestion of
DNTs occurs, emetics are not recommended due to the potential for central nervous system depression;
the mouth should be rinsed, and water can be administered for dilution if the patient can swallow, has a 
good gag reflex, and is not drooling (Bentur and Keyes 2004; Currance et al. 2007).  Gastric lavage and
administration of activated charcoal may be considered shortly following ingestion provided airways are
protected (Bentur and Keyes 2004; Currance et al. 2007).
3.11.2 Reducing Body Burden
There are no data to support the use of hemodialysis, forced diuresis, hyperbaric oxygen, or
hemoperfusion for treatment of methemoglobinemia alone, but these treatments may provide adjunctive
care after DNT ingestion when supportive care is inadequate (Bentur and Keyes 2004).
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
Methods for reducing DNT-induced methemoglobinemia (Bentur and Keyes 2004) are the same as those 
recommended for treating methemoglobinemia caused by overexposure to nitrate and/or nitrite (Agency 
for Toxic Substances and Disease Registry 2013; Leikin and Paloucek 2008; Seifert 2004).  Severe 
methemoglobinemia (methemoglobin levels generally >30% of total hemoglobin) can be reduced by
intravenous administration of methylene blue (1–2 mg/kg).  Exchange transfusions may be considered for
patients who do not respond to methylene blue (particularly patients with glucose-6-phosphate
dehydrogenase deficiency or hemoglobin M), and patients where methylene blue is contraindicated (e.g., 
patients on serotonin uptake inhibitors).  In symptomatic patients, 100% oxygen and assisted ventilation 
should be considered; seizures can be treated with oxygen and benzodiazepines, followed by
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phenobarbital (Seifert 2004).  Hyperbaric oxygen therapy may be of some benefit, but has not been 
demonstrated in controlled studies (Leikin and Paloucek 2008; Seifert 2004).
3.12  ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of DNTs is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the
initiation of a program of research designed to determine the health effects (and techniques for developing
methods to determine such health effects) of DNTs.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of DNTs
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
2,4-DNT; 2,6-DNT; 2,3-, 2,5-, 3,4-, and 3,5-DNT; and Tg-DNT are summarized in Figures 3-11, 3-12, 
3-13, and 3-14, respectively.  The purpose of these figures is to illustrate the existing information
concerning the health effects of 2,4-, 2,6-, 2,3-, 2,5-, 3,4-, 3,5-, and Tg-DNT.  Each dot in the figure
indicates that one or more studies provide information associated with that particular effect.  The dot does
not necessarily imply anything about the quality of the study or studies, nor should missing information in 
this figure be interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for
Identifying Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic
Substances and Disease Registry 1989), is substance-specific information necessary to conduct
comprehensive public health assessments.
Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from
the scientific literature.
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Figure 3-11.  Existing Information on Health Effects of 2,4-Dinitrotoluene
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Figure 3-12.  Existing Information on Health Effects of 2,6-Dinitrotoluene
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Figure 3-13.  Existing Information on Health Effects of 2,3-, 2,5-, 3,4-, and 
3,5-Dinitrotoluene
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Figure 3-14.  Existing Information on Health Effects of Technical-Grade 
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3.12.2 Identification of Data Needs 
There are no data on the health effects of 2,3-, 2,5-, 3,4-, or 3,5-DNT in humans by any route of exposure.  
As shown in Figures 3-11 (2,4-DNT), 3-9 (2,6-DNT), and 3-11 (Tg-DNT), there are limited data on 
health effects in humans, primarily for Tg-DNT, following inhalation exposure. With the exception of
animal oral LD50 values, the animal data for 2,3-, 2,5-, 3,4-, and 3,5-DNT are limited to a single 14-day 
gavage study in rats (Figure 3-13).
The available reports generally lack quantitative information on exposure levels.  Human data are
particularly sparse.  Most toxicity studies have focused on the main systemic effects of obvious clinical
significance, as described in the previous sections.
The toxicity of these chemicals has been extensively investigated in animals after oral exposure, but not
after inhalation exposure, and only in a very limited way after dermal exposure. The potential
carcinogenicity of these chemicals has been investigated following oral exposure in typical chronic
bioassays as well as in less-than-lifetime studies.
Acute-Duration Exposure. Although there are no human data available from acute-duration oral
exposure to 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, or 3,5-DNT, data currently available from animal studies of 2,3-,
2,4-, 2,5-, 2,6-, and 3,4-DNT are appropriate for evaluation of oral toxicity (Lent et al. 2012a; USAPHC
2011a, 2011b, 2011c, 2011d, 2011e, 2011f; U.S. Army 1975, 1978a; Vernot et al. 1977).  In gavage
studies in rats and mice, LD50 values of 1,120 and 1,070 mg/kg, respectively, were identified for 2,3-DNT
(Vernot et al. 1977).  The LD50 values for 2,4-DNT determined after gavage dosing ranged from 270 to 
650 mg/kg in rats and from 1,340 to 1,954 mg/kg in mice (U.S. Army 1975, 1978a; Vernot et al. 1977). 
Gavage dosing of 2,5-DNT identified LD50 values of 710 mg/kg in rats and 1,230 mg/kg in mice (Vernot
et al. 1977).  After oral administration of 2,6-DNT, LD50 values ranged from 180 to 795 mg/kg in rats and 
from 621 to 807 mg/kg in mice (U.S. Army 1975, 1978a; Vernot et al. 1977).  Ataxia was observed in 
these animals before death. Oral LD50 values of 1,070 and 1,410 mg/kg 3,4-DNT in rats and mice were 
determined after gavage dosing (Vernot et al. 1977). Decreased body weight gain was noted in rats 
administered 2,4-DNT via gavage at 398 mg/kg and observed for 48 hours and in rats administered 
2,6-DNT at ≥50 mg/kg and observed for 48 hours; body weight loss occurred at 199 mg/kg 2,6-DNT
(Deng et al. 2011).  After 14 days of gavage administration of 2,4-, 2,6-, or 3,4-DNT, decreased body
weights were observed at doses of 142, 35, and 227 mg/kg/day, respectively (Lent et al. 2012a USAPHC
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2011b, 2011d, 2011e). Slight cyanosis was observed in rats administered 60 mg/kg 2,4-DNT by gavage
for 5 days (Lane et al. 1985), but no changes in hematological parameters were found in rats fed up to 
273 mg/kg/day in the diet for 14 days (McGown et al. 1983). Evidence of erythrocytosis (increased red
blood cells, hemoglobin, and hematocrit) was observed in rats administered 2,4-DNT at ≥99 mg/kg and in 
rats administered 2,6-DNT at 199 mg/kg at 24 and/or 48 hours after dosing (Deng et al. 2011).  Increased
incidences of splenic extramedullary hematopoiesis were seen in male Sprague-Dawley rats exposed by
gavage for 14 days to DNT isomers; the LOAELs for this effect were 275, 71, 39, 68, and 57 mg/kg/day
for 2,3-, 2,4-, 2,5-, 2,6-, and 3,4-DNT; 3,4-DNT did not induce this effect at doses up to 39 mg/kg/day
(Lent et al. 2012a USAPHC 2011a, 2011b, 2011c, 2011d, 2011e, 2011f). Hepatic effects, including
increased blood cholesterol and alanine aminotransferase levels, and renal effects, such as hyaline droplet
accumulation, were observed in rats fed 2,4-DNT in the diet for 14 days (McGown et al. 1983).  Sinusoid 
congestion was noted in the livers of rats treated with 2,4-DNT at 398 mg/kg and in rats treated with 
2,6-DNT at 199 mg/kg and evaluated at 24 or 48 hours; levels of albumin in the serum were also 
increased in rats treated with 2,4-DNT at 99 mg/kg (Deng et al. 2011).  In studies by Lent et al. (2012a;
USAPHC 2011a, 2011b, 2011c, 2011d, 2011e, 2011f) of male rats exposed by gavage to DNT isomers 
for 14 days, single cell necrosis and increased glycogen deposition were observed at 36 mg/kg/day
2,4-DNT; hepatocellular and oval cell hyperplasia, along with hepatocellular hypertrophy were observed 
at 35 mg/kg/day 2,6-DNT. The other isomers did not induce hepatic effects at the doses up to those 
causing lethality. Effects on the male reproductive tract, including decreased organ weights and testicular
lesions, were seen in rats exposed for 14 days by gavage to doses of 142, 68, and 19 mg/kg/day of 2,4-, 
2,6-, and 3,5-DNT, respectively (Lent et al. 2012a; USAPHC 2011b, 2011d, 2011f).
There were no acute-duration inhalation or dermal studies in humans available for evaluation. The LD50 
value determined after exposure to 2,6-DNT as an aerosol in rats (combined males and females) was 
0.43 mg/L (0.24 mg/L for males and 0.66 mg/L for females) (CMA 1991).  Treated rats showed evidence
of respiratory distress (exaggerated breathing, ataxia, and lethargy); rats that died experienced lung
congestion and increased relative lung weights.  Both 2,4- and 2,6-DNT were shown to be mild primary
dermal irritants in rabbits (U.S. Army 1975, 1978a).  Additional acute inhalation studies and dermal
studies would be useful for determining route-specific toxicity.
Intermediate-Duration Exposure. Currently available animal studies using repeated-dose exposure
are appropriate for evaluation of oral toxicity for both 2,4- and 2,6-DNT (Ellis et al. 1985; Hazleton 
Laboratories 1977, 1982; Hong et al. 1985; Jones-Price et al. 1982; Lee et al. 1985; McGown et al. 1983;
U.S. Army 1976, 1978b, 1979); no data were located regarding repeated-dose toxicity for 2,3-, 2,5-, 3,4-, 
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or 3,5-DNT.  Methemoglobinemia and its sequelae (Heinz bodies, anemia, reticulocytosis), 
hemosiderosis, extramedullary hematopoiesis, and cyanosis have been observed in animals after oral
treatment with 2,4-, 2,6-, or Tg-DNT (Hazleton Laboratories 1977, 1982; U.S. Army 1976, 1978b).  Mild 
hepatocellular dysplasia was observed in mice fed 2,4-DNT in the diet for 13 weeks (Hong et al. 1985;
U.S. Army 1978b), but no hepatotoxicity was observed after 2,4-DNT administration to rats or dogs for 
the same duration (U.S. Army 1978a, 1978b).  However, treatment with 2,6-DNT did cause bile duct
hyperplasia in rats and mice (U.S. Army 1976).  This lesion, as well as hepatic degeneration, was
observed in dogs dosed with 2,6-DNT (U.S. Army 1976).
Oral administration of 2,4-DNT to rats, mice, or dogs for 13 weeks did not cause any significant adverse 
renal effects (Hong et al. 1985; U.S. Army 1978b).  Administration of 2,6-DNT to dogs for 13 weeks 
caused renal inflammation and degeneration, which were not observed in rats or mice (U.S. Army 1976).  
Decreased body weight gain or weight loss was observed in rats and mice after administration of
2,4-DNT (Hong et al. 1985; Lee et al. 1985; Leonard et al. 1987; NCI 1978; U.S. Army 1978b, 1979) and 
in rats, mice, and dogs after administration of 2,6-DNT (U.S. Army 1976).  Subchronic inhalation would 
be useful for determination of toxic effects in order to derive an MRL for 2,4-DNT and to determine a
mechanism of action from routes of exposure that are more characteristic of occupational exposure.
Chronic-Duration Exposure and Cancer. There are no data available in humans regarding the 
carcinogenicity of 2,3-, 2,5-, 2,6-, 3,4-, or 3,5-DNT.  A retrospective cohort mortality study performed 
using data from workers at ammunition plants that used 2,4-DNT or Tg-DNT found no increases in 
mortality due to either malignant neoplasms as a whole or from particular cancers (Levine et al. 1986b).
However, the small cohort examined in this study limited its statistical power.  Both 2,4- and 2,6-DNT
have been found to cause hepatocellular carcinoma in rats (Leonard et al. 1987; U.S. Army 1979).  Renal
cancer was observed in mice after administration of 2,4-DNT in the diet (U.S. Army 1979).  EPA has
derived a cancer slope factor for oral exposure to 2,4-DNT/2,6-DNT mixture (IRIS 2003). No animal
data pertaining to the carcinogenicity of 2,3-, 2,5-, 3,4-, or 3,5-DNT were located.  
Excessive mortality rates from ischemic heart disease and residual diseases of the circulatory system were 
observed in ammunition plant workers (Levine et al. 1986a).  Because it is expected that these workers 
would have a lower incidence of cardiovascular disease due to the healthy worker effect, this finding is 
unusual.  Further epidemiological studies to verify these findings are needed; newer analyses should 
control for risk factors, particularly cigarette smoking, which was not done by the Levine et al. (1986a)
study.
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No data were located regarding the chronic toxicity of 2,3-, 2,5-, 3,4-, or 3,5-DNT.  The currently 
available studies in laboratory animals on the effects of 2,4- and 2,6-DNT after chronic exposure are 
appropriate for evaluation of chronic oral toxicity (Ellis et al. 1985; Hazleton Laboratories 1982; Lee et
al. 1985; Leonard et al. 1978; NCI 1978; U.S. Army 1978b, 1979).  Hematological effects, including
anemia, compensatory anemia, methemoglobinemia, and Heinz bodies, have been observed after chronic
administration of 2,4-DNT to dogs, mice, and rats (Ellis et al. 1985; Hong et al. 1985; U.S. Army 1978b, 
1979). Data were insufficient for the derivation of a chronic-duration oral MRL for 2,6-DNT.  Severe 
hepatocellular changes, such as degeneration and vacuolation and dysplasia, were found in rats, mice, and
dogs administered 2,4- or 2,6-DNT for chronic durations in oral exposure studies (Ellis et al. 1985; Hong
et al. 1985; Leonard et al. 1987; U.S. Army 1979).  Renal cystic dysplasia was observed in mice, but not
rats or dogs, treated orally with 2,4-DNT for chronic-duration periods (Hong et al. 1985; U.S. Army
1979).  Chronic-duration studies have not been performed in mice using 2,6-DNT to determine whether
these findings would also result after administration of this isomer.  Although no histopathological effects
were found in adrenal, pituitary, or thyroid glands of rats after chronic oral administration of Tg-DNT,
increases in parathyroid hyperplasia, fatty metamorphosis, and vascular ectasia were found (Hazleton
Laboratories 1982).  Further studies may be useful to verify these findings.  Effects on body weight, 
including body weight loss, were reported in almost all chronic-duration oral studies (Ellis et al. 1985;
Hazleton Laboratories 1982; Hong et al. 1985; Leonard et al. 1987; NCI 1978; U.S. Army 1979).  
A well-controlled chronic inhalation study and dermal studies would be useful for determination of the
potential for route-specific toxicity.  In addition, for both 2,4- and 2,6-DNT, well-controlled 
epidemiological evaluations of larger occupationally exposed populations would contribute valuable
insights regarding the human relevancy of chronic health effects observed in animal studies.
Genotoxicity. All isomers of DNT (2,3-, 2,4-, 2,6-, 3,4-, and 3,5-DNT) have caused gene mutations in 
one or more reverse mutation assays using S. typhimurium (Couch et al. 1981; Dellarco and Prival 1989;
Spanggord et al. 1982b; Tokiwa et al. 1981; U.S. Army 1978a).  However, the test system has given
variable results because of the need for metabolic activation and the sensitivity of the tester strains. In
vivo assays using 2,4-DNT have shown UDS and S-phase synthesis using rat hepatocytes (Ashby et al.
1985; Mirsalis and Butterworth 1982; Mirsalis et al. 1989), chromosomal aberrations using human 
lymphocytes (Huang et al. 1995), and DNA binding in rat hepatocytes (Chadwick et al. 1993; La and 
Froines 1993).  The genotoxicity of Tg-DNT is believed to be due to the potent genotoxicity of 2,6-DNT,
as evidenced in an in vivo-in vitro hepatocyte UDS system (Mirsalis and Butterworth 1982).  Both 
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2,4- and 2,6-DNT have induced DNA adducts in rat liver (La and Froines 1992, 1993).  Studies currently
available for 2,4- and 2,6-DNT are considered to be appropriate for evaluation of genotoxicity.
Reproductive Toxicity. The currently available laboratory data on reproductive toxicity are
considered appropriate for evaluation of oral exposure of animals to both isomers.  Several studies in rats,
mice, and dogs with either isomer have shown impairment of the male reproductive system.  The effects 
observed include testicular atrophy, degeneration of the seminal vesicles, and decreased sperm production 
(Bloch et al. 1988; U.S. Army 1976, 1978b, 1979).  In vitro studies have shown that the testicular
degeneration is due, at least in part, to structural changes in Sertoli cells (Reader and Foster 1990).
Animal studies of reproductive toxicity using inhalation exposure would provide information relative to 
occupational exposure conditions. 
Several assessments of reproductive function in exposed workers have been performed that did not detect
differences in sperm production or fertility rates as a result of exposure (Hammill et al. 1982; Levine et al. 
1985a; NIOSH 1982).  However, an earlier study reported a significant reduction in the sperm counts of 
exposed workers, as well as an increase, of marginal statistical significance, in the number of spontaneous 
abortions in their wives (NIOSH 1980).  These studies were all limited by the small exposure populations
studied and the lack of historical individual exposure monitoring.  Further epidemiological studies of
larger exposed occupational populations with exposure data may be considered useful since questions of
potential reproductive effects associated with these exposures have not yet been clearly resolved.
Developmental Toxicity. No data are available regarding developmental effects in humans after oral
exposure to DNTs, but animal studies that have been performed show possible developmental effects.
The only developmental effect observed in a three-generation reproductive study in rats using 2,4-DNT
was a decrease in pup viability.  This decrease was attributed to maternal neglect and a high incidence of
maternal death during parturition. Tg-DNT administered to pregnant dams caused a decrease in relative 
liver weight in postpartum pups and possible transient neurotoxicity (Jones-Price et al. 1982).  Further
studies may be useful to elucidate these effects.  Additional animal studies using 2,4- and 2,6-DNT by
oral and inhalation routes should analyze fetal and maternal blood for hematological parameters. This is 
recommended because any factor that could reduce the amount of oxygen to developing tissue is expected 
to have adverse consequences in the offspring.
Immunotoxicity. Although no data are available regarding immunological or lymphoreticular effects 
in humans, some data on these end points are available in animals. The currently available information
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on the potential immunotoxic effects of 2,4- and 2,6-DNT is sufficient to describe the sensitizing potential 
of DNTs.  Mild sensitization has been reported in guinea pigs after dermal exposure to 2,6-DNT, but not
2,4-DNT (U.S. Army 1975, 1978a).  No effects on IgE, the antibody associated with allergic or
hypersensitive reactions, were reported in rats or dogs exposed to either the 2,4- or the 2,6-DNT isomer
(Ellis et al. 1985; Lee et al. 1985; U.S. Army 1976, 1978b).  Studies have not been performed that would 
describe effects on immunocompetence following exposure to DNTs.  A battery of immunotoxicity tests
would provide a better assessment of possible effects in humans.
Neurotoxicity. The nervous system has been shown to be a major target of 2,4- and 2,6-DNT toxicity
in animals (Ellis et al. 1985; Kozuka et al. 1979; Lee et al. 1979, 1985; U.S. Army 1979).  Clinical signs
in dogs have included incoordination and stiffness of the hind legs leading to complete paralysis;
cerebellar vacuolation, hypertrophy, and focal gliosis; and cerebellar and brain stem hemorrhage.  In 
mice, depression and hyperexcitability were observed, while some rats administered 2,4-, 2,6-, 3,4-, and 
3,5-DNT showed neuromuscular symptoms (including facial twitching, ataxia, and/or limb paralysis).
Acute-duration exposure of rats to 3,5-DNT resulted in inflammatory infiltrates in the brain. More
systematic examination of the neurological effects of these compounds in laboratory animals would be 
useful to fully assess behavioral abnormalities and morphological damage to the nervous system.
Although results of an in vitro study in neuroblastoma cells show that 2,4-DNT is cytotoxic and produced 
cell death (Banerjee et al. 1999), the biochemical mechanisms of DNT neurotoxicity is not known.
Generalized symptoms of neurotoxicity, including headache, sleepiness, dizziness, and tingling pain in 
the extremities were reported in workers occupationally exposed to 2,4-DNT (McGee et al. 1947; Perkins
1919).  However, the more recent occupational studies performed failed to examine workers for
symptoms of neurotoxicity (Hammill et al. 1982; Levine et al. 1985a; NIOSH 1980, 1982).  Because the
early reports of potential neurotoxicity in exposed workers have not been followed-up in more recent
studies, neurological examination of workers in occupational studies could provide additional information 
regarding the potential magnitude of neurotoxic effects.
Epidemiological and Human Dosimetry Studies. Epidemiology studies of workers exposed to 
DNTs suggest a potential for heart disease in exposed populations (Levine et al. 1986a).  Doses of DNTs
associated with heart disease in humans have not been determined.  Further studies with historical cohort
monitoring data and control for potentially confounding factors such as concomitant exposure to other
chemicals and cigarette smoking would be useful to verify these findings.
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Animal studies have indicated that the male reproductive system is a target of DNT toxicity.
Epidemiological studies have provided only suggestive evidence of a reproductive effect in workers
exposed to DNTs.  Studies of larger worker populations may help to determine more conclusively the 
magnitude of the potential for reproductive toxicity in exposed humans.
Other effects that were observed in animal studies but not confirmed in human populations include liver
and kidney toxicity, neurotoxicity, and cancer.  Well-controlled epidemiological studies examining these
end points in humans would be useful.
Biomarkers of Exposure and Effect
Exposure.  A rapid, accurate method for determining exposure to DNTs has been developed using
spectrophotometric analysis of complexes of primary arylamines, which result from the reduction of
DNTs and its metabolites (Smith et al. 1995).
Effect. Epidemiological studies that correlate quantitative estimates of exposure with disease outcomes 
would be useful.  Studies that identify subtle physiological changes, such as altered blood chemistry
indices, associated with a particular disease state are not available.
A disease registry is not currently available. The development of a registry of exposures and diseases 
would provide a useful reference tool for assessing the variations in exposure concentrations and health 
effects from, for example, geography, season, regulatory actions, presence of hazardous waste landfills, or
manufacturing and use facilities.  These assessments, in turn, would provide a better understanding of the
needs for some types of research or data acquisition based on the current exposure concentrations.
Absorption, Distribution, Metabolism, and Excretion. The toxicokinetics of 2,4- and 2,6-DNT
in rats by the oral route have been extensively studied.  That Tg-DNT is absorbed and excreted in the 
urine by humans in an occupational setting (where the main routes of absorption are considered to be
inhalation and dermal) has also been documented.  There are no data available in animals on the 
toxicokinetics of DNTs by the dermal or inhalation routes.  Toxicokinetics studies in rats administered the
test materials by the inhalation and dermal routes would be critical in understanding possible differences 
in the toxicity of DNTs by different routes of administration.  The main routes of exposure of humans are
dermal and inhalation.  Understanding the possible differences in toxicity in animals by different routes
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would be valuable in determining the significance of findings in humans who may be exposed by
inhalation or dermal routes.
Comparative Toxicokinetics. Absorption and excretion studies in several species indicate that there 
are considerable differences between mice and the other species evaluated. More detailed study of the 
metabolism of DNTs by mice, including the role of biliary excretion and enterohepatic cycling, would 
assist in understanding why the metabolism in mice is different from other species and which species may
be the most appropriate model for evaluating hazards and risks to humans.
Methods for Reducing Toxic Effects. The most important method for reducing the toxic effects of
DNTs is removal of the person from the area of exposure.  Skin and eyes should be rinsed copiously
(Bronstein and Currance 1994), although absorption through the skin has not been adequately examined.  
Gastric lavage, with subsequent administration of activated charcoal, and cathartics may be of some 
benefit in reducing peak absorption after oral exposure to DNTs. Methylene blue treatment is used with
patients presenting with serious methemoglobinemia (Bentur and Keyes 2004). No additional studies are
considered necessary at this time to examine further methods for reducing body burden of DNTs.  Further
studies on supportive therapy after DNT exposure, such as the use of hemodialysis, forced diuresis, 
hyperbaric oxygen, or hemoperfusion might be useful.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and
developmental effects expressed either prenatally or during childhood, are discussed in detail in the
Developmental Toxicity subsection above.
There is inadequate experimental evidence to evaluate if the pharmacokinetics of DNTs are different in
children.  There are no studies on whether DNTs or their active metabolites can cross the placenta or be 
excreted in breast milk, so it cannot be determined if fetuses may be exposed in utero or if infants may be
exposed via breast milk ingestion. There are also no data to show if DNTs and their metabolites are 
stored in maternal tissues and thus might be later mobilized during gestation or lactation; however, DNTs
and their metabolites are not likely to be stored because of their low octanol-water partition coefficient.
There is little experimental evidence to evaluate whether the metabolism of DNTs or their mechanisms of
action are different in children.  As discussed in Section 3.7, newborns are highly sensitive to the
methemoglobin-generating effect of DNTs because of their deficiency in methemoglobin reductase 
(Gruener 1976), which reduces methemoglobin back to hemoglobin.  In addition, newborns have a high 
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concentration of fetal hemoglobin in their erythrocytes.  It will be useful to determine if fetal hemoglobin
is more sensitive to the methemoglobin-generating effect of DNTs.  It will also be helpful to have data on 
the metabolism and mechanism of action of DNTs on children to determine if children are more
vulnerable than adults to health effects from exposure to DNTs, as some enzymes involved in DNT
metabolism are known to have developmental regulation.  There are no biomarkers of exposure or effect
that have been validated in children or in adults exposed as children.  There are no data to determine
whether there are any interactions with other chemicals unique to children, or whether interactions
observed in adults also occur in children.  Although DNTs are shown to be genotoxic, it is not known if
parental exposure to DNT may affect children via parental germ cells, or if DNTs may indirectly affect 
the fetus during maternal exposure. 
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:
Exposures of Children.
3.12.3 Ongoing Studies 
No ongoing studies were identified for DNTs.
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4. CHEMICAL AND PHYSICAL INFORMATION
4.1  CHEMICAL IDENTITY
Information regarding the chemical identity of the individual isomers of DNT is located in Table 4-1.
4.2  PHYSICAL AND CHEMICAL PROPERTIES 
Information regarding the physical and chemical properties of the individual isomers of DNT is located in
Table 4-2.  Data regarding specific isomers of DNT have been provided whenever possible. The isomers 
of DNT have many similar traits, including identical molecular weights, but also have distinguishable 
qualities.  For instance, 2,4-DNT has higher melting and boiling points and a greater solubility in water
than 2,6-DNT (HSDB 2012).  
DNTs are generally produced as a technical-grade mixture, which consists of approximately 76.5%
2,4-DNT and 18.8% 2,6-DNT.  The remaining ~5% consists of other isomers of DNT and minor
contaminants such as TNT and the mononitrotoluenes (HSDB 2012).  Unspecified forms of DNT (DNT
not otherwise specified or NOS) can be characterized under the CAS Registry Number of 25321-14-6.  
Where information pertains to Tg-DNT or DNT NOS, it has been so noted. 
   
 
  
 
 
 
 
 
  
    
 
 
 
 
 
 
 
 
    
    
 
 
 
 
    
     
     
    
 
 
 
 
 
     
   
 
 
 
 
 
 
 
 
 
 
 
     
     
 
Table 4-1.  Chemical Identity of Dinitrotoluenes
Characteristic Informationa 
Chemical name 2,3-Dinitrotoluene 2,4-Dinitrotoluene 2,5-Dinitrotoluene
Synonym(s) 1-Methyl­ 1-Methyl­ 2-Methyl­
2,3-dinitrobenzene; 2,4-dinitrobenzene; 1,4-dinitrobenzene;
2,3-DNT 2,4-dinitrotoluol; 2,5-DNT
2,4-DNT
Registered trade name(s) No data No data No data
Chemical formula C7H6N2O4 C7H6N2O4 C7H6N2O4
Chemical structure
NO2 NO2 NO2 
NO2 
O2N 
NO2 
Identification numbers:
CAS registry 602-01-7 121-14-2 619-15-8
NIOSH RTECS XT1400000 XT1575000 XT1750000
EPA hazardous waste
No data U105 No data
OHM/TADS 7800118
DOT/UN/NA/IMDG shipping IMO 6.1 IMO 6.1 IMO 6.1
UN 1600 (molten) UN 1600 (molten) UN 1600 (molten)
UN 2038 (solid or UN 2038 (solid or UN 2038 (solid or
liquid) liquid) liquid)
HSDB 5499 1144 5504
NCI No data NCI-C01865 No data
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Table 4-1.  Chemical Identity of Dinitrotoluenes
Characteristic Informationa 
Chemical name 2,6-Dinitrotoluene 3,4-Dinitrotoluene 3,5-Dinitrotoluene
Synonym(s) 1-Methyl­ 4-Methyl­ 1-methyl­
2,6-dinitrotoluene; 1,2-Dinitrobenzene; 3,5-dinitrobenzene;
2,6-DNT 3,4-DNT 3,5-DNT
Registered trade name(s) No data No data No data
Chemical formula C7H6N2O4 C7H6N2O4 C7H6N2O4
Chemical structure
O2N NO2 
NO2 
O2N NO2 
NO2 
Identification numbers:
CAS registry 606-20-2 610-39-9 618-85-9
NIOSH RTECS XT1925000 XT2100000 XT2150000
EPA hazardous waste
U106 No data No data
OHM/TADS 8300219
DOT/UN/NA/IMDG shipping IMO 6.1 IMO 6.1 IMO 6.1
UN 1600 (molten) UN 1600 (molten) UN 1600 (molten)
UN 2038 (solid or UN 2038 (solid or UN 2038 (solid or
liquid) liquid) liquid)
HSDB 2931 5501 6463
NCI No data No data No data
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aAll information obtained from HSDB 2012
CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 
RTECS = Registry of Toxic Effects of Chemical Substances
   
 
  
 
 
 
 
 
  
    
    
    
    
    
   
 
 
     
    
    
     
     
    
    
 
  
 
    
 
  
 
 
 
    
     
     
   
 
   
 
       
   
 
    
 
    
    
    
    
  
 
 
 
 
 
 
 
 
 
 
 
184DINITROTOLUENES
4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Dinitrotoluenes
Property Informationa 
Chemical name 2,3-Dinitrotoluene 2,4-Dinitrotoluene 2,5-Dinitrotoluene
Molecular weight 182.14 182.14 182.14
Color Yellow Yellow No data
Physical state Solid Solid Solid
Melting point 59–61 °C 71 °C 52.5 °C
Boiling point 284 °Cb 300 °C (slight
decomposition)
284 °Cb 
Density No data 1.3208 (71 °C) 1.282 (111 °C)
Odor No data Slight No data
Odor threshold:
Water No data No data No data
Air No data No data No data
Solubility:
Water 220 mg/L (25 °C,
estimated)b
270 mg/L (22 °C) 220 mg/L (25 °C,
estimated)b 
Organic solvents No data Soluble in acetone,
alcohol, benzene,
ethanol, diethyl ether,
pyridine, carbon 
disulfide
Soluble in ethanol; very
soluble in carbon 
disulfide
Partition coefficients:
Log Kow 2.18 (estimated)b 1.98 2.18 (estimated)b 
Log Koc No data 2.56c No data
Vapor pressure at 20 °C 3.97x10-4 torr 
(estimated)d 
1.4x10-4 torr 3.97x10-4 torr 
(estimated)d 
Henry's law constant at 25 °C
Autoignition temperature 9.26x10-8 atm-m3/mol
(estimated)b
5.4x10-8 atm-m3/mole 9.26x10-8 atm-m3/mol
(estimated)b 
Flashpoint
Flammability limits No data No data No data
Conversion factors No data 404 °F 404 °F
No data No data No data
Explosive limits 1 ppm=7.40 mg/m3
1 mg/m3=0.13 ppm
1 ppm=7.40 mg/m3
1 mg/m3=0.13 ppm
1 ppm=7.40 mg/m3
1 mg/m3=0.13 ppm
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Table 4-2.  Physical and Chemical Properties of Dinitrotoluenes
Property Informationa 
Chemical name 2,6-Dinitrotoluene 3,4-Dinitrotoluene 3,5-Dinitrotoluene
Molecular weight 182.14 182.14 182.14
Color Yellow to red Red Yellow to red
Physical state Solid Solid Solid
Melting point 66 °C 58.3 °C 93 °C 
Boiling point 285 °C 284 315 °Cb 
Density 1.2833 (111 °C) 1.2594 (111 °C) 1.2772 (111 °C)
Odor Slight Slight No data
Odor threshold:
Water No data No data No data
Air No data No data No data
Solubility:
Water 180 mg/L (20 °C) 100 mg/L (25 °C)f 145 mg/L (25 °C)
Organic solvents Soluble in ethanol,
chloroform
Soluble in ethanol and 
carbon disulfide;
slightly soluble in 
chloroform
Soluble in benzene,
ethyl ether, ethanol,
chloroform, carbon 
disulfide
Partition coefficients:
Log Kow 2.10 2.08g 2.18 (estimated)b
Log Koc No data No data No data
Vapor pressure at 20 °C 5.67x10-4 torr 3.97x10-4 torr 
(estimated)d 
4.05x10-4 torrh
Henry's law constant at 25 °C
Autoignition temperature 7.47x10-7 atm-m3/mol
(estimated)b
9.26x10-8 atm-m3/mol
(estimated)b 
9.26x10-8 atm-m3/mol
(estimated)b 
Flashpoint
Flammability limits No data No data No data
Conversion factors 404 °F 404 °F No data
No data No data No data
Explosive limits 1 ppm=7.40 mg/m3
1 mg/m3=0.13 ppm
1 ppm=7.40 mg/m3
1 mg/m3=0.13 ppm
1 ppm=7.40 mg/m3
1 mg/m3=0.13 ppm
aAll information obtained from HSDB 2012 unless otherwise stated.
bEPA 2011
cU.S. Army 1980
dNeely and Blau 1985
eAltschuh et al. 1999
fChemicals Inspection Testing Institute 1992
gNakagawa et al. 1992
hAIChE 1992
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5.1  PRODUCTION
Tables 5-1 and 5-2 list the facilities in each state that manufacture or process 2,4- and 2,6-DNT,
respectively, and the intended use and range of maximum amounts of 2,4- and 2,6-DNT that are stored on 
site.  The data listed in Tables 5-1 and 5-2 are derived from the Toxics Release Inventory (TRI13 2015).  
Only certain types of facilities were required to report; therefore, this is not an exhaustive list.  In 2013, 
there were facilities located in nine states that produced, processed or used 2,4-DNT and facilities located
in four states that produced, processed, or used 2,6-DNT.  The number of individual facilities and the
amount produced on site varied in each state. The other isomers of DNT are not contained in the TRI
database.
5.2  IMPORT/EXPORT
No information was found concerning U.S. imports and exports of DNTs.
According to the 2011 Directory of Chemical Producers, 2,4- and 2,6-DNT were domestically
manufactured by three corporations including Air Products and Chemicals, Inc. (production site:
Pasadena, Texas), the BASF Corporation (production site:  Geismar, Louisiana) and Bayer Material
Science, LLC (production site:  Baytown, Texas) (SRI 2011).  No information regarding the other
isomers of DNT was included in the directory.  While no production volumes were reported, data
collected by the EPA Inventory Update Reporting (IUR) system indicated that <500,000 pounds of
2,4-DNT were produced domestically in 2006 (EPA 2012a).  The United Nations Screening Information 
Data Set (SIDS) Initial Assessment Report for Dinitrotoluene (mixed isomers) reported that the global
production capacity of DNT is about 1.6 Mio t (1.6 million tons) annually (UNEP 2004).  
2,4- and 2,6-DNT are generally produced as a mixture called Tg-DNT, which contains approximately
76.5% 2,4-DNT and 18.8% 2,6-DNT (with the remainder consisting of other isomers and minor
contaminants such as TNT and mononitrotoluenes) (HSDB 2012).  This mixture is commercially
prepared in a two-step process. Toluene is nitrated with concentrated sulfuric and nitric acid resulting in 
the production of mononitrotoluene (U.S. Army 1987).  Mononitrotoluene can be nitrated with mixed 
acids to yield dinitrotoluene (EPA 2008a).  
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Table 5-1.  Facilities that Produce, Process, or Use 2,4-Dinitrotoluene
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
IA 1 100,000 999,999 8
IL 1 1,000 9,999 8
IN 3 0 999 12
KY 1 100,000 999,999 12
LA 1 0 99 14
OH 1 1,000 9,999 12
TX 3 1,000 9,999 8, 12
UT 1 10,000 99,999 12
VA 2 100,000 999,999 7
aPost office state abbreviations used.
bAmounts on site reported by facilities in each state.
cActivities/Uses:
1.  Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7.  Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14.  Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI13 2015 (Data are from 2013)
   
 
   
 
 
 
 
 
 
 
 
 
     
     
     
     
     
 
  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
189DINITROTOLUENES
5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-2.  Facilities that Produce, Process, or Use 2,6-Dinitrotoluene
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
IN 1 100 999 12
KY 1 10,000 99,999 12
OH 1 1,000 9,999 12
TX 1 0 99 8
aPost office state abbreviations used.
bAmounts on site reported by facilities in each state.
cActivities/Uses:
1.  Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7.  Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14.  Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI13 2015 (Data are from 2013)
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5.3  USE 
The most commercially important use of DNTs is as a chemical intermediate in the production of TDI.  
TDI is a precursor to polyurethane polymers (HSDB 2012).  Additionally, DNTs are used in the
production of TNT, as a plasticizer in propellants, and as a waterproofing, plasticizing, and gelatinizing
agent in explosives (HSDB 2012).  DNTs are also used as intermediates in the production of dyes and as
modifiers for smokeless powders in the munitions industry (HSDB 2012). 
5.4  DISPOSAL
2,4-DNT and 2,6-DNT are listed as toxic substances under Section 313 of the Emergency Planning and
Community Right to Know Act (EPCRA) under Title III of the Superfund Amendments and 
Reauthorization Act (SARA) (EPA 1995).  Disposal of wastes containing DNTs is controlled by a 
number of federal regulations (see Chapter 8).
Limited information is available regarding the appropriate disposal of DNTs.  NIOSH recommends that
small quantities be swept onto paper or other flammable material and incinerated in a suitable combustion 
chamber.  Larger quantities should be reclaimed; if this is not practical, then they should be dissolved in
fuel oil and atomized in a suitable combustion chamber (HSDB 2012).  The ultimate disposal of DNTs
can be achieved by controlled incineration in an incinerator unit equipped with an alkaline scrubber
(HSDB 2012).  DNTs have also been proposed as a potential candidate for rotary kiln incineration at 820– 
1,600 °C or fluidized bed incineration at 450–980 °C, with residence times of seconds for gases and
liquids and longer for solids (HSDB 2012).
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6. POTENTIAL FOR HUMAN EXPOSURE
6.1  OVERVIEW
2,4- and/or 2,6-DNT have been identified in at least 98 of the 1,699 hazardous waste sites that have been
proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2007). Information on the
other isomers was not available. The number of sites evaluated for DNTs is not known.  The frequency
of these sites can be seen in Figure 6-1. 
The available data provide a complex and incomplete view of the overall potential for human exposure to 
isomers of DNT.  Little direct knowledge of the magnitude of environmental exposure pathways exists.
Data regarding exposure of humans to DNTs have been obtained primarily from the workplace.
DNTs have been found in waste water and groundwater in and around munitions sites (Jenkins et al.
1986), and 4-nitrotoluene and dinitrobenzene, structural analogues of DNTs, are taken up by plants
(McFarlane et al. 1987). However, predictions of environmental exposure pathways based on 
measurements of structural analogues of DNTs are severely limited by the complex abiotic reactions of
DNTs in the environment and by the different pathways, rates, and products of biological reduction 
and/or oxidation of 2,4- and 2,6-DNT.
The relatively low log octanol-water partition coefficients (log Kow) of the DNT isomers (1.98–2.18)
suggest that DNTs released to the environment would not bioaccumulate.  Measured bioconcentration 
factors also indicate that DNTs are not expected to bioaccumulate in fish and other aquatic species (Lang
1997; NITE 2002).  DNTs are not highly adsorbed to soil or sediment and may leach from the soil surface
to groundwater.  DNTs are degraded by oxidation, photolysis, and biotransformation in water or soil, 
resulting in a variety of degradation products.  Volatilization is expected to occur slowly from water and 
soil surfaces and the rate of hydrolysis is negligible.
Studies of occupational exposures to DNTs indicate that inhalation and dermal contact can result in 
absorption of DNTs into the body.  The general population is not expected to be exposed to DNTs unless 
they reside near a source area, in which case, dermal contact and incidental ingestion pathways are the
likely routes of exposure.
192 DINITROTOLUENES 
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Figure 6-1.  Frequency of NPL Sites with 2,4- and 2,6-Dinitrotoluene 
Contamination 
Frequency 
of 
NPL Sites 
Derived from HazDat 
2007
1 
2 
3 
4 
5 
6-7
   
 
  
 
 
 
   
 
  
    
        
 
    
  
  
      
 
  
   
   
  
 
     
     
   
  
    
    
  
   
 
  
   
    
  
 
 
 
 
 
 
193DINITROTOLUENES
6.  POTENTIAL FOR HUMAN EXPOSURE
6.2  RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing
facilities are required to report information to the TRI only if they employ 10 or more full-time
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI
chemical in a calendar year (EPA 2005).
Section 112 of the Clean Air Act (CAA) lists 2,4-DNT as one of the original hazardous air pollutants
(HAPs) known to cause, or suspected of causing, cancer or other serious human health effects or
ecosystem damage (EPA 2000b).  EPA's National Emission Inventory (NEI) database collects 
information about sources that emit criteria air pollutants and their precursors, and HAPs for the
50 United States, Washington DC, Puerto Rico, and the U.S. Virgin Islands (prior to 1999, criteria
pollutant emission estimates were maintained in the National Emission Trends [NET] database and HAP
emission estimates were maintained in the National Toxics Inventory [NTI] database). The NEI database 
derives emission data from multiple sources including state and local environmental agencies; the TRI
database; computer models for on-road and off-road emissions; and databases related to EPA's Maximum
Achievable Control Technology (MACT) programs to reduce emissions of hazardous air pollutants.  
Using composite data from the NTI database from 1990 to 1993, it was estimated that the annual
emissions of 2,4-DNT in the United States was approximately 3.5 tons per year during that time frame 
(EPA 2000b).  Data downloaded from the 2005 NEI indicated that the total emission of 2,4-DNT was
approximately 4 tons, with the biggest source arising from nonpoint source waste disposal.  
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6.2.1 Air
Estimated releases of 7,621 pounds (~3.5 metric tons) of 2,4- and 2,6-DNT to the atmosphere from nine
domestic manufacturing and processing facilities in 2013, accounted for about 99% of the estimated total
environmental releases from facilities required to report to the TRI (TRI13 2015).  These releases are
summarized in Tables 6-1 and 6-2. The TRI database does not contain information regarding the other
isomers of DNT.
The Great Lakes Regional Air Toxic Emissions Inventory Project estimated that 1,894 pounds of
2,4-DNT were emitted to the air of the Great Lakes watershed in 2002 (Great Lakes Commission 2006).
The overwhelming majority of these emissions arose from local point and area sources such as production 
or use facilities.  No data were available for the other isomers of DNT.
Minute amounts of nitrotoluene are formed by the photochemical reaction of toluene, nitrogen oxides, and
sunlight (Atkinson et al. 1980).  Although DNTs could be formed subsequently, they would be subject to
photolysis and would not be likely to accumulate enough to contribute significantly to human exposure.
6.2.2  Water
Estimated releases of 2 pounds (~0.001 metric tons) of 2,4- and 2,6-DNT to the water from nine domestic
manufacturing and processing facilities in 2013, accounted for about 0.3% of the estimated total
environmental releases from facilities required to report to the TRI (TRI13 2015).  These releases are
summarized in Tables 6-1 and 6-2. The TRI database does not contain information regarding the other
isomers of DNT.
The detection of DNTs in water has been reported (Feltes et al. 1990; Shackelford and Keith 1976;
Staples et al. 1985).  Both 2,4- and 2,6-DNT are recognized as major components in waste waters from
TNT manufacturing facilities (Spanggord and Suta 1982; Spanggord et al. 1982a).  DNTs occur in 
samples of TNT waste waters at concentrations of 0.04–48.6 mg/L (2,4-DNT) and 0.06–14.9 mg/L
(2,6-DNT).  The occurrence of DNTs in waste waters from other manufacturing uses (e.g., polyurethane
forms) has not been reported.  The frequency of detection of DNTs in surface waters, as indicated in the 
STORET database (Staples et al. 1985), is low.  Slightly over 1% of the stations reported detectable
quantities of DNTs, and the median of positive samples was <10 μg/L (0.01 mg/L).  The presence of
DNTs was not detected in samples of sediment or biota.
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Table 6-1.  Releases to the Environment from Facilities that Produce, Process, or
 
Use 2,4-Dinitrotoluenea
 
Reported amounts released in pounds per yearb 
Total release
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek On- and off-site
IA 1 500 0 0 0 0 500 0 500
IL 1 0 0 0 0 0 0 0 0
IN 3 2 0 0 0 0 2 0 2
KY 1 5,500 0 0 0 0 5,500 0 5,500
LA 1 0 0 0 0 0 0 0 0
OH 1 2 0 0 21 0 2 21 23
TX 3 14 0 0 0 0 14 0 14
UT 1 2 0 0 0 0 2 0 2
VA 2 0 2 0 0 1 2 1 3
Total 14 6,020 2 0 21 1 6,022 22 6,044
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used.
 
dNumber of reporting facilities.
 
eThe sum of fugitive and point source releases are included in releases to air by a given facility.
 
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal
 
and metal compounds).
 
gClass I wells, Class II-V wells, and underground injection.
 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface 

impoundments, other land disposal, other landfills.
 
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for
 
disposal, unknown.
 
jThe sum of all releases of the chemical to air, land, water, and underground injection wells.
 
kTotal amount of chemical transferred off-site, including to POTWs.
 
RF = reporting facilities; UI = underground injection
Source:  TRI13 2015 (Data are from 2013)
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Table 6-2.  Releases to the Environment from Facilities that Produce, Process, or
 
Use 2,6-Dinitrotoluenea
 
Reported amounts released in pounds per yearb 
Total release
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek On- and off-site
IN 1 1 0 0 0 0 1 0 1
KY 1 1,600 0 0 0 0 1,600 0 1,600
OH 1 0 0 0 21 0 0 21 21
TX 1 0 0 0 0 0 0 0 0
Total 4 1,601 0 0 21 0 1,601 21 1,622
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used.
 
dNumber of reporting facilities.
 
eThe sum of fugitive and point source releases are included in releases to air by a given facility.
 
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal
 
and metal compounds).
 
gClass I wells, Class II-V wells, and underground injection.
 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface 

impoundments, other land disposal, other landfills.
 
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for
 
disposal, unknown
 
jThe sum of all releases of the chemical to air, land, water, and underground injection wells.
 
kTotal amount of chemical transferred off-site, including to POTWs.
 
RF = reporting facilities; UI = underground injection
Source:  TRI13 2015 (Data are from 2013)
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6.2.3 Soil 
Estimated releases of 42 pounds (~0.019 metric tons) of 2,4- and 2,6-DNT to soils from 6 domestic
manufacturing and processing facilities in 2013, accounted for about 0.6% of the estimated total
environmental releases from facilities required to report to the TRI (TRI13 2015).  The TRI database does
not contain information regarding the other isomers of DNT.  There were no reported releases to
underground injection wells. These releases are summarized in Tables 6-1 and 6-2.
The extensive use of DNTs as intermediates in the synthesis of TDI and polyurethane foam is not a
reported source of releases to soil. However, DNTs can be contaminants in the soil from explosives, 
propellants, etc.  Residues of DNTs were observed to be deposited onto the surface of military live-fire
training soil (Jenkins 2006).  As a result, mean surface soil concentrations ranged from <0.001 to 
84 mg/kg for 2,4-DNT and from <0.001 to 4.6 mg/kg for 2,6-DNT (Jenkins 2006).
6.3  ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
The water solubilities of DNTs are moderate (Callahan et al. 1979), and the octanol-water partition 
coefficients are low (EPA 1982c).  As a result, there is a potential for DNTs to leach from soil into
groundwater.  
The solubility of nitroaromatic compounds in seawater and pure water at different temperatures was 
examined by Luning Prak and O’Sullivan (2007) and Kholod et al. (2011).  Luning Prak and O’Sullivan 
(2007) found that the solubility in both seawater and pure water was observed to increase with increasing
temperatures (5–40 °C) and decrease with increasing salinity (0–100%) for 2,3-DNT and 2,6-DNT.
Kholod et al. (2011) found that the Conductor-like Screening model for Real Solvents (COSMO-RS) was 
effective in estimating the solubility of 2,5-DNT.  The same trends that were observed in the experimental
values were also observed in the estimated values. These solubility models are useful in the
characterization of the fate of nitro compounds in marine systems.
U.S. Army (1980) determined partitioning of 2,4-DNT onto environmental media and found that the soil
organic carbon partition coefficient (Koc), the octanol-water partition coefficient (log Kow), and the
partition bioconcentration factor (Kb) were 364, 2, and 64, respectively.  EPA (1982c) calculated 
sediment-water partitioning coefficients of 45 and 92 for 2,4- and 2,6-DNT, respectively.  Depending on 
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the nature of the sediment load, the total concentration of DNTs carried in the soil and water column 
could be high.  The low Henry’s Law constants for the isomers of DNT (see Table 4-2) suggest that
volatilization from water and moist soil surfaces will occur slowly.  U.S. Army (1980) used 
experimentally determined volatilization rate constants of 2,4-DNT obtained under laboratory conditions, 
to extrapolate a volatilization rate constant for 2,4-DNT in an environmental aquatic water body with a
depth of approximately 6.5 feet and ambient temperature of about 20 °C.  Using this extrapolated rate
constant, a volatilization half-life of >400 days is estimated for 2,4-DNT.
Steady-state whole-fish bioconcentration factors (BCFs) of 2,4-DNT measured in carp during two 
different equilibrium periods were 9.15 and 4.15 (Lang et al. 1997).  BCF values of DNT (mixed isomers
CAS Registry Number 25321-14-6) measured in carp over a 6-week incubation period were 0.6–2.9 at a
nominal concentration of 0.25 ppm and 3.2–21.2 at a nominal concentration of 0.025 ppm (NITE 2002).  
BCF values of <2.7 were also measured for 3,4-DNT in carp over a 6-week incubation period (NITE
2002).  These data suggest that bioaccumulation in fish and other aquatic organisms will be low.
Direct measurement of plant uptake of DNTs has not been made, but plant uptake is predicted to occur
based on its low octanol-water partition coefficient.  Structural analogy with 1,3-dinitrobenzene and 
4-nitrotoluene (McFarlane et al. 1987) suggests that 2,4- and 2,6-DNT would be readily taken up by
plants.  Plant uptake of related nitroaromatic compounds such as 2,4,6-TNT and its byproduct, 4-amino-
2,6-DNT, has also been observed and is inversely proportional to soil organic carbon content (Pennington
1988).  The relative concentrations in the plants was root > stem > leaves > seed and food (U.S. Army
1990).  
Uptake of 2,4-DNT was observed in a cell suspension culture of separate plantlets, Senecio jacobaea, 
Saponaria officinalis, and Phragmitis australis. The concentration of 2,4-DNT was reduced to 20 mg/L
from 50 mg/L after 17 days by S. jacobaea (yellowweed).  Concentrations of 2,4-DNT were rapidly
decreased after 6 days by S. officinalis (soap wort). The reduction products, 4-amino-2-nitrotoluene and 
2-amino-4-nitrotoluene were observed after 2 days.  No reduction products were observed after
metabolism of 2,4-DNT with P. austrailis (reed) given that the uptake of 2,4-DNT by P. australis was 
much slower than in the other plantlets (Podlipna et al. 2015).
Root uptake by plants can be inhibited by the increase of sorption to the soil.  Sorption can reduce the
bioavailability of organic compounds to target organisms.  In a bioavailability and phytotoxicity study, 
the toxicity of 2,4-DNT to the aquatic duckweed plant was significantly reduced by sorption to potassium
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smectite clay (Roberts 2007).  In general, 2,4-DNT is expected to adsorb to suspended soil and sediment
in water based on its Koc. Nitroaromatic compounds adsorb to the soil mainly by forming electron-donor
acceptor complexes with clays (Haderlein 1996).  In anoxic conditions, sorption of the tested aromatic
compounds followed the order of DNTs>ANT>DATs, where monoamines (ANT) and diaminotoluenes
(DAT) were the derivatives of DNTs (Yang 2008).
The toxicity of the transformation products of 2,6-DNT was studied by Nipper et al. (2005) in spiked 
sandy, fine-grained marine sediments and in seawater.  In environments with the spiked sediments,
toxicity to the micro-algae, Ulva fasciata, decreased as 2,6-DNT was biotransformed to 2-amino­
6-nitrotoluene.  Subsequent studies indicated that toxicity to the copepod Schizopera knabeni increased
with biotransformation. Therefore, 2-amino-6-nitrotoluene was more toxic than 2,6-DNT to the copepod, 
and less toxic to the micro-algae.  Likewise, in environments with the spiked seawater tests, 2-amino­
6-nitrotoluene was also more toxic than its parent compound to the copepod, but not to the micro-algae.
These studies indicate that toxicity to the 2,6-DNT degradation products vary with the environment and 
species.
The Pre-Biologic Screen (PBS) model for ecotoxicologic effects (Gillett 1983) estimates a score (heavy
concern, concern, or no concern) for a compound determined by the octanol-water partition coefficient,
the Henry's Law constant, and the half-life in the medium of interest.  The score indicates the compound's
potential for (a) bioaccumulation and multi-media/multispecies effects, (b) bioaccumulation and long­
term effects, (c) persistence and interactions in the water column, including plant uptake and leaching, 
and (d) direct and indirect effects in the atmosphere (e.g., smog formation, plant fumigation, stratospheric
modification).  Both 2,4- and 2,6-DNT are of concern or heavy concern only for (c), persistence and
interactions in the water column, depending on the value used for half-life.  Since the degradation of
DNTs is so dependent on environmental conditions and the presence of effective microorganisms, the
protective view that DNTs are of heavy concern for persistence in water, plant uptake, and leaching to 
groundwater may be warranted.  The lack of concern for bioaccumulation, multimedia/multispecies
action, and atmospheric action also appears to be justified.
6.3.2 Transformation and Degradation
6.3.2.1  Air
Based on their rapid photolysis in water, DNTs are presumed to be subject to oxidation of its methyl
group, decarboxylation, ring oxidation, and/or nitroreduction in air and sunlight.  DNTs are slowly
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degraded in the atmosphere by reaction with photochemically produced hydroxyl radicals; the half-life in
air is estimated to be approximately 50 days for the DNT isomers (EPA 2011).
6.3.2.2  Water
DNTs may be degraded in water through several mechanisms, including photolysis, microbial
biodegradation, ozonation and chlorination, and oxidation by strong oxidants such as hydrogen peroxide, 
ozone, or oxone (Bausum et al. 1992; EPA 1979; Freedman et al. 1996; Ho 1986; Noguera and Freedman 
1996; U.S. Navy 1977).  Ho (1986) studied photooxidation of 2,4-DNT in aqueous solution in the
presence of hydrogen peroxide and suggested the following degradation pathway of 2,4-DNT:  2,4-DNT
→ 1,3-dinitrobenzene → hydroxynitrobenzene derivatives → carboxylic acids → CO2, H2O, and HNO3. 
Oxidation of aqueous 2,4-DNT with hydrogen peroxide or ultraviolet (UV) irradiation alone was very
slow, and elimination was not complete.  Dillert et al. (1995) reported that degradations of DNTs and 
several other nitroaromatics were accelerated in irradiated TiO2 suspensions and that the degradation rates
were dependent solution pH and light intensity.  At given temperature, pH, and photo intensity, 
degradation rates were shown to decrease in order of 2-nitrotoluene > nitrobenzene > DNTs
> 1,3-dinitrobenzene > TNT > trinitrobenzene, and the degradations followed first-order kinetics. The 
photocatalytic oxidation of 2,6-DNT in aqueous suspension of TiO2 produces ammonium and nitrate ions
as the predominant species (Kumar and Davis 1997).
The presence and potential toxicity of DNTs in waste water have spurred considerable study of the abiotic 
and biotic fate of 2,4- and 2,6-DNT.  U.S. Army (1980) reported that the half-lives of DNTs in 
three sunlit natural waters were 3–10 hours, whereas the photolysis half-life in distilled water was
43 hours.  At different latitudes and sunlight conditions, they estimated that the photolysis half-life in
waters would range from approximately 1.8 days (summer sunlight conditions) to 11.5 days (winter
conditions).  Simmons and Zepp (1986) found that dissolved or suspended humic substances greatly
enhance (10–17 times) indirect photolysis of nitroaromatic compounds with a nitro group ortho to a
methyl group.
DNTs may be also degraded by ozonation and chlorination.  Lee and Hunter (1985) reported that both
ozone and chlorine produced <17% reduction of 2,6-DNT, whereas 2,4-DNT was more vulnerable,
yielding about 35% reduction by chlorine and 60% reduction by ozone.  Contact time did not appear to
have any impact on the reduction rates.
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Studies have shown that DNTs can be used as a sole carbon source for microorganisms commonly
detected in natural waters.  Using bay water obtained near an Army munitions facility as inoculum, >90%
degradation of 2,4-DNT was observed after 6 days following a 2–3-day lag period (U.S. Army 1980).  
Under anaerobic conditions, the half-life of 2,6-DNT in non-acclimated sewage was found to be 28 days, 
with no loss of the compound under aerobic conditions during the same period (Hallas and Alexander
1983).  Liu et al. (1984) reported complete biotransformation of 2,4-DNT within 14 days under anaerobic
conditions using a fresh sample of activated sludge diluted with distilled water as inoculum.  The
intermediates of biotransformation were identified as 2-amino-4-nitrotoluene, 4-amino-2-nitrotoluene, 
2-nitroso-4-nitrotoluene, and 4-nitroso-2-nitrotoluene.  Parrish (1977) investigated 190 fungal species 
from 98 genera, but found only 5 capable of 2,4-DNT biotransformation.  Valli et al. (1992) reported 
degradation of 2,4-DNT as the sole source of carbon and energy by the lignin-degrading fungus
Phanerochaete chrysosporium under aerobic conditions, resulting in stoichiometric release of nitrate.
Several additional studies have shown biodegradation of DNTs from microorganisms isolated from areas 
that are frequently exposed to DNTs and other structurally similar compounds such as TNT (Bausum et
al. 1992; Freedman et al. 1996).  Bausum et al. (1992) found complete degradation of 20 ppm 2,4-DNT
and 20 ppm 2,6-DNT in water samples taken downstream a short distance from the Radford Army
Ammunition Plant in Radford, Virginia.  A lag time was noted prior to the breakdown for both of the two 
compounds with 2,4-DNT exhibiting the shorter lag time.  Microbial enrichment cultures were developed
from the collected water samples by exposing the cultures to increasing concentrations of 2,4- and 
2,6-DNT.  Degradation and visible turbidity in the suspension medium were noted up to a level of
130 ppm.  In a separate but related study, degraded DNTs were shown to be converted to CO2 with
2,4-DNT conversion occurring at a greater rate than that of 2,6-DNT; concentrations ranged from 0.004 to 
10.0 ppm (Bausum et al. 1992).  The rate of mineralization to CO2 was concentration dependent and 
increased with increasing concentration.
In the Bradley et al. (1994) study, a culture of microorganisms taken from aquifer sediments at an
explosives-contaminated site was observed to be capable of transforming 2,4- and 2,6-DNT. Breakdown 
products from 2,4-DNT degradation included 4-amino-2-nitrotoluene and 2-amino-4-nitrotoluene.  
Carbon dioxide was released during the degradation process.  Aminonitrotoluene isomers were also 
detected as breakdown products of a solution of 2,4-DNT and ethanol (Freedman et al. 1996).  The
Freedman et al. (1996) study exposed an inoculum from a wastewater treatment plant at an ammunition 
plant to a solution of 2,4-DNT and ethanol and a solution of 2,4-DNT and ether.  The concentration of
2,4-DNT at each application was 0.55 mM and the concentrations of ethanol and ether were 600 and 
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142 mg/L, respectively.  Ethanol and ether were chosen because they are often found in munitions
manufacturing waste-water streams along with 2,4-DNT.  As stated above, aminonitrotoluene isomers
were detected as products of the solution containing 2,4-DNT and ethanol.  The degradation of ethanol
was believed to be driving a partial reduction of 2,4-DNT before the oxidation of 2,4-DNT took place.  In 
contrast, ether at the applied concentration slowed the rate of 2,4-DNT degradation.  Low chemical
oxygen demand during the studies suggests that DNTs were mineralized to a significant degree.
Spanggord et al. (1991) studied the degradation pattern of 2,4-DNT using, water samples obtained from
the Waconda Bay located near a TNT manufacturing facility (Volunteer Army Ammunition Plant) in 
Chattanooga, Tennessee.  Samples were enriched with 2,4-DNT and incubated for 5 days.  The
Pseudomonas sp. strain aerobically degraded 2,4-DNT as a sole source of carbon, and the nitro groups
were oxidatively removed without prior reduction to the amines.  Since this Pseudomonas sp. strain used
2,4-DNT as a carbon source, it may be useful for the removal of other nitrotoluenes from contaminated
soils or from industrial waste streams.  Likewise, it may also be useful since the oxidative removal of the 
nitro groups bypasses the accumulation of toxic amino derivatives.
The co-metabolism of 2,4-DNT with ethanol, methanol, and acetic acid has been studied under anaerobic
conditions (Cheng et al. 1995).  High concentrations of ethanol accelerated the reductive transformation
of 2,4-DNT by supporting the growth of the anaerobic bacteria.  The rate of 2,4-DNT biotransformation
was much higher with the addition of ethanol than with the addition of methanol or acetic acid in
anaerobic conditions (Cheng et al. 1995).  In a culture using a continuous flow laboratory fermentor under
anaerobic conditions with both 2,4-DNT and ethanol as substrates, 2,4-DNT was completely transformed
to 2,4-diaminotoluene (Cheng et al. 1996).  During the biotransformation, two intermediates were formed:
2-amino-4-nitrotoluene and 4-amino-2-nitrotoluene.  
2-Amino-4-nitrotoluene and 4-amino-2-nitrotoluene were also formed in the transformation of 2,4-DNT
to 2,4-aminotoluene by the marine microbial culture, Shweanella marisflava EP1. S. marisflavi EP1 acts 
to reduce 2,4-DNT during respiration under anaerobic conditions by using lactate as an electron donor
(Huang et al. 2015).
The products formed from anoxic biotransformation of 2,4-DNT by two denitrifying enrichment cultures
with ethanol provided as a primary substrate were characterized in one study (Noguera and Freedman 
1997).  One culture was developed with inoculum acclimated to 2,4-DNT, the other with activated sludge 
that was not routinely exposed to nitroaromatic compounds.  The acclimated culture consumed 2,4-DNT
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twice as fast as the unacclimated culture, with reduction of 2,4-DNT to aminonitrile toluenes as the initial 
pathway.  The principal metabolites identified in the acclimated culture were 6-nitroindazole, 
2-nitrotoluene, and 4-nitrotoluene, as well as products from acetylation at the para position (4-acetamide­
2-nitrotoluene and 4-acetamidetoluene).  Reduction of aminonitrotoluenes to 2,4-diaminotoluene also 
occurred, and its subsequent disappearance resulted in accumulation of significant amount of
nonfilterable material in both cultures. The soluble metabolites formed from the unacclimated culture 
were more hydrophilic.  Initial characterization of the highly hydrophilic metabolites indicated 
approximately equal amounts of negatively-charged and neutral compounds.
Biotransformation of DNT by a Pseudomonas aeruginosa strain, which was isolated from the waste water
of the Radford Army Ammunition Plant (RAAP) located in Radford, Virginia was observed under both 
aerobic and anoxic conditions (Noguera and Freedman 1996).  The biotransformation was mainly
reductive under both of these conditions and was reflective of the cometabolic transformations that can
occur in the presence of easily degradable organic matter such as ethanol. P. aeruginosa reduced both 
nitro groups of DNTs resulting in the primary breakdown products of 4-amino-2-nitrotoluene and 
2-amino-4-nitrotoluene, with small amounts of 2,4-diaminotoluene also formed. Several DNT
metabolites from acetylation of the arylaminos were also identified, including 4-acetamide-2-nitrotoluene, 
2-acetamide-4-nitrotoluene, 4-acetamide-2-aminotoluene, and 2,4-diacetamidetoluene.
Clostridium acetobutylicum has received interest in anaerobic TNT bioremediation systems due to their
ability to rapidly reduce aryl nitro groups.  Results indicated that dihydroxylaminotoluenes are the
predominant primary intermediates in the transformation of the DNT isomers by C. acetobutylicum and 
that further metabolism of the dihydroxylaminotoluenes in cell cultures and extracts resulted in the 
formation of arylamines through hydroxylamine reduction (Hughes 1999).
6.3.2.3  Sediment and Soil
Microorganisms indigenous to surface soils collected at a munitions-contaminated site were reported to 
transform 2,4- and 2,6-DNT to amino-nitro intermediates within 70 days (Bradley et al. 1994).  Another
study showed that composting can decrease the concentrations of explosives, such as TNT, in 
contaminated soil, but neither 2,4- nor 2,6-DNT was detected in the compost (Griest et al. 1993).  A study
of soil sample handling times indicated that lower temperatures retard the breakdown of 2,4-DNT (Grant
et al. 1995).  2,4-DNT was observed to be more stable than TNT in contaminated soils (Grant et al. 1995).
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DNTs were not readily biodegradable using a standardized Organisation for Economic Co-operation and 
Development (OECD) test.  3,4-DNT and mixed isomers of DNT (CAS Registry Number 25321-14-6)
achieved 0% of their theoretical biochemical oxygen demand (BOD) over a 14-day incubation period 
using an activated sludge inoculum and the modified MITI (OECD 301 C) test (NITE 2002).  The DT50 of
2,4-DNT in an organic soil (82% sand, 13% silt, 5.1% clay, 2.3% organic carbon) was reported as 7 days 
and the DT90 was 191 days (UNEP 2004); however, other studies cited in this report indicated limited 
degradation of DNT under environmental conditions.  In a test system maintained under anaerobic
conditions, performed according to EPA-Guideline No. 796.3140, 0% biodegradation was observed 
within 56 days (UNEP 2004).
In a study conducted by Nishino et al. (1999), the mineralization of 2,4- and 2,6-DNT was examined in 
soil slurries.  DNT-degrading bacteria cultures commonly used in contaminated water systems were 
examined to see if they were able to degrade DNTs in contaminated soils. It was found that
microorganisms indigenous to the soils did not convert DNTs to aminonitrotoluenes during the short
incubation times required to mineralize DNTs.  DNT-degrading bacteria, however, removed over 99% of
the initial DNTs in the soil after 2–3 days of incubation.  Disappearance of DNTs was accompanied by
14CO2 release and stoichiometric appearance of nitrite.
In another study, soil from a former ammunition plant was anaerobically treated in a laboratory slurry
reactor.  2,4-DNT was completely reduced to undetectable levels in the reactor. The contaminated soil
was also tested in a larger technical scale where the soil slurry was treated anaerobically and subsequently
aerobically to complete the bioremediation process.  An overall reduction of > 99% of the contaminants
was observed, and ecotoxicological tests showed that the toxicity of the soil could not be detected after
the anaerobic/aerobic process (Lenke et al. 1998).
The biotransformation of 2,4- and 2,6-DNT by the indigenous microflora contained in marine sediment
from a shipwreck site near Halifax Harbour was studied by Yang et al. (2008).  Incubation of 2,4- and 
2,6-DNT in anaerobic sediment-water slurries at 10 °C led to the disappearance of both 2,4- and 2,6-DNT
and their reduction to their monoamine derivatives in 10 days.  The derivatives were progressively
reduced even further to 2,4- and 2,6-diaminotoluenes in a series of 50 days for 2,4-DNT and 35 days for
2,6-DNT.
The biodegradation of sorbed 2,4-DNT by the Burkholderia sp. strain was examined in a clay-rich 
aggregated porous medium by Ortega-Calvo et al. (1999).  Burkholderia sp. exhibited sensitivity to the
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cold and was unable to complete the degradation process at low temperatures (Monti 2005).  Therefore,
P. fluorescens was genetically modified (by intergeneric transformation of the DNT genes from the
Burkholderia sp. strain to the P. fluorescens strain) to use 2,4-DNT as the sole nitrogen source to
completely degrade the compound (Monti 2005). P. fluorescens was shown to be capable of degrading
2,4-DNT in temperatures as low as 10 °C and significantly decreased the toxic effects of 2,4-DNT on
specific plants.
The correlation between the mutagenicity and biodegradability of TNT and its analogs, including 2,4- and 
2,6-DNT, was reported in Maeda et al. (2007). The umu test using luminescent bacteria was employed to
assess the mutagenicity and biodegradability of the nitroaromatic compounds.  The Pseudomonas sp.
strain TM15 bacteria isolated from TNT contaminated soils in Japan was found to biotransform the 
aromatic compounds harboring three nitro groups efficiently, although 2,4- and 2,6-DNT had low 
degradation rates.  It was demonstrated that the mutagenicity, induced by the nitroaromatic compounds, 
increased with biodegradability. 
In the presence of ultraviolet (UV) exposure, photo-transformation of 2,6-DNT began immediately after
simulated solar radiation (SSR) in sandy and fine-grained sediment, with 89% being photo-transferred
after 24 hours, and none remaining for photo-transfer after 72 hours (Nipper et al. 2004).
6.4  LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to DNTs depends in part on the reliability of
supporting analytical data from environmental samples and biological specimens.  Concentrations of
DNTs in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits of
current analytical methods.  In reviewing data on DNT levels monitored or estimated in the environment, 
it should also be noted that the amount of chemical identified analytically is not necessarily equivalent to
the amount that is bioavailable. The analytical methods available for monitoring DNTs in a variety of
environmental media are detailed in Chapter 7.
6.4.1 Air
Concentrations of DNTs in the ambient air have been reported to be low (0.03–0.1 mg/m3) or 
undetectable (Woollen et al. 1985). Occupationally, concentrations of 2,4-DNT found in the stationary
air and the personal air of the mechanical plant operating room, rest rooms, and office ranged from
<0.1 to 20 µg/m3 (<1x10-4–0.020 mg/m3) (Letzel et al. 2003).  NIOSH (1980) measured breathing zone air
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concentrations of Tg-DNT that ranged from not detected (below detection limits) to 23 μg/m3 
(0.023 mg/m3) (TWA).  Tg-DNT concentrations in area air samples ranged from not detected to 
420 μg/m3 (0.42 mg/m3) (TWA).  NIOSH (1982) reported that area air samples in a manufacturing
facility contained TWA concentrations of Tg-DNT that ranged from not detected to 890 μg/m3 
(0.89 mg/m3). Levine et al. (1985b) also measured personal air samples of 2,4-DNT at 10–440 μg/m3 
(0.01–0.44 mg/m3) and 2,4- and 2,6-DNT at 50–590 μg/m3 (0.05–0.590 mg/m3) in the workplace.
6.4.2 Water
DNTs are rarely detected in public drinking water supplies.  2,4-DNT and 2,6-DNT are priority 
pollutants, and amendments to the Safe Drinking Water Act require that they be monitored for by large
community water systems (CWSs) and non-transient non-community water systems (NTNCWSs) and a 
statistically representative sample of qualifying small CWSs and NTNCWSs (EPA 2008a, 2008b).
Contaminant occurrence data collected under the First Unregulated Contaminant Monitoring Regulation 
(UCMR 1) showed only a single detection of DNTs. Since the health reference level (0.05 μg/L or 
5x10-5 mg/L) for each isomer was below the minimum reporting level of 2 μg/L (0.002 mg/L), the data
were reported as only as detections exceeding this level.  Among the small public water systems 
(797 tested), there were no detections of 2,4-DNT in 3,251 samples taken, and there was only 1 detection
out of 30,513 samples obtained from large systems throughout the United States (3,076 tested). This
single detection of 333 μg/L (0.333 mg/L) was in a surface water sample obtained from an entry point
source at a large public water system in the State of Tennessee (EPA 2008b).  2,6-DNT was not detected
in any of the 33,765 samples (both large and small systems) for which it was tested.  A total of
3,873 public water systems were tested for 2,6-DNT, of which 1,970 relied on ground water sources and 
1,903 relied on surface water sources (EPA 2008b).
DNTs have been detected in surface water and groundwater near source locations such as munitions sites.
Concentrations of 2,4- and 2,6-DNT obtained from a small brook and the Losse River, Germany adjacent
to a former ammunition plant were 0.5–13.0 and 0.1–7.6 μg/L (5x10-4–0.013 and 1x10-4–0.0076 mg/L), 
respectively (Feltes et al. 1990).  Two ponds located on a closed munition site in Germany had 
concentrations of 2,4-DNT ranging from 0.8 to 1.2 μg/L (8x10-4–0.0012 mg/L) and concentrations of
2,6-DNT ranging from 0.07 to 0.3 μg/L (7x10-5–3x10-4 mg/L) (Feltes et al. 1990).  Monitoring studies at
three polluted locations of the Elbe River in Germany found concentrations of 2,4-DNT of 0.1–1.3 μg/L
(1x10-4–0.0013 mg/L), while concentrations of 2,6-DNT were 0.08–0.5 μg/L (8x10-5–5x10-4 mg/L)
(Feltes et al. 1990).  Sohr et al. (1995) reported 2,4- and 2,6-DNT concentrations of 0.7 and 3.1 μg/L
   
 
  
 
 
 
        
     
 
    
     
     
   
   
   
  
     
 
     
 
     
   
      
     
   
   
  
 
     
 
     
      
   
    
    
 
     
  
    
 
 
 
 
 
207DINITROTOLUENES
6.  POTENTIAL FOR HUMAN EXPOSURE
(7x10-4 and 0.0031 mg/L), respectively, at contaminated warfare sites in Germany.  Other less-
contaminated sites contained 28 ng/L (2.8x10-6 mg/L) 2,4-DNT and 19 ng/L 2,6-DNT (1.95x10-5 mg/L)
(Sohr et al. 1995).  In the seawater of Dokai Bay in Japan, 2,4- and 2,6-DNT were measured at levels of
not detected (ND)–206 and ND–14.8 µg/L (ND–0.206 and ND–0.0148 mg/L), respectively, in an area 
receiving effluent from an industrial plant (Hashimoto et al. 1982).  2,3-DNT was also detected, but at
much lower levels (ND–0.412 μg/L) (ND–4.12x10-4 mg/L). DNT levels as high as 10,000 μg/L
(10 mg/L) were reported in potable groundwater at the Joliet Army Ammunition Plant located in Will 
County, Illinois (EPA 2008a).  The dates that these levels were obtained are not known. Levels were also
reported as 3,200 (3.2 mg/L) and 2,700 mg/L (2.7 mg/L) in 1989 (Agency for Toxic Substances and
Disease Registry 2009); however, current levels of DNTs may be significantly lower. 2,3-, 2,5-, 3,4-, and 
3,5-DNT isomers were identified in both monitoring wells and a few private water supply wells near the
Badger Army Ammunition Plant site in Wisconsin (EPA 2008a).
6.4.3 Sediment and Soil
Hoke et al. (1993) reported that only low concentrations of 2,4- and 2,6-DNT were detected in sediment
of the Great Calumet River-Indian Harbor.  Concentrations of 2,4-DNT in sediment pore water ranged
from the detection limit of 0.01 to 0.07 μg/L (1x10-5–7x10-5 mg/L).  2,4-DNT concentrations in sediment
pore water ranged from 0.1 to 1.7 μg/L (1x10-4–0.0017 mg/L).  2,6-DNT was not detected in sediment
samples (limit of detection [LOD]=0.01 μg/L or 1x10-5 mg/L) and subsequently was not analyzed for in 
sediment pore water.  2,4-DNT and 2,6-DNT were identified in bed sediment collected from 20 major
river basins in the United States for the 1992–1995 sampling period (Lopes and Furlong 2001).  The
maximum detected concentrations were reported as 170 μg/kg for 2,4-DNT (detected in 0.6% of 519 sites
sampled) and 93 μg/kg (detected in 1% of 518 sites sampled) for 2,6-DNT.
Concentrations ranging from <0.1 mg/kg (detection limit) to 117 mg/kg of 2,4-DNT were found at the
Joliet Army Ammunition Plant, in Joliet, Illinois, an NPL site.  2,6-DNT was detected on this site at
concentrations ranging from <0.1 to 8 mg/kg (Simini et al. 1995).  The concentrations of 2,4- and 
2,6-DNT were reported as 19 and 1.38 g/kg, respectively, in soil samples obtained at the Volunteer Army
Ammunition Plant located in Chattanooga, Tennessee and levels of 2,4- and 2,6-DNT were reported as 
8.9 and 0.48 g/kg, respectively, in soil samples obtained at the Badger Army Ammunition Plant located in 
Wisconsin (UNEP 2004). The concentration of 2,4-DNT in soil samples at the Gyttorp facility in
Sweden, which was used for explosives manufacturing from 1864 to 1995 was 4 g/kg (UNEP 2004).  The
concentrations of 2,4- and 2,6-DNT measured in soil samples obtained from the decommissioned TNT
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manufacturing facility in Hessisch Lichtenau Germany were reported as 3.6 and 2.5 g/kg, respectively
(UNEP 2004).  
Residues of DNTs were detected on the surface of military live-fire training soil (Jenkins 2006).  Mean 
surface soil concentrations ranged from <0.001 to 84 mg/kg for 2,4-DNT and from <0.001 to 4.6 mg/kg
for 2,6-DNT at 23 military firing ranges in the United States and Canada (Jenkins 2006).
6.4.4 Other Environmental Media 
Neither 2,4- nor 2,6-DNT were detected in samples of fish obtained from Lake Michigan tributaries and
Grand Traverse Bay (Camanzo et al. 1987).  DNTs were monitored for, but were not detected in, fish 
from Great Lakes harbors and tributaries in Ohio and Wisconsin (DeVault 1985).
6.5  GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Sources of exposure to DNTs for the general population include processing facilities that manufacture or
process DNTs, as well as hazardous waste sites that release this chemical.  Populations residing near
ammunition or explosive manufacturing facilities may be exposed to contaminated groundwater or soil.  
Exposure pathways to DNTs include dermal contact and incidental ingestion pathways.  Since DNTs are
not frequently detected in air, inhalation exposure to the general population is expected to be low.  
Occupational exposure to DNTs may occur from its use in the manufacture of toluene diisocyanate, in the 
production of explosives, in the manufacture of azo dye intermediates, and in organic synthesis in the
preparation of toluidines and dyes (IARC 1996).  Exposure may also occur at facilities that store or
dispose the substance.  Occupational exposure will involve inhalation, dermal contact, and incidental
ingestion, with inhalation the most likely exposure pathway.
Studies on occupational exposure to DNTs are limited.  Levine et al. (1985b) evaluated the 7-hour TWA
personal exposure of workers to Tg-DNT and measured urinary metabolites of DNTs at a DNT
manufacturing plant.  Breathing zone exposure level of production unit operators to both 2,4- and 
2,6-DNT averaged 0.26 mg/m3 (2.6x10-4 mg/L).  Air exposure concentrations of loaders, who load storage
tanks, collect samples, and perform cleaning tasks, averaged 0.32 mg/m3 (3.2x10-4 mg/L).  Exposure of
maintenance mechanics averaged 0.12 mg/m3 (1.2x10-4 mg/L), and the exposure of acid-stripper operators
was 0.06 mg/m3 (6x10-5 mg/L).  The highest personal air monitoring concentrations and levels of urinary
metabolites were found to be for loaders, followed by process operators. The levels of urinary
metabolites of DNTs in loaders and operators exceeded those that would have resulted from the inhaled 
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concentrations, although the workers wore gloves for operations that might have led to dermal exposure.  
Woollen et al. (1985) carried out biological monitoring studies of 28 workers at an explosives factory.  
The 2,4-DNT metabolite, 2,4-dinitrobenzoic acid was not detected or was present at very low levels in
urine samples prior to the start of work; however, it was detected in all post-shift urine samples. The 
weakly mean post-shift urine concentration of 2,4-dinitrobenzoic acid was 17 mg/L. Concentrations of
2,4-DNT in air samples of the plant ranged from 0.02 to 2.68 mg/m3 (2.0x10-5–0.00268 mg/L). It was 
concluded that air concentrations could not solely account for the observed excretion levels of the
metabolite, 2,4-dinitrobenzoic acid, indicating probable dermal uptake or inadvertent ingestion. 
A cross-sectional study with 82 employees who dismantled military waste at the mechanical plant in
Saxony, Germany was undertaken by Letzel et al. (2003).  The maximum concentrations of 2,4-DNT in 
the ambient air was 20 µg/m3 (0.02 mg/m3). The maximum concentrations in the urine of workers
regularly exposed to the ammunition were 2.1 µg/L (0.0021 mg/L) for 2,4-DNT, 95 µg/L (0.095 mg/L)
for 2,4-dinitrobenzoic acid, and 3.6 µg/L (0.0036 mg/L) for 2,6-DNT.
In another study, Levine et al. (1986a) reported increases of heart disease among workers at two 
ammunition plants; one of which is located in Joliet, Illinois and the other located in Radford, Virginia. 
DNTs were manufactured and purified at the plant in Joliet, Illinois and were used in single-base 
propellant formulations at the plant in Radford, Virginia.  
OSHA established an 8-hour TWA Permissible Exposure Limit (PEL) for DNTs (mixed isomers) as 
1.5 mg/m3, with skin designation to indicate the potential significant contribution to the overall exposure 
by the cutaneous route (OSHA 2013).  The American Conference of Governmental Industrial Hygienist
(ACGIH)’s Threshold Limit Value (TLV) for DNTs (mixed isomers) is 0.2 mg/m3 (2x10-4 mg/L), with
skin notation (ACGIH 2014). TLV is the time-weighted average concentration for a conventional 8-hour
workday and a 40-hour workweek to which it is believed that nearly all workers may be repeatedly
exposed without adverse effect.  The National Institute of Occupational Safety and Health (NIOSH)
determined the Recommended Exposure Limit (REL) for DNTs (mixed isomers) as 1.5 mg/m3
(0.0015 mg/L), with skin designation (NIOSH 2015).
6.6  EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
   
 
  
 
 
 
      
  
     
    
     
   
  
    
 
   
     
   
     
  
 
     
 
     
  
       
   
       
  
 
   
  
     
 
       
 
       
   
 
 
 
 
 
 
210DINITROTOLUENES
6.  POTENTIAL FOR HUMAN EXPOSURE
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
No studies are available that monitor the level of exposure of children to DNTs.  No measurements have 
been made of DNTs or their metabolite levels in amniotic fluid, meconium, cord blood, or neonatal blood 
to test for prenatal exposure, nor have measurements been made of DNTs or metabolite levels in breast
milk.  However, because of the low octanol-water partition coefficients of DNTs and excretion in the
urine, they are not expected to accumulate in maternal tissues.
Although DNTs can degrade in the environment, they have been detected at high levels at artillery sites or
ammunition producing facilities.  Therefore, children playing in soil contaminated with DNTs have the 
potential to be more exposed than adults, both because of this behavior and because of their larger skin 
surface area in proportion to their body weight for dermal absorption.  Also, children drinking well water
contaminated with DNTs might be exposed to more of the chemical than adults would be due to the fact
that children drink more fluids per kilogram of body weight than adults.  Significant dietary exposure is
unlikely as DNTs are not expected to accumulate in animal tissues.  However, ingestion of vegetables and
crops grown in DNT-contaminated areas could be a source of exposure.
There were no studies that examine potential exposure of children from their parents work clothes, skin, 
hair, tools, or other objects removed from the workplace.  No information is available concerning
exposure from consumer products because DNTs are used mainly for military and industrial purposes. 
Although DNTs are genotoxic in in vivo test systems, they have been found to be negative in dominant
lethal mutations (U.S. Army 1979) and spermatocyte DNA repair (Working and Butterworth 1984).  
There is no evidence that exposure of parental germ cells to the active forms of DNTs could plausibly
occur since DNTs do not accumulate in tissue.
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6.7  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
In addition to individuals who are occupationally exposed to DNTs (see Section 6.5), there may be groups
within the general population that have potentially high exposures (higher than background levels) to 
DNTs. These populations include individuals living in proximity to sites where DNTs were produced or
sites where DNTs were disposed, and individuals living near one of the NPL hazardous waste sites where 
isomers of DNT have been detected in some environmental media (HazDat 2007).
Based on the available information, it appears that the highly-exposed populations would be workers
exposed in manufacturing facilities.
Members of the general population are likely to be exposed only if they are near a local source of
contamination, such as an industrial discharge or an abandoned waste site. There is also the possibility of
exposure to DNTs from the gradual turnover of former military bases to local communities for public use.  
DNTs do not appear to be widespread in the environment, and they were not frequently detected at
hazardous waste sites.
6.8  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of DNTs is available.  Where adequate information is not 
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of DNTs.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
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6.8.1 Identification of Data Needs 
Physical and Chemical Properties. Information regarding the physical and chemical properties of
a chemical is essential for estimating the partitioning of the chemical in the environment.  Information on
the physical and chemical properties of DNTs is presented in Chapter 4 and the data appear to be
adequate (HSDB 2012).  The isomers of DNT have many similar traits, including identical molecular
weights, but 2,4-DNT has higher melting and boiling points and a greater solubility in water than
2,6-DNT (HSDB 2012).  DNTs are generally produced as a technical-grade mixture comprised of 95%
2,4- and 2,6-DNT and 5% other substances.  
Production, Import/Export, Use, Release, and Disposal. According to the Emergency
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this
information for 2013, became available in October 2014.  This database is updated yearly and should 
provide a list of industrial production facilities and emissions.
USITC statistics on synthetic organic chemical production (USITC 1987) do not describe DNT
production.  Uses of DNTs appear to be well characterized (HSDB 2012). The most commercially
important use of DNT is as a chemical intermediate in the production of toluene diisocyanate, a precursor
to polyurethane polymers (HSDB 2012).  DNTs are recognized as potentially hazardous chemicals and 
are subject to a variety of regulations (see Chapter 8), but disposal practices and restrictions are not
adequately documented.
Environmental Fate. The low octanol-water partition coefficients of the DNT isomers predict that
DNTs released to the environment would not bioaccumulate and would be weakly bound to soil organic
matter.  Bioconcentration data also supports the notion that 2,4-DNT is not bioaccumulative in fish (NITE
2002; Lang 1997).  The relatively low volatility and high solubility of DNTs indicate that they will tend 
to remain in water for long periods of time unless acted upon by light, oxygen, or biota, creating the
potential for transportation to groundwater or surface water (Jenkins et al. 1986).  DNTs have been found 
in waste water and groundwater in and around sites where munitions have been historically used (Jenkins 
et al. 1986; Spanggord and Suta 1982; UNEP 2004).  The occurrence of DNTs in waste water from other
manufacturing uses such as polyurethane forms has not been reported.
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Given the importance of information about the behavior of DNTs in the water column, and the extensive 
range of available information relative to that topic (EPA 1982c; Gillett 1983; Hashimoto et al. 1982, 
1984; Jenkins et al. 1986; U.S. Army 1980), the absence of substantive information about DNT releases 
to, or fate in, soils and air is less troublesome than it might be for many chemicals.  Data on the
persistence of DNTs in the vadose zone (the unsaturated zone lying between the ground level and the top 
of the groundwater) and groundwater are needed, as well as measured rates of plant uptake and
metabolism.  Because of the structurally specific nature of biotransformations, more information on the 
fate of DNT metabolites would be welcome.
Bioavailability from Environmental Media. No information is currently available that describes
the bioavailability of DNTs in food.  Data on bioavailability of soil/sediment residues would be helpful.  
Neither 2,4- nor 2,6-DNT were detected in samples of fish obtained from Lake Michigan tributaries and 
Grand Traverse Bay (Camanzo et al. 1987).  DNTs were not detected in fish from Great Lakes harbors 
and tributaries in Ohio and Wisconsin (DeVault 1985).
Food Chain Bioaccumulation. Limited information indicates that DNTs are not widely distributed
in the environment.  Residues of DNTs have a low frequency of detection in water samples. These data 
indicate that bioaccumulation may not be an area of concern (Callahan et al. 1979; EPA 1982c). The log
Kow values for 2,4- and 2,6-DNT are 1.98 and 2.10, respectively (Callahan et al. 1979; EPA 1982c), 
indicating that bioaccumulation is not likely to occur. BCFs also indicate that DNTs are not expected to 
bioaccumulate in fish (NITE 2002; Lang 1997). Degradation of DNTs forms a variety of products.
Additional information would help to confirm or refute indications of low potential for bioaccumulation 
of DNTs in foods.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of DNTs in 
contaminated media at hazardous waste sites are needed so that the information obtained on levels of
DNTs in the environment can be used in combination with the known body burden of DNTs to assess the 
potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites.
The sparse information base suggests that widespread contamination by DNTs has not occurred (Staples
et al. 1985).  DNTs were detected at very low frequencies in drinking water (EPA 2008b).  Analyses of
wastewaters indicate that local contamination may occur (Feltes et al. 1990; Shackelford and Keith 1976;
Spanggord and Suta 1982; Spanggord et al. 1982a).  DNTs were also present in the sediment and soil near
source areas (Hoke 1993; Simini 1995; Jenkins 2006).
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Exposure Levels in Humans. No studies of exposure of the general population were found, and the
occupational studies (Levine et al. 1985b; Woollen et al. 1985) are inadequate to ascertain "background"
or nonoccupational exposure.  Based on available information, the highly-exposed populations are those 
workers exposed in manufacturing facilities.  Members of the general population are likely to be exposed 
only in that they are near a local source of contamination.  Toxicokinetic data on occupationally- and 
environmentally-exposed humans will be helpful.  Measurements of DNTs and their metabolite levels in
blood and urine will be useful to provide an estimate of internal dose of exposure.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. No exposure or body burden studies have been conducted on children;
consequently, it is not known if children differ from adults in their weight-adjusted intake of DNTs, or if
unique exposure pathways for children exist.  Since DNTs are not a widespread environmental
contaminant, there are only two likely potential sources of exposure for children.  Children living near a
DNT-contaminated site might be exposed if DNTs have moved offsite in contaminated environmental
media.  If such a situation were identified, further site-specific studies of children’s exposure could be 
conducted.  Children whose parents work in manufacturing facilities that produce or use DNTs and are 
occupationally exposed to significant quantities of DNTs might potentially be exposed to DNTs
transported home on their parents’ work clothes, skin, hair, tools, or other objects removed from the
workplace.  If such a significant occupational exposure setting were identified, they might be the subject
of a take-home exposure study.
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for 2,4- and 2,6-DNT were located. This substance is
not currently one of the compounds for which a sub-registry has been established in the National
Exposure Registry.  The substance will be considered in the future when chemical selection is made for
sub-registries to be established.  The information that is amassed in the National Exposure Registry
facilitates the epidemiological research needed to assess adverse health outcomes that may be related to
exposure to this substance.
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The development of an exposure registry would provide valuable data on exposure levels and frequency.
In addition to providing information on exposure levels and duration, a registry would be useful in 
identifying sources of exposure such as hazardous waste sites and manufacturing and use facilities.
Knowledge about exposure levels and sources would be valuable in developing strategies to control
unnecessary sources and these exposures. The ability to correlate sources and exposure levels with health
effects would be useful in identifying disease conditions that may result from exposure to the chemical.
6.8.2 Ongoing Studies 
No ongoing studies sponsored by NIH or EPA were identified for DNTs.
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7. ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that are available for detecting,
measuring, and/or monitoring DNTs, their metabolites, and other biomarkers of exposure and effect to 
DNTs.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the
analytical methods used for environmental samples are the methods approved by federal agencies and
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other
methods presented in this chapter are those that are approved by groups such as the Association of
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).
Additionally, analytical methods are included that modify previously used methods to obtain lower
detection limits and/or to improve accuracy and precision.
7.1  BIOLOGICAL MATERIALS
The need to determine DNTs in biological materials could arise from occupational exposure in the
manufacture and processing of 2,4,6-TNT and from exposure to waste water and waste disposal sites 
associated with TNT manufacture.  It has been noted (Jenkins et al. 1986) that "one of the Army's most
serious water pollution problems is the disposal of wash waters used to clean equipment and interior
surfaces at munitions manufacturing and demilitarization facilities." The same reference mentions the 
generation of large quantities of waste water from these facilities.
Although there are numerous occupational monitoring studies, a limited number of methods regarding the
determination of DNTs in biological samples are available in the literature.  DNTs have been determined 
in ocean floor fauna using thin layer chromatography (TLC) (U.S. Navy 1972).  Procedures have been
described for the examination of swabs for traces of explosives, including 2,6-DNT using high-
performance liquid chromatography (HPLC) with electrochemical detection at a pendent drop electrode
(Lloyd 1983a).  These techniques can be applied to biological materials such as skin surfaces exposed to
explosives.  DNTs and their metabolites were determined in blood and urine by gas chromatography (GC)
techniques (Turner et al. 1985; Woollen et al. 1985) and in urine by TLC (Woollen et al. 1985). 
Qualitative determination of DNTs and their metabolites can also be performed after reduction to primary
arylamines and subsequent coupling of diazo compounds to produce a colored complex, which absorbs
light at 550 nm (Smith et al. 1995).
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Dichloromethane is the solvent of choice for extracting DNTs from water samples (EPA 1982a) and from
wastes (EPA 1986a).  Reversed-phase high-performance liquid chromatography (RP-HPLC) is attractive 
for the determination of DNTs in waste water because it enables direct analysis of aqueous samples 
(Jenkins et al. 1986).  A medium similar to the mobile phase used in this HPLC separation, i.e., 50/38/12 
(v/v/v) water/methanol/acetonitrile, should be suitable for extracting DNTs from low-lipid biological 
samples and for subsequent HPLC determination after sample cleanup.
In a study conducted by Honeychurch et al. (2003), screen-printed carbon electrodes (SPCEs) were used 
as disposable sensors for the measurement of 2,6-DNT using a stripping voltammetric method. 
Voltammograms showed the appearance of two reduction peaks that corresponded to the formation of the
hydroxylamine derivatives from the reduction of the nitro groups and one oxidation peak possibly from
the formation of the nitrosamines.  The detection limit was 161 ng/mL (0.161 mg/L) and the sensors were 
evaluated by determining concentrations of 2,6-DNT in spiked and unspiked potable water, saliva, and 
dust wipes.  Percent recoveries for spiked samples were 92.8–113% for potable water, 41.0–52.0% for
saliva, and 67.6–79.1% for dust wipes.  2,6-DNT was not detected in unspiked samples.  This new study
indicates that SPCEs could possibly be used in the analytical detection of DNTs in occupational settings.
Methods for the determination of the DNTs in biological samples are given in Table 7-1.
7.2  ENVIRONMENTAL SAMPLES 
The basic method for collecting DNTs from the ambient atmosphere is adsorption on a solid phase, such 
as granular adsorbents (silica gel), filters, and impingers, followed by removal with solvents such as 
chloroform.  Bubbler collectors can also be used for direct collection of analyte in a non-volatile solvent 
such as ethylene glycol.  Other instrumentation for the detection of 2,4-DNT and other explosives will
accept both air and surface particulate samples (Nacson et al. 1994). The instruments consist of capillary
GC columns terminating in an electron capture detector (ECD); the detection limit for 2,4-DNT is 20 ppt
(2x10-5 ppm) (Nacson et al. 1994).  Also available is a portable version that is useful for a wide variety of
applications, such as security checks, mail or passports, or in high-risk facilities (Nacson et al. 1994).
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Table 7-1. Analytical Methods for Determining Dinitrotoluenes in Biological
 
Materials
 
Analytical Sample Percent
Sample matrix Preparation method method detection limit recovery Reference
Urine containing Hydrolysis of metabolites, GC/MS 0.1 mg/L NR Turner et al.
DNTs and extraction, derivatization 1985
metabolites
Urine containing Zinc-catalyzed reduction of UV/VIS 100 ng/mL (0.1 NR Smith et al. 
DNTs and DNT with hydrochloric acid to mg/L) 1995
metabolites primary arylamines; diazotize 
and couple with N-(1-naph­
thyl)ethylene diamine to 
produce a colored complex
with characteristic adsorption 
at 550 nm
Urine containing Extraction with ethyl acetate GC 0.1 mg/L NR Woollen et
metabolites al. 1985
Urine Extraction with ethyl acetate TLC 0.1 mg/La NR Woollen et
al. 1985
Plant tissue Extract with sonication; Reverse­ 0.086B0.109 98.2 U.S. Army
cleanup on flonsil; alumina phase LC mg/L 1998
(LC); inject UV/VIS
Skin Swab with ethanol HPLC/ED 5.6 ng/mLa 97 Lloyd 1983a
(0.0056 mg/L) (2,6-DNT);
93 
(2,4-DNT)
Blood Extraction with toluene GC 0.00001 mg/mLa Woollen et
(0.01 mg/L) al. 1985
Ocean floor NR TLC NR U.S. Navy
fauna 1972
Skin Swab with ethanol HPLC/ED 5.6 ng/mLa 97 Lloyd 1983a
(0.0056 mg/L) (2,6-DNT);
93 
(2,4-DNT)
aLowest detected concentration.
DNT = dinitrotoluene; ECD = electron capture detection; ED = electrochemical detection; GC = gas chromatography;
HPLC = high-performance liquid chromatography; LC = liquid chromatography; MS = mass spectrometry; NR = not
reported; TLC = thin layer chromatography; UV/VIS = ultra-violet/visible spectroscopy
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Sylvia et al. (2000) developed a Surface-Enhanced Raman Spectroscopy (SERS) to potentially detect 2,4-DNT
vapors above TNT-based landmines.  This method of detection exhibited reproducible results, sensitive detection
levels of ≤5 ppb (0.005 ppm) 2,4-DNT, and spectra that demonstrated high signal-to-noise ratios collected in 
30 seconds.  While only preliminary blind testing was done, vapor-phase SERS is a promising
instrumental method for the detection of explosive vapors.
Albert and Walt (2000) developed a novel cross-reactive optical microsensor for high-speed detection of
low-level explosives and explosive-like vapors.  This porous silica-based sensor, was used to detect
DNTs in water vapor at a level of 23 ppb in clean dry air.
Likewise, a field developed instrument with artificial cross-reactive optical sensors was employed for the
detection of 2,4-DNT vapors in spiked soil and aqueous and ground samples.  Two types of fluorescence
based vapor sensors were developed: one sensor was semiselective for the nitroaromatic compounds 
(NAC), while the other was non-specific and cross reactive. The fluorescent sensors were exposed to
multiple solvents and were validated/calibrated by making measurements of known and estimated
concentrations of 2,4-DNT.  The system has demonstrated the ability to detect 120 ppb 2,4-DNT vapor in 
blind humidified samples and has been exclusively used in field tests (Albert et al. 2001).
DNTs are most commonly extracted with dichloromethane from water samples (EPA 1982a) and from
wastes (EPA 1986a).  A continuous countercurrent liquid-liquid extraction method is useful in extracting
DNTs from surface water samples (Deroux et al. 1996). The advantage of this method is that it is capable 
of extractions from large sample volumes and unfiltered natural water samples (Deroux et al. 1996).  A
sonic extraction-liquid chromatographic method has been used for detection of 2,4-DNT in soils (Bauer et
al. 1990; Griest et al. 1993).  A simple screening method has been developed for the detection of 2,4-DNT
in field soil samples that utilizes the spectrophotometer for identification by colorometrics after an initial 
reaction of the extract with potassium hydroxide and sodium sulfite (Jenkins and Walsh 1992).
A biosensor has been developed by Smirnova et al. (2004) for the detection of DNTs in soil and
groundwater.  The genetic system from the Burkholderia sp. strain DNT was examined and used to 
develop the prototype cell-based biosensor. The central element of the biosensor was found to be two
crystal structures of the transcriptional regulator DntR with acetate and thiocyanate occupying the
inductor-binding cavity.  Analysis of this biosensor was done to model how 2,4-DNT might bind to DntR
and to ultimately make conclusions on how the specificity of the biosensor might be enhanced. 
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The analysis of DNTs is normally done by GC with a variety of detectors, including flame ionization
detector (FID), electron capture detection (ECD), Hall electrolytic conductivity detector (HECD),
thermionic specific detector (TSD), fourier transform infrared (FT-IR), thermal energy analyzer (TEA), or 
mass spectrometry (MS).  It has been noted (EPA 1986b) that 2,4-DNT is "subject to erratic (gas)
chromatographic behavior."  When mass spectrometry is used to analyze water samples for DNT, electron
impact (EI) is preferentially used because many structure-specific fragments will be formed, which can be 
used for identification of isomers (Feltes et al. 1990). To improve the accuracy of mass spectroscopic 
techniques in the identification of pollutants in aqueous and solid matrices, EPA has developed the
method of isotope dilution (EPA 1989).  Isotope dilution employs stable, isotopically labeled analogs of
both 2,4- and 2,6-DNT to be used as internal standards in GC/MS analysis (EPA 1989).  Negative-ion 
chemical ionization has been shown to have a higher sensitivity and selectivity than EI, however, and 
should be used when determining traces of nitroaromatic compounds in complex aqueous mixtures
(Feltes et al. 1990).
The quenching of the photoluminescence of porous silicone films in a flowing air stream once the films 
were exposed to DNTs was monitored and the quantity of DNTs was detected in a study by Content et al.
(2000).  This detection was achieved by catalytic oxidation of DNTs.  The detection limit of 2 ppb was
observed for 2,4-DNT.
TLC and high-performance thin layer chromatography (HPTLC) have also been used to identify and 
quantify 2,4- and 2,6-DNT in soil and water samples from contaminated waste sites (Griest et al. 1993; 
Sohr et al. 1995; Steuckart et al. 1994).  GC analysis is difficult because of the large amounts of humic
acids present which cause overlap of matrix signals without cleanup; therefore, HPTLC can be a more 
advantageous method (Steuckart et al. 1994).  Cleanup is not necessary with HPTLC, except in the
analysis of soil samples (Steuckart et al. 1994).
A sensitive method for the analysis of DNTs in drinking water has been developed using wide-bore fused 
silica capillary column GC with an ECD (Hable et al. 1991). The detection limits of this method are
0.04 μg/L (4x10-5 mg/L) for 2,4-DNT and 0.003 μg/L (3x10-6 mg/L) for 2,6-DNT; these detection limits
are sensitive enough to meet the suggested requirements for EPA health advisories and water quality
criteria.
Also, HPLC with UV-detection for nitroaromatic compounds and amperometric detection for
aminoaromatic and phenolic compounds were used by Spiegel and Welsch (1997) for the monitoring of
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the degradation products of explosives in groundwater.  These methods of detection were reported to be
extremely sensitive.  2,4-DNT and 2,6-DNT were observed to be nearly completely metabolized as seen
by their decrease in the chromatograms. Spiegel et al. (2005) found that HPLC-EC was more effective in
detecting trace compounds, whereas HPLC-UV was found to be effective in detecting chemicals in highly
contaminated groundwater.  Detection limits ranged from 1 to 40 pg/L for HPLC-EC.
For the determination of 2,4-DNT in munitions manufacture waste water, RP-HPLC was chosen by
Jenkins et al. (1986) because it enables direct analysis of samples in aqueous solution without prior
extraction, attains adequate detection limits without preconcentration, and avoids problems with analyte 
thermal instability. The detection limit for 2,4-DNT was 10 μg/L (0.01 mg/L) with a standard deviation 
of 3.4 μg/L (0.034 mg/L) for concentrations up to 250 μg/L (0.25 mg/L).  A convenient method for
analysis of 2,4- and 2,6-DNT in contaminated soils used high performance liquid chromatography with 
minimal sample preparation (Preslan et al. 1993).  Likewise, DNTs were also measured in field soil
samples by using a method that included the fortification of DNTs in the soil, recovery of DNTs by 
pressurized fluid extraction, and measurement of DNTs by gas and liquid chromatography-MS (Campbell
et al. 2003).  Compared with the former EPA method SW-846 8330, this method provided a quicker time
frame needed to complete an extraction (15 minutes as opposed to 18 hours) and MS confirmation of the
analytes.  The limit of quantitation for 2,4-DNT was 0.05 µg/g.
Methods for the determination of DNTs in environmental samples are summarized in Table 7-2.
7.3  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of DNTs is available.  Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of DNTs.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if
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Table 7-2. Analytical Methods for Determining Dinitrotoluenes in Environmental
 
Samples
 
Sample Analytical Sample Percent
matrix Preparation method method detection limit recovery Reference
Air
Air
Air
Air
Water
Water
Water
Water
Water
Water
Water
Silica gel, desorb with 
chloroform
Dispersed on glass
beads, glass tube, and 
Flowmeter/mixer;
exposure to dry synthetic
air
Collect sample and insert
into analyzer
Collect sample and insert
into analyzer
Extraction with 
dichloromethane
Extraction with 
dichloromethane
Extraction with 
dichloromethane; add 
methanol
Adjust pH of spiking 
solution to >11 with 
NaOH; extraction with 
dichloromethane; add 
anhydrous sodium
sulfate; filter; rotary
evaporate
Counter current liquid-
liquid extraction method
Adjust to pH 12 and 
pump into column;
remove organic phase;
add to retirnate and 
adjust to pH 2 before 
pumping into column
Spike H2O sample with 
standards; conduct SPE;
elute and dry under
nitrogen
GC
FT-IR/MCT
detector,
NMR
GC/ECD
Fluorescent
sensing film
GC/ECD or
TEA
GC/MS 
(electron 
impactBfull 
scan)
GC/MS
Liquid-liquid 
extraction 
with GC/MS
GC/MS
(EI and 
PICI)
GC/MS
TLC
(254 nm)
0.1 mg/m3 
(1x10-4 mg/L)
2 ppb 
(0.002 ppm)
(2,4-DNT)
20 ppt
(2x10-5 ppm)
(2,4-DNT)
NR
ECD:
3.8x10-14 g/s
(2,4-DNT);
TEA:
1.77x10-11 g/s
(2,4-DNT)
47 pg (2,6-DNT)
5 ppb
(0.005 ppm)
0.8 μg/L 
(8x10-4 mg/L)(2, 
4-DNT); 1.4 μg/L 
(1.4x10-4 mg/L)
(2,6-DNT)
2 ng/L 
(2x10-6 mg/L)
2 ng/L 
(2x10-6 mg/L)
20 ng (scanner)
40 ng (visually)
70–84
96 
(2,4-DNT);
100 
(2,6-DNT)
89
89
diol-119­
115.3
RP-18­
100.6-102
Hunt et al. 1980
Content et al. 2000
Nacson et al. 1994
Xin et al. 2011
Feltes et al. 1990
Feltes et al. 1990
Yinon 1996
Yook et al. 1994
Deroux et al. 1996
Deroux et al. 1996
Kessel and Hauck
1996
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Table 7-2. Analytical Methods for Determining Dinitrotoluenes in Environmental
 
Samples
 
Sample Analytical Sample Percent
matrix Preparation method method detection limit recovery Reference
Drinking Extraction with 0.5 mL 
water toluene; rotate 
30 minutes at 15 RPM
Groundwater Extraction with 
and surface dichloromethane; acidify
water water sample with HCl
and extract with isobutyl­
methyl ketone;
concentrate in rotary
evaporator; dissolve 
residues in 
dichloromethane
Groundwater	 Extraction with 
dichloromethane
Groundwater	 Expose three samples to 
different amounts of
sunlight; inject sample,
loop
Groundwater	 Salting-Out Extraction 
(SOE)
Waste water Diluted directly with 
(for 2,4-DNT) methanol and acetonitrile
Waste water	 Extraction with 
dichloromethane
Waste water	 Extraction with dichloro­
methane, exchange to 
hexane
Waste water	 Extraction with 
dichloromethane;
EPA Method 8090
Non-water Extraction with 
miscible dichloromethane;
waste EPA Method 8090
GC/ECD
TLC
HPTLC­
AMD
HPLC/UV
(245 nm)
HPLC/EC
HPLC/UV
GC/IDMS
GC/ECD
GC/MS
GC/ECD
0.003 μg/L 
(3x10-6 mg/L)
(2,6-DNT);
0.04 μg/L 
(4x10-5 mg/L)
(2,4-DNT)
10–20 ng/spot
20 ng (2,4- and 
2,6-DNT)
0.01–0.1 μg/L
(1x10-5– 
1x10-4 mg/L)
1–40 pg/L
4.6 μg/L
(0.0046 mg/L)
10 μg/L
(0.01 mg/L)
NR
5.7 μg/L
(0.0057 mg/L)
(2,4-DNT);
1.9 μg/L 
(0.0019 mg/L)
(2,6-DNT)
2,000 μg/L
(2 mg/L)
(2,4-DNT);
1,000 μg/L
(1 mg/L)
(2,6-DNT)
93–103 
(2,6-DNT);
93–96 
(2,4-DNT)
–
–
NR
10 
(2,4-DNT);
17 
(2,6-DNT)
Hable et al. 1991
Sohr et al. 1995
Steukart et al. 1994
Spiegel and Welsch 
1997
Spiegel et al. 2005
Jenkins et al. 1986
EPA 1980
EPA 1982a
EPA 1986a
EPA 1986a
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Table 7-2. Analytical Methods for Determining Dinitrotoluenes in Environmental
 
Samples
 
Sample Analytical Sample Percent
matrix Preparation method method detection limit recovery Reference
Biosludge Extraction with sulfuric
acid and 
dichloromethane
Soil Extraction with 
acetonitrile in ultrasonic
bath; flocculate 
supernatant with CaCl2; 
filter
Soil Dilution directly with
methanol
Soil Extraction with acetone;
filter supernatant; react
with potassium hydroxide 
and sodium sulfite
Soil Grind soil; extraction with 
acetone in ultrasonic
bath; centrifuge; add 
5 mL toluene and remove 
acetone; dry toluene 
extract over anhydrous
sodium sulfate
Soil Fortification, extraction
Soil, Extraction
sediment,
solid waste
Soil, Extraction with 
sediment, dichloromethane
solid waste
Soil, Extraction
sediment,
solid waste
Soil, water, Extraction with dichloro­
and methane; addition of
municipal isotopically labeled 
sludges analog
Soil/compost	 Acid leaching followed by
sonic extraction
Soil/compost	 Extraction with 
acetonitrile; combine with
CaCl2; derivatize with 
TFAA, then
deactivate with H2O 
GC/TEA
SE/LC
HPLC/PDA
Spectro­
photometry
HPTLC/
AMD
HPLC-DAD,
LC/MS, 
GC/MS
GC/MS
GC/FT-IR
GC/FT-IR
GC/MS
HPLC
HPLC
0.05 mg/L
40–80 pg/μL
(0.04– 
0.08 mg/L)
2 μg/g (2,4-DNT)
20 ng (2,4- and 
2,6-DNT)
0.05 µg/g
660 μg/kg
10 μg/L
(0.01 mg/L)
10 μg/L
(0.01 mg/L)
10 μg/mL
(10 mg/L)
0.055– 
0.248 mg/Lc 
–
84
95–97
NR
NR
NR
NR
Phillips et al. 1983
Bauer et al. 1990
Emmrich et al. 1993
Jenkins and Walsh 
1992
Steuckart et al. 1994
Campbell et al. 2003
EPA 1986b
EPA 1986c
Gurka et al. 1987
EPA 1989
Griest et al. 1993
Preslan et al. 1993
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Table 7-2. Analytical Methods for Determining Dinitrotoluenes in Environmental
 
Samples
 
Sample Analytical Sample Percent
matrix Preparation method method detection limit recovery Reference
Materials Swab with ethanol HPLC/ED 5.6 μg/L 97 Lloyd 1983b
exposed to (0.056 mg/L) (2,6-DNT);
DNT (bomb 93 
debris) (2,4-DNT)
Materials Swab surface and insert GC/ECD 20 ppt Nacson et al. 1994
exposed to into outlet port (2x10-5 mg/L)
DNT (2,4-DNT)
Phenolic and Inject sample, loop- SFC oxidative-250 pg – Wallenborg et al.
nitroaromatic separate using super­ (230 nm) reductive-100 pg 1997
compounds critical CO2 as mobile 
phase
Explosives Extract in acetonitrile and MECC 0.55–0.74 mg/L – Oehrle 1996
dilute in pH 7 buffer; (214 nm)
inject hydrostatistically
and detect by UV
aAnalyses for both 2,4-DNT and 2,6-DNT unless otherwise noted.

bMinimum detection to ECD.
 
cVaried over course of experiment.
 
AMD = automated multiple development; CaCl2 = calcium chloride; CO2 = carbon dioxide; DAD = diode array
 
detection; DNT = dinitrotoluene; ECD = electron-capture detection; ED = electrochemical detection; EI = electron
 
ionization; FT-IR = fourier transform infrared; GC = gas chromatography; HCl = hydrochloric acid; HPLC = high-

performance liquid chromatography; HPTLC = high-performance thin layer chromatography; IDMS = isotope dilution 

mass spectrometry; LC = liquid chromatography; MCT = mercury cadmium telluride; MECC = micellar electrokinetic
 
capillary chromatography; MS = mass spectrometry; NaOH = sodium hydroxide; NMR = nuclear magnetic
 
resonance; NR = not reported; PDA = photodiode array detection; PICI = positive ion chemical ionization;
 
RPM = revolutions per minute; SE = solid extraction; SFC = super critical fluid chromatography; SFE = supercritical
 
fluid extraction; SPE = solid-phase extraction; TDM = thermal desorption modulator interface; TEA = thermal energy
 
analysis; TFAA = trifluoroacetic anhydride; TLC = thin layer chromatography; UV = ultraviolet absorption
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met would reduce the uncertainties of human health assessment.  This definition should not be interpreted 
to mean that all data needs discussed in this section must be filled.  In the future, the identified data needs 
will be evaluated and prioritized, and a substance-specific research agenda will be proposed.
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect. The available methods for the 
determination of DNTs and their metabolites in biological samples are inadequate.  Although one method 
exists for determination of DNTs and their metabolites in urine (Smith et al. 1995; Turner et al. 1985;
Woolen et al. 1985), blood (Woolen et al. 1985), and skin (Lloyd 1983a; Nacson et al. 1994), there is a
need for modern validated standard methods of analysis for such data in plant and animal tissues and 
exudates.  Methods do exist for water and waste water (EPA 1982a, 1982b) and for solid wastes (EPA
1986a, 1986b, 1986c).  A method that employs the use of SPCEs has the potential to be useful for
examining biological samples such as potable water, saliva, and dust wipes (Honeychurch et al. 2003).  
The need also exists for good methods to determine DNT biomarkers in biological materials.  The
determination of this compound in plant and animal tissues and exudates would be useful to help 
determine exposure.
7.3.2 Ongoing Studies 
No ongoing studies regarding analytical methods sponsored by NIH or EPA were identified for DNTs.
Methods for Determining Parent Compounds and Degradation Products in Environmental
Media. DNTs can be analyzed in water, air, and waste samples with reasonable selectivity and
sensitivity (EPA 1986a, 1986b, 1986c, 1989; Gurka et al. 1987; Nacson et al. 1994; Yinon 1996; Yook et
al. 1994).  Therefore, there is a reasonable database in this area.
There exists an ongoing effort to develop a "Master Analytical Scheme" for organic compounds in water
(Michael et al. 1988).  The overall goal is to detect and measure quantitatively organic compounds at
0.1 μg/L in drinking water, l μg/L in surface waters, and 10 μg/L in effluent waters.  Analytes include 
numerous semivolatile compounds and some compounds that are only "semi-soluble" in water, as well as
volatile compounds (boiling point <150 °C).  It may be anticipated that improved methods for the
determination of semivolatile DNT isomers in environmental samples may be developed as part of this 
effort.
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MRLs are substance specific estimates, which are intended to serve as screening levels, are used by
ATSDR health assessors and other responders to identify contaminants and potential health effects that
may be of concern at hazardous waste sites.
As summarized in Table 8-1, ATSDR has derived individual acute-duration oral MRLs for 6 DNT
isomers (2,3-DNT, 2,4 DNT, 2,5-DNT, 2,6-DNT, 3,4-DNT and 3,5-DNT), intermediate-duration oral
MRLs for 2,4-DNT and 2,6-DNT, and a chronic-duration oral MRL for 2,4-DNT.
The International Agency for Research on Cancer (IARC) classifies 2,4- and 2,6-DNT as Group 2B
carcinogens (possibly carcinogenic to humans) and 3,5-DNT as a Group 3 carcinogen (not classifiable as
to its carcinogenicity to humans) (IARC 2015).  The U.S. EPA classifies the 2,4-/2,6-DNT mixture as B2 
(probable human carcinogen) (IRIS 2003).  The American Conference of Governmental Industrial
Hygienists (ACGIH) has classified the 2,4-/2,6-DNT mixture as an A3 carcinogen (confirmed animal
carcinogen with unknown relevance to humans) (ACGIH 2014).
OSHA requires employers of workers who are occupationally exposed to the 2,4-/2,6-DNT mixture to 
institute engineering controls and work practices to reduce and maintain employee exposure at or below 
permissible exposure limits (PEL) of 1.5 mg/m3 (OSHA 2013).
The EPA (IRIS 2002) has derived an oral reference dose (RfD) of 0.002 mg/kg/day for 2,4-DNT based on 
a NOAEL of 0.2 mg/kg/day for neurotoxicity, Heinz bodies, and biliary tract hyperplasia in Beagle dogs 
in a 2-year feeding study (Ellis et al. 1985). The EPA (IRIS 2003) also derived an oral slope factor (q1*)
of 0.068 (mg/kg/day)-1 based on multiple tumor types in female rats (U.S. Army 1979) for the
2,4-/2,6-DNT mixture.
Tg-DNT and 3,4-DNT are on the Comprehensive Environmental Response, Compensation, and Liability
Act (CERCLA) list of hazardous substances and reportable quantities and have been assigned a reportable 
quantity (RQ) limit of 10 pounds combined (EPA 2014d). 2,4-DNT, and 2,6-DNT also appear on the
CERCLA list of chemicals and have been assigned RQ limits of 10 and 100 pounds, respectively (EPA
2014d).
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The 2,4-/2,6-DNT mixture is designated as a hazardous substances under Section 311 of the Clean Water
Act; any discharge of these chemicals over a specified threshold level (10 pounds) into navigable waters
is subject to reporting requirements (EPA 2013d).
The international and national regulations, advisories, and guidelines regarding DNTs in air, water, and 
other media are summarized in Table 8-2.
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Table 8-1. Oral Minimal Risk Levels (MRLs) for Dinitrotoluenes
Isomer 2,3-DNT 2,4-DNT 2,5-DNT 2,6-DNT 3,4-DNT 3,5-DNT
Acute-duration
MRL
(mg/kg/day) 0.09
Critical effect Kidney and 
hematopoietic
effects in rats
Point of 275 mg/kg/day
departure (LOAEL)
Uncertainty 3,000 (10L,
factora 10A, 10H, 3D)
Intermediate-duration
MRL
 
(mg/kg/day)
 
Critical effect
 
Point of 
departure
 
Uncertainty
 
factora
 
Chronic-duration
MRL
 
(mg/kg/day)
 
Critical effect
 
Point of 
departure
 
Uncertainty
 
factora
 
0.05 0.007
Neurotoxicity in Splenic lesions
dogs in rats
5 mg/kg/day 2.05 mg/kg/day
(NOAEL) (BMDL10)
100 (10A, 10H)	 300 (10A, 10H,
3D)
0.007
Hematological
effects in dogs
0.67 mg/kg/day
(BMDL1SD)
100 (10A, 10H)
0.001
Hematological
effects in dogs
0.12 mg/kg/day
(BMDL1SD)
100 (10A, 10H)
0.09	 0.03
Hematological Hematopoietic
effects in dogs effects in rats
9.31 mg/kg/day 8.05 mg/kg/day
(BMDL1SD) (BMDL10)
100 (10A, 10H)	 300 (10A, 10H,
3D)
0.004
Splenic lesions
in dogs
4 mg/kg/day
(LOAEL)
1000 (10L, 10A,
10H)
0.03
Testicular
effects in rats
10 mg/kg/day
(NOAEL)
300 (10A, 10H,
3D)
aUncertainty factors are comprised of uncertainty associated with use of a LOAEL (L), extrapolation from animals to 
humans (A), human variability (H), and/or database limitations (D).
BMDL10 = lower 95% confidence limit on the benchmark dose (BMD10) associated with a response rate that differs
from the control response rate by 10%; BMDL1SD = lower 95% confidence limit on the benchmark dose (BMD1SD) 
associated with a change of 1 standard deviation from the controls; DNT = dinitrotoluene; LOAEL = lowest-observed­
adverse-effect-level; NOAEL = no-observed-adverse-effect level
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Table 8-2.  Regulations, Advisories, and Guidelines Applicable to Dinitrotoluenes
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification IARC 2015
2,4-DNT Group 2Ba 
2,6-DNT Group 2Ba 
3,5-DNT Group 3b 
WHO Air quality guidelines No data WHO 2010
Drinking water quality guidelines No data WHO 2011
NATIONAL
Regulations and 
Guidelines:
a. Air
ACGIH TLV (8-hour TWA) ACGIH 2014
DNTc,d 0.2 mg/m3 
AIHA ERPGs No data AIHA 2014 
DOE PAC-1e DOE 2012a
DNTc, 2,4-, 2,6-, and 3,4-DNT 0.6 mg/m3 
PAC-2e 
DNTc 1.1 mg/m3 
2,4-DNT 4.9 mg/m3 
2,6-DNT 12 mg/m3 
3,4-DNT 33 mg/m3 
PAC-3e 
DNTc, 2,4-, 2,6-, and 3,4-DNT 200 mg/m3 
EPA AEGLs No data EPA 2014a
Hazardous air pollutant EPA 2013a
2,4-DNT Yes 42 USC 7412
NAAQS No data EPA 2014c
NIOSH REL (10-hour TWA) NIOSH 2015
DNTc,f,g 1.5 mg/m3 
IDLH
DNTc,f,g 50 mg/m3 
OSHA PEL (8-hour TWA) for general industry OSHA 2013
DNTc,g 1.5 mg/m3 29 CFR 1910.1000,
Table Z-1
PEL (8-hour TWA) for construction
DNTc,g 1.5 mg/m3 
OSHA2014a
29 CFR 1926.55,
Appendix A
PEL (8-hour TWA) for shipyards
DNTc,g 1.5 mg/m3 
OSHA 2014b
29 CFR 1915.1000
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Table 8-2.  Regulations, Advisories, and Guidelines Applicable to Dinitrotoluenes
Agency Description Information Reference
NATIONAL(cont.)
b. Water
EPA Designated as hazardous substances in EPA 2013b
accordance with Section 311(b)(2)(A) of 40 CFR 116.4
the Clean Water Act
DNTc, 2,4-, 2,6-, and 3,4-DNT Yes
Drinking water standards and health EPA 2012b
advisories
1-day health advisory for a 10-kg 
child
2,4-DNT 1 mg/L
2,6-DNT 0.4 mg/L
10-day health advisory for a 10-kg 
child
2,4-DNT 1 mg/L
2,6-DNT 0.04 mg/L
DWEL
2,4-DNT 0.1 mg/L
2,6-DNT 0.04 mg/L
10-4 Cancer risk
2,4-DNT 0.005 mg/L
2,6-DNT 0.005 mg/L
National primary drinking water standards No data EPA 2009
National recommended water quality
criteria: human health for the 
consumption of
EPA 2013c
2,4-DNT
Water plus organism 0.11 μg/Lh,i 
Organism only 3.4 μg/Lh,i 
Reportable quantities of hazardous
substances designated pursuant to 
Section 311 of the Clean Water Act
EPA 2013d
40 CFR 117.3
DNT 10 pounds
c. Food
FDA EAFUSj No data FDA 2013
d. Other
ACGIH Carcinogenicity classification ACGIH 2014
DNT A3c,k 
EPA Carcinogenicity classification
2,4-/2,6-DNT mixture; no CASRN B2l 
IRIS 2003
Oral slope factor
2,4-/2,6-DNT mixture; no CASRN 0.68 (mg/kg/day)-1 
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Table 8-2.  Regulations, Advisories, and Guidelines Applicable to Dinitrotoluenes
Agency Description Information Reference
NATIONAL(cont.)
 
EPA (cont.)
 RfC
2,4-DNT
RfD
2,4-DNT
Identification and listing of hazardous
waster
2,4-DNT
2,6-DNT
Inert pesticide ingredients in pesticide
products
Superfund, emergency planning, and 
community right-to-know
Designated CERCLA hazardous
substance and reportable quantity
DNTc and 3,4-DNT
2,4-DNT
2,6-DNT
Effective date of toxic chemical
release reporting
DNT
 
2,4-DNT
 
2,6-DNT
 
Extremely hazardous substances
and its threshold planning quantity
TSCA chemical lists and reporting 
periods
2,4-DNT
Effective date
Reporting date
TSCA health and safety data reporting
2,4-DNT
 
Effective date
 
Reporting date
 
IRIS 2002
No data
0.002 mg/kg/day
EPA 2013e
40 CFR 261,
Appendix VIIIU105
U106
No data EPA 2014c
EPA 2014d
40 CFR 302.4
10 poundsm 
10 poundsn 
100 poundso 
EPA 2014e
40 CFR 372.65
01/01/1990
01/01/1987
01/01/1987
No data EPA 2014f
40 CFR 355,
Appendix A
EPA 2014f
40 CFR 712.30
03/11/1994
05/10/1994
EPA 2014g
40 CFR 716.120
03/11/1994
06/30/1998
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Table 8-2.  Regulations, Advisories, and Guidelines Applicable to Dinitrotoluenes
Agency Description Information Reference
NATIONAL(cont.)
NTP Carcinogenicity classification No data NTP 2014
aGroup 2B: possibly carcinogenic to humans.

bGroup 3: not classifiable as to its carcinogenicity to humans
 
cTg-DNT is composed primarily of the 2,4- and 2,6-DNT isomers and the other four isomers (2,3-, 2,5-, 3,4-, and 

3,5-DNT) make up only 5% of Tg-DNT.

dSkin: refers to the potential significant contribution to the overall exposure by the cutaneous route.
 
eDefinitions of PAC terminology are available from U.S. Department of Energy (DOE 2012b).
 
fNIOSH potential occupational carcinogen.
 
gSkin designation.

hThis criterion is based on carcinogenicity of 10-6 risk.
 
iEPA has updated its national recommended water quality criteria for human health. The comment period for the 

draft water quality criteria ended August 13, 2014. A final update has not been issued yet, but the proposed criteria 

for 2,4-DNT is 0.0378 μg/L for water + organism and 0.711 μg/L for organism only (EPA 2014b).
 
jThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 

additives or listed or affirmed as GRAS.
 
kA3: confirmed animal carcinogen with unknown relevance to humans.
 
lGroup B2: probable human carcinogen.
 
mDesignated CERCLA hazardous substance pursuant to Section 311(b)(2) and Section 307(a) of the Clean Water
 
Act.
 
nDesignated CERCLA hazardous substance pursuant to Section 311(b)(2) and Section 307(a) of the Clean Water
 
Act, Section 112 of the Clean Air Act, and Section 3001 of RCRA.
 
oDesignated CERCLA hazardous substance pursuant to Section 311(b)(2) and Section 307(a) of the Clean Water
 
Act, and Section 3001 of RCRA.
 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;
 
AIHA = American Industrial Hygiene Association; CERCLA = Comprehensive Environmental Response,
 
Compensation, and Liability Act; CFR = Code of Federal Regulations; DNT = dinitrotoluene; DOE = Department of
 
Energy; DWEL = drinking water equivalent level; EAFUS = Everything Added to Food in the United States;
 
EPA = Environmental Protection Agency; ERPG = emergency response planning guidelines; FDA = Food and Drug 

Administration; GRAS = Generally Recognized As Safe; IARC = International Agency for Research on Cancer;
 
IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information System; NAAQS = National
 
Ambient Air Quality Standards; NIOSH = National Institute for Occupational Safety and Health; NTP = National
 
Toxicology Program; OSHA = Occupational Safety and Health Administration; PAC = Protective Action Criteria;
 
PEL = permissible exposure limit; RCRA = Resource Conservation and Recovery Act; REL = recommended 

exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; TLV = threshold limit values;
 
TSCA = Toxic Substances Control Act; TWA = time-weighted average; WHO = World Health Organization
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms
at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or
exposure. These may suggest potential topics for scientific research, but are not actual research studies.
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Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or
irreversible health effects.
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.
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Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of individuals in a population who develop a specified condition to the total
number of individuals in that population who could have developed that condition in a specified time
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors. The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.
   
 
  
 
 
 
  
  
 
   
  
 
     
 
 
   
   
    
  
 
 
 
 
  
  
      
      
 
 
 
 
 
  
 
   
  
 
    
    
  
 
    
 
 
  
    
 
 
     
   
   
 
 
  
   
 
 
 
 
 
264DINITROTOLUENES
10.  GLOSSARY
Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no
statistically or biologically significant increases in frequency or severity of adverse effects seen between
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based
and physiologically-based.  A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end
points.  These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments
representing organs or tissue groups with realistic weights and blood flows. These models require a 
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variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Prospective Study—A type of cohort study in which the pertinent observations are made on events
occurring after the start of the study.  A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a
professional judgment of the entire database on the chemical. The RfDs are not applicable to
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of
this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
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Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or
inherited characteristic that is associated with an increased occurrence of disease or other health-related
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes
continually.  No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods.  The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour
workday or 40-hour workweek.
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system.
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APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach. They are below levels that might cause adverse health effects in the people most sensitive to
such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method
suitable for this route of exposure.  MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that
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are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Human Health Sciences, expert panel peer reviews, and agency-wide MRL
Workgroup reviews, with participation from other federal agencies and comments from the public. They
are subject to change as new information becomes available concomitant with updating the toxicological
profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously published levels.
For additional information regarding MRLs, please contact the Division of Toxicology and Human 
Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop
F-57, Atlanta, Georgia 30329-4027.
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MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: 2,3-DNT
CAS Numbers: 602-01-7
Date: February 2016
Profile Status: Final
Route: [ ] Inhalation   [X] Oral
Duration: [X] Acute [ ] Intermediate   [ ] Chronic
Graph Key: 4
Species: Rat
Minimal Risk Level: 0.09 [X] mg/kg/day   [ ] ppm
References: Lent EM, Crouse CB, Quinn MJ, et al.  2012a.  Comparison of the repeated dose toxicity of
isomers of dinitrotoluene. Int J Toxicol 31(2):143-157.
U.S. Army Public Health Command (USAPHC).  2011a.  Toxicology Study No. 87-XE-08G0A-08, 
October 2011, Toxicology Portfolio.  Fourteen-day oral toxicity and in vivo genotoxicity of 2,3­
dinitrotoluene in rats, June-July 2008.  USAPHC, Aberdeen Proving Ground, Maryland.
Experimental design:  In a comparative toxicity study, groups of six male Sprague-Dawley rats were 
given 2,3-DNT via gavage doses of 0, 17, 34, 69, 138, 275, or 550 mg/kg/day for 14 days. Both untreated 
and vehicle control groups were included.  Evaluations during the study included twice daily observations
for morbidity and clinical signs and measurement of body weight and food consumption on days 0, 1, 3, 
7, and 14.  Prior to sacrifice at the end of exposure, blood was collected for evaluation of hematology
(total and differential white blood cell counts; red blood cell count; hemoglobin, hematocrit, MCV, MCH, 
mean corpuscular hemoglobin concentration [MCHC], red cell distribution width; platelet count; and 
mean platelet volume) and serum chemistry (albumin, ALP, ALT, AST, BUN, calcium, cholesterol, 
creatinine, glucose, globulin, LDH, total bilirubin, total protein, sodium, potassium, and chlorine)
assessments.  All animals received gross necropsy and organ weight determinations (brain, heart, kidney,
epididymides, liver, spleen, and testes).  Microscopic examination of organs with exposure-related
changes in weight was performed for controls and any dose groups exhibiting changes in the
corresponding organ weights.
Effects noted in study and corresponding doses: All rats exposed to 550 mg/kg/day died or were
sacrificed moribund within the first 2–3 days of dosing.  Clinical signs of toxicity were observed only in 
this dose group.  In the surviving dose groups, there were no statistically significant differences from
control in body weight or food consumption, although body weight was lower (~9% less than vehicle 
controls) in the 275 mg/kg/day group.  In addition, there were no significant, treatment-related changes in
hematology or clinical chemistry parameters.  The authors noted 2.3-fold increases in ALP, ALT, and 
AST in the 138 mg/kg/day group, but the difference from control was not statistically significant, and
comparable increases were not seen at in the higher dose group (275 mg/kg/day).  Significantly increased 
relative (to body weight) liver and kidney weights were observed at 275 mg/kg/day (20 and 14% higher
than vehicle controls, respectively); lower body weights in this group likely contributed to the changes.  
Absolute organ weights and organ weights relative to brain weight were not significantly different from 
controls.  There were no accompanying histopathology lesions in the liver, nor were there clinical
chemistry changes indicative of liver or kidney injury. In animals surviving to terminal sacrifice,
however, renal lesions were observed at 275 mg/kg/day, including trace tubular dilatation in 2/6 rats
(compared with 1/6 controls) and trace lymphocytic infiltration in 4/6 rats (compared with 1/6 controls).  
In addition, extramedullary hematopoiesis (3/6 rats) and lymphoid hyperplasia (1/6) of the spleen, as well
as lymphoid depletion (1/6), were observed at 275 mg/kg/day.  These lesions were not seen in controls.  
   
 
  
 
 
  
  
    
      
    
 
  
       
 
 
 
       
        
        
        
        
        
 
 
 
      
 
 
  
 
 
 
    
 
  
 
        
    
    
  
        
    
    
    
 
 
 
     
    
   
     
 
 
   
 
 
 
 
 
 
A-4DINITROTOLUENES
APPENDIX A  
Although none of these incidences was statistically significantly increased in pairwise comparisons with
controls, the group sizes were very small, and the increases are considered to be biologically significant.  
Kidneys and spleens of animals in the lower dose groups were not examined microscopically.  Results of
this study identify an acute-duration LOAEL for kidney and splenic effects (see Table A-1) of
275 mg/kg/day, respectively, in rats. A NOAEL for kidney and splenic effects cannot be determined in 
the absence of histopathology examinations in lower dose groups.
Table A-1. Renal and Splenic Effects in Rats Exposed to 2,3-DNT for 14 Days
Dose (mg/kg/day)
End point 0 17 34 69 138 275 550
Renal tubular dilatation 1/6a ND ND ND ND 2/6 NA
Renal lymphocytic infiltration 1/6 ND ND ND ND 4/6 NA
Splenic extramedullary hematopoiesis 0/6 ND ND ND ND 3/6 NA
Splenic lymphoid hyperplasia 0/6 ND ND ND ND 1/6 NA
Splenic lymphoid depletion 0/6 ND ND ND ND 1/6 NA
aNumber affected/number examined.
DNT = dinitrotoluene; NA = not applicable; all animals in this group died or were sacrificed moribund; ND = no data;
histopathology examinations were not performed on these animals.
Sources: Lent et al. 2012a; USAPHC 2011a 
Dose and end point used for MRL derivation: 
[] NOAEL   [X] LOAEL 275 mg/kg/day was the LOAEL for renal and hematopoietic effects (renal
tubular dilatation, renal lymphocytic infiltration, splenic extramedullary hematopoiesis and lymphoid 
hyperplasia).
The LOAEL value of 275 mg/kg/day for renal and hematopoietic effects in rats was identified as the POD
for derivation of the acute-duration oral MRL for 2,3-DNT (Lent et al. 2012a; USAPHC 2011a).  A 
NOAEL was not determined from the study as the target organs (kidney and spleen) were not examined 
microscopically in lower dose groups. Available data were not suitable for BMD modeling, as incidence 
data were limited to the 275 mg/kg/day group and the control group. The POD of 275 mg/kg/day was
divided by an uncertainty factor of 3,000 (10 for use of a LOAEL, 10 for extrapolation from animals to 
humans, and 10 for human variability, and 3 for database limitations), resulting in an acute-duration oral
MRL for 2,3-DNT of 0.09 mg/kg/day.
Uncertainty Factors used in MRL derivation:
[X]  10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
[X]  3 for database limitations (the only other data available are from an acute lethality study)
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.
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If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure?  No.
Other additional studies or pertinent information which lend support to this MRL: The only other acute-
duration oral study of 2,3-DNT was an acute lethality study, in which LD50 values of 1,120 and
1,070 mg/kg were identified in rats and mice, respectively (Vernot et al. 1977).  
Agency Contact (Chemical Manager): Carolyn Harper
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MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: 2,4-DNT
CAS Numbers: 121-14-2
Date: February 2016
Profile Status: Final
Route: [ ] Inhalation   [X] Oral
Duration: [X] Acute [ ] Intermediate   [ ] Chronic
Graph Key: 14
Species: Dog
Minimal Risk Level:  0.05   [X] mg/kg/day  [ ] ppm
References: Ellis HV, Hong CB, Lee CC, et al.  1985.  Subchronic and chronic toxicity studies of
2,4-dinitrotoluene.  Part I.  Beagle dog.  J Am Coll Toxicol 4:233-242.
U.S. Army.  1978b. Mammalian toxicity of munitions compounds.  Phase II:  Effects of multiple doses.  
Part II:  2,4-Dinitrotoluene.  Progress report no. 3.  Fort Detrick, MD:  U.S. Army, Medical
Bioengineering Research and Development Laboratory.  ADA061715.
Experimental design: In a subchronic study, beagle dogs (4/sex/group) were administered 0, 1, 5, or
25 mg/kg/day 2,4-DNT for up to 13 weeks.  2,4-DNT was mixed with lactose and administered as 
capsules.  Dogs were observed daily for behavioral changes and clinical signs of toxicity.  Body weights 
were recorded weekly.  Blood was taken before initiation of treatment and at 4, 8, and 13 weeks for
evaluation of hematological parameters (erythrocyte, reticulocyte, platelet, and total and differential 
leukocyte counts; Heinz bodies; hematocrit, hemoglobin, and methemoglobin concentrations; mean cell
volume, hemoglobin, and hemoglobin concentration) and clinical chemistry analyses (glucose, urea 
nitrogen, sodium, potassium, calcium, magnesium, and chloride; and the serum enzyme activity of
aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase).  Animals (1 sex/group)
were sacrificed after 4 or 13 weeks of continuous treatment; an additional dog/sex/group was
discontinued treatment after 4 or 13 weeks and sacrificed after 4 weeks of recovery.  The two high-dose
dogs removed from treatment at 4 weeks were not sacrificed until 8 months after cessation of treatment to
test the reversibility of effects after a longer recovery period. When animals were sacrificed moribund or
at study termination, they were examined for gross lesions.  Major organs and tissues (heart, liver, spleen, 
kidneys, adrenals, and gonads) were weighed; “various” tissues (not specified) were subjected to
histopathology.  To evaluate the immunologic response to 2,4-DNT, the concentration of IgE in the serum
was assessed after treatment for 4, 8, or 13 weeks or after treatment for 4 or 13 weeks followed by
recovery for 4 weeks.  Bone marrow and kidney cultures were also maintained and cytogenetic analyses 
(evaluation of chromosome number and morphology) were performed.
Effects noted in study and corresponding doses: Data for acute-duration oral exposure were obtained 
from daily cageside observations for behavioral changes and clinical signs of toxicity during the first
14 days of treatment.  No mortality was observed during the first 14 days of treatment.  No behavioral
changes or clinical signs of toxicity were observed in dogs treated with 1 or 5 mg/kg/day.  Neurotoxicity
was observed at 25 mg/kg/day.  Evidence of neurotoxicity, identified as loss of hind leg control, was first
observed in a female dog on day 12 of treatment. Three additional male dogs showed similar signs on
day 14 of treatment.  All high-dose dogs showed signs of neurotoxicity after treatment for 12–22 days.  
The onset and severity of toxic signs reportedly varied among dogs within the same treatment group;
some dogs were moribund at the same time that others began experiencing symptoms.  In individual dogs, 
symptom severity varied over time, with no duration-related pattern of severity.  Although incidence data
were not reported, the study authors noted that the neurotoxic effects most often observed in the 13-week
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study were incoordination of the hind legs and stiffness that produced an abnormal hopping gait.  Some
dogs experienced paralysis of the hind legs.  In severe cases, stiffness progressed from the hind legs to the
trunk, forelegs, neck, and head.  Histopathological assessments conducted at 4 or 13 weeks showed 
lesions of the central nervous system, including generalized vacuolization, hypertrophy, mitosis of the
endothelium and focal gliosis in the cerebellum, and/or perivascular hemorrhage in the cerebellum and
brain stem in high-dose animals (2/2 and 3/3 animals evaluated at 4 and 13 weeks, respectively).
However, the study authors noted that the most severe of these lesions occurred in dogs that developed 
toxic signs of neurotoxicity late in the study (time to onset of symptoms not reported).  Results of this
study identify acute-duration NOAEL and LOAEL values for neurotoxicity in dogs of 5 and 
25 mg/kg/day, respectively.
Dose and end point used for MRL derivation: 
[X] NOAEL   [ ] LOAEL [] 5 mg/kg/day was the NOAEL for 
neurological effects (loss of hind leg control).
The NOAEL value of 5 mg/kg/day for neurotoxicity in dogs was identified as the POD for derivation of
the acute-duration oral MRL for 2,4-DNT (Ellis et al. 1985; U.S. Army 1978b).  Neurotoxicity data were
not suitable for BMD modeling, since effects were only observed at the highest dose tested. Therefore,
the NOAEL value for 5 mg/kg/day was used at the POD.  This value was divided by an uncertainty factor
of 100 (10 for extrapolation from animals to humans and 10 for human variability), resulting in an acute-
duration oral MRL for 2,4-DNT of 0.05 mg/kg/day.
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure?  No.
Other additional studies or pertinent information which lend support to this MRL: No other acute-
duration studies were located in which neurotoxicity was reported after oral exposure to 2,4-DNT.  Other
acute-duration studies in rodents identified hepatic effects (single cell necrosis and glycogen deposition) 
and hematological effects (splenic extramedullary hematopoesis) in male Sprague-Dawley rats treated at
36 and 71 mg/kg/day (respectively) via gavage for 14 days (Lent et al. 2012a; USAPHC 2011b), slight
cyanosis in male Sprague-Dawley rats treated at 60 mg/kg (the lowest tested dose) for 5 days (Lane et al.
1985), and decreased fertility in CD-1 female mice dosed with 250 mg/kg 2,4-DNT for 2 days (Soares 
and Lock 1980).  Neurotoxicity was observed in beagle dogs after subchronic or chronic treatment with 
2,4-DNT.  Clinical signs of neurotoxicity (including incoordination and paralysis), sometimes 
accompanied by central nervous system lesions (generalized vacuolization, hypertrophy, mitosis of the
endothelium and focal gliosis in the cerebellum, and perivascular hemorrhages of the cerebellum and 
brain stem) were reported in dogs (4/sex/group) dosed with 25 mg/kg 2,4-DNT for up to 13 weeks (Ellis
et al. 1985; U.S. Army 1978b) and in dogs (6 sex/group) treated at 1.5 (one dog) or 10 mg/kg/day (all
dogs) for up to 24 months (Ellis et al. 1985; U.S. Army 1979).  Dogs appear to be the most sensitive
species for 2,4-DNT-induced neurotoxicity; in CD rats and CD-1 mice treated with 2,4-DNT for up to 
24 months, neurotoxic effects were absent or occurred at much higher doses in similarly designed studies 
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(U.S. Army 1978b, 1979).  Neuromuscular effects similar to those observed in dogs occurred in rats
administered 2,4-DNT at 266 or 145 mg/kg/day (for males and females, respectively) for up to 13 weeks, 
but not in rats treated with 2,4-DNT at up to 34 or 45 mg/kg/day (for males and females, respectively) for
24 months.  Mice treated with 2,4-DNT at 413 or 468 mg/kg/day (for males and females, respectively) for
up to 13 weeks or 898 mg/kg/day for 24 months did not show clinical signs of neurotoxicity (U.S. Army
1978b, 1979).
Agency Contact (Chemical Manager): Carolyn Harper
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MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: 2,4-DNT
CAS Numbers: 121-14-2
Date: February 2016
Profile Status: Final
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute [X] Intermediate   [ ] Chronic
Graph Key: 32
Species: Dog
Minimal Risk Level:  0.007 [X] mg/kg/day  [ ] ppm
References: U.S. Army.  1979.  Mammalian toxicity of munitions compounds.  Phase III: Effects of
lifetime exposure.  Part I. 2,4-Dinitrotoluene.  Final report no. 7.  Fort Detrick, MD:  U.S. Army and 
Medical Bioengineering Research Development Laboratory.  ADA077692.  
Ellis HV, Hong CB, Lee CC, et al.  1985.  Subchronic and chronic toxicity studies of 2,4-dinitrotoluene.  
Part I.  Beagle dog.  J Am Coll Toxicol 4:233-242.
Experimental design:  Young beagle dogs (6 dogs/sex/group; age not specified) were administered 0, 0.2, 
1.5, or 10 mg/kg 2,4-DNT in capsules for 24 months. Dogs were observed daily for behavioral changes
and clinical signs of toxicity.  Body weights were recorded weekly.  Feed consumption was measured
during 1 week each month starting in month 6.  Blood was taken before initiation of treatment and after 3, 
6, 9, 12, 18, and 24 months of exposure for assessment of hematological parameters (erythrocyte, 
reticulocyte, platelet, and total and differential leukocyte counts; Heinz bodies, clotting time, hematocrit,
hemoglobin, and methemoglobin concentrations; and mean cell volume, hemoglobin, and hemoglobin 
concentration) and clinical chemistry (fasting glucose, urea nitrogen, levels of sodium, potassium, 
calcium, magnesium, chloride, and bilirubin [high-dose dogs with toxic signs], and the serum enzyme
activities of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase) analyses.
Animals (one male and one female/group) were sacrificed after 12 or 24 months of continuous treatment;
an additional dog/sex/group was discontinued from treatment at these time points and were sacrificed 
after a 4-week recovery period to evaluate the reversibility of effects (including clinical signs, hematology
and clinical chemistry, organ weights, and histopathological effects).  Animals that were moribund during
the study and those that survived to study termination were sacrificed and examined for gross lesions;
major organs and tissues (including the brain, heart, liver, spleen, kidneys, adrenals, thyroids, pituitary, 
and gonads) were weighed, and comprehensive histopathological analyses (35 tissues) were performed.  
Effects noted in study and corresponding doses: Intermediate-duration oral exposure of dogs to 2,4-DNT
produced methemoglobinemia, anemia, and compensatory hematopoiesis (Ellis et al. 1985; U.S. Army
1979).  Hematological effects of 2,4-DNT are initiated by methemoglobin production, which occurs when 
the ferrous iron in complex with the heme groups of hemoglobin is oxidized to ferric iron.  Ferric iron 
does not bind oxygen, resulting in anemia.  Ferric iron also contributes to the denaturation of hemoglobin 
and subsequent removal of erythrocytes from the blood.  Heinz bodies are also detected as granules in
erythrocytes resulting from denatured hemoglobin.  Increased hematopoiesis is typically observed as a
compensatory response to decreased erythrocyte count. Hematological effects consistent with
development of methemoglobinemia were observed in dogs administered oral 2,4-DNT at all intermediate
duration time points (3, 6, and 9 months).  Although effects at all time points were qualitatively similar, 
hematological changes observed after 9 months of exposure were more consistent and pronounced than 
those observed at the 3- and 6-month time periods.  Therefore, only data from the 9-month evaluation 
were considered for derivation of the intermediate-duration oral MRL.  The only significant effects
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observed at the intermediate-duration time points were changes to hematological parameters.  At the mid-
and low dose, no clinical signs of toxicity, behavioral changes, or effects on clinical chemistry parameters 
were observed at the intermediate-duration time points at any of the doses tested.  At the high dose, 
clinical signs of neurotoxicity (decreased muscle control and incoordination), sometimes accompanied by
decreased body weight, were observed; these effects contributed to the death of four of six dogs within 
the first 20 weeks of the study.
Effects on hematological parameters in male and female dogs administered oral 2,4-DNT for 9 months
are summarized in Table A-2.  Male and female dogs exposed to 2,4-DNT for 9 months at doses of
1.5 and 10 mg/kg/day showed detectable amounts of methemoglobin in the serum (the initiating
hematological effect), with changes reaching statistical significance in males and females in the 
10 mg/kg/day group. In female dogs administered 10 mg/kg/day, statistically significant decreases in
erythrocyte count, hematocrit, and hemoglobin, a statistically significant increase in reticulocyte count, 
and the presence of Heinz bodies in serum were observed.  Similar hematological effects were observed
in female dogs administered 0.2 and 1.5 mg/kg/day, although effects did not reach statistical significance,
most likely because the power of the study to detect statistically significant changes was compromised by
the small number of dogs per treatment group. However, based on a clinically significant increase in 
methemoglobin levels of 225% in female dogs administered 1.5 mg/kg/day, the NOAEL and LOAEL
values for hematological effects in this study are 0.2 and 1.5 mg/kg/day, respectively. Effects on
hematological parameters in male dogs were similar to those in female dogs, although changes did not
reach statistical significance in the 10 mg/kg/day group, possibly due to low numbers of male dogs
evaluated (hematological data available for only two males in the 10 mg/kg/day group).  After treatment
for 18 or 24 months, slight or no anemia, near-normal reticulocyte levels, no Heinz bodies, and minimal
amounts of methemoglobin were detected, likely reflective of an adaptive response.  Recovery from
hematological effects also occurred in dogs allowed to recover for 4 weeks after dosing for 12 or
24 months.  
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Table A-2.  Hematological Effects in Beagle Dogs Exposed to 2,4-DNT for
9 Months
Dose (mg/kg/day)
End point 0 0.2 1.5 10
Males
Erythrocyte count
(x10/mm)
6.51±0.12 (6)a 6.23±0.18 (6)
[↓4]
6.36±0.13 (6)
[↓2]
6.36±0.13 (2)
[↓2]
Heinz bodies (%) 0.0±0.0(6) 0.0±0.0(6)
[NA]
0.0±0.0(6)
[NA]
1.8±0.6(2)b 
[NA]
Reticulocytes (%) 0.69±0.15 (6) 0.55±0.09 (6)
[↓20]
0.57±0.11 (6)
[↓17]
1.39±0.47 (2)
[↑101]
Hematocrit (%) 46.7±1.0 (6) 45.3±1.1 (6)
[↓3]
45.0±0.9 (6)
[↓4]
42.0±3.0 (2)
[↓10]
Hemoglobin (%) 16.6±0.3 (6) 15.4±0.4 (6) 15.7±0.3 (6) 15.7±0.3 (6)
Methemoglobin (%) 0.0±0.0 (6) 0.0±0.0 (6)
[NA]
0.9±0.6 (6)
[NA]
2.8±0.3 (2)b
[NA]
Females
Erythrocyte count
(x10/mm)
6.49±0.24 (6)a 5.90±0.17 (6)
[↓9]
5.78±0.21 (6)
[↓11]
5.05±0.17 (6)b
[↓22]
Heinz bodies (%) 0.0±0.0(6) 0.0±0.0(6)
[NA]
0.0±0.0(6)
[NA]
0.84±0.21 (6)b
[NA]
Reticulocytes (%) 0.60±0.08 (6) 0.70±0.17 (6)
[↑17]
0.45±0.10 (6)
[↓25]
1.33±0.19 (6)b
[↑122]
Hematocrit (%) 46.0±1.3 (6) 42.8±1.7 (6)
[↓7]
42.5±1.2 (6)
[↓8]
37.2±1.6 (6)b
[↓19]
Hemoglobin (%) 16.1±0.5 (6) 14.7±0.6 (6)
[↓9]
14.8±0.5 (6)
[↓8]
13.3±0.5 (6)b
[↓17]
Methemoglobin (%) 0.4±0.4 (6) 0.0±0.0 (6)
[↓100]
1.3±0.6 (6)
[↑225]
2.8±0.7 (6)b
[↑600]
aValues are means±standard error (number of animals) [percent change from controls].

bStatistically significant based on analyses performed by the study authors (Dunnett’s multiple comparison
 
procedure).
 
DNT = dinitrotoluene; NA = not applicable
Sources:  Ellis et al. 1985; U.S. Army 1979
Dose and end point used for MRL derivation: 
[ ] NOAEL   [ ] LOAEL  [X] BMDL 0.67 mg/kg/day as a BMDL1SD for hematological effects (decreased
hematocrit)
Results of hematology assessments show that intermediate-duration, oral exposure of dogs to 2,4-DNT
induced methemoglobinemia, anemia, and compensatory hematopoiesis (Ellis et al. 1985; U.S. Army
1979).  Changes in several hematological parameters, including decreased erythrocyte count, hematocrit,
and hemoglobin and increased reticulocytes, methemoglobin, and Heinz bodies were observed after
treatment with 2,4-DNT for 3, 6, and 9 months.  However, hematological effects at 9 months were more
pronounced and consistent than those observed at 3 and 6 months; therefore, hematological effects 
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observed at 9 months were identified as the critical effect for derivation of the intermediate-duration oral
MRL.  To determine the POD, hematological data from female dogs treated with 2,4-DNT for 9 months
were further evaluated by BMD analysis. The following data sets in female dogs were selected for BMD
modeling:  erythrocyte count, reticulocytes, hematocrit, hemoglobin, and methemoglobin.  Data on Heinz
bodies in serum were not selected for BMD modeling, since these granules were detected in high-dose
animals only (i.e., all-or-nothing response); the absence of changes at lower dose levels suggests that
these data would not be suitable for modeling.  Hematological data from male dogs were not considered 
for additional BMD analyses due to the low number of dogs evaluated in the 10 mg/kg/day group (for
most hematological parameters, data were available for only two dogs).
To determine the POD for derivation of the intermediate-duration oral MRL, all available continuous-
variable models in the EPA BMDS (version 2.1) were fit to the data for increased methemoglobin, 
increased reticulocytes, decreased hemoglobin, decreased erythrocyte count, and decreased hematocrit
(Ellis et al. 1985; U.S. Army 1979). The BMD and the 95% lower confidence limit (BMDL) were 
estimated for doses associated with a change of 1 standard deviation from the controls, and are in units of
mg/kg/day.  For continuous data, in the absence of a clear criteria as to what level of change should be
considered adverse, the BMR is defined as a change equal to 1 standard deviation from the control mean 
(EPA 2000a).  Adequate model fit is judged by three criteria:  goodness-of-fit (p>0.1), visual inspection 
of the dose-response curve, and scaled residual at the data point (except the control) closest to the
predefined BMR.  Among all of the models providing adequate fit to the data, the lowest benchmark dose
(BMDL, the lower limit of a one-sided 95% CI on the BMD) is selected as the POD when differences 
between the BMDLs estimated from these models are >3-fold; otherwise, the BMDL from the model with 
the lowest AIC is chosen.
Neither the constant nor the non-constant variance model provided an adequate fit to the data for
decreased erythrocyte count or increased methemoglobin; therefore, these data were not considered
suitable for BMD modeling.  BMD model prediction for increased reticulocytes, decreased hemoglobin, 
and decreased hematocrit are shown in Tables A-3, A-4, and A-5, respectively.  Of models meeting
adequate fit criteria for each hematological parameter, the lowest BMDL1SD values were 5.64 mg/kg/day
for increased reticulocytes (polynomial 3-degree; Figure A-1), 3.66 mg/kg/day for decreased hemoglobin 
(exponential model 2; Figure A-2), and 0.67 mg/kg/day for decreased hematocrit (exponential model 4;
Figure A-3).  Of these, the lowest BMDL1SD of 0.67 mg 2,4-DNT/kg/day for decreased hematocrit was 
selected as the POD for derivation of the intermediate-duration oral MRL for 2,4-DNT. This value was 
divided by an uncertainty factor of 100 (10 for animals to human extrapolation and 10 for human 
variability), resulting in an intermediate-duration oral MRL of 0.007 mg/kg/day. 
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Table A-3.  Model Predictions for 2,4-DNT for Increased Reticulocytes (%) in Female 

Dogs Following 9 Months of Exposure (U.S. Army 1979)
 
Test for Scaled residualsc 
significant Dose Dose BMD1SD BMDL1SD 
Model
difference 
p-valuea 
Variance
p-valueb 
Means
p-valueb 
below
BMD
above 
BMD AIC
Overall
largest
(mg/kg/ 
day)
(mg/kg/ 
day)
Constant variance
Exponential (model 2)d 0.0007 0.12 0.23 -1.32 0.09 -1.32 -21.60 5.55 4.35
Exponential (model 3)d 0.0007 0.12 0.18 -0.98 5.59x10-8 -0.98 -20.75 9.40 4.58
Exponential (model 4)d 0.0007 0.12 0.06 -1.51 0.21 -1.50 -18.93 4.61 3.19
Exponential (model 5)d 0.0007 0.12 NA -0.98 8.61x10-8 -0.98 -18.75 9.17 1.59
Hilld 0.0007 0.12 NA -0.98 -9.04x10-7 -0.98 -18.75 9.10 1.60
Lineare 0.0007 0.12 0.17 -1.51 0.21 -1.51 -20.93 4.61 3.19
Polynomial (2-degree)e 0.0007 0.12 0.36 -1.06 0.02 -1.06 -22.50 6.69 5.60
Polynomial 
(3-degree)e,f 
0.0007 0.12 0.40 -0.99 0.003 -0.99 -22.72 7.64 5.64
Powerd 0.0007 0.12 0.18 -0.98 3.56x10-10 -0.98 -20.75 9.31 3.68
aValues >0.05 fail to meet conventional goodness-of-fit criteria.

bValues <0.10 fail to meet conventional goodness-of-fit criteria.
 
cScaled residuals at doses immediately below and above the BMD; also the largest residual at any dose.

dPower restricted to ≥1.
eCoefficients restricted to be positive.
fSelected model.  Constant variance model provided adequate fit to variance data. With constant variance model
applied, all models, except for the Exponential 4 and 5 and Hill models, provided adequate fit to means.  BMDLs for
models providing adequate fit were considered to be sufficiently close (differed by <2–3-fold), so the model with the 
lowest AIC was selected.
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated with 
the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote benchmark
response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
DNT = dinitrotoluene; NA = not applicable (BMDL computation failed); SD = standard deviation
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Figure A-1.  Fit of Polynomial 3-Degree Model to Data on 2,4-DNT for
 
Increased Reticulocytes (%) in Female Dogs Following 

9 Months of Exposure (U.S. Army 1979)
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Table A-4.  Model Predictions for 2,4-DNT for Decreased Hemoglobin (%) in 

Female Dogs Following 9 Months of Exposure (U.S. Army 1979)
 
Test for Scaled residualsc 
significant Dose Dose BMD1SD BMDL1SD 
Model
difference 
p-valuea 
Variance
p-valueb 
Means
p-valueb AIC
below
BMD
above 
BMD
Overall 
largest
(mg/kg/ 
day)
(mg/kg/ 
day)
Constant variance
Exponential
(model 2)d,e 
0.04 0.92 0.14 -0.40 0.10 1.46 41.47 5.90 3.66
Exponential (model 3)d 0.04 0.92 0.14 -0.40 0.10 1.46 41.47 5.90 3.66
Exponential (model 4)d 0.04 0.92 0.07 0.29 -0.03 -1.36 42.88 2.43 0.01
Exponential (model 5)d 0.04 0.92 0.07 0.29 -0.03 -1.36 42.88 2.43 0.01
Hilld NA NA NA NA NA NA NA NA NA
Linearf 0.04 0.92 0.14 -0.43 0.09 1.48 41.52 6.12 3.94
Polynomial (2-degree)f 0.04 0.92 0.14 -0.43 0.09 1.48 41.52 6.12 3.94
Polynomial (3-degree)f 0.04 0.92 0.14 -0.43 0.09 1.48 41.52 6.12 3.94
Powerd 0.04 0.92 0.14 -0.43 0.09 1.48 41.52 6.12 3.94
aValues >0.05 fail to meet conventional goodness-of-fit criteria.

bValues <0.10 fail to meet conventional goodness-of-fit criteria.
 
cScaled residuals at doses immediately below and above the BMD; also the largest residual at any dose.

dPower restricted to ≥1.
eSelected model.  Constant variance model provided adequate fit to variance data. With constant variance model
applied, all models, except for the Exponential 4 and 5 and Hill model (computation failed), provided adequate fit to 
means.  BMDLs for models providing adequate fit were considered to be sufficiently close (differed by <2–3-fold), so
the model with the lowest AIC was selected (the Exponential 3 model converged on to the Exponential 2).
fCoefficients restricted to be negative.
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
DNT = dinitrotoluene; NA = not applicable (BMDL computation failed); SD = standard deviation
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Figure A-2.  Fit of the Exponential 2 Model to Data on 2,4-DNT for
Decreased Hemoglobin (%) in Female Dogs Following 9 Months
of Exposure (U.S. Army 1979)
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Table A-5.  Model Predictions for 2,4-DNT for Decreased Hematocrit (%) in Female 

Dogs Following 9 Months of Exposure (U.S. Army 1979)
 
Test for Scaled residualsc 
significant Dose Dose BMD1SD BMDL1SD 
Model
difference 
p-valuea 
Variance
p-valueb 
Means
p-valueb AIC
below
BMD
above 
BMD
Overall
largest
(mg/kg/ 
day)
(mg/kg/ 
day)
Constant variance
Exponential (model 2)d 0.01 0.79 0.26 -0.42 0.09 1.24 89.65 4.60 3.04
Exponential (model 3)d 0.01 0.79 0.26 -0.42 0.09 1.24 89.65 4.60 3.04
Exponential
(model 4)d,e 0.01 0.79 0.14 0.21 -0.01 -1.10 91.12 2.19 0.67
Exponential (model 5)d 0.01 0.79 0.14 0.21 -0.01 -1.10 91.12 2.19 0.67
Hilld NA NA NA NA NA NA NA NA NA
Linearf 0.01 0.79 0.25 -0.45 0.09 1.26 89.71 4.86 3.32
Polynomial (2-degree)f 0.01 0.79 0.25 -0.45 0.09 1.26 89.71 4.86 3.32
Polynomial (3-degree)f 0.01 0.79 0.25 -0.45 0.09 1.26 89.71 4.86 3.32
Powerd 0.01 0.79 0.25 -0.45 0.09 1.26 89.71 4.86 3.32
aValues >0.05 fail to meet conventional goodness-of-fit criteria.

bValues <0.10 fail to meet conventional goodness-of-fit criteria.
 
cScaled residuals at doses immediately below and above the BMD; also the largest residual at any dose.

dPower restricted to ≥1.
eSelected model. Constant variance model provided adequate fit to variance data. With constant variance model
applied, all models, except for the Hill model (computation failed), provided adequate fit to means.  BMDLs for
models providing adequate fit were not considered to be sufficiently close (differed by >2–3-fold), so the model with 
the lowest BMDL was selected (the Exponential 5 model converged on to the Exponential 4).
fCoefficients restricted to be negative.
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated 
with the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote 
benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom; 
DNT = dinitrotoluene; NA = not applicable (BMDL computation failed); SD = standard deviation
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Figure A-3.  Fit of the Exponential 4 Model to Data on 2,4-DNT for
 
Decreased Hematocrit (%) in Female Dogs Following 9 Months
 
of Exposure (U.S. Army 1979)
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Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure?  No.
Other additional studies or pertinent information which lend support to this MRL:  The hematological
effects observed in this study are consistent with well-characterized effects observed after exposure to
aromatic amines and with effects observed at higher doses in other studies of intermediate duration (Hong
et al. 1985; Lee et al. 1985; Kozuka et al. 1979; U.S. Army 1978b).  Similar hematological effects 
(anemia, accompanied by the presence of Heinz bodies) were observed in beagle dogs treated at
25 mg/kg/day (but not 5 mg/kg/day) for up to 13 weeks (Ellis et al. 1985; U.S. Army 1978b).  Dogs
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appear to be the most sensitive species.  In Wistar rats, methemoglobin was increased substantially after
treatment with 2,4-DNT at 347 mg/kg/day for 6 months (Kozuka et al. 1979).  Milder hematological
effects (mild reticulocytosis and hemosiderosis of the spleen) were also observed in CD rats treated at
93 or 108 mg/kg/day (for males or females, respectively) for up to 13 weeks (Lee et al. 1985; U.S. Army
1978b).  Mice treated with 2,4-DNT for up to 13 weeks showed evidence of hematological effects (mild
anemia, characterized by increased reticulocytes and decreased hematocrit and hemoglobin) only at the 
highest tested dose (413 mg/kg/day for males or 468 mg/kg/day for females) (Ellis et al. 1985; U.S. Army
1978b).  Hematological effects were also observed in 2-year studies in beagle dogs, CD rats, and CD-1 
mice, with dogs being the most sensitive species.  Female dogs treated with 2,4-DNT at 1.5 mg/kg/day
showed decreased erythrocyte count, hematocrit, and hemoglobin after 12 months; similar effects were 
observed in dogs of both sexes at 10 mg/kg/day (U.S. Army 1979).  Anemia occurred at higher doses in
2-year studies in rats (≥3.9 mg/kg/day) and mice (898 mg/kg/day).
Agency Contact (Chemical Manager): Carolyn Harper
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MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: 2,4-DNT
CAS Numbers: 121-14-2
Date: February 2016
Profile Status: Final
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute   [ ] Intermediate  [X] Chronic
Graph Key: 57
Species: Dog
Minimal Risk Level:  0.001   [X] mg/kg/day   [ ] ppm
References: U.S. Army.  1979.  Mammalian toxicity of munitions compounds.  Phase III: Effects of
lifetime exposure.  Part I. 2,4-Dinitrotoluene.  Final report no. 7.  Fort Detrick, MD:  U.S. Army and 
Medical Bioengineering Research Development Laboratory.  ADA077692.  
Ellis HV, Hong CB, Lee CC, et al.  1985.  Subchronic and chronic toxicity studies of 2,4-dinitrotoluene.  
Part I.  Beagle dog.  J Am Coll Toxicol 4:233-242.
Experimental design:  Young beagle dogs (6 dogs/sex/group; age not specified) were administered 0, 0.2, 
1.5, or 10 mg/kg/day 2,4-DNT in capsules for 24 months.  Dogs were observed daily for behavioral
changes and clinical signs of toxicity.  Body weights were recorded weekly.  Feed consumption was 
measured during 1 week each month starting in month 6.  Blood was taken before initiation of treatment
and after 3, 6, 9, 12, 18, and 24 months of exposure for assessment of hematological parameters
(erythrocyte, reticulocyte, platelet, and total and differential leukocyte counts; Heinz bodies; clotting time, 
hematocrit, hemoglobin, and methemoglobin concentrations; and mean cell volume, hemoglobin, and 
hemoglobin concentration) and clinical chemistry (fasting glucose, urea nitrogen, sodium, potassium, 
calcium, magnesium, chloride, and bilirubin [high-dose dogs with toxic signs], and the serum enzyme
activities of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase) analyses.
Animals (one male and one female/group) were sacrificed after 12 or 24 months of continuous treatment;
an additional dog/sex/group was discontinued from treatment at these time points and were sacrificed 
after a 4-week recovery period to evaluate the reversibility of effects (including clinical signs, hematology
and clinical chemistry, organ weights, and histopathological analyses).  Animals that were moribund 
during the study and those that survived to study termination were sacrificed and examined for gross
lesions; major organs and tissues (including the brain, heart, liver, spleen, kidneys, adrenals, thyroids, 
pituitary, and gonads) were weighed, and comprehensive histopathological analyses (35 tissues) were 
performed.  
Effects noted in study and corresponding doses:  Chronic-duration oral exposure of dogs to 2,4-DNT at
≥1.5 mg/kg/day produced anemia and compensatory hematopoiesis (Ellis et al. 1985; U.S. Army 1979).  
Hematological effects of 2,4-DNT are initiated by methemoglobin production, which occurs when the
ferrous iron in complex with the heme groups of hemoglobin is oxidized to ferric iron.  Ferric iron does
not bind oxygen, resulting in anemia.  Ferric iron also contributes to the denaturation of hemoglobin and 
subsequent removal of erythrocytes from the blood.  Heinz bodies (granules of denatured hemoglobin) are
also detected within erythrocytes.  Increased hematopoiesis is typically observed as a compensatory
response to decreased erythrocyte count.
Hematological effects consistent with the development of methemoglobin-induced anemia and 
compensatory hematopoiesis were observed after dosing for 12 months in dogs administered 1.5 and 
10 mg/kg/day (Table A-6).  Female dogs administered 2,4-DNT at 1.5 mg/kg/day for 12 months showed 
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statistically significant reductions in erythrocyte count, hematocrit, and hemoglobin concentration after
treatment.  At 10 mg/kg/day, more pronounced changes in these hematological parameters were observed, 
with statistically significant reductions in erythrocyte count, hematocrit, and hemoglobin and a 
statistically significant increase in reticulocyte count. In the low-dose group, similar hematological
effects (decreased erythrocyte count and decreased hematocrit) were observed in female dogs, but these 
changes were not statistically significant. Effects on hematological parameters in male dogs were similar
to those seen in female dogs, although many changes (with the exception of reticulocytes) did not reach
statistical significance in the 10 mg/kg/day group, possibly due to low numbers of male dogs evaluated 
(hematological data available for only two males in the 10 mg/kg/day group).  After treatment for 18 or
24 months in both males and females, only slight or no anemia, near normal reticulocyte levels, no Heinz
bodies, and minimal amounts of methemoglobin were detected, likely reflective of an adaptive response.
Therefore, only data from the 12-month evaluation were considered for derivation of the chronic-duration 
oral MRL.  
No clinical signs of toxicity, behavioral changes, or effects on hematological or clinical chemistry
parameters were observed in dogs administered 2,4-DNT at 0.2 mg/kg/day.  Four high-dose dogs (three
males and one female) exhibited severe signs of neurotoxicity (characterized by decreased muscle control
and incoordination), sometimes accompanied by a reduction in body weight.  These effects contributed to
the death of three of six high-dose dogs (all males) prior to study termination (study weeks 8–20).  
Clinical signs of neurotoxicity were also noted intermittently in one male dog administered 2,4-DNT at
1.5 mg/kg/day.  Although biliary hyperplasia was noted at necropsy in male and female dogs
administered 2,4-DNT, the frequency of the response did not exhibit dose-dependence. 
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Table A-6.  Hematological Effects in Beagle Dogs Exposed to 2,4-DNT for
12 Months
Dose (mg/kg/day)
End point 0 0.2 1.5 10
Males
Erythrocyte count
(x10/mm)
5.96±0.22 (6)a 5.33±0.16 (6)
[↓11]
5.69±0.19 (6)
[↓5]
5.22±0.19 (2)
[↓12]
Heinz bodies (%) 0.0±0.0(6) 0.0±0.0(6)
[NA]
0.0±0.0(6)
[NA]
0.52±0.37 (2)b
[NA]
Reticulocytes (%) 0.40±0.09 (6) 0.78±0.13 (6)
[↑95]
0.66±0.11 (6)
[↑65]
1.23±0.23 (2)b
[↑208]
Hematocrit (%) 45.2±0.9 (6) 41.8±1.2 (6)
[↓8]
44.7±0.8 (6)
[↓1]
44.0±4.0 (2)
[↓3]
Hemoglobin (%) 15.1±0.4 (6) 14.1±0.3 (6)
[↓7]
14.8±0.4 (6)
[↓2]  
14.2±1.2 (2)
[↓6]
Methemoglobin (%) 0.0±0.0 (6) 0.0±0.0 (6)
[NA]
0.0±0.0 (6)
[NA]
0.0±0.0 (2)
[NA]
Females
Erythrocyte count
(x10/mm)
5.87±0.20 (6)a 5.54±0.14 (6)
[↓6]
4.69±0.25 (6)b
[↓20]
4.45±0.26 (6)b
[↓24]
Heinz bodies (%) 0.0±0.0(6) 0.0±0.0(6)
[NA]
0.0±0.0(6)
[NA]
0.5±0.2 (6)b
[NA]
Reticulocytes (%) 0.39±0.04 (6) 0.84±0.07 (6)b
[↑115]
0.45±0.06 (6)
[↑15]
1.59±0.18 (6)b
[↑308]
Hematocrit (%) 45.8±1.1 (6) 44.7±1.3 (6)
[↓2]
41.8±1.2 (6)b
[↓9]
40.8±0.6 (6)b
[↓11]
Hemoglobin (%) 15.1±0.4 (6) 15.1±0.4 (6)
[0]
13.7±0.8 (6)b
[↓9]
12.9±0.2 (6)b
[↓15]
Methemoglobin (%) 0.0±0.0 (6) 0.6±0.6 (6)
[NA]
0.0±0.0 (6)
[NA]
0.0±0.0 (6)
[NA]
aValues are means±standard error (number of animals) [percent change from controls].
 
bStatistically significant based on analyses performed by the study authors (Dunnett’s multiple comparison
 
procedure).
 
DNT = dinitrotoluene; NA = not applicable
Sources:  Ellis et al. 1985; U.S. Army 1979
Dose and end point used for MRL derivation: 
[ ] NOAEL   [ ] LOAEL  [X] BMDL 0.12 mg/kg was the BMDL1SD for hematological effects (decreased
erythrocyte count).
Results of hematology assessments show that chronic-duration, oral exposure of dogs to 2,4-DNT
induced anemia and compensatory hematopoiesis (Ellis et al. 1985; U.S. Army 1979). Changes in 
several hematological parameters, including decreased erythrocyte count, hematocrit, and hemoglobin
were observed after treatment with 2,4-DNT at 1.5 mg/kg/day for 12 months (Table A-6). Hematological 
effects were selected as the critical effect rather than neurotoxicity, which was observed only
intermittently in one of six dogs exposed to 1.5 mg/kg/day.  Hematological data are expressed as group 
means; therefore, these data are considered more robust than observations of intermittent neurotoxicity in 
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a single animal. To determine the POD for derivation of the chronic-duration oral MRL for 2,4-DNT,
hematological data from female dogs treated with 2,4-DNT for 12 months were further evaluated by
BMD analysis. The following data sets in female dogs were selected for BMD modeling:  erythrocyte 
count, hematocrit, and hemoglobin.  Hematological data from male dogs were not considered for
additional BMD analyses due to the low number of dogs evaluated in the 10 mg/kg/day group (data were
available for only two dogs).  All available continuous-variable models in the EPA BMDS (version 2.1)
were fit to the data. The BMD and the 95% lower confidence limit (BMDL) were estimated for doses 
associated with a change of 1 standard deviation from the controls, and are in units of mg/kg/day.  For
continuous data, in the absence of a clear criteria as to what level of change should be considered adverse, 
the BMR is defined as a change equal to 1 standard deviation from the control mean (EPA 2000a).
Adequate model fit is judged by three criteria:  goodness-of-fit (p>0.1), visual inspection of the dose-
response curve, and scaled residual at the data point (except the control) closest to the predefined BMR.
Among all of the models providing adequate fit to the data, the lowest benchmark dose (BMDL, the lower
limit of a one-sided 95% CI on the BMD) is selected as the POD when differences between the BMDLs 
estimated from these models are >3-fold; otherwise, the BMDL from the model with the lowest AIC is
chosen.  
Neither the constant nor the non-constant variance model provided an adequate fit to the data for
decreased hemoglobin; therefore, these data were not considered suitable for BMD modeling.  BMD
model prediction for hematocrit and erythrocyte count are shown in Tables A-7 and A-8, respectively.  Of
models meeting adequate fit criteria, the lowest BMDL1SD values for each hematological end point were 
0.13 mg/kg/day for decreased hematocrit (exponential 4 model; Figure A-4) and 0.12 mg/kg/day for
decreased erythrocyte count (exponential 4 model; Figure A-5).  Of these, the lowest BMDL1SD of 0.12 
mg/kg/day for decreased erythrocyte count was selected as the POD for derivation of the intermediate-
duration oral MRL for 2,4-DNT.  This value was divided by an uncertainty factor of 100 (10 for animals
to human extrapolation and 10 for human variability), resulting in a chronic-duration oral MRL of 0.001 
mg/kg/day. 
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Table A-7.  Model Predictions for 2,4-DNT for Decreased Hematocrit (%) in Female 

Dogs Following 12 Months of Exposure (U.S. Army 1979)
 
Test for Scaled residualsc 
significant Dose Dose BMD1SD BMDL1SD 
Model
difference 
p-valuea 
Variance
p-valueb 
Means
p-valueb 
below
BMD
above 
BMD
Overall
largest AIC
(mg/kg/ 
day)
(mg/kg/ 
day)
Constant variance
Exponential (model 2)d 0.01 0.34 0.06 -1.82 0.29 -1.82 78.08 6.77 4.09
Exponential (model 3)d 0.01 0.34 0.06 -1.82 0.29 -1.82 78.08 6.77 4.09
Exponential
(model 4)d,e 
0.01 0.34 0.92 -0.07 0.04 -0.07 74.50 0.61 0.13
Exponential (model 5)d 0.01 0.34 0.92 -0.07 0.04 -0.07 74.50 0.61 0.13
Hilld NA NA NA NA NA NA NA NA NA
Linearf 0.01 0.34 0.06 -1.83 0.27 -1.83 78.15 6.96 4.31
Polynomial (2-degree)f 0.01 0.34 0.06 -1.83 0.27 -1.83 78.15 6.96 4.31
Polynomial (3-degree)f 0.01 0.34 0.06 -1.83 0.27 -1.83 78.15 6.96 4.31
Powerd 0.01 0.34 0.06 -1.83 0.27 -1.83 78.15 6.96 4.31
aValues >0.05 fail to meet conventional goodness-of-fit criteria.

bValues <0.10 fail to meet conventional goodness-of-fit criteria.
 
cScaled residuals at doses immediately below and above the BMD; also the largest residual at any dose.
 
dPower restricted to ≥1.
eSelected model.  Constant variance model provided adequate fit to variance data. With constant variance model
 
applied, the only models that provided adequate fit to the means were the Exponential 4 and 5 models (the Exponential
 
5 converged on to the Exponential 4).
 
fCoefficients restricted to be negative.
 
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated with 

the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote benchmark
 
response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
 
DNT = dinitrotoluene; NA = not applicable (BMDL computation failed); SD = standard deviation
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Figure A-4.  Fit of Exponential 4 Model to Data on 2,4-DNT for Decreased
 
Hematocrit (%) in Female Dogs Following 12 Months of Exposure
 
(U.S. Army 1979)
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Table A-8.  Model Predictions for Decreased Erythrocyte Count in Dogs Treated with
2,4-DNT for 12 Months
Test for Scaled residualsc 
significant Dose Dose BMD1SD BMDL1SD 
difference Variance Means below above Overall (mg/kg/ (mg/kg/ 
Model p-valuea p-valueb p-valueb BMD BMD largest AIC day) day)
Constant variance
Exponential (model 2)d 0.0005 0.46 0.005 -2.40 0.43 -2.40 6.16 5.11 3.21
Exponential (model 3)d 0.0005 0.46 0.005 -2.40 0.43 -2.40 6.16 5.11 3.21
Exponential 0.0005 0.46 0.91 -0.08 0.05 -0.08 -2.55 0.35 0.12
(model 4)d,e 
Exponential (model 5)d 0.0005 0.46 0.91 -0.08 0.05 -0.08 -2.55 0.35 0.12
Hilld NA NA NA NA NA NA NA NA NA
Linearf 0.0005 0.46 0.004 -2.41 0.35 -2.41 6.47 5.58 3.69
Polynomial (2-degree)f 0.0005 0.46 0.004 -2.41 0.35 -2.41 6.47 5.58 3.69
Polynomial (3-degree)f 0.0005 0.46 0.004 -2.41 0.35 -2.41 6.47 5.58 3.69
Powerd 0.0005 0.46 0.004 -2.41 0.35 -2.41 6.47 5.58 3.69
aValues >0.05 fail to meet conventional goodness-of-fit criteria.

bValues <0.10 fail to meet conventional goodness-of-fit criteria.
 
cScaled residuals at doses immediately below and above the BMD; also the largest residual at any dose.
 
dPower restricted to ≥1.
eSelected model.  Constant variance model provided adequate fit to variance data. With constant variance model
 
applied, the only models that provided adequate fit to the means were the Exponential 4 and 5 models (the Exponential
 
5 converged on to the Exponential 4).
 
fCoefficients restricted to be negative.
 
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated with 

the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote benchmark
 
response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
 
DNT = dinitrotoluene; NA = not applicable (BMDL computation failed); SD = standard deviation
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Figure A-5.  Fit of Exponential Model 4 to Data on Decreased Erythrocyte Count in 

Female Dogs Treated with 2,4-DNT for 12 Months
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Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure?  No.
Other additional studies or pertinent information which lend support to this MRL:  The hematological
effects observed in this study are consistent with effects observed at higher doses in studies of
intermediate duration (Hong et al. 1985; Lee et al. 1985; Kozuka et al. 1979; U.S. Army 1978b).  Dogs
were the most sensitive species in studies of chronic duration.  In a 2-year study, male CD rats 
administered 2,4-DNT at 3.9 mg/kg/day showed decreased erythrocyte count after treatment for
12 months.  Additional evidence for anemia, including further reductions in red blood cell count, 
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decreased hematocrit, decreased hemoglobin, and a compensatory increase in reticulocytes, was observed
in male and female rats administered high-dose 2,4-DNT (34 and 45 mg/kg/day for males and females, 
respectively) for 12 or 18 months (Lee et al. 1985; U.S. Army 1979).  CD-1 mice administered 2,4-DNT
for 2 years showed no evidence of methemoglobin-induced anemia or compensatory reticulocytosis, 
except for decreased erythrocyte count and hemoglobin, and increased numbers of reticulocytes at the 
highest tested dose (898 mg/kg/day) (Lee et al. 1985; U.S. Army 1979). 
Agency Contact (Chemical Manager): Carolyn Harper
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MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: 2,5-DNT
CAS Numbers: 619-15-8
Date: February 2016
Profile Status: Final
Route: [ ] Inhalation   [X] Oral
Duration: [X] Acute [ ] Intermediate   [ ] Chronic
Graph Key: 4
Species: Rat
Minimal Risk Level: 0.007 [X] mg/kg/day   [ ] ppm
References: Lent EM, Crouse CB, Quinn MJ, et al.  2012a.  Comparison of the repeated dose toxicity of
isomers of dinitrotoluene. Int J Toxicol 31(2):143-157.
U.S. Army Public Health Command (USAPHC).  2011c.  Toxicology Study No. 87-XE-08G0E-10, 
October 2011, Toxicology Portfolio.  Fourteen-day oral toxicity and in vivo genotoxicity of 2,5­
dinitrotoluene in rats, January 2009-March 2010.  USAPHC, Aberdeen Proving Ground, Maryland.
Experimental design:  In a comparative toxicity study, groups of six male Sprague-Dawley rats were 
given 2,5-DNT via gavage doses of 0, 10, 19, 39, 77, 154, or 308 mg/kg/day for 14 days. Both untreated 
and vehicle control groups were included.  Evaluations during the study included twice daily observations
for morbidity and clinical signs and measurement of body weight and food consumption on days 0, 1, 3, 
7, and 14.  Prior to sacrifice at the end of exposure, blood was collected for evaluation of hematology
(total and differential white blood cell counts; red blood cell count; hemoglobin, hematocrit, MCV, MCH, 
MCHC, red cell distribution width; platelet count; and mean platelet volume) and serum chemistry
(albumin, ALP, ALT, AST, BUN, calcium, cholesterol, creatinine, glucose, globulin, LDH, total
bilirubin, total protein, sodium, potassium, and chlorine) assessments.  All animals received gross
necropsy and organ weight determinations (brain, heart, kidney, epididymides, liver, spleen, and testes).  
Microscopic examination of organs with exposure-related changes in weight was performed for controls 
and any dose groups exhibiting changes in the corresponding organ weights.
Effects noted in study and corresponding doses: One rat exposed to 308 mg/kg/day died prematurely; the 
timing of death was not reported.  Clinical signs of toxicity consisting of cyanosis, squinting, prostrate
posture, rapid or labored breathing, hunched posture, dark urine, red discharge around the nose, and
discolored or soft feces were observed at ≥154 mg/kg/day.  There were no differences from control in 
body weight or food consumption of exposed groups.  Dose-related hematology changes were noted,
including decreased red blood cells at ≥77 mg/kg/day; increased MCV and MCH at ≥154 mg/kg/day; and 
increased red blood cell distribution width (at 77 and 154 mg/kg/day, but not at 308 mg/kg/day).  Total 
white blood cell count was increased at 308 mg/kg/day, resulting from a nonsignificant increase in
lymphocytes; in addition, the percent of eosinophils was decreased at this dose. There were no clinically
significant, dose-related changes in serum chemistry parameters.  At gross necropsy, dark and enlarged
spleens were observed in 6/6 rats in the 154 mg/kg/day group and in 4/5 surviving rats exposed to 
308 mg/kg/day.  In addition, dark spleens were noted in 3/6 and 1/6 rats of the 77 and 39 mg/kg/day dose
groups.  Absolute and relative organ weight increases occurred in the heart at the highest dose (~70%
higher than controls).  Marked, statistically significant increases (≥90%) in absolute and relative spleen 
weight were observed at doses ≥77 mg/kg/day.  In addition, nonsignificant, but dose-related, increases of 
20% or more were seen at ≥19 mg/kg/day. No other organ weight changes were observed.  Histo­
pathology findings in the spleen consisted of mild-to-moderate extramedullary hematopoiesis in 3/6 rats 
exposed to 39 mg/kg/day and all rats exposed to higher doses; one vehicle control exhibited trace 
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extramedullary hematopoiesis. Table A-9 shows the splenic effects. The authors also reported mild-to­
moderate fibrosis (4/5 rats given 308 mg/kg/day) and trace-to-moderate inflammation (2/5 rats given 308 
mg/kg/day) in the heart.  Results of this study identify an acute-duration LOAEL of 39 mg/kg/day for
hematopoietic system effects in rats. A NOAEL cannot be defined in the absence of spleen
histopathology at lower doses, particularly in light of the spleen weight increases at lower doses.
Table A-9. Splenic Effects in Rats Exposed to 2,5-DNT for 14 Days
Dose (mg/kg/day)
End point 0 10 19 39 77 154 308
Mild-to-moderate 
extramedullary
hematopoiesis
(number exposed/ 
number examined)
Absolute spleen 
weight (g)
Spleen weight relative 
to body weight
Spleen weight relative 
to brain weight
0/6
0.6533±
0.07016 (6)a 
0.1851±
0.01497 (6)
39.4777±
13.39556 
(6)
ND
0.7185±
0.0.1107 (6)
[↑10]
0.2159±
0.03228 (6)
[↑17]
45.1837±
14.36118 
(6) [↑14]
ND
0.7733±
0.010433 
(6) [↑18]
0.2223±
0.03484 (6)
[↑20]
39.8441±
5.59536 (6)
[↑1]
3/6
0.9203±
0.12979 (6)
[↑41]
0.259±
0.04213 (6)
[↑40]
46.0439±
6.72756 (6)
[↑17]
5/5
1.2428±
016262b (6) 
[↑90]
0.3591±
0.03192b (6)
[↑94]
62.8775±
8.01491b (6)
[↑59]
6/6
0.1.8722±
0.22994b (6)
[↑187]
0.546±
0.0586b (6)
[↑195]
95.9326±
14.5203b (6)
[↑143]
5/5
2.2824±
0.46711b (5)
[↑249]
0.6721±
0.10433b (5) 
[↑263]
122.6007±
27.29763b 
(5) [↑211]
aValues are means±standard deviation (number of animals) [percent change from controls].

bStatistically significant based on analyses performed by the study authors (Tukey’s or Dunnett’s multiple comparison test).
 
DNT = dinitrotoluene; ND = no data; histopathology examination was not performed for these animals
Sources:  Lent et al. 2012a; USAPHC 2011c 
Dose and end point used for MRL derivation: 
[] NOAEL   [ ] LOAEL [X] BMDL 2.05 mg/kg/day was the BMDL10 for hematopoietic effects (mild-to­
moderate extramedullary hematopoiesis).
Hematopoietic system toxicity was identified as the most sensitive effect of acute-duration oral exposure
to 2,5-DNT, based on the LOAEL value of 39 mg/kg/day in rats administered 2,5-DNT via gavage for
14 days (Lent et al. 2012a; USAPHC 2011c).  To determine the POD, the incidence of extramedullary
hematopoiesis and the absolute and relative spleen weights (relative to body weight and relative to brain
weight) were subjected to BMD modeling. For quantal data (incidence of extramedullary hematopoiesis), 
the BMD and the 95% lower confidence limit (BMDL) were estimated for doses associated with a 10%
increase in incidence over the control incidence, and are in units of mg/kg/day.  For continuous data
(spleen weights), the BMD and the 95% lower confidence limit (BMDL) were estimated for doses 
associated with a 1 standard deviation increase over the control value, and are also in units of mg/kg/day.  
Adequate model fit is judged by three criteria:  goodness-of-fit (p>0.1), visual inspection of the dose-
response curve, and scaled residual at the data point (except the control) closest to the predefined BMR.
Among all of the models providing adequate fit to the data, the model with the lowest benchmark dose 
(BMDL, the lower limit of a one-sided 95% CI on the BMD) is selected when differences between the 
BMDLs estimated from these models are >3-fold; otherwise, the model with the lowest AIC is chosen.
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No model fit was achieved with the data on spleen weight relative to brain weight, so this end point was
not considered further.  BMD model predictions for incidence of extramedullary hematopoiesis and 
increases in absolute and relative spleen weights are shown in Tables A-10, A-11 and A-12, respectively.
The BMDLs from the best-fitting models for each parameter were 2.05 mg/kg/day (BMDL10) for
increased incidence of extramedullary hematopoiesis (multistage one-degree; Figure A-6); 7.71
mg/kg/day (BMDL1SD) for increased absolute spleen weight (Exponential Model 5; Figure A-7) and 8.26
mg/kg/day (BMDL1SD) for increased relative spleen weight (Exponential model 5; Figure A-8).  The
lowest BMDL of 2.05 mg/kg/day was selected as the POD.  The POD of 2.05 mg/kg/day was divided by
an uncertainty factor of 300 (10 for extrapolation from animals to humans, 10 for human variability, and 3 
for database limitations), resulting in an acute-duration oral MRL for 2,5-DNT of 0.007 mg/kg/day.
Table A-10. Incidence of Mild-to-Moderate Extramedullary Hematopoiesis
 
in the Spleen of Male Sprague-Dawley Rats Administered 2,5-DNT via
 
Gavage for 14 Days
 
χ2 Scaled residualsb 
Goodness- Dose Dose 
of-fit below above Overall BMD10 BMDL10 
Model DF χ2 p-valuea BMD BMD AIClargest (mg/kg) (mg/kg)
Gammac 4 0.00 1.00 0.00 -0.01 0.06 10.32 28.28 2.77
Logistic 3 0.00 1.00 0.00 0.00 0.00 12.32 34.60 9.23
LogLogisticd 4 0.00 1.00 0.00 0.00 0.00 10.32 34.52 7.43
LogProbitd 3 0.00 1.00 0.00 0.00 0.00 12.32 33.45 6.14
Multistage (1-degree)e,f 4 1.50 0.83 0.00 -0.90 -0.90 12.40 3.69 2.05
Multistage (2-degree)e 4 0.32 0.99 0.00 -0.35 0.44 10.82 13.76 2.52
Multistage (3-degree)e 4 0.02 1.00 0.00 -0.06 0.14 10.36 20.56 2.74
Multistage (4-degree)e 3 0.01 1.00 0.00 -0.02 0.08 12.33 21.54 2.71
Probit 3 0.00 1.00 0.00 0.00 0.00 12.32 30.40 8.31
Weibullc 3 0.00 1.00 0.00 0.00 0.00 12.32 25.68 2.77
aValues <0.1 fail to meet conventional goodness-of-fit criteria.
 
bScaled residuals at doses immediately below and above the benchmark dose; also the largest residual at any dose.
 
cPower restricted to ≥1.
dSlope restricted to ≥1.
eBetas restricted to ≥0.
fSelected model. All models provided adequate fit to the data.  BMDLs for models providing adequate fit were not
sufficiently close (differed by >3-fold), so the model with the lowest BMDL was selected (Multistage 1-degree).
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the dose associated with the selected
benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote benchmark response: i.e.,
10 = dose associated with 10% extra risk); DF= degrees of freedom; DNT = dinitrotoluene
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Figure A-6.  Fit of Multistage (1-Degree) Model to Data on 2,5-DNT, Incidence of
 
Mild-to-Moderate Extramedullary Hematopoiesis in the Spleen of Rats 

Exposed for 14 Days (Lent et al. 2012a; USAPHC 2011c)
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Table A-11. Model Predictions for Increased Absolute Spleen Weight in Male
 
Sprague-Dawley Rats Administered 2,5-DNT via Gavage for 14 Days
 
Test for Scaled residualsc 
Model
significant
difference
p-valuea 
Variance
p-valueb 
Means
p-valueb 
Dose 
below
BMD AIC
Dose 
above 
BMD
Overall 
largest
BMD1SD 
(mg/kg)
BMDL1SD 
(mg/kg)
All doses
Constant variance
Lineard <0.0001 <0.0001 0.005 -0.24 0.88 2.92 -72.15 41.35 34.02
Non-constant variance
Exponential
(model 2)e 
<0.0001 0.87 <0.0001 -0.53 -0.14 -2.47 -87.77 18.74 13.56
Exponential
(model 3)e 
<0.0001 0.87 <0.0001 -0.53 -0.14 -2.47 -87.77 18.74 13.56
Exponential
(model 4)e 
<0.0001 0.87 0.51 0.62 -0.07 1.39 -108.51 8.50 6.15
Exponential
(model 5)e,f 
<0.0001 0.87 0.88 0.32 0.13 0.52 -109.15 15.01 7.78
Hille <0.0001 0.87 0.78 0.36 0.16 0.72 -108.73 15.46 NA
Lineard <0.0001 0.87 0.21 -0.15 -0.32 -1.90 -106.70 10.58 NA
Polynomial
(2-degree)d 
<0.0001 0.87 0.21 -0.15 -0.32 -1.90 -106.70 10.58 7.81
Polynomial
(3-degree)d 
<0.0001 0.87 0.21 -0.15 -0.32 -1.90 -106.70 10.58 7.81
Polynomial
(4-degree)d 
<0.0001 0.87 0.21 -0.15 -0.32 -1.90 -106.70 10.58 7.81
Polynomial
(5-degree)d 
<0.0001 0.87 0.21 -0.15 -0.32 -1.90 -106.70 10.58 7.81
Polynomial
(6-degree)d 
<0.0001 0.87 0.21 -0.15 -0.32 -1.90 -106.70 10.58 7.81
Powere <0.0001 0.87 0.21 -0.15 -0.32 -1.90 -106.70 10.58 7.81
aValues >0.05 fail to meet conventional goodness-of-fit criteria.

bValues <0.10 fail to meet conventional goodness-of-fit criteria.
 
cScaled residuals at doses immediately below and above the benchmark dose; also the largest residual at any dose.

dCoefficients restricted to be positive.
 
ePower restricted to ≥1
	
fSelected model.  Constant variance model did not fit the variance data, but non-constant variance model did. With
 
non-constant variance model applied, all models, except for the Exponential 2 and 3, the Hill and the Linear models,
 
provided adequate to the data (BMDL computation failed for the Hill and the Linear). BMDLs for models providing 

adequate fit were sufficiently close (differed by <2–3-fold), so the model with the lowest AIC was selected
 
(exponential model 5).
 
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated 

with the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote 

benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
 
DNT = dinitrotoluene; NA = not applicable (BMDL computation failed or the BMD was higher than the highest dose 

tested); SD = standard deviation
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Figure A-7.  Fit of Exponential Model 5 to Data on 2,5-DNT for Increased Absolute
 
Spleen Weight in Rats Exposed for 14 Days (Lent et al. 2012a; USAPHC 2011c)
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Table A-12. Model Predictions for Model Predictions for Increased Relative 

Spleen Weight in Male Sprague-Dawley Rats Administered 2,5-DNT via
 
Gavage for 14 Days
 
Test for Scaled residualsc 
significant Dose  Dose 
difference Variance Means below above Overall BMD1SD BMDL1SD 
Model p-valuea p-valueb p-valueb BMD BMD AIClargest (mg/kg) (mg/kg)
All doses
Constant variance
Lineard <0.0001 0.0007 0.0005 -0.68 -0.55 3.28 -183.44 35.89 29.69
Non-constant variance
Exponential (model <0.0001 0.37 <0.0001 -0.25 0.38 -2.52 -190.27 19.37 14.06
2)e 
Exponential (model <0.0001 0.37 <0.0001 -0.25 0.38 -2.52 -190.27 19.37 14.06
3)e 
Exponential (model <0.0001 0.37 0.22 0.34 0.78 1.60 -213.48 8.74 6.32
4)e 
Exponential (model
5)e,f 
<0.0001 0.37 0.39 1.07 0.14 1.07 -214.23 17.64 8.26
Hille <0.0001 0.37 0.29 1.11 0.18 -0.83 -213.46 18.31 NA
Lineard <0.0001 0.37 0.06 0.66 -0.42 -1.98 -210.46 11.04 NA
Polynomial
(2-degree)d 
<0.0001 0.37 0.06 0.66 -0.42 -1.98 -210.46 11.04 8.13
Polynomial
(3-degree)d 
<0.0001 0.37 0.06 0.66 -0.42 -1.98 -210.46 11.04 8.13
Polynomial
(4-degree)d 
<0.0001 0.37 0.06 0.66 -0.42 -1.98 -210.46 11.04 8.13
Polynomial
(5-degree)d 
<0.0001 0.37 0.06 0.66 -0.42 -1.98 -210.46 11.04 8.13
Polynomial
(6-degree)d 
<0.0001 0.37 0.06 0.66 -0.42 -1.98 -210.46 11.04 8.13
Powere <0.0001 0.37 0.06 0.66 -0.42 -1.98 -210.46 11.04 8.13
aValues >0.05 fail to meet conventional goodness-of-fit criteria.

bValues <0.10 fail to meet conventional goodness-of-fit criteria.
 
cScaled residuals at doses immediately below and above the benchmark dose; also the largest residual at any dose.

dCoefficients restricted to be positive.
 
ePower restricted to ≥1
	
fSelected model.  Constant variance model did not fit the variance data, but non-constant variance model did. With
 
non-constant variance model applied, the Exponential 4 and 5 models provided adequate to the data (BMDL 

computation failed for the Hill and the Linear models). BMDLs for models providing adequate fit were sufficiently
 
close (differed by <3-fold), so the model with the lowest AIC was selected (Exponential model 5).
 
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated 

with the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote 

benchmark response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
 
DNT = dinitrotoluene; NA = not applicable (BMDL computation failed or the BMD was higher than the highest dose 

tested); SD = standard deviation
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Figure A-8.  Fit of Exponential Model 5 to Data on 2,5-DNT for Increased Relative 

Spleen Weight in Rats Exposed for 14 Days (Lent et al. 2012a; USAPHC 2011c)

Exponential Model 5, with BMR of 1 Std. Dev. for the BMD and 0.95 Lower Confidence Level for BMD 
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Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
[X]  3 for database limitations (the only other data available are from an acute lethality study)
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure?  No.
Other additional studies or pertinent information which lend support to this MRL: LD50 values of
710 and 1,230 mg/kg/day, respectively, were reported in male Sprague-Dawley rats and male CF-1 mice
exposed to 2,5-DNT (Vernot et al. 1977); no additional information was provided. No other acute-
duration oral studies of 2,5-DNT were located, nor were there any studies of longer durations.  
   
 
  
 
 
  
 
 
 
 
 
A-37DINITROTOLUENES
APPENDIX A  
Agency Contact (Chemical Manager): Carolyn Harper
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MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: 2,6-DNT
CAS Numbers: 606-20-2
Date: February 2016
Profile Status: Final
Route: [ ] Inhalation   [X] Oral
Duration: [X] Acute [ ] Intermediate   [ ] Chronic
Graph Key: 8
Species: Dog
Minimal Risk Level:  0.09   [X] mg/kg/day  [ ] ppm
References: U.S. Army.  1976.  Mammalian toxicity of munitions compounds.  Phase II:  Effects of
multiple doses.  Part III:  2,6-Dinitrotoluene.  Progress report no. 4.  Fort Detrick, MD:  U.S. Army, 
Medical Bioengineering Research and Development Laboratory.  ADA062015.
Experimental design:  Young beagle dogs (4 dogs/sex/group; age not specified) were administered 0, 4, 
20, or 100 mg/kg 2,6-DNT in capsules for 13 weeks (U.S. Army 1976).  Dogs were observed daily for
behavioral changes and clinical signs of toxicity.  Body weights were recorded weekly.  Feed
consumption was measured daily.  Blood was taken before initiation of treatment and at 2, 4, 8, and 
13 and/or 17 weeks (4-week post-treatment recovery period) for hematological (erythrocyte, reticulocyte,
platelet, and total and differential leukocyte counts; Heinz bodies; hematocrit, hemoglobin, and 
methemoglobin concentrations; and mean cell volume, hemoglobin, and hemoglobin concentration) and 
clinical chemistry (glucose, urea nitrogen, levels of sodium, potassium, calcium, magnesium, and 
chloride; and serum enzyme activities of aspartate aminotransferase, alanine aminotransferase, and
alkaline phosphatase) analyses.  No additional assessments were conducted for acute-duration exposure.  
Assessments conducted for intermediate-duration exposure (4–13 weeks and 4-week post-treatment
recovery period) included hematology and clinical chemistry; gross pathological examination, organ 
weights (heart, liver, spleen, kidneys, adrenals, and gonads), and microscopic examination of tissues
(“various” tissues, not specified) were assessed in animals dying before the end of treatment, and at the 
end of the 13-week treatment period and the 4-week post-treatment recovery period.  Bone marrow and 
kidney cultures were also maintained and cytogenetic analyses (of chromosome number and morphology)
were performed.
Effects noted in study and corresponding doses: Acute-duration oral exposure of dogs to 2,6-DNT at
≥20 mg/kg/day show the development of anemia and compensatory hematopoiesis (U.S. Army 1976) 
(data summarized in Table A-13).  Hematological effects of 2,6-DNT are initiated by methemoglobin
production, which occurs when the ferrous iron in complex with the heme groups of hemoglobin is
oxidized to ferric iron.  Ferric iron does not bind oxygen, resulting in anemia.  Ferric iron also contributes
to the denaturation of hemoglobin and subsequent removal of erythrocytes from the blood.  Heinz bodies
(granules of denatured hemoglobin) are also detected within erythrocytes.  Increased hematopoiesis is 
typically observed as a compensatory response to decreased erythrocyte count. Since immature 
erythrocytes are typically larger, mean cell volume and mean cell hemoglobin tend to be increased.  Dogs
treated at 20 mg/kg/day showed a statistically significant decrease in erythrocyte count and a significant 
increase in mean cell hemoglobin.  At 100 mg/kg/day, more pronounced changes in these hematological
parameters were observed; dogs showed statistically significant reductions in erythrocyte count,
hematocrit, and hemoglobin and a statistically significant increase in reticulocyte count.  In the low-dose
group, similar hematological effects (decreased erythrocyte count, hemoglobin, and hematocrit, and 
increased reticulocytes) were observed, but these changes did not achieve statistical significance. Mid-
and high-dose dogs (but not low-dose dogs) continued to show signs of anemia and compensatory
   
 
  
 
 
 
  
   
   
 
   
  
 
 
 
    
    
 
 
 
 
 
    
 
 
 
 
   
 
 
 
 
 
   
 
 
 
 
 
   
 
 
 
 
 
   
 
 
 
 
 
    
 
 
 
 
 
 
   
  
 
 
    
 
   
 
  
  
 
 
   
    
 
      
     
   
   
 
 
 
 
 
 
   
 
 
 
 
 
 
A-39DINITROTOLUENES
APPENDIX A  
hematopoiesis (decreased hematocrit and hemoglobin, and increased numbers of reticulocytes) for the 
duration of the 13-week study.  Dogs treated at 20 mg/kg/day for 4 or 13 weeks and then removed from
treatment showed recovery from hematological effects after 4 weeks; dogs treated at 100 mg/kg/day for
4 weeks did not show complete recovery until 19 weeks after cessation of treatment.
Table A-13.  Hematological effects in Beagle Dogs Exposed to 2,6-DNT for
2 Weeks
Dose (mg/kg/day)
End point 0 4 20 100
Erythrocyte count (x10/mm) 5.62±0.16 (8)a 5.06±0.10 (8)
[↓10]
4.73±0.20 (8)b
[↓16]
1.85±0.28 (7)b
[↓67]
Heinz bodies (%) 0.00±0.00 (8) 0.00±0.00 (8)
[NA]
0.00±0.00 (8)
[NA]
0.00±0.00 (7) [NA]
Reticulocytes (%) 0.76±0.07 (8) 1.10±0.13 (8)
[↑45]
1.43±0.32 (8)
[↑88]
16.99±3.33 (7)b
[↑2,136]
Hematocrit (%) 42.1±1.7 (8) 38.9±0.6 (8)
[↓8]
39.3±1.2 (8)
[↓7]
22.9±2.8 (7)b
[↓46]
Hemoglobin (%) 14.8±0.5 (8) 13.3±0.2 (8)
[↓10]
13.0±0.4 (8)
[↓12]
6.3±0.9 (7)b
[↓57]
Methemoglobin (%) 0.0±0.0 (8) 0.0±0.0 (8)
[NA]
0.0±0.0 (8)
[NA]
0.0±0.0 (7)
[NA]
Mean cell hemoglobin (micro µg) 26.3±0.2 (8) 26.3±0.3 (8)
[0]
27.7±0.3 (8)b
[↑5]
34.4±1.2 (7)b
[↑31]
aValues are means±standard error (number of animals) [percent change from controls].

bStatistically significant based on analyses performed by the study authors (Dunnett’s multiple comparison
 
procedure).
 
DNT = dinitrotoluene; NA = not applicable
Source: U.S. Army 1976
Although incidence data were not reported, the study authors noted that at least three dogs (sex not
specified) administered 2,6-DNT at 100 mg/kg/day showed clinical signs of toxicity (listlessness,
incoordination, lack of balance, pale gums, dark urine, and weakness, particularly of the hind limbs)
within the first 2 weeks of the study,.  One dogs (a male) died during week 2.  Similar (but milder) 
symptoms were reported in mid-dose dogs starting in week 4.  No clinical signs of toxicity were observed
in dogs administered the low dose of 2,6-DNT.
Histopathological assessments of tissues were not conduced in animals exposed for only 2 weeks.
However, after 13-week of treatment, mild splenic hematopoiesis was noted in low-dose animals.
Numerous lesions were detected in mid- and high-dose dogs; the number and severity of these lesions was
increased at the high-dose.  Affected organs included the liver (bile duct hyperplasia, degeneration, 
inflammation, and/or extramedullary hematopoiesis), kidney (degeneration and inflammation, dilated 
tubules), spleen (extramedullary hematopoiesis and lymphoid depletion), and testes (degeneration and
atrophy of spermatogenic cells.
Dose and end point used for MRL derivation: 
[ ] NOAEL   [ ] LOAEL  [X] BMDL 9.31 mg/kg was the BMDL1SD for hematological effects (decreased
erythrocyte count).
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Results of hematology assessments show that acute-duration, oral exposure of dogs to 2,6-DNT induced 
anemia and compensatory hematopoiesis (U.S. Army 1976). Statistically significant changes in
hematological parameters, including decreased erythrocyte count and increased mean cell hemoglobin,
were observed after treatment with 2,6-DNT at 20 mg/kg/day for 2 weeks (Table A-13). Changes to other
hematological parameters only reached statistical significance at 100 mg/kg/day.  Therefore, the most
sensitive hematological parameters were erythrocyte count and mean cell hemoglobin. To determine the
POD for derivation of the acute-duration oral MRL for 2,6-DNT, erythrocyte count and mean cell
hemoglobin further evaluated by BMD analysis.  All available continuous-variable models in the EPA
BMDS (version 2.1) were fit to the data. The BMD and the 95% lower confidence limit (BMDL) were 
estimated for doses associated with a change of 1 standard deviation from the controls, and are in units of
mg/kg/day.  For continuous data, in the absence of a clear criteria as to what level of change should be
considered adverse, the BMR is defined as a change equal to 1 standard deviation from the control mean 
(EPA 2000a).  Adequate model fit is judged by three criteria:  goodness-of-fit (p>0.1), visual inspection 
of the dose-response curve, and scaled residual at the data point (except the control) closest to the
predefined BMR.  Among all of the models providing adequate fit to the data, the lowest benchmark dose
(BMDL, the lower limit of a one-sided 95% CI on the BMD) is selected as the POD when differences 
between the BMDLs estimated from these models are >3-fold; otherwise, the BMDL from the model with 
the lowest AIC is chosen.
Neither the constant nor the non-constant variance model provided an adequate fit to the data for mean 
cell hemoglobin; therefore, these data were not considered suitable for BMD modeling.  With non-
constant variance model applied, the linear, polynomial, and power models provided an adequate fit to the
data for erythrocyte count (Table A-14).  The polynomial and power models converged to the linear
model. The figure shown from the linear model (Figure A-9) is representative of figures from the 
polynomial and power models (not shown).  The BMDL1SD value of 9.31 mg/kg/day derived from this
model was selected as the POD.  This value was divided by an uncertainty factor of 100 (10 for animals
to human extrapolation and 10 for human variability), resulting in an acute-duration oral MRL of 0.09 
mg/kg/day.
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Table A-14.  Model Predictions for Decreased Erythrocyte Count in Dogs Treated
with 2,6-DNT for 2 Weeks
Scaled residualscTest for
significant Dose Dose BMD1SD BMDL1SD 
difference Variance Means below above Overall (mg/kg/ (mg/kg/ 
Model p-valuea p-valueb p-valueb BMD BMD largest AIC day) day)
Constant variance
Lineard <0.0001 0.08 0.25 -1.22 0.12 -1.22 -4.12 14.39 11.60
Non Constant variance
Exponential (model 2)e <0.0001 0.18 0.09 -1.55 1.26 -1.55 -3.38 8.15 6.00
Exponential (model 3)e <0.0001 0.18 0.04 -1.60 0.64 -1.60 -1.90 11.15 6.17
Exponential (model 4)e <0.0001 0.18 0.09 -1.55 1.26 -1.55 -3.38 8.15 5.84
Exponential (model 5)e <0.0001 0.18 0.04 -1.60 0.64 -1.60 -1.90 11.15 6.07
Hille NA NA NA NA NA NA NA NA NA
Lineard,f <0.0001 0.18 0.16 -1.42 0.13 -1.42 -4.47 12.21 9.31
Polynomial (2-degree)d <0.0001 0.18 0.16 -1.42 0.13 -1.42 -4.47 12.21 9.31
Polynomial (3-degree)d <0.0001 0.18 0.16 -1.42 0.13 -1.42 -4.47 12.21 9.31
Powere <0.0001 0.18 0.16 -1.42 0.13 -1.42 -4.47 12.21 9.31
aValues >0.05 fail to meet conventional goodness-of-fit criteria.

bValues <0.10 fail to meet conventional goodness-of-fit criteria.
 
cScaled residuals at doses immediately below and above the BMD; also the largest residual at any dose.
 
dCoefficients restricted to be negative.
 
ePower restricted to ≥1.
	
fSelected model.  Constant variance model did not provide adequate fit to variance data, but non-homogenous variance 

model did. With non-constant variance model applied, all models, except for the Exponential (means <0.1) and Hill
 
models (computation failed), provided adequate fit to the means.  The polynomial and power models all converged to 

the linear model.
 
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the exposure concentration associated with 

the selected benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote benchmark
 
response: i.e., 10 = exposure concentration associated with 10% extra risk); DF = degrees of freedom;
 
DNT = dinitrotoluene; NA = not applicable (BMDL computation failed); SD = standard deviation
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Figure A-9.  Fit of Linear Model to Data on Decreased Erythrocyte Count in Dogs
 
Treated with 2,6-DNT for 2 Weeks
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BMDs and BMDLs indicated are associated with a change of 1 standard deviation from the control, and are in units
of mg/kg/day.
Source: U.S. Army 1976
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
 
Was a conversion used from intermittent to continuous exposure?  No.
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Other additional studies or pertinent information which lend support to this MRL:  Hematological effects 
consistent with methemoglobinemia-induced anemia and compensatory hematopoiesis have been
observed in laboratory animals orally exposed to 2,6-DNT for acute and intermediate durations.  No 
chronic-duration studies were identified that evaluated hematological effects after exposure to 2,6-DNT.
Hematological effects (increased hemoglobin, hematocrit, and increased erythrocyte count, granulocyte,
and reticulocyte counts) were observed in female Sprague-Dawley rats administered 2,6-DNT at
199 mg/kg/day via gavage for 48 hours (Deng et al. 2011) and in male Sprague-Dawley rats exposed to
134 mg/kg/day via gavage for 14 days (Lent et al. 2012a; USAPHC 2011d).  In intermediate-duration 
studies, dogs appear to more sensitive than rats or mice.  In dogs orally exposed to 2,6-DNT at
4 mg/kg/day for 4 or 13 weeks, extramedullary erythropoiesis in the spleen secondary to methemoglobin­
emia and anemia was observed (U.S. Army 1976).  Changes in hematological parameters associated with
anemia and compensatory hematopoiesis (including decreased hematocrit and hemoglobin, and increased 
numbers of reticulocytes) occurred at 20 and 100 mg/kg/day.  The incidence and severity of these effects 
were more pronounced at 100 mg/kg/day.  Similar effects were observed in rats (U.S. Army 1976).  In 
CD rats administered 2,6-DNT at ≥7 mg/kg/day and sacrificed after treatment for 4 or 13 weeks, 
increased incidences of extramedullary hematopoiesis and/or splenic hemosiderosis (increased iron 
accumulation) were observed.  However, changes in hematological parameters (measured at 4, 8, and
13 weeks) indicative of anemia and compensatory hematopoiesis (including significant decreases in
erythrocyte count, hematocrit, hemoglobin, and increased reticulocytes) were observed only at the highest
tested dose (145 and 155 mg/kg/day for male and female rats, respectively); these effects were most
pronounced after treatment for 4 weeks.  Although histopathological effects (extramedullary
hematopoiesis) were observed in CD-1 mice administered 2,6-DNT at ≥51 mg/kg/day (but not
11 mg/kg/day) for 4 or 13 weeks, no statistically significant changes in hematological parameters were 
seen.  The study authors indicated that some blood samples clotted, making hematological analyses 
impossible to perform.  The small number of animals evaluated likely contributed to the identification of
histopathological findings of the spleen in the apparent absence of 2,6-DNT-induced hematological
effects. The results of intermediate-duration studies indicate that hematological effects (or
histopathological effects secondary to methemoglobinemia and anemia) are the most sensitive effects 
after exposure to 2,6-DNT; additional effects observed in intermediate-duration studies occurred at higher
doses than hematological effects.
Agency Contact (Chemical Manager): Carolyn Harper
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MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: 2,6-DNT
CAS Numbers: 606-20-2
Date: February 2016
Profile Status: Final
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute [X] Intermediate   [ ] Chronic
Graph Key: 18
Species: Dog
Minimal Risk Level:  0.004   [X] mg/kg/day   [ ] ppm
Reference: U.S. Army.  1976. Mammalian toxicity of munitions compounds.  Phase II:  Effects of
multiple doses.  Part III:  2,6-Dinitrotoluene.  Progress report no. 4.  Fort Detrick, MD:  U.S. Army, 
Medical Bioengineering Research and Development Laboratory.  ADA062015
Experimental design:  Young beagle dogs (4 dogs/sex/group; age not specified) were administered 0, 4, 
20, or 100 mg/kg 2,6-DNT in capsules for 13 weeks (U.S. Army 1976).  Dogs were observed daily for
behavioral changes and clinical signs of toxicity.  Body weights were recorded weekly.  Feed
consumption was measured daily.  Blood was taken before initiation of treatment and at 2, 4, 8, and 
13 and/or 17 weeks (4-week post-treatment recovery period) for hematological (erythrocyte, reticulocyte,
platelet, and total and differential leukocyte counts; Heinz bodies; hematocrit, hemoglobin, and 
methemoglobin concentrations; and mean cell volume, hemoglobin, and hemoglobin concentration) and 
clinical chemistry (glucose, urea nitrogen, levels of sodium, potassium, calcium, magnesium, and 
chloride; and serum enzyme activities of aspartate aminotransferase, alanine aminotransferase, and
alkaline phosphatase) analyses.  Animals (1 sex/group) were sacrificed after 4 or 13 weeks of continuous 
treatment; an additional dog/sex/group was discontinued treatment after 4 or 13 weeks and sacrificed after
4 weeks of recovery (week 8 or 17) to evaluate the reversibility of effects.  The two high-dose dogs
removed from treatment at 4 weeks were not sacrificed until 19 weeks after cessation of treatment to test
the reversibility of effects after a longer recovery period.  When animals were moribund or at study
termination, they were examined for gross lesions; major organs and tissues were weighed (heart, liver,
spleen, kidneys, adrenals, and gonads); and “various” tissues (number not specified) were subjected to
histopathological examinations.  Bone marrow and kidney cultures were also maintained and cytogenetic
analyses (of chromosome number and morphology) were performed.
Effects noted in study and corresponding doses: Intermediate-duration oral exposure of dogs to 2,6-DNT
at 4 mg/kg/day produced extramedullary erythropoiesis (formation of erythrocytes outside of the bone
marrow) in the spleen secondary to methemoglobinemia and anemia (U.S. Army 1976).  Hematological
effects and compensatory erythropoiesis induced by 2,6-DNT are initiated by methemoglobin production, 
which occurs when the ferrous iron in complex with the heme groups of hemoglobin is oxidized to ferric
iron.  Ferric iron does not bind oxygen, resulting in anemia.  Ferric iron also contributes to the
denaturation of hemoglobin and subsequent removal of erythrocytes from the blood.  Increased 
erythropoiesis is typically observed as a compensatory response to decreased erythrocyte count.
Mortality occurred in dogs administered 20 and 100 mg/kg/day.  Two mid-dose female dogs died in 
week 9; all high-dogs died by week 8.  Effects observed in dogs treated at 20 and 100 mg/kg/day were
clinical signs of neurotoxicity (listlessness, incoordination, and lack of balance), decreased feed
consumption and subsequent reductions in body weight, and changes in hematological parameters
associated with anemia and compensatory hematopoiesis (including decreased hematocrit and
hemoglobin, and increased numbers of reticulocytes). The incidence and severity of these effects were
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more pronounced at 100 mg/kg/day relative to 20 mg/kg/day.  Dogs administered 2,6-DNT at
4 mg/kg/day showed no clinical signs of toxicity, and although similar hematological effects occurred, 
these changes were not statistically significant.  No significant effects on clinical chemistry end points 
were observed in any 2,6-DNT treatment group.  In general, dogs treated at 20 mg/kg/day for 4 or
13 weeks and then removed from treatment showed recovery from neurotoxicity and hematological
effects after 4 weeks; dogs treated at 100 mg/kg/day for 4 weeks did not show complete recovery until
19 weeks after cessation of treatment.
Histopathological evaluation of the spleen showed an increased incidence of extramedullary
erythropoiesis, an adaptive response to 2,6-DNT-induced methemoglobinemia and anemia, in dogs
administered ≥4 mg/kg/day for 4 or 13 weeks (Table A-15).  The incidence and severity of this lesion was 
dose-related.  Additional histopathological changes observed dogs administered 2,6-DNT at 20 or
100 mg/kg/day for 4 or 13 weeks included effects on the thymus (involution), liver (extramedullary
hematopoiesis, bile duct hyperplasia, degeneration, and inflammation), kidneys (degeneration, 
inflammation, and diluted tubules), and testes (degeneration and/or decreased spermatogenesis). High-
dose dogs also showed evidence of lymphoid depletion in the spleen and lymph nodes.  No other
treatment-related histopathological changes were observed in dogs dosed with 2,6-DNT at 4 mg/kg/day 
for 13 weeks.
Table A-15. Extramedullary Erythropoiesis of the Spleen in Beagle Dogs Exposed 
to 2,6-DNT for 4 or 13 Weeks
Timepoint Dose (mg/kg/day)
(weeks) 0 4 20 100
4 0/2a 1/2 2/2 2/2
(mild) (moderate) (1 mild; 1 markedly severe)
13 0/2 2/2 3/3 4/4
(1 minimal; 1 mild) (1 minimal, 1 mild, 1 moderate) (2 marked, 2 markedly severe)
aNumber examined/number affected (severity of lesion).
DNT = dinitrotoluene
Source: U.S. Army 1976
Dose and end point used for MRL derivation: 
[ ] NOAEL   [X] LOAEL  4 mg/kg/day for mild extramedullary erythropoiesis in the spleen.
The LOAEL value of 4 mg/kg/day for an increased incidence of extramedullary erythropoiesis in the
spleens of dogs was identified as the POD for derivation of the intermediate-duration oral MRL for
2,6-DNT (U.S. Army 1976).  Histopathology data were not suitable for BMD modeling, since the number
of animals evaluated at each dose and time was small (n=2 animals). Therefore, the LOAEL value for
4 mg/kg/day was used at the POD.  This value was divided by an uncertainty factor of 1,000 (10 for use
of a LOAEL, 10 for extrapolation from animals to humans, and 10 for human variability), resulting in an 
acute-duration oral MRL for 2,6-DNT of 0.004 mg/kg/day.
Uncertainty Factors used in MRL derivation:
[X]  10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
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[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure?  No.
Other additional studies or pertinent information which lend support to this MRL: Similar
histopathological effects (extramedullary hematopoiesis and/or splenic hemosiderosis), indicative of an
adaptive response to anemia and compensatory erythropoiesis, were observed in CD rats administered
2,6-DNT at ≥7 mg/kg/day and in CD-1 mice administered 2,6-DNT at ≥51 mg/kg/day (but not
11 mg/kg/day) for 4 or 13 weeks (U.S. Army 1976).  Hematological effects were also identified in
intermediate-duration studies.  In these studies, dogs appear to be the most sensitive species.  Dogs treated
at 20 mg/kg/day showed a statistically significant decrease in erythrocyte count and a significant increase
in mean cell hemoglobin at 2 weeks.  At 100 mg/kg/day, more pronounced changes in these
hematological parameters were observed; statistically significant reductions in erythrocyte count,
hematocrit, and hemoglobin and a statistically significant increase in reticulocyte count were observed.  In
CD rats, changes in hematological parameters indicative of anemia (significant decreases in erythrocyte
count, hematocrit, and hemoglobin) and compensatory hematopoiesis (increased reticulocytes) were 
observed only at the highest tested dose (145 and 155 mg/kg/day for male and female rats, respectively).  
Although histopathological effects (extramedullary hematopoiesis) was observed in CD-1 mice 
administered 2,6-DNT at 51 mg/kg/day (but not 11 mg/kg/day), no statistically significant changes in 
hematological parameters were seen after treatment for 4 or 13 weeks. The study authors indicated that
some blood samples clotted, making hematological analyses impossible to perform. The small number of
animals evaluated likely contributed to the identification of histopathological findings of the spleen in the
apparent absence of 2,6-DNT-induced hematological effects.
Agency Contact (Chemical Manager): Carolyn Harper
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MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: 3,4-DNT
CAS Numbers: 610-39-9
Date: February 2016
Profile Status: Final
Route: [ ] Inhalation   [X] Oral
Duration: [X] Acute [ ] Intermediate   [ ] Chronic
Graph Key: 1
Species: Rat
Minimal Risk Level: 0.03 [X] mg/kg/day  [ ] ppm
References: Lent EM, Crouse CB, Quinn MJ, et al.  2012a.  Comparison of the repeated dose toxicity of
isomers of dinitrotoluene. Int J Toxicol 31(2):143-157.
U.S. Army Public Health Command (USAPHC).  2011e. Toxicology Study No. 87-XE-08G0B-08, October 2011,
Toxicology Portfolio.  Fourteen-day oral toxicity and in vivo genotoxicity of 3,4-dinitrotoluene in rats, June-July 
2008.  USAPHC, Aberdeen Proving Ground, Maryland.
Experimental design:  In a comparative toxicity study, groups of six male Sprague-Dawley rats were 
given 3,4-DNT via gavage doses of 0, 7, 14, 28, 57, 113, or 227 mg/kg/day for 14 days. Both untreated 
and vehicle control groups were included.  Evaluations during the study included twice daily observations
for morbidity and clinical signs and measurement of body weight and food consumption on days 0, 1, 3, 
7, and 14.  Prior to sacrifice at the end of exposure, blood was collected for evaluation of hematology
(total and differential white blood cell counts; red blood cell count; hemoglobin, hematocrit, MCV, MCH, 
MCHC, red cell distribution width; platelet count; and mean platelet volume) and serum chemistry
(albumin, ALP, ALT, AST, BUN, calcium, cholesterol, creatinine, glucose, globulin, LDH, total
bilirubin, total protein, sodium, potassium, and chlorine) assessments.  All animals received gross 
necropsy and organ weight determinations (brain, heart, kidney, epididymides, liver, spleen, and testes).  
Microscopic examination of organs with exposure-related changes in weight was performed for controls
and any dose groups exhibiting changes in the corresponding organ weights.
Effects noted in study and corresponding doses: All rats in the study of 3,4-DNT survived until
scheduled sacrifice.  Rats in the highest dose group (227 mg/kg/day) exhibited clinical signs of toxicity
including cyanosis, lethargy, dark urine, facial twitching, and hypoactivity or staring behavior; one rat
exposed to 113 mg/kg/day exhibited dark urine.  High-dose rats had lower body weights than controls
throughout the study, and a biologically significant (but not statistically significant) 10% reduction in 
terminal body weight was observed at this dose.  Food intake was also decreased at this dose, albeit not at
a level that reached statistical significance.  Both hemoglobin and hematocrit were lower than controls at
all doses of 3,4-DNT, with statistically significant reductions at doses of 14, 28, and 113 mg/kg/day.  The
authors indicated that both parameters remained within reference ranges at all doses.  White blood cell
counts were not affected by treatment, but the percent of neutrophils was increased and percent of
lymphocytes was decreased at 14, 28, and 227 mg/kg/day; a clear dose-response relationship was not
evident.  Other hematology parameters were not affected by treatment, and none of the serum chemistry
parameters exhibited a dose-related change.  There were no gross necropsy findings of note. The only
treatment-related organ weight change was an increase (≥13% compared with vehicle controls) in relative 
liver-to-body weight at the two highest doses (≥113 mg/kg/day); absolute liver weight was not affected,
and there were no treatment-related histopathology findings in the liver.  Relative liver weights may have
been altered as a consequence of the lower body weights seen at the highest doses. Microscopic lesions 
were noted in the heart, spleen, and kidney.  One rat in the highest dose group exhibited mild myocardial
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fibrosis, inflammation, and necrosis.  Splenic lesions, of trace-to mild severity, were observed at doses 
≥57 mg/kg/day, including extramedullary hematopoiesis (2/6, 2/5, and 3/6 rats at the three highest doses)
and lymphoid hyperplasia (3/6, 2/5, 2/6 at 57, 113, and 227 mg/kg/day respectively) (see Table A-16).  
Spleens were not examined in lower dose animals. Microscopic lesions of the kidney occurred in the high
dose group, and included trace-to-moderate proximal tubule degeneration (1/6 rats), renal tubular
basophilia (4/6), and lymphocytic infiltration (5/6); kidneys from animals in lower dose groups were not
examined. Results of this study identify an acute-duration LOAEL value for hematopoietic system
effects of 57 mg/kg/day in rats. A NOAEL for hematopoietic system effects cannot be determined in the
absence of histopathology examinations in lower dose groups.
Table A-16. Splenic Lesions in Rats Exposed to 3,4-DNT for 14 Days
Dose (mg/kg/day)
End point 0 7 14 28 57 113 227
Extramedullary hematopoiesis 0/6a ND ND ND 2/6 2/5 3/6
Lymphoid hyperplasia 0/6 ND ND ND 3/6 2/5 2/6
aNumber affected/number examined
DNT = dinitrotoluene; ND = no data; histopathology examination was not performed for these animals.
Sources: Lent et al. 2012a; USAPHC 2011e 
Dose and end point used for MRL derivation: 
[] NOAEL [ ] LOAEL [X] BMDL 8.05 mg/kg/day was the BMDL10 for hematopoietic effects (trace­
to-mild extramedullary hematopoiesis and lymphoid hyperplasia).
Hematopoietic system toxicity was identified as the most sensitive effect of acute-duration oral exposure
to 3,4-DNT, based on the LOAEL value of 57 mg/kg/day in rats administered 3,4-DNT via gavage for
14 days (Lent et al. 2012a; USAPHC 2011e). To select a POD, the following data sets were subjected to
BMD modeling: incidences of extramedullary hematopoiesis and lymphoid hyperplasia of the spleen. The
BMD and the 95% lower confidence limit (BMDL) were estimated for doses associated with a 10%
increase in incidence over the control incidence, and are in units of mg/kg/day.  Adequate model fit is
judged by three criteria:  goodness-of-fit (p>0.1), visual inspection of the dose-response curve, and scaled
residual at the data point (except the control) closest to the predefined BMR.  Among all of the models 
providing adequate fit to the data, the model with the lowest benchmark dose (BMDL, the lower limit of a 
one-sided 95% CI on the BMD) is selected when differences between the BMDLs estimated from these 
models are >3-fold; otherwise, the model with the lowest AIC is chosen.  
BMD model predictions for incidences of extramedullary hematopoiesis and lymphoid hyperplasia of the
spleen are shown in Tables A-17 and A-18, respectively. The BMDL10 values from the best-fitting
models for were the same (8.05 mg/kg/day) for both increased incidence of extramedullary hematopoiesis
(log-logistic; Figure A-10) and increased incidence of lymphoid hyperplasia of the spleen (log-logistic; 
Figure A-11).  Thus, the BMDL10 of 8.05 mg/kg/day was selected as the POD.  The POD of
8.05 mg/kg/day was divided by an uncertainty factor of 300 (10 for extrapolation from animals to 
humans, 10 for human variability, and 3 for database limitations), resulting in an acute-duration oral MRL
for 3,4-DNT of 0.03 mg/kg/day.
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Table A-17. Model Predictions for Incidence of Extramedullary
 
Hematopoiesis in the Spleen of Male Sprague-Dawley Rats
 
Administered 3,4-DNT via Gavage for 14 Days
 
χ2 Scaled residualsb 
Goodness- Dose Dose 
of-fit below above Overall BMD10 BMDL10 
Model DF χ2 p-valuea BMD BMD AIClargest (mg/kg) (mg/kg)
Gammac 3 0.86 0.83 0.00 0.74 0.74 25.48 25.51 14.32
Logistic 2 1.80 0.41 0.76 0.44 -0.96 29.20 64.08 37.29
LogLogisticd,e 3 0.34 0.95 0.00 0.44 0.44 25.01 18.56 8.05
LogProbitd 3 1.86 0.60 0.00 1.02 1.02 26.32 40.34 24.07
Multistage (1-degree)f 3 0.86 0.83 0.00 0.74 0.74 25.48 25.51 14.32
Multistage (2-degree)f 3 0.86 0.83 0.00 0.74 0.74 25.48 25.51 14.32
Multistage (3-degree)f 3 0.86 0.83 0.00 0.74 0.74 25.48 25.51 14.32
Probit 2 1.77 0.41 0.79 0.43 -0.91 29.10 60.21 36.19
Weibullc 3 0.86 0.83 0.00 0.74 0.74 25.48 25.51 14.32
aValues <0.1 fail to meet conventional goodness-of-fit criteria.

bScaled residuals at doses immediately below and above the benchmark dose; also the largest residual at any dose.
 
cPower restricted to ≥1.
dSlope restricted to ≥1.
eSelected model.  All models provided adequate fit to the data.  BMDLs for models providing adequate fit were not
sufficiently close (differed by >3-fold), so the model with the lowest BMDL was selected (LogLogistic; also has the 
lowest AIC).
fBetas restricted to ≥0.
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the dose associated with the selected
benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote benchmark response:
i.e., 10 = dose associated with 10% extra risk); DF = degrees of freedom; DNT = dinitrotoluene
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Figure A-10.  Fit of Log-logistic Model to Data on Incidence of Extramedullary
 
Hematopoiesis in Rats Treated with 3,4-DNT for 14 Days
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Table A-18.  Model Predictions for Incidence of Lymphoid Hyperplasia in 
the Spleen of Male Sprague-Dawley Rats Administered 3,4-DNT via
Gavage for 14 Days
χ2 Scaled residualsb 
Goodness- Dose Dose 
of-fit below above Overall BMD10 BMDL10 
Model DF χ2 p-valuea BMD BMD AIClargest (mg/kg) (mg/kg)
Gammac 2 0.86 0.83 0.00 0.74 0.74 25.48 25.51 14.32
Logistic 2 1.80 0.41 0.76 0.44 -0.96 29.20 64.08 37.29
LogLogisticd,e 3 0.34 0.95 0.00 0.44 0.44 25.01 18.56 8.05
LogProbitd 2 1.86 0.60 0.00 1.02 1.02 26.32 40.34 24.07
Multistage (1-degree)f 2 0.86 0.83 0.00 0.74 0.74 25.48 25.51 14.32
Multistage (2-degree)f 2 0.86 0.83 0.00 0.74 0.74 25.48 25.51 14.32
Multistage (3-degree)f 2 0.86 0.83 0.00 0.74 0.74 25.48 25.51 14.32
Probit 2 1.77 0.41 0.79 0.43 -0.91 29.10 60.21 36.19
Weibullc 2 0.86 0.83 0.00 0.74 0.74 25.48 25.51 14.32
aValues <0.1 fail to meet conventional goodness-of-fit criteria.

bScaled residuals at doses immediately below and above the benchmark dose; also the largest residual at any dose.
 
cPower restricted to ≥1.
dSlope restricted to ≥1.
eSelected model.  All models provided adequate fit to the data.  BMDLs for models providing adequate fit were not
sufficiently close (differed by >3-fold), so the model with the lowest BMDL was selected (LogLogistic).
fBetas restricted to ≥0.
AIC = Akaike Information Criterion; BMD = maximum likelihood estimate of the dose associated with the selected
benchmark response; BMDL = 95% lower confidence limit on the BMD (subscripts denote benchmark response:
i.e., 10 = dose associated with 10% extra risk); DF = degrees of freedom; DNT = dinitrotoluene
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Figure A-11.  Fit of Log-logistic Model to Data on Incidence of Lymphoid 
Hyperplasia in Rats Treated with 3,4-DNT for 14 Days
Log-Logistic Model, with BMR of 10% Extra Risk for the BMD and 0.95 Lower Confidence Limit for the B 
Fr
ac
tio
n 
A
ffe
ct
ed
 
0.8
 0.6
 0.4
 0.2
 0
BMDL BMD 
Log-Logistic 
0  50  100  150  200 
dose 
13:35 12/23 2014 
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
[X]  3 for database limitations (no other toxicological studies of this isomer are available)
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
 
Was a conversion used from intermittent to continuous exposure?  No.
 
Other additional studies or pertinent information which lend support to this MRL: No other acute-

duration oral studies of 3,4-DNT were located, nor were there any studies of longer durations.  
Agency Contact (Chemical Manager): Carolyn Harper
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MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: 3,5-DNT
CAS Numbers: 618-85-9
Date: February 2015
Profile Status: Final
Route: [ ] Inhalation   [X] Oral
Duration: [X] Acute [ ] Intermediate   [ ] Chronic
Graph Key: 4
Species: Rat
Minimal Risk Level: 0.03 [X] mg/kg/day  [ ] ppm
References: Lent EM, Crouse CB, Quinn MJ, et al. 2012a. Comparison of the repeated dose toxicity of
isomers of dinitrotoluene Int J Toxicol 31(2):143-157.
U.S. Army Public Health Command (USAPHC).  2011f.  Toxicology Study No. 87-XE-08G0F-10, 
October 2011, Toxicology Portfolio.  Fourteen-day oral toxicity and in vivo genotoxicity of
3,5-dinitrotoluene in rats, January 2009-March 2010. USAPHC, Aberdeen Proving Ground, Maryland.
Experimental design:  In a comparative toxicity study, groups of six male Sprague-Dawley rats were 
given 3,5-DNT via gavage doses of 0, 5, 10, 19, 39, 77, or 155 mg/kg/day for 14 days. Both untreated 
and vehicle control groups were included.  Evaluations during the study included twice daily observations
for morbidity and clinical signs and measurement of body weight and food consumption on days 0, 1, 3, 
7, and 14.  Prior to sacrifice at the end of exposure, blood was collected for evaluation of hematology
(total and differential red blood cell counts; red blood cell count; hemoglobin, hematocrit, MCV, MCH, 
MCHC, red cell distribution width; platelet count; and mean platelet volume) and serum chemistry
(albumin, ALP, ALT, AST, BUN, calcium, cholesterol, creatinine, glucose, globulin, LDH, total
bilirubin, total protein, sodium, potassium, and chlorine) assessments.  All animals received gross 
necropsy and organ weight determinations (brain, heart, kidney, epididymides, liver, spleen, and testes).  
Microscopic examination of organs with exposure-related changes in weight was performed for controls 
and any dose groups exhibiting changes in the corresponding organ weights.
Effects noted in study and corresponding doses: All rats exposed to 77 and 155 mg/kg/day 3,5-DNT died
or were sacrificed moribund within the first 8 days on study, as did one rat in the 39 mg/kg/day group.  
Clinical signs of toxicity were observed at the lethal doses; in addition, animals exposed to 
≥39 mg/kg/day were reported to exhibit neurological signs progressing from facial twitching to paralysis
of the forelimbs.  It is not clear whether these signs were seen only in the animals that were moribund or
if some neurological signs were seen in animals that survived treatment. Mean terminal body weight was 
decreased by 13% at 39 mg/kg/day; treatment did not affect food intake.  The only hematology or clinical
chemistry changes possibly attributable to treatment were increased albumin, total protein, and total
bilirubin at 39 mg/kg/day.  Gross necropsy findings among animals surviving to termination included 
small testis size in three rats given 19 mg/kg/day and in five rats given 39 mg/kg/day.  These findings
were confirmed by organ weight measurements indicating significant reductions (≥40%) in absolute and 
relative testes weights at these doses.  Brain weight relative to body weight was increased by 30%
(relative to vehicle controls) in the 39 mg/kg/day group; no other organ weight changes were reported.  
Testicular histopathology changes were observed in all rats exposed to doses ≥19 mg/kg/day (see Table 
A-19); these included mild-to-severe tubular degeneration and trace-to-severe multinucleated giant cell 
formation.  Trace lymphoid depletion was observed in the spleens of 1/6 rats in each of the groups
exposed to 10 and 19 mg/kg/day; no lesions were seen at 39 mg/kg/day.  Finally, mild or moderate
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inflammatory infiltrates were observed in the brains of 3/6 rats exposed to 39 mg/kg/day. Results of this 
study identify acute-duration NOAEL and LOAEL values for testicular lesions of 10 and 19 mg/kg/day,
respectively, in rats. 
Table A-19. Testes Effects in Rats Exposed to 3,5-DNT for 14 Days
Dose (mg/kg/day)
End point 0 5 10 19 39a 77 155
Tubular degeneration 0/6b 0/6 0/6 6/6c 6/6c NA NA
Multinucleated giant cell formation 0/6 0/6 0/6 6/6c 5/6c NA NA
aIncludes one animal that died or was sacrificed moribund before the end of the study.

bNumber affected/number examined.
 
cStatistically significant at p<0.05 based on Fisher’s exact test performed for this review.
 
DNT = dinitrotoluene; NA = not applicable; all rats died or were sacrificed moribund at these doses
Sources: Lent et al. 2012a; USAPHC 2011f 
Dose and end point used for MRL derivation: 
[X] NOAEL   [ ] LOAEL [ ] BMDL 10 mg/kg/day was the NOAEL for testicular effects (mild-to-severe 
tubular degeneration and trace-to-severe multinucleated giant cell formation).
Testicular toxicity was identified as the most sensitive effect of acute-duration oral exposure to 3,5-DNT,
based on the LOAEL value of 19 mg/kg/day in rats administered 3,5-DNT via gavage for 14 days (Lent et
al. 2012a; USAPHC 2011f). The NOAEL value of 10 mg/kg/day was used as the POD.  Available data 
were not suitable for BMD modeling, as the incidences of testicular lesions increased from 0/6 in the
control group to 6/6 at the LOAEL.  The POD of 10 mg/kg/day was divided by an uncertainty factor of 
300 (10 for extrapolation from animals to humans, 10 for human variability, and 3 for database
limitations), resulting in an acute-duration oral MRL for 3,5-DNT of 0.03 mg/kg/day.
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
[X]  3 for database limitations (no other toxicological studies of this isomer are available)
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure?  No.
Other additional studies or pertinent information which lend support to this MRL: No other acute-
duration oral studies of 3,5-DNT were located, nor were there any studies of longer durations.  
Agency Contact (Chemical Manager): Carolyn Harper
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Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended
audience is the general public, especially people living in the vicinity of a hazardous waste site or
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic,
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight­
of-evidence discussions for human health end points by addressing the following questions:
1.	 What effects are known to occur in humans?
2.	 What effects observed in animals are likely to be of concern to humans?
3.	 What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.
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MRLs should help physicians and public health officials determine the safety of a community living near
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational
exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement,
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used
in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure 
(LSE) tables.
Chapter 3
Health Effects
Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable,
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.
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LEGEND
See Sample LSE Table 3-1 (page B-6)
(1)	 Route of Exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each
route of exposure and will not, therefore, have all five of the tables and figures.
(2)	 Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.
In this example, an inhalation study of intermediate exposure duration is reported.  For quick
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3)	 Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4)	 Key to Figure. Each key number in the LSE table links study information to one or more data
points using the same key number in the corresponding LSE figure.  In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5)	 Species. The test species, whether animal or human, are identified in this column.  Chapter 2,
"Relevance to Public Health," covers the relevance of animal data to human toxicity and
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL.
(6)	 Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al.
1981).
(7)	 System.  This column further defines the systemic effects. These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8)	 NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
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(9)	 LOAEL.  A LOAEL is the lowest dose used in the study that caused a harmful health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs.
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile.
(11)	 CEL.  A CEL is the lowest exposure level associated with the onset of carcinogenesis in
experimental or epidemiologic studies.  CELs are always considered serious effects. The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing
measurable cancer increases.
(12)	 Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health
effects observed within the acute and intermediate exposure periods are illustrated.
(14)	 Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15)	 Levels of Exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16)	 NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the
LSE table.
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(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q1*).
(19)	 Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.
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1 →	 Table 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation
LOAEL (effect)Exposure 
Less serious Serious (ppm)Key to 	 frequency/ NOAEL
(ppm)figurea Species duration System (ppm)	 Reference
2
3
4
→ INTERMEDIATE EXPOSURE
5
→ Systemic ↓
18 Rat
→
CHRONIC EXPOSURE
Cancer
38 Rat
39 Rat
40 Mouse
6
↓
13 wk
5 d/wk
6 hr/d
18 mo
5 d/wk
7 hr/d
89–104 wk
5 d/wk
6 hr/d
79–103 wk
5 d/wk
6 hr/d
7 8 9
↓ ↓ ↓
Resp 3b 10 (hyperplasia)
11
↓
20	 (CEL, multiple
organs)
10	 (CEL, lung tumors,
nasal tumors)
10	 (CEL, lung tumors,
hemangiosarcomas)
10
↓
Nitschke et al. 1981
Wong et al. 1982
NTP 1982
NTP 1982
12 →	 a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).
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Chronic (≥ 365 days) Intermediate (15-364 days)
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APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLX 95% lower confidence limit on the BMDX 
BMDS Benchmark Dose Software 
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor
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DOT Department of Transportation
DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register
FSH follicle stimulating hormone
g gram
GC gas chromatography
gd gestational day
GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization
IRIS Integrated Risk Information System
Kd adsorption ratio
kg kilogram
kkg metric ton
Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill
LDLo lethal dose, low
LDH lactic dehydrogenase
LH luteinizing hormone
LOAEL lowest-observed-adverse-effect level
LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie
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MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor
MFO mixed function oxidase
mg milligram
mL milliliter
mm millimeter
mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System
NLM National Library of Medicine
nm nanometer
nmol nanomole
NOAEL no-observed-adverse-effect level
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
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OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell
REL recommended exposure level/limit
RfC reference concentration
RfD reference dose
RNA ribonucleic acid
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act
TWA time-weighted average
UF uncertainty factor
U.S. United States
USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell
WHO World Health Organization
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> greater than
≥ greater than or equal to
= equal to
< less than
≤ less than or equal to
% percent
α alpha
β beta
γ gamma
δ delta
μm micrometer
μg microgram
q1* cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result
 
 
 
 
 
 
 
 
 
 
 
